



# FORMULARY

## 處方集

二〇一六年五月十五日  
**2016 Edition**

## 目 錄

壹、處方集使用說明.....	I
貳、內文索引.....	II-XXX
參、內文.....	1-336
肆、附錄.....	附 1-31
伍、學名商品名索引.....	索引 1-28

## 處方集使用說明

藥品名	懷孕分級 <sup>a</sup>	授乳安全性 <sup>b</sup>
<b>Dosage Form:</b> 商品名及本院備有之劑型 <藥品代碼>		
<b>Use:</b> 臨床應用		
<b>Dose:</b> 劑量		
<b>Adverse Reactions:</b> 不良反應		
<b>Precautions:</b> 注意事項		
<b>Contraindications:</b> 禁忌		

附註：

**懷孕分級<sup>a</sup>** 依據 FDA 懷孕危險性級數

- A. 依對照試驗無法證實對胎兒有危險
- B. 動物試驗無法顯示具有危險性，但無人體試驗之充分研究
- C. 動物試驗有致畸胎性，但無人體試驗之充分研究
- D. 對胎兒具有危險性，使用時需衡量治療效益與危險性
- X. 動物或人體試驗具致畸胎性，孕婦禁用

a. 懷孕分級資料來源（上標表示）：**C**

1. 第 6 版：Drugs in pregnancy and lactation
2. PDR 2008
3. MARTINDALE
4. Micromedex
5. Package circulars
6. Drug information handbook

**授乳安全性<sup>b</sup>** 授乳安全性其表示：

**Unknown:** 未有文獻資料

**Unsafe:** 不建議使用

**Safe:** 在餵乳期可安全使用

b. 授乳安全性資料來源（上標表示）：**Safe<sup>1</sup>**

1. Micromedex
2. PDR 2008
3. Package circulars
4. Drug information handbook
5. 第 6 版：Drug in pregnancy and lactation

## 目 錄

內文

頁碼

1. ANALGESICS.....	1
1.1. Narcotics Agonist.....	1
Buprenorphine .....	1
Codeine .....	1
Desud Plus <sup>®</sup> .....	1
Fentanyl.....	2
Meperidine.....	2
Morphine.....	2
Nalbuphine.....	3
Tracetin <sup>®</sup> .....	3
1.2. NSAIDs.....	3
1.2.1. Non-COX-2 Selectives.....	3
Diclofenac sodium.....	3
Diclofenac potassium .....	4
Etofenamate .....	4
Flurbiprofen .....	4
Ibuprofen.....	4
Indomethacin .....	5
Ketorolac.....	5
Naproxen.....	5
1.2.2. COX-2 Selectives.....	5
Celecoxib .....	5
Etodolac .....	6
Etoricoxib.....	6
Parecoxib .....	6
1.3. Analgesic Miscellaneous.....	7
Acetaminophen.....	7
Glucosamine .....	7
2. ANESTHETICS .....	9
2.1. General Anesthetics .....	9
Desflurane .....	9
Dexmedetomidine.....	9
Isofluran .....	9
Ketamine .....	10
Midazolam .....	10
Propofol.....	10
Sevoflurane .....	11
Thiamylal .....	11
2.2. Local Anesthetics.....	11

Bupivacaine .....	11
Epinephrine and Articaine .....	12
Lidocaine .....	12
Lidocaine and Epinephrine .....	13
Ropivacaine .....	13
<b>2.3. Neuromuscular blockers .....</b>	<b>14</b>
Cisatracurium.....	14
Pancuronium .....	14
Rocuronium .....	14
Succinylcholine .....	15
<b>3. ANTIMICROBIALS.....</b>	<b>16</b>
<b>    3.1. Aminoglycosides .....</b>	<b>16</b>
Amikacin.....	16
Gentamicin.....	16
Isepamicin.....	17
Neomycin.....	17
<b>    3.2. Antifungals .....</b>	<b>17</b>
Amphotericin B .....	17
Anidulafungin .....	18
Caspofungin .....	18
Fluconazole.....	19
Flucytosine.....	19
Itraconazole.....	20
Liposomal Amphotericin B .....	20
Nystatin.....	21
Posaconazole.....	21
Terbinafine .....	22
Voriconazole .....	22
<b>    3.3. Antimalarials .....</b>	<b>23</b>
Hydroxychloroquine.....	23
<b>    3.4. Antiparasitics .....</b>	<b>23</b>
Levamisole.....	23
Mebendazole .....	24
Praziquantel .....	24
<b>    3.5. Antituberculars .....</b>	<b>25</b>
Ethambutol (EMB) .....	25
Isoniazid (INH) .....	25
Pyrazinamide (PZA) .....	26
Rifabutin .....	26
Rifampin (RIF) .....	26
Rifater <sup>®</sup> .....	27

Rifinah® .....	27
Streptomycin.....	28
<b>3.6. Anti- HIVs .....</b>	<b>29</b>
<b>3.6.1. Integrase Inhibitor .....</b>	<b>29</b>
Raltegravir .....	29
<b>3.6.2. Nucleoside Reverse Transcriptase Inhibitors (NRTI) .....</b>	<b>29</b>
Combivir® .....	29
Kivexa® .....	29
Lamivudine (3-TC).....	29
Zidovudine (AZT) .....	29
Tenofovir.....	30
Truvada® .....	30
<b>3.6.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) .....</b>	<b>31</b>
<b>3.6.4. Protease Inhibitors (PI).....</b>	<b>32</b>
Kaletra® .....	32
<b>3.6.5. NNRTI + NRTI .....</b>	<b>33</b>
Atripla® .....	33
Ganciclovir.....	34
Valganciclovir .....	34
<b>3.8. Anti-Herpetics.....</b>	<b>34</b>
Acyclovir .....	34
Valaciclovir .....	35
<b>3.9. Anti-Influenzas .....</b>	<b>36</b>
Oseltamivir.....	36
<b>3.10. Antivirals .....</b>	<b>36</b>
<b>3.10.1. Hepatitis .....</b>	<b>36</b>
Adefovir dipivoxil .....	36
Interferon Beta-1b .....	36
Lamivudine .....	37
Entecavir .....	37
Peginterferon Alfa-2a .....	37
Peginterferon Alfa-2b .....	38
Ribavirin .....	38
Telbivudine .....	38
<b>3.10.2. Multiple Sclerosis.....</b>	<b>39</b>
Interferon Beta-1b .....	39
<b>3.11. Carbapenems .....</b>	<b>39</b>
Doripenem .....	39

Ertapenem .....	39
Imipenem and Cilastatin.....	40
Meropenem .....	40
<b>3.12. Cephalosporins .....</b>	<b>41</b>
<b>3.12.1. 1st Generations .....</b>	<b>41</b>
Cefadroxil .....	41
Cefazolin .....	41
Cephalexin .....	42
<b>3.12.2. 2nd Generations .....</b>	<b>42</b>
Cefmetazole .....	42
Cefuroxim .....	42
<b>3.12.3. 3rd Generations .....</b>	<b>43</b>
Cefixime.....	43
Cefotaxime.....	43
Ceftazidime .....	44
Ceftriaxone.....	44
Flomoxef .....	45
<b>3.12.4. 4th Generations .....</b>	<b>45</b>
Cefepime.....	45
<b>3.13. Penicillins .....</b>	<b>46</b>
<b>3.13.1. Natural Penicillins .....</b>	<b>46</b>
Penicillin G Sodium .....	46
<b>3.13.2. Antistaphylococcal Penicillins .....</b>	<b>46</b>
Dicloxacillin .....	46
Oxacillin .....	47
<b>3.13.3. Aminopencillins .....</b>	<b>47</b>
Amoxicillin .....	47
Ampicillin .....	47
Amoxicillin and Clavulanic acid.....	48
Subacillin <sup>®</sup> (Unasyn) .....	49
<b>3.13.4. Antipseudomonal Penicillins .....</b>	<b>49</b>
Piperacillin .....	49
Tapimycin <sup>®</sup> .....	50
<b>3.14. Quinolones.....</b>	<b>50</b>
Ciprofloxacin .....	50
Levofloxacin .....	51
Moxifloxacin.....	51
<b>3.15. Macrolides .....</b>	<b>52</b>
Azithromycin .....	52
Clarithromycin.....	52

Erythromycin .....	53
<b>3.16. Sulfonamides .....</b>	<b>53</b>
Sulfamethoxazole-Trimethoprim (SMZ-TMP) .....	53
<b>3.17. Tetracyclines .....</b>	<b>54</b>
Doxycycline .....	54
Minocycline .....	54
<b>3.18. Antimicrobial Miscellaneous .....</b>	<b>55</b>
Clindamycin.....	55
Colistin.....	55
Daptomycin .....	56
Fusidic acid .....	56
Linezolid .....	56
Metronidazole .....	57
Teicoplanin.....	57
Tigecycline.....	58
Vancomycin .....	58
<b>4. ANTINEOPLASTIC AGENTS.....</b>	<b>60</b>
<b>4.1. Chemo therapy.....</b>	<b>60</b>
<b>4.1.1. Alkylating Agents .....</b>	<b>60</b>
Carboplatin.....	60
Chlorambucil .....	60
Cisplatin .....	60
Cyclophosphamide .....	61
Dacarbazine .....	61
Estramustine .....	61
Ifosfamide .....	62
Melphalan .....	62
Oxaliplatin .....	62
Temozolomide .....	63
<b>4.1.2. Antimetabolites .....</b>	<b>63</b>
Capecitabine .....	63
Cytarabine .....	63
Fludarabine .....	64
Fluorouracil (5-FU) .....	64
Gemcitabine .....	64
Mercaptopurine (6-MP).....	65
Methotrexate .....	65
Ufur <sup>®</sup> .....	66
Pemetrexed.....	66
TS-1 <sup>®</sup> .....	66
<b>4.1.3. Antibiotics .....</b>	<b>67</b>

Bleomycin .....	67
Doxorubicin .....	67
Doxorubicin liposomal .....	67
Epirubicin.....	68
Hydroxyurea .....	68
Idarubicin .....	69
Mitomycin.....	69
Mitoxantrone.....	69
<b>4.1.4. Vinca Alkaloids.....</b>	<b>70</b>
Docetaxel .....	70
Etoposide .....	70
Paclitaxel.....	71
Vinblastine .....	71
Vincristine .....	71
Vinorelbine.....	72
<b>4.1.5. Proteasome Inhibitor Miscellaneous.....</b>	<b>72</b>
Asparaginase.....	72
All-trans-retinoic acid (Tretinoin).....	72
Irinotecan .....	73
Topotecan.....	73
Thalidomide .....	74
<b>4.2. Hormone Antagonists.....</b>	<b>74</b>
<b>4.2.1 Antiandrogen.....</b>	<b>74</b>
Bicalutamide .....	74
Cyproterone .....	74
Flutamide .....	75
<b>4.2.2 Antiestrogens.....</b>	<b>75</b>
Tamoxifen .....	75
<b>4.2.3. Gonadotropine-Releasing Hormone Analogs .....</b>	<b>75</b>
Goserelin .....	75
Leuprolide depot.....	75
Leuprolide acetate .....	76
<b>4.2.4. Progestins.....</b>	<b>76</b>
Megestrol .....	77
<b>4.2.5. Aromatase Inhibitors .....</b>	<b>77</b>
Anastrozole .....	77
Letrozole .....	77
Exemestane .....	77
<b>4.3. Target therapy .....</b>	<b>78</b>
<b>4.3.1. Monoclonal Antibodies .....</b>	<b>78</b>

Bevacizumab.....	78
Cetuximab .....	78
Pertuzumab .....	78
Rituximab.....	79
Trastuzumab.....	79
<b>4.3.2. Protein-Tyrosine Kinase Inhibitors .....</b>	<b>80</b>
Afatinib .....	80
Axitinib .....	80
Crizotinib .....	80
Dasatinib .....	81
Erlotinib .....	81
Gefitinib .....	81
Imatinib .....	82
Lapatinib .....	82
Pazopanib .....	82
Regorafenib.....	83
Sorafenib .....	83
Sunitinib.....	84
<b>4.3.3. Proteasome Inhibitor .....</b>	<b>84</b>
Bortezomib.....	84
<b>4.3.4. mTOR Kinase Inhibitor .....</b>	<b>84</b>
Everolimus .....	85
<b>4.4. Antineoplastic Miscellaneous.....</b>	<b>85</b>
Concentrated fermented soy milk .....	85
Drug eluting microsphere.....	85
Mesna.....	86
Polysaccharide-K (Kawartake) .....	86
Picibanil <sup>®</sup> (OK-432) .....	86
Trastuzumab emtansine .....	87
<b>5. Biologic and Immunologic Agents .....</b>	<b>88</b>
<b>5.1. Vaccines-virus.....</b>	<b>88</b>
自費疫苗 .....	88
Hepatitis A vaccine .....	88
Hepatitis B vaccine.....	88
Influenza virus vaccine.....	88
Pneumococcal vaccine polyvalent .....	88
Pneumococcal 13-valent conjugate vaccine .....	89
Varicella virus vaccine.....	89
Zoster virus vaccine.....	89
Quadrivalent human papillomavirus .....	89
Human Papillomavirus Vaccine Types16/18 .....	90

Rotavirus vaccine .....	90
Pneumococcal vaccine polyvalent .....	91
<b>公費疫苗 .....</b>	<b>92</b>
<b>5.2. Toxoids .....</b>	<b>93</b>
Tetanus toxoid.....	93
<b>5.3. Antitoxins and Antivenins .....</b>	<b>93</b>
Antivenin of <i>A. acutus</i> .....	93
Antivenin polyvalent hemorrhagic .....	93
Antivenin polyvalent neurotropic .....	93
<b>5.4. Immune Globulins .....</b>	<b>94</b>
Antithymocyte immunoglobulin (rabbit).....	94
Cytomegalovirus immune globulin (human).....	94
Hepatitis B immune globulin (HBIG) .....	95
Immune globulin (Human) (IVIG) .....	95
Gammaglobulin .....	96
Tetanus Immune Globulin (TIG) .....	96
<b>5.5. Immunologic Agents .....</b>	<b>97</b>
Abatacept .....	97
Adalimumab .....	97
Azathioprine .....	98
Basiliximab .....	98
Cyclosporine .....	98
Everolimus .....	99
Golimumab .....	99
Hydroxychloroquine.....	100
Leflunomide.....	100
Mycophenolate acid.....	100
Mycophenolate mofetil.....	101
Palivizumab .....	101
Penicillamine .....	101
Sirofimab .....	102
Tacrolimus .....	102
Tocilizumab .....	103
Ustekinumab .....	103
<b>5.6. Biologic and Immunologic Miscellaneous.....</b>	<b>104</b>
HTK solution .....	104
<b>6. CARDIOVASCULAR.....</b>	<b>105</b>
<b>6.1. Cardiac Glycosides .....</b>	<b>105</b>
Digoxin .....	105
<b>6.2. Antiarrhythmic Agents .....</b>	<b>105</b>
6.2.1. Class I-B .....	105

Lidocaine .....	105
Mexiletine .....	106
Phenytoin (Diphenylhydantoin) .....	106
6.2.2. Class I-C .....	106
Propafenone .....	106
6.2.3 Class II.....	107
Propranolol.....	107
6.2.4 Class III.....	107
Amiodarone .....	107
Dronedarone .....	108
6.2.5. Class IV .....	108
Diltiazem.....	108
Verapamil .....	109
6.2.6 Antiarrhythmic Miscellaneous .....	109
Adenosine .....	109
6.3. Calcium Channel Blocking Agents.....	110
6.3.1. Dihydropyridines.....	110
Amlodipine .....	110
Amtrel <sup>®</sup> .....	110
Caduet <sup>®</sup> .....	110
Exforge <sup>®</sup> .....	111
Exforge HCT <sup>®</sup> .....	111
Lacidipine .....	111
Nicardipine.....	111
Nifedipine .....	111
Nimodipine .....	112
Sevikar <sup>®</sup> .....	112
6.3.2. Non-Dihydropyridines.....	113
Diltiazem.....	113
Verapamil .....	113
6.4. Vasodilators .....	113
6.4.1. Organic Nitrates .....	113
Isosorbide dinitrate .....	113
Isosorbide -5- mononitrate .....	113
Nitroglycerin.....	113
Nitroglycerin and 5% Dextrose.....	114
6.4.2 Peripheral Vasodilators.....	114
Hydralazine.....	114
Minoxidil .....	115
6.4.3 Other vasodilators .....	115

Nicorandil .....	115
<b>6.5. Antiadrenergics and Sympatholytics .....</b>	<b>115</b>
<b>6.5.1. Beta-Blockers.....</b>	<b>115</b>
Atenolol.....	115
Bisoprolol.....	116
Propranolol.....	116
<b>6.5.2. Alpha and Beta Blocker Agents .....</b>	<b>116</b>
Carvedilol.....	116
Labetalol .....	116
<b>6.5.3. Alpha-adrenergic Blockers .....</b>	<b>117</b>
Alfuzosin.....	117
Doxazosin .....	117
Silodosin .....	117
Tamsulosin .....	117
<b>6.5.4. Alpha-2Adrenergic Agents .....</b>	<b>117</b>
Clonidine.....	117
<b>6.6. Angiotensin-Converting Enzyme Inhibitors.....</b>	<b>118</b>
Captopril .....	118
Enalapril.....	118
Fosinopril .....	118
Amtrel <sup>®</sup> .....	119
<b>6.7. Angiotensin II Receptor Antagonists .....</b>	<b>119</b>
Exforge <sup>®</sup> .....	119
Exforge HCT <sup>®</sup> .....	119
Hyzaar <sup>®</sup> .....	119
Irbesartan .....	119
Olmesartan .....	120
Sevikar <sup>®</sup> .....	120
Valsartan.....	120
<b>6.8. Direct Renin Inhibitor .....</b>	<b>120</b>
Aliskiren.....	121
<b>6.9. Alpha-adrenergic agonists .....</b>	<b>121</b>
Methyldopa anhydrous .....	121
<b>6.10.Antihyperlipidemic Agents .....</b>	<b>121</b>
<b>6.10.1. HMG-CoA Reductase Inhibitors.....</b>	<b>121</b>
Atorvastatin.....	121
Caduet <sup>®</sup> .....	122
Fluvastatin .....	122
Linicor F.C.T <sup>®</sup> .....	122
Pravastatin .....	122

Rosuvastatin.....	123
Vytorin® .....	123
<b>6.10.2 Fibric Acid Derivatives.....</b>	<b>123</b>
Choline fenofibrate.....	123
Fenofibrate .....	124
Gemfibrozil.....	124
<b>6.10.4. Cholesterol Absorption Inhibitor.....</b>	<b>124</b>
Ezetimibe .....	124
Vytorin® .....	125
<b>6.11 Vasopressors .....</b>	<b>125</b>
Dobutamine.....	125
Dopamine.....	125
Ephedrine.....	126
Epinephrine.....	126
Isoproterenol .....	127
Norepinephrine .....	127
<b>6.12. Cardiovascular Miscellaneous.....</b>	<b>128</b>
Alprostadol .....	128
Ivabradine .....	129
Levosimendan.....	129
Milrinone .....	130
<b>7. DERMATOLOGYS.....</b>	<b>131</b>
<b>7.1. Acne Preparations .....</b>	<b>131</b>
Adapalene .....	131
Benzoyl Peroxide.....	131
Clindamycin.....	131
Isotretinoin .....	131
Tazarotene .....	132
<b>7.2 Antiseptics and Germicides.....</b>	<b>132</b>
Povidone iodine .....	132
<b>7.3. Anti-Infective Agents .....</b>	<b>133</b>
Acyclovir .....	133
Amorolfine.....	133
Biomycin® .....	133
Butenafine .....	134
Clotrimazole .....	134
Fradiomycin .....	134
Fusidic acid .....	134
Gentamicin.....	134
Ketoconazole .....	135
Metronidazole .....	135

Pasca <sup>®</sup> .....	135
Polyphenon E.....	136
Sulconazole.....	136
<b>7.4. Antipsoriatics .....</b>	<b>136</b>
Acitretin .....	136
Calcipotriol .....	137
Betamethasone and Calcipotriol .....	137
Methoxsalen.....	137
<b>7.5. Anti-Hemorrhoid Agents .....</b>	<b>138</b>
Posuline <sup>®</sup> .....	138
Xylmol <sup>®</sup> .....	138
<b>7.6. Alopecias .....</b>	<b>139</b>
Finasteride .....	139
Minoxidil .....	139
<b>7.7. Anti-Pruritus .....</b>	<b>140</b>
Sinbaby Lotion <sup>®</sup> .....	140
C.B. <sup>®</sup> .....	140
Doxepin.....	140
<b>7.8. Atopic Dermatitis .....</b>	<b>140</b>
Pimecrolimus .....	141
Tacrolimus .....	141
<b>7.9. Burn Preparations .....</b>	<b>141</b>
Silver sulfadiazine .....	141
<b>7.10. Corticosteroids .....</b>	<b>142</b>
<b>7.10.1 Single Preparations .....</b>	<b>142</b>
Betamethasone.....	142
Clobetasol .....	142
Clobetasone.....	142
Diflucortolone.....	143
Fluocinonide .....	143
Sensation of burning of skin .....	143
Fluticasone .....	143
Hydrocortisone .....	143
Mometasone.....	144
<b>7.10.2. Mixed Preparations .....</b>	<b>144</b>
Flucort-F <sup>®</sup> .....	144
Ecosone <sup>®</sup> .....	144
<b>7.11. Keratolytic Agents .....</b>	<b>145</b>
Duofilm <sup>®</sup> .....	145
Salicylic acid.....	145

Ureson® .....	145
<b>7.12. Scabicides and Pediculicides .....</b>	<b>145</b>
Benzyl benzoate.....	145
Ulex® .....	146
<b>7.13. Obstetrics Preparations .....</b>	<b>146</b>
Clotrimazole .....	146
Dinoprostone (PGE2) .....	146
Estradiol .....	147
Estrogens conjugated.....	147
Policresulen.....	147
<b>7.14. Dermatology Miscellaneous.....</b>	<b>148</b>
Antiscar® .....	148
Cadexomeriodine .....	148
Heparinoid .....	148
Hydroquinone .....	148
Zinc oxide .....	149
<b>8. GASTROENTEROLOGY.....</b>	<b>150</b>
<b>8.1. Antacids and Antiflatulents .....</b>	<b>150</b>
Algitab® .....	150
Aluzaine® .....	150
Dried Aluminum hydroxide Gel .....	150
Dimethicone.....	150
Lederscon® .....	151
Magnesium oxide .....	151
Peichia® .....	152
Strocain® .....	152
<b>8.2. Antidiarrheals .....</b>	<b>152</b>
Diocatahedral.....	152
Loperamide .....	153
Nifuroxazide .....	153
<b>8.3. Antiemetics .....</b>	<b>153</b>
Aprepitant .....	153
Fosaprepitant.....	153
Diphenidol .....	154
Meclizine .....	154
Granisetron.....	155
Palonosetron .....	155
<b>8.4. Antiulcers .....</b>	<b>155</b>
8.4.1.H <sub>2</sub> -Blockers.....	156
Cimetidine.....	156
Famotidine .....	156

Ranitidine.....	156
8.4.2. Proton Pump Inhibitors(PPI) .....	157
Esomeprazole.....	157
Dexlansoprazole .....	158
Pantoprazole .....	158
Rabeprazole .....	158
8.4.3. Antiulcer Miscellaneous .....	159
Bismuth Subcarbonate.....	159
Misoprostol (PGE1).....	159
Sucralfate .....	160
8.5. Digestive Enzymes .....	160
Biotase <sup>®</sup> .....	160
Lactobacillus.....	160
Pancrelipase .....	160
8.6. Gastrointestinal Stimulants .....	161
Domperidone .....	161
Metoclopramide.....	161
Mosapride .....	162
8.7. Laxatives .....	162
Bisacodyl .....	162
SlipFeel <sup>®</sup> .....	163
GI Klean powder <sup>®</sup> .....	164
Lactulose .....	164
Magnesium citrate .....	165
Normacol <sup>®</sup> .....	165
8.8. Antidiobesity Agents.....	166
Orlistat.....	166
8.9. Spasmolytics.....	166
Atropine .....	166
Hyoscyamine .....	167
Otilonium bromide .....	167
Pinaverium .....	168
Scopolamine bromobutylate.....	168
8.10. Inflammatory Bowel Disease .....	168
Hydrocortisone .....	168
Mesalazine .....	169
Sulfasalazine .....	169
8.11. Gastroenterology Miscellaneous.....	170
Flopropione .....	170
Gabexate mesilate.....	170
Glutathione.....	170

Glycyrrhizin .....	171
Lanreotide Autogel .....	171
Octreotide.....	171
Silymarin.....	172
Somatostatin .....	172
Sulpiride.....	173
Terlipressin.....	173
Ursodeoxycholic acid .....	174
<b>9. HEMATOLOGYS.....</b>	<b>175</b>
9.1. Anticoagulants .....	175
Dabigatran.....	175
Heparin.....	175
Rivaroxaban .....	176
Warfarin .....	177
9.2. Anticoagulants (low-molecular-weight heparin) ....	177
Enoxaparin .....	177
Tinzaparin .....	177
9.3. Antiplatelet Agents.....	178
9.3.1. Aggregation Inhibitors.....	178
Anagrelide .....	178
Aspirin.....	178
Cilostazol .....	179
Clopidogrel .....	179
Dipyridamole .....	180
Tirofiban.....	180
9.3.2. Antianemics .....	181
Ferric chloride hexahydrate.....	181
Ferric hydroxide polymaltose .....	181
Folic acid.....	181
Hydroxocobalamin .....	182
Leucovorin calcium (Calcium folinate).....	182
9.4. Antihemophilic Agents.....	183
9.4.1. Antihemophilic Factors .....	183
Antihemophilic factor VIII (recombinant) .....	183
9.4.2. Heparin Antagonists .....	183
Protamine .....	183
9.4.3. Warfarin Antagonists .....	184
Phytomenadione (Vitamin K1) .....	184
9.5. Hematopoietic Agents.....	184
9.5.1. Recombinant Human Erythropoietins .....	184

Darbepoetin alfa .....	184
Epoetin beta .....	184
Methoxypolyethylene (glycol-epoetin beta).....	185
<b>9.5.2. Colony Stimulating Factors .....</b>	<b>185</b>
Human granulocyte colony stimulating factor (G-CSF) 185	
Pegfilgrastim.....	186
<b>9.6. Hemorrheologic Agents .....</b>	<b>186</b>
Cinnarizine.....	186
Flunarizine .....	187
Nicergoline.....	187
Piracetam .....	187
<b>9.7. Hemostatics .....</b>	<b>188</b>
Pentoxifylline.....	188
Tranexamic acid.....	188
<b>9.8. Plasma Expanders .....</b>	<b>188</b>
Albumin .....	188
Dextran low molecule 40 .....	189
Tetraspan (HES) <sup>®</sup> .....	189
<b>9.9. Thrombolytic Agents .....</b>	<b>190</b>
Alteplase, tissue plasminogen activator (t-PA).....	190
Urokinase.....	191
<b>10. DIAGNOSTIC AGENTS.....</b>	<b>192</b>
<b>10.1. Adrenocortical Insufficiencies.....</b>	<b>192</b>
Cortisone.....	192
<b>10.2. Liver Functions.....</b>	<b>192</b>
Indocyanine green (ICG).....	192
Gadoxetic acid .....	192
<b>10.3. Myasthenia Gravis .....</b>	<b>193</b>
Neostigmine .....	193
<b>10.4. Skin Test .....</b>	<b>193</b>
Penicillin skin test.....	193
Tuberculin Purified Protein Derivative (PPD) .....	193
<b>10.5. Thyroid Functions .....</b>	<b>193</b>
Thyrotropin alfa.....	194
<b>10.6. Thallium Myocardial Perfusion Scintigraphy.....</b>	<b>194</b>
Adenosine .....	194
Dipyridamole .....	194
<b>10.7. Radiopaque Contrast Agents .....</b>	<b>194</b>
10.7.1. Iodinated-Ionics.....	194
Sodium and meglumine ioxitalamate .....	195

10.7.2. Iodinated-Non-Ionics .....	195
Iodixanol .....	195
Iohexol .....	195
Iopamidol .....	196
Iopromide.....	196
10.7.3. Oily Contrast Mediums .....	196
Ethiodized oil.....	196
10.7.4. Contrast Mediums for MRI.....	197
Gadobenate dimeglumine.....	197
Gadobutrol .....	197
Gadodiamide.....	198
Gadoxetic acid .....	198
10.8. Radiopaque Miscellaneous.....	198
Fluorescein sodium.....	198
Gonadorelin .....	198
Patent blue-V .....	199
<b>11. ENDOCRINE AND METABOLIC .....</b>	<b>200</b>
11.1. Estrogens .....	200
Estradiol .....	200
Estrogens conjugated.....	200
11.2. Selective Estrogen Receptor Modulators .....	200
Raloxifene .....	200
11.3. Progestins .....	201
Hydroxyprogesterone caproate .....	201
Levonorgestrel .....	201
Medroxyprogesterone.....	202
Progesterone .....	202
11.4. Estrogen and Progestin Combination.....	203
Diane-35 <sup>®</sup> .....	203
Premelle Lite <sup>®</sup> .....	203
Tibolone .....	203
YAZ <sup>®</sup> .....	203
11.5. Ovulation Stimulants.....	204
Choriogonadotropin alfa ( $\gamma$ -hCG) .....	204
Clomiphene .....	204
Follitropin alfa .....	204
Follitropin beta .....	205
Gonadorelin .....	205
Menopur <sup>®</sup> .....	206
11.6. Androgens.....	206
Abiraterone .....	206

Methyltestosterone .....	206
Testosterone .....	207
<b>11.8. Antigonadotropics .....</b>	<b>207</b>
Ganirelix .....	207
Gestrinone .....	208
<b>11.9. Antiandrogen Hormomes .....</b>	<b>208</b>
Dutasteride .....	208
Finasteride.....	208
<b>11.10. Growth Hormone .....</b>	<b>209</b>
Somatropin.....	209
<b>11.11. Abortifacients .....</b>	<b>209</b>
Dinoprostone (PGE2) .....	209
Mifepristone (RU486) .....	210
Misoprostol (PGE1).....	210
<b>11.12. Uterotonics.....</b>	<b>210</b>
Ergometrine .....	210
Methylergometrine .....	210
Oxytocin.....	210
<b>11.13. Uterine Relaxants .....</b>	<b>211</b>
Ritodrine .....	211
<b>11.14. Hyperprolactinemias .....</b>	<b>211</b>
Cabergoline .....	211
<b>11.15. Bisphosphonates .....</b>	<b>212</b>
Clodronate .....	212
Fosamax plus <sup>®</sup> .....	212
Ibandronate .....	212
Zoledronic acid .....	213
<b>11.16. Antidiabetic Agents .....</b>	<b>214</b>
<b>11.16.1. Insulins .....</b>	<b>214</b>
Humalog Mix <sup>®</sup> 50(Rapid-intermediate acting) .....	215
Insulin aspart (Rapid-acting).....	215
Insulin detemir (Intermediate-acting) .....	215
Insulin glargine (Long-acting) .....	216
NovoMix <sup>®</sup> 30 flexpen(Rapid-intermediate acting) .....	216
NPH (Isophane insulin suspension) (Intermediate-acting)..	217
Regular Insulin (Neutral) (Short-acting) .....	217
<b>11.16.2. Sulfonylureas.....</b>	<b>218</b>
Amaryl M <sup>®</sup> .....	218
Gliclazide .....	218
Glimepiride .....	218

Glipizide.....	218
11.16.3. Meglitinides.....	219
Repaglinide .....	219
11.16.4. Alpha-Glucosidase Inhibitors.....	219
Acarbose .....	219
11.16.5. Biguanides.....	219
Actosmet® .....	219
GalvusMet® .....	219
Metformin .....	220
11.16.6. Thiazolidinediones.....	220
Actosmet® .....	220
Pioglitazone .....	220
11.16.7. Antihypoglycemics .....	221
Glucagon .....	221
11.16.8. Dipeptidyl Peptidase 4 Inhibitors .....	221
GalvusMet® .....	221
Sitagliptin.....	222
Saxagliptin .....	222
Vildagliptin .....	222
11.16.9. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist .....	223
Exenatide .....	223
Liraglutide.....	223
11.16.10. Sodium-Glucose Cotransporter 2(SGLT2) inhibitor .....	224
Dapagliflozin .....	224
Empagliflozin .....	224
11.17. Adrenocortical Steroids .....	224
Cortisone.....	224
Dexamethasone.....	225
Fludrocortisone .....	225
Hydrocortisone .....	226
Methylprednisolone .....	226
Prednisolone .....	227
Triamcinolone .....	228
11.18. Gout Related Agents .....	228
Allopurinol.....	228
Benzbromarone.....	229
Colchicine .....	229
Febuxostat.....	229

11.19. Thyroid Agents.....	230
11.19.1. Thyroid Hormones.....	230
Levothyroxine.....	230
11.19.2. Antithyroid Drugs.....	230
Methimazole .....	230
Propylthiouracil .....	231
11.19.3. Iodine Products.....	231
Lugol's solution .....	231
11.20. Posterior Pituitary Hormones .....	231
Desmopressin (DDAVP) .....	231
Vasopressin .....	232
11.21. Calcitonin-Salmon .....	233
Calcitonin.....	233
11.22. Parathyroid Hormone Analogues .....	233
Teriparatide .....	233
11.23. Endocrine and Metabolic Miscellaneous .....	233
Strontium.....	234
Denosumab .....	234
<b>12. NEUROLOGYS .....</b>	<b>235</b>
12.1 Anticonvulsants .....	235
Carbamazepine .....	235
Clonazepam .....	235
Diazepam .....	236
Levetiracetam .....	236
Oxcarbazepine .....	237
Phenytoin (Diphenylhydantoin) .....	238
Phenobarbital .....	238
Valproic acid .....	239
12.2. Adjuvant Anticonvulsants .....	239
Gabapentin .....	239
Lamotrigine.....	240
Topiramate .....	241
Vigabatrin.....	241
12.3. Skeletal Muscle Relaxants .....	242
Baclofen .....	242
Methocarbamol .....	242
Tizanidine .....	243
12.4. Migraines.....	243
Dihydroergotamine.....	243
Sumatriptan.....	243

<b>12.5. Parkinsonian Agents.....</b>	<b>244</b>
Amantadine.....	244
Biperiden.....	244
Entacapone.....	245
Levodopa and Benserazide.....	245
Carbidopa and Levodopa .....	245
Levodopa and Carbidopa and Entacapone .....	246
Trihexyphenidyl.....	246
Rasagiline.....	247
<b>12.6. Dopaminergics .....</b>	<b>247</b>
Pramipexole .....	247
Ropinirole .....	248
Rotigotine.....	248
<b>12.7. Myasthenias .....</b>	<b>249</b>
Pyridostigmine.....	249
<b>12.8. Amyotrophic lateral sclerosis (ALS) .....</b>	<b>249</b>
Riluzole.....	249
<b>12.9. Neuromuscular blockers.....</b>	<b>249</b>
Botulinum Toxin Type A .....	250
<b>12.10. Alzheimer's Disease.....</b>	<b>250</b>
Donepezil .....	250
Memantine .....	250
Rivastigmine .....	251
<b>12.11. Antivertigo Preparations .....</b>	<b>251</b>
Betahistine .....	251
Cinnarizine.....	252
Diphenidol .....	252
Flunarizine .....	252
Meclizine .....	252
<b>13. NUTRIENTS AND NUTRITIONAL AGENTS .....</b>	<b>253</b>
<b>13.1. Electrolytes .....</b>	<b>253</b>
5% Dextrose.....	253
10% Dextrose.....	253
50% Dextrose.....	253
0.9% NaCl+5% Dextrose .....	253
0.225% NaCl+5% Dextrose .....	253
0.45% NaCl.....	253
0.45% NaCl+2.5% .....	254
Dextrose .....	254
0.9% NaCl.....	254
0.9% NaCl irrigation .....	254

3% NaCl.....	254
23.5% NaCl.....	254
Lactated Ringer.....	254
Water for injection .....	254
Sterile water for irrigation .....	255
Calcium chloride.....	256
Calcium polystyrene sulfonate .....	256
Magnesium sulfate ( $MgSO_4$ ).....	257
Potassium chloride.....	257
Potassium chloride solution (ready-to-use) .....	257
Potassium phosphate .....	258
Sodium bicarbonate .....	259
Trace element <sup>®</sup> .....	259
<b>13.2. Amino Acids .....</b>	<b>260</b>
Alany-glutamine .....	260
Clinimix N9G15E <sup>®</sup> .....	261
Ketosteril <sup>®</sup> .....	261
Oliclinomel N4-550E <sup>®</sup> emulsion .....	262
<b>Amino acid.....</b>	<b>263</b>
Moriamin-SN .....	263
Amiyu .....	263
Aminopoly-H .....	263
Aminosteril-infant .....	263
Aminoplasmal.....	263
<b>13.3. Lipids .....</b>	<b>264</b>
Lipofundin .....	264
Lipovenoes MCT .....	264
<b>13.4. Vitamins .....</b>	<b>264</b>
Alinamin-F <sup>®</sup> 50.....	264
Alpha-Tocopherol acetate (Vitamin E) .....	264
Ascorbic acid (Vitamin C).....	265
Calcitriol (Vitamin D <sub>3</sub> ) .....	265
Mecobalamin (Vitamin B <sub>12</sub> ) .....	265
Multivitamins.....	266
Phytomenadione (Vitamin K <sub>1</sub> ) .....	266
Pyridoxal phosphate (Vitamin B <sub>6</sub> ) .....	267
Vitamin B complex.....	267
<b>13.5. Minerals.....</b>	<b>267</b>
Bio-Cal <sup>®</sup> .....	267
Calcium acetate.....	268
Calcium carbonate .....	268

Lanthanum carbonate hydrate .....	268
Sevelamer carbonate.....	269
Zinc gluconate .....	269
<b>13.6. Nutritional Agents Miscellaneous.....</b>	<b>269</b>
All-right calcium suspension <sup>®</sup> .....	269
<b>14. OPHTHALMOLOGYS.....</b>	<b>271</b>
<b>14.1. Antibacterials .....</b>	<b>271</b>
Chloramphenicol .....	271
Gentamicin.....	271
Levofloxacin .....	271
Moxifloxacin.....	272
Sulfamethoxazole .....	272
Tetracycline.....	272
Tobramycin .....	272
<b>14.2. Antibacterials and Corticosteroids .....</b>	<b>273</b>
Tobradex <sup>®</sup> .....	273
<b>14.3. Corticosteroids .....</b>	<b>273</b>
Fluorometholone (FML) .....	273
Prednisolone .....	273
<b>14.4. Antivirals .....</b>	<b>274</b>
Acyclovir .....	274
<b>14.5. Glaucomas .....</b>	<b>274</b>
<b>14.5.1. Beta-Blockers.....</b>	<b>274</b>
Levobunolol .....	274
<b>14.5.2. Alpha-2-Agonists .....</b>	<b>274</b>
Brimonidine .....	274
<b>14.5.3. Carbonic Anhydrase Inhibitors .....</b>	<b>275</b>
Azarga <sup>®</sup> .....	275
Brinzolamide.....	275
Combigam <sup>®</sup> .....	275
<b>14.5.4. Prostaglandin Agonists.....</b>	<b>276</b>
Bimatoprost.....	276
Travoprost .....	276
<b>14.5.5. Miotics .....</b>	<b>276</b>
Carbachol .....	277
Pilocarpine .....	277
<b>14.6. Mydriatics and Cycloplegics .....</b>	<b>277</b>
Atropine sulphate.....	277
Cyclopentolate .....	277
Mydrin-P <sup>®</sup> .....	278

Phenylephrine .....	278
Tropicamide .....	278
<b>14.7. Cataracts .....</b>	<b>279</b>
Azapentacene .....	279
<b>14.8. Ocular Decongestants and Anti-Allergys .....</b>	<b>279</b>
Cromolyn .....	279
Cyanocobalamin (Vitamin B <sub>12</sub> ).....	279
Emedastine.....	280
Olopatadine.....	280
<b>14.9. Dry Eye Products.....</b>	<b>280</b>
Carbomer .....	280
Duratears® .....	280
Optive® .....	280
Propylene glycol .....	281
Tears naturale® .....	281
Tears naturale® Free .....	281
<b>14.10. Ophthalmology Miscellaneous .....</b>	<b>282</b>
Aflibercept .....	282
BSS® .....	282
BSS® plus.....	282
Cyclosporine .....	283
Proparacaine .....	283
Ranibizuma .....	283
<b>15. PSYCHIATRYS .....</b>	<b>285</b>
<b>15.1. Antidepressants .....</b>	<b>285</b>
15.1.1. Tricyclic-Tertiary Amines (TCA).....	285
Amitriptyline.....	285
Imipramine.....	285
15.1.2. Serotonin-Norepinephrine Reuptake Inhibitors .....	285
Atomoxetine .....	285
Duloxetine.....	286
Venlafaxine .....	286
15.1.3. Selective Serotonin Reuptake Inhibitors (SSRI) .....	287
Escitalopram .....	287
Paroxetine .....	287
Sertraline .....	287
15.1.4. 5-HT <sub>2</sub> Receptor Antagonists .....	288
Trazodone .....	288

15.1.5. Alpha-2 Antagonist.....	288
Mirtazapine .....	288
15.1.6. Dopamine Reuptake Inhibitors .....	288
Bupropion .....	288
15.2. Antipsychotic Agents .....	288
15.2.1. Phenothiazine Derivatives .....	289
Prochlorperazine.....	289
15.2.2. Benzisothiazoyl Piperazine Derivatives .....	289
Ziprasidone .....	289
15.2.3. Thioxanthene Derivatives .....	289
Deanxit® .....	289
15.2.4. Phenylbutylpiperadine Derivatives .....	290
Haloperidol .....	290
15.2.5. Dibenzzapine Derivatives.....	290
Clozapine .....	290
Quetiapine .....	290
Zotepine .....	291
15.2.6. Benzisoxazole Derivatives.....	291
Paliperidone .....	291
Risperidone .....	292
15.2.7. Thienobenzodiazepine Derivatives .....	292
Olanzapine .....	292
15.2.8. Selective D <sub>2</sub> Antagonists.....	293
Amisulpride .....	293
Sulpiride.....	293
15.2.9. Quinolinone Derivatives.....	293
Aripiprazole .....	294
15.3. Sedatives and Hypnotics .....	294
15.3.1. Barbiturates .....	294
Phenobarbital .....	294
15.3.2. Non-Barbiturates .....	295
Hydroxyzine .....	295
Zaleplon .....	295
15.3.3. Benzodiazepines.....	295
Alprazolam.....	296
Diazepam .....	296
Estazolam.....	296
Fludiazepam.....	296
Lorazepam .....	296
Midazolam .....	297

Triazolam .....	297
15.3.4. Sedative and Hypnotics Miscellaneous .....	297
Buspirone .....	297
15.4. Antimanic Agents.....	298
Carbamazepine .....	298
Lamotrigine.....	298
Lithium.....	298
15.5. Sympathomimetics and Anorexiants.....	298
Midodrine.....	298
Methylphenidate .....	299
Modafinil .....	299
15.6. Smoking Deterrents .....	299
Nicotine patch.....	299
Varenicline .....	300
<b>16. RENAL AND GENITOURINARY AGENTS.....</b>	<b>301</b>
16.1. Impotence Agents .....	301
16.1.1. Phosphodiesterase-5 inhibitor.....	301
Sildenafil .....	301
Tadalafil .....	301
Vardenafil.....	301
16.1.2. Impotence Miscellaneous .....	302
Dapoxetine .....	302
16.2. Urinary Alkalizers .....	302
Potassium citrate.....	302
16.3. Benign Prostatic Hyperplasias (BPH).....	303
16.3.1. Alpha-adrenergic Blockers.....	303
Alfuzosin.....	303
Doxazosin .....	303
Silodosin .....	303
Tamsulosin .....	304
16.3.2. 5-Alpha Reductase Inhibitor .....	304
Dutasteride .....	304
Finasteride.....	304
16.4. Bladder Spasms .....	305
16.4.1. Cholinergics .....	305
Bethanechol .....	305
16.4.2. Antimuscarinics .....	305
Propiverine.....	305
Solifenacin .....	305
Tolterodine .....	305

16.4.3. Bladder Spasm Miscellaneous .....	306
Imipramine.....	306
<b>16.5. Diuretics .....</b>	<b>306</b>
<b>16.5.1. Thiazides .....</b>	<b>306</b>
Exforge HCT <sup>®</sup> .....	306
Indapamide.....	306
Trichlormethiazide.....	307
<b>16.5.2. Loop Diuretics.....</b>	<b>307</b>
Bumetanide .....	307
Furosemide.....	307
<b>16.5.3. Potassium-Sparing Diuretics.....</b>	<b>308</b>
Spironolactone .....	308
<b>16.5.4. Carbonic Anhydrase Inhibitors .....</b>	<b>308</b>
Acetazolamide .....	308
<b>16.5.5. Potassium-Sparing diuretics and Thiazides ..</b>	<b>309</b>
Amizide <sup>®</sup> .....	309
<b>16.5.6. Osmotic Diuretics.....</b>	<b>309</b>
Glycetose <sup>®</sup> .....	309
Mannitol.....	309
<b>16.5.7. Diuretic Miscellaneous .....</b>	<b>310</b>
Tolvaptan.....	310
<b>17. RESPIRATORY AGENTS.....</b>	<b>311</b>
<b>17.1. Bronchodilators .....</b>	<b>311</b>
<b>17.1.1. Sympathomimetics Beta-2-Agonists .....</b>	<b>311</b>
Fenoterol .....	311
Indacaterol .....	311
Procaterol .....	311
Salbutamol .....	312
Terbutaline .....	312
<b>17.1.2 Methylxanthiens .....</b>	<b>312</b>
Aminophylline .....	312
Theophylline .....	313
<b>17.1.3. Anticholinergics .....</b>	<b>313</b>
Ipratropium .....	313
Combivent UDV.....	314
Tiotropium .....	314
<b>17.2. Leukotriene Receptor Antagonists .....</b>	<b>314</b>
Montelukast .....	314
<b>17.3. Respiratory Inhalant Products .....</b>	<b>315</b>
<b>17.3.1. Inhaled Steroids.....</b>	<b>315</b>

Budesonide.....	315
Fluticasone .....	315
Mometasone.....	316
Triamcinolone.....	316
<b>17.3.2. Inhaled Steroids and Bronchodilators .....</b>	<b>317</b>
Symbicort® turbuhaler.....	317
Seretide® .....	317
<b>17.3.3. Inhaled Anticholinergic agents and Bronchodilators.....</b>	<b>318</b>
Anoro® ellipta .....	318
<b>17.3.4. Mast Cell Stabilizers.....</b>	<b>318</b>
Cromolyn .....	318
Ketotifen .....	319
<b>17.4. Lung Surfactants .....</b>	<b>319</b>
Beractant .....	319
<b>17.5. Antihistamines .....</b>	<b>319</b>
<b>17.5.1. Sedations .....</b>	<b>319</b>
Chlorpheniramine .....	319
Cyproheptadine.....	320
Dexchlorpheniramine .....	320
Hydroxyzine .....	320
Mequitazine .....	321
<b>17.5.2. Non-Sedations .....</b>	<b>321</b>
Cetirizine.....	321
Levocetirizine .....	321
Loratadine .....	322
LoraPseudo® .....	322
Fexofenadine.....	322
<b>17.5.3. H<sub>1</sub> Antagonist .....</b>	<b>323</b>
Cinnarizine.....	323
<b>17.6. Cold Preparations.....</b>	<b>323</b>
Peace® .....	323
<b>17.7. Antitussives and Expectorants .....</b>	<b>323</b>
Benzonatate.....	323
Consrine® .....	324
Liquid Brown mixture® .....	324
Codicon-U® (Medicon-A).....	324
Medicon® .....	325
Secorine® .....	325
<b>17.8. Mucolytics .....</b>	<b>325</b>

Acetylcysteine.....	325
Ambroxol .....	326
Bromhexine.....	326
Mercaptoethanesulphonate(Mesna) .....	326
<b>17.9. Nasal Decongestants .....</b>	<b>327</b>
Epinephrine .....	327
Oxymetazoline.....	327
<b>17.10. Ear Preparations .....</b>	<b>328</b>
Ofloxacin .....	328
<b>17.11. Mouth and Lip Preparations .....</b>	<b>328</b>
Chlorhexidine .....	328
Dexamethasone.....	328
Pilocarpine .....	329
Triamcinolone .....	329
<b>18. ANTIDOTES .....</b>	<b>330</b>
<b>18.1. For Acetaminophen .....</b>	<b>330</b>
Acetylcysteine.....	330
Charcoal .....	330
Spherical absorptive carbon.....	331
<b>18.2. For Irons .....</b>	<b>331</b>
Deferoxamine .....	331
<b>18.3. For Benzodiazepines .....</b>	<b>332</b>
Flumazenil .....	332
<b>18.4. For High Dose Methotrexate .....</b>	<b>332</b>
Leucovorin calcium (Calcium folinate).....	332
<b>18.5. For Opioids .....</b>	<b>333</b>
Naloxone .....	333
<b>18.6. For Organophosphates .....</b>	<b>334</b>
Pralidoxime (PAM).....	334
<b>18.7. For Anesthesias .....</b>	<b>334</b>
Dantrolene.....	334
<b>18.7. For Methaemoglobininaemia.....</b>	<b>335</b>
Methylthioninium .....	335
<b>18.8. For Anticholinergic syndrome .....</b>	<b>335</b>
Physostigmine.....	335

# 1. ANALGESICS

## 1.1. Narcotics Agonist

### Buprenorphine

C Unsafe<sup>1</sup>

#### Dosage Forms

Temgesic® 0.2mg/sublingual tab <KBUPREN>

#### Use

Long-acting narcotic analgesic effective for moderate-to-severe pain

#### Dose

Children 6-12yrs: **SL** 16-25 kg: 0.1 mg; 25-37.5 kg: 0.1-0.2 mg; 37.5-50 kg: 0.2-0.3 mg q6-8h

Adults and  $\geq$  12 yrs: **SL** 1-2 tab q6-8h

#### Adverse Reactions

Drowsiness, nausea, vomiting, dizziness, sedation, vertigo

#### Precautions

不可咀嚼。

### Codeine

C Safe<sup>1</sup>

#### Dosage Forms

Codeine® 15mg/ml/amp <CCODEIN>

Codeine® 30mg/tab <KCODE01>

#### Use

Analgesia, antitussive

#### Dose

Adults: **PO** 15-60mg q4-6h as needed, **IM/SC** 5-20mg q4-6h

Children: **PO/IM/SC** 0.5mg/kg/dose q4-6h as needed; **max: 60mg/dose**

#### Adverse Reactions

Constipation, nausea, vomiting, drowsiness, sedation, respiratory depression

#### Precautions

Do not administer IV

### Desud Plus ®

C Unsafe<sup>1</sup>

#### Dosage forms

Buprenorphine 8mg and Naloxone 2mg/Sub.tab<KBUPRE1>

#### Use

Opioid dependency

#### Dose

**SL** 12-16mg (Buprenorphine)/day

#### Adverse Reactions

Constipation, sedation, drowsiness, nausea, vomiting

#### Precautions

1.Buprenorphine 會增加總膽內壓力，故膽道功能異常病患需小心使用。

2.Drug-drug interaction: Buprenorphine (Opioids)與 benzodiazepines 併用時會增加鎮靜及致命性呼吸抑制的發生風險，且同時服用這兩種藥物於操作機械或開車時須小心。

## Fentanyl

C<sup>1</sup> Safe<sup>1</sup>

### Dosage Forms

Fentanyl-Fresenius<sup>®</sup> 500mcg/10ml/amp <CFENTAN>

Fentanyl<sup>®</sup> 100mcg/2ml/amp <CFENTA2>

Durogesic D-Trans<sup>®</sup> transdermal 12mcg/hr/patch <WFENTA3>

Fentanyl<sup>®</sup> transdermal 25mcg/hr/patch <WFENTA1>

Painky<sup>®</sup> 200mcg/buccal soluble films < KFENTAN>

### Use

Analgesia

### Dose

**IM/IV** 50-100mcg/dose before surgery

**Transdermal** 12-50mcg/hr, replace patch 72 hrs, dose over 300mcg/hr, may require opiate agonists of administration.

**Transdermal** 25mcg/patch 相當於 **IM** morphine 8-15mg/day 亦相當 **PO** morphine 30-60mg/day

**Painky<sup>®</sup>**: initial 200mcg, if titration required, increase dose in 200 mcg increments once per episode; do not redose within a single episode of breakthrough pain and separate single doses by ≥2 hours

### Adverse Reactions

Confusion, dizziness, sedation, constipation, dry mouth, nausea, vomiting, pruritus, sweating, urinary retention

### Precautions

貼片：門診每次處方限 15 天；口頰錠：門診每次處方限 15 天。

## Meperidine

C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Pethidine<sup>®</sup> 50mg/ml/amp <CMEPERI>

Pethidine<sup>®</sup> 50mg/tab <KMEPERI>

### Use

Analgesia

### Dose

**IM/IV/SC/PO** 50-150mg q3-4h

### Adverse Reactions

Dizziness, sedation, nausea, vomiting, respiratory depression

### Precautions

具活性代謝物易蓄積造成 seizures，老年人及腎功能不佳者應小心使用。

## Morphine

C<sup>4</sup> Safe<sup>1</sup>

### Dosage Forms

Morphine<sup>®</sup> 10mg/ml/amp <CMORPHI>

Morphine<sup>®</sup> 20mg/ml/amp <C20MOR>

Morphine<sup>®</sup> 15mg/tab <KMORPH3>

MST<sup>®</sup> 30mg/tab (controlled release) <KMORPH2>

### Use

Analgesia

### Dose

**IM/SC** 5-20mg q4-6h

**PO** 5-30mg q4h; controlled release: 30mg qd-q12h

#### **Adverse Reactions**

Constipation, nausea, urinary retention, vomiting, dizziness, headache, light-headedness, sedation, weakness

#### **Precautions**

MST<sup>®</sup> controlled release 不宜磨粉。

**B** **Safe<sup>1</sup>**

### **Nalbuphine**

#### **Dosage Forms**

Bain<sup>®</sup> 10mg/ml/amp <CNALBUP>

#### **Use**

Analgesia

#### **Dose**

**IM/IV/SC** 10mg q3-6h

#### **Adverse Reactions**

Dizziness, sedation, nausea, vomiting, sweatiness, histamine release.

**C** **Unknown<sup>1</sup>**

### **Traceton<sup>®</sup>**

#### **Dosage Forms**

1 tab: Tramadol 37.5mg+Acetaminophen 325mg <KULTRAC>

#### **Use**

Acute pain, acute oral surgery pain

#### **Dose**

**PO** 1-2 tab q4-6h; **max: 8 tab/day**

#### **Adverse Reactions**

Anxiety, confusion, fatigue, headache, somnolence

#### **Precautions**

1.肝、腎功能不良(Clcr<30mL/min)者應調降劑量。

2.不建議與其它含有 tramadol 或 acetaminophen 的藥品一起併服。

## **1.2. NSAIDs**

### **1.2.1. Non-COX-2 Selectives**

**C** **Unknown<sup>1</sup>**

### **Diclofenac sodium**

#### **Dosage Forms**

Voren<sup>®</sup> 12.5mg/supp <WDICL02>

#### **Use**

Osteoarthritis, pain, primary dysmenorrhea, rheumatoid arthritis, fever

#### **Dose**

Children: **RECT** 0.5-2mg/kg/day in 2-3 doses

Adults: **RECT** 1-2 supp prn; **max: 150mg/day**

#### **Adverse Reactions**

Skin rash, pruritus, dry skin, and lacrimation

## **Diclofenac potassium**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Voran-K® 25mg/tab <KDICLOF>

### **Use**

Osteoarthritis, pain, primary dysmenorrheal, rheumatoid arthritis, fever

### **Dose**

Adults: **PO** 3-4 tab/day

### **Adverse Reactions**

Skin rash, pruritus, dry skin, lacrimation

## **Etofenamate**

### **Dosage Forms**

Teiria® gel 10%, 40g/tube <WETOGEN>

### **Use**

Inflammation and pain

### **Dose**

**Topical** bid-tid

### **Adverse Reactions**

Pruritus, erythema, local irritation

### **Precautions**

健規：每月至多處方一支；不得併服口服或外用同類之藥品。

## **Flurbiprofen**

**B<sup>1</sup> Safe<sup>5</sup>**

### **Dosage Forms**

Flurbiprofen PAP® patch 14g/patch (3.33mg/g) <WFURBPI>

### **Use**

Relief of local pain and inflammation

### **Dose**

**Transdermal** A replace patch 12hrs

### **Adverse Reactions**

Itching, redness, numbness and tingling at the site of the application

### **Precautions**

健規：每月處方至多 16 片；不得併用口服或外用 NSAID 之藥品。

## **Ibuprofen**

**C<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Ibuprofen® 400mg/tab <KIBUPR1>

Ibuprofen® 1.2g/60ml/bot <KIBUPR2>

### **Use**

Osteoarthritis, pain, primary dysmenorrheal, rheumatoid arthritis, fever

### **Dose**

Children 6 mon-12 yrs: **PO** 5-10mg/kg q6-8h

Adults:

Light to moderate pain: **PO** 400mg q4-6h

Rheumatoid arthritis and osteoarthritis: **PO** 1200-2400mg/day tid-qid

### **Adverse Reactions**

Headache, nervousness, fatigue, itching, rash, urticaria

### Indomethacin

C<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Indoy<sup>®</sup> 25mg/cap <KINDOME>

Indomen<sup>®</sup> 50mg/supp <WINDOME>

#### Use

Management of inflammatory diseases and rheumatoid disorders

#### Dose

PO 25-50mg tid; **max: 200mg/day**

Supp 50mg bid-tid

#### Adverse Reactions

Nausea, vomiting, abdominal pain, constipation, diarrhea, dyspepsia

### Ketorolac

C<sup>1</sup> Safe<sup>1</sup>

#### Dosage Forms

Keto<sup>®</sup> 30mg/ml/amp <CKETORO>

Keto<sup>®</sup> 10mg/cap <KKETORO>

#### Use

Moderately, severe acute pain

#### Dose

Adults and ≥ 16 yrs: IM/IV 30-60mg q6h, **max: 120mg/day**; PO 10 mg q4-6h; **max: 40 mg/day**

#### Adverse Reactions

Peptic ulcers, GI bleeding

#### Precautions

1. 健規：針劑每次不得連續使用超過 5 天，疼痛之短期療法。

2. 老年人及腎功能不佳者應調降劑量。

#### Contraindications

不建議使用於<16 歲的兒童。

### Naproxen

C<sup>1</sup> Safe<sup>1</sup>

#### Dosage Forms

Naposin<sup>®</sup> 250mg/tab <KNAPR01>

#### Use

Rheumatoid arthritis, acute gout, osteoarthritis, dysmenorrheal, fever

#### Dose

PO 250mg tid-qid

#### Adverse Reactions

Dizziness, rash, headache, nervousness, pruritus, rash, tinnitus, edema

## 1.2.2. COX-2 Selectives

### Celecoxib

C<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Celebrex<sup>®</sup> 200mg/cap <KCELECO>

## **Use**

Rheumatoid arthritis, osteoarthritis, dysmenorrhea, postoperative pain

## **Dose**

**PO** 200mg qd-bid

## **Adverse Reactions**

Headache, peripheral edema, insomnia, dizziness, rash

## **Precautions**

Hypertension, CHF, history of liver or renal dysfunction or coagulation defects

## **Etodolac**

**C<sup>5</sup> Unknown<sup>3</sup>**

## **Dosage Forms**

Lacoxa® SR 400mg/tab <KETODO2>

## **Use**

Rheumatoid arthritis, osteoarthritis, gout arthritis

## **Dose**

**PO** 1-2 tab qd; **max: 1200 mg/day**

## **Adverse Reactions**

Headache, peripheral edema, constipation, diarrhea, dyspepsia

## **Precautions**

- 1.嚴重腎病患者須小心使用。
- 2.為緩釋劑型須整顆吞服，不可撥半或咀嚼。
- 3.服藥期間須避免併用酒精性飲料。

## **Etoricoxib**

**C<sup>5</sup> Unknown<sup>3</sup>**

## **Dosage Forms**

Arcoxia® 60mg/tab <KETORIC>

## **Use**

Rheumatoid arthritis, osteoarthritis, gout arthritis

## **Dose**

### Osteoarthritis

**PO** 30-60 mg once daily

### Rheumatoid arthritis

**PO** 90 mg once daily

### Acute gouty arthritis

**PO** 120 mg once daily

## **Adverse Reactions**

Headache, peripheral edema, constipation, diarrhea, dyspepsia, fatigue, insomnia, ALT increased, AST increased

## **Precautions**

有缺血性心臟疾病病史之患者須謹慎使用。

## **Contraindications**

嚴重腎病患者(Clcr <30ml/min)

## **Parecoxib**

**C<sup>5</sup> Unsafe<sup>3</sup>**

## **Dosage Forms**

Dynastat<sup>®</sup> 40mg/vial <CPARECO>

#### Use

Treatment (not more than 4 days) of postoperative pain

#### Dose

IVP/IM(深部肌肉注射) 40mg PRN, followed every 12-24hrs by 20mg as required; max.: **80mg/day**

#### Adverse Reactions

Hypokalemia, insomnia, hypoesthesia, dry socket, back pain

#### Precautions

1. 以 2ml 之 0.9%NaCl、5%Dextrose、0.45%NaCl/5%Dextrose 溶液稀釋，配製後藥液僅供一次使用，已抽取未用完溶液應丟棄，如完全未使用於室溫 25°C 下可存放 12 小時

2. 肝功能不全需調整劑量

#### Contraindications

1. Lactated ringer(造成藥品沉澱)及注射用水(非等張溶液)不宜作為稀釋調配溶液。
2. 不可與 Opioid 類藥物混合給藥。
3. 哺乳及懷孕婦女。

### 1.3. Analgesic Miscellaneous

#### Acetaminophen

**C<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Forms

Depyretin<sup>®</sup> 500mg/tab <KACETA1>

Anti-phen<sup>®</sup> syrup 1440mg/60ml/bot <KACETA2>

#### Use

Relief of mild to moderate pain, fever

#### Dose

Children: PO 10-15mg/kg/dose q4-6h; max: **2.6g/day**

Adults: PO 500mg tid-qid; max: **4g/day**

#### Adverse Reactions

Hypothermia, rash

#### Precautions

Anti-phen<sup>®</sup> 開封後室溫下可放兩個月

#### Glucosamine

**C<sup>1</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Camine<sup>®</sup> 250mg/cap <KGLUCOS>

#### Use

Improvement of symptoms of osteoarthritis

#### Dose

##### Mild or moderate

PO 500mg bid AC for 6wks

##### Severe

PO initial 500mg tid AC for 8 wks, maintenance 500mg bid AC for 3-4

months

### **Adverse Reactions**

Constipation, diarrhea, dyspepsia, nausea, vomiting, peripheral edema, tachycardia, drowsiness, headache, insomnia

### **Precautions**

1. 健保給付每日最大劑量 750mg，增加劑量需事先審查，每一療程最長 12 週。

2. 建議飯前 15 分鐘服藥。

## 2.ANESTHETICS

### 2.1. General Anesthetics

#### Desflurane

B<sup>1</sup> Unknown<sup>1</sup>

##### Dosage Forms

Suprane® 吸入劑 240ml/bot <WDESFLU>

##### Use

Inhalation for induction and maintenance of general anesthesia

##### Dose

Initial 3%, increased in 0.5-1% increments every 2-3 breaths;  
maintenance: 2.5-8.5%

##### Adverse Reactions

Coughing, breathholding, apnea, increased secretions, laryngospasm,  
oxyhemoglobin desaturation, pharyngitis

#### Dexmedetomidine

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Precedex® 200mcg/2ml/vial < CDEXMED >

##### Use

Sedation, intubated/mechanically ventilated ICU patients

##### Dose

###### ICU sedation

Adult: initial, 0.5-1 mcg/kg IV over 10 min; followed by 0.2-0.7 mcg/kg/hr  
continuous **IVF** for a max of 24 hr

###### Procedural sedation

Adult: initial, 0.5-1 mcg/kg IV over 10 min; followed by 0.2-1mcg/kg/hr  
continuous **IVF** for a max of 24 hr

##### Adverse Reactions

Hypotension, nausea, xerostomia, bradycardia

##### Precautions

1. 儲存於15-30°C。
2. 以 NS 稀釋至 50ml，開瓶稀釋後儲存於 2-8°C 勿超過24小時。
- 3.健規：限用於短期可拔管之 18 歲以上外科病患，術後 24 小時內需鎮靜與止痛病患使用，且使用時間不得超過 24 小時。
- 4.全的病患應考慮減低劑量肝功能不。

##### Contraindication

Amphotericin B, diazepam

#### Isoflurane

C<sup>1</sup> Unknown<sup>1</sup>

##### Dosage Forms

Forane® 吸入劑100ml/bot <WISOFLU>

##### Use

Inhalation for induction and maintenance of general anesthesia

##### Dose

Induction: 1.5-3% with oxygen-air mixture  
Maintenance: 1-2.5% with oxygen-air mixture

### Adverse Reactions

Respiratory depression, hypotension, arrhythmias, nausea, vomiting, malignant hyperthermia

## Ketamine

A **Safe<sup>1</sup>**

### Dosage Forms

Ketalar® 500mg/10ml/vial <CKETAMI>

### Use

Induction and maintenance of anesthesia

### Dose

IM 6.5-13mg/kg or IV 1-4.5mg/kg over 60 sec

### Adverse Reactions

Respiratory depression, hypotension, bradycardia, arrhythmia

### Precautions

建議開封或稀釋後 24 小時內使用完畢。

## Midazolam

D **Unknown<sup>1</sup>**

### Dosage Forms

Uzolam® 5mg/ml/amp <CMIDA01>

Midatin® 15mg/3ml/amp <CMIDA02>

### Use

Effective for anesthesia induction sedation

### Dose

#### Induction of anesthesia

Unpremedication IV 0.3-0.35mg/kg(usual total dose ≤ 20mg) over 20-30 sec; **max: 0.6mg/kg**

Premedication IV 0.15-0.2mg/kg(usual total dose ≤ 15mg) over 5-10sec

#### ICU sedation

IV initial 0.03-0.3mg/kg(usual total dose ≤ 15mg); maintenance 0.03-0.2mg/kg/hr

#### Preoperative sedation

IM 0.07-0.1mg/kg (Uzolam® 禁用 IM)

### Adverse Reactions

Hiccoughs, excessive somnolence, headache, respiratory arrest

### Precautions

1. 本品可使用 NS, D5W, D10W 稀釋，混合比例為 100-1000ml 加 15mg midazolam。

2. 稀釋後溶液，室溫下可保存 24 小時或在 5°C 下存放 3 天。

### Contraindication

不可與鹼性溶液混合，在 sodium bicarbonate 中會產生沉澱

## Propofol

B **Unknown<sup>1</sup>**

### Dosage Forms

Fresofol® 200mg/20ml/amp <CPOPO1>

Fresofol<sup>®</sup> 500mg/50ml/vial <CPOPO2>

### Use

Induction and maintenance of anesthesia, sedation during intensive care

### Dose

#### Anesthesia

20-40mg **IV** every 10 sec until induction onset (2-2.5mg/kg). Maintenance **IVF** 50-200mcg/kg/min or **IV bolus** 20-50mg increments as needed

#### Sedation in ICU

0.3-3mg/kg/hr

### Adverse Reactions

Hypotension, apnea, convulsions, hiccups, cough, hot flashes

### Precautions

1. 健規：每次使用以不超過 72 小時為原則。
2. 可用 D5W, NS 稀釋，最大稀釋量為 1:4 (濃度不可低於 2mg/ml)，並於 6 小時內使用完畢。
3. 本品與其他種類脂肪同一注射管路，時間不宜超過 12 小時。

**B<sup>5</sup>** **Unknown<sup>3</sup>**

## Sevoflurane

### Dosage Forms

Ultane<sup>®</sup> 250ml/bot <WSEVOFL>

### Use

Induction and maintenance of general anesthesia

### Dose

0.5-3% concentration with oxygen-air mixture

### Adverse Reactions

Hypotension, bradycardia, nausea, vomiting, laryngospasm, agitation

## Thiamylal

### Dosage Forms

Citosol<sup>®</sup> 500mg/20ml/amp <CTHIAM>

### Use

Induction anesthesia, sedation, seizure

### Dose

**IV** initial 2-3ml test dose, then 2-3ml every 30-40sec, maintenance 1-4ml as need; **max: 1g/dose**

### Adverse Reactions

Vomiting, nausea, headache, vertigo, hypotension

## 2.2. Local Anesthetics

**C<sup>4</sup>** **Safe<sup>1</sup>**

### Bupivacaine

### Dosage Forms

Marcaine<sup>®</sup> 0.5%, 20ml/vial <CBUPI01>

Marcaine<sup>®</sup> spinal 0.5%, 4ml/amp <CBUPI02>

Marcaine<sup>®</sup> spinal heavy 0.5% (with glucose 8%), 4ml/amp <CBUPI03>

## **Use**

Anesthesia, analgesia

## **Dose**

Individualized dosage

## **Adverse Reactions**

Hypotension, nausea, bradycardia

## **Epinephrine and Articaine**

**C<sup>1</sup> Unknown<sup>1</sup>**

## **Dosage Forms**

Septanest® 4 %, 1.7 ml/cartridge (epinephrine: articaine= 1:100000), 1 Cartridge®: Epinephrine 0.017mg+Articaine HCl 68mg <CLIDOC5>

## **Use**

Anesthesia

## **Dose**

Adult: 0.3-0.5ml, **max. articaine dose:< 7 mg/kg**

Children: 0.06-0.07 ml/kg, **max: 0.175 ml/kg.**

## **Adverse Reactions**

Headache, pain, hypotension, paresthesia, gingivitis

## **Precautions**

使用 Septanest® 48 小時內不應哺乳。

## **Contraindication**

不可 IV 、 DM 、 hyperthyroidism

## **Lidocaine**

**B<sup>1</sup> Unknown<sup>1</sup>**

## **Dosage Forms**

Lidocaine® injection 2%, 100mg/5ml/amp <CLIDOC1>

Xylocaine® injection 1%, 50mg/5ml/amp <WLIDOC1>

Xylocaine® injection 2%, 400mg/20ml/vial <WLIDOC3>

Xylocaine® jelly 2%, 30g/tube <WLIDOC4>

Xylocaine® pump spray 10%, 50ml/bot <WLIDOC5>

Lidopat® 5% 700mg/patch<WLIDOC8>

Liprido cream® 30g/tub (Lidocaine 25mg+Prilocaine 25mg)<WLIPRID>

Liprido cream® 450g/bot (Lidocaine 25mg+Prilocaine 25mg)<WLIPRI1>

## **Use**

Acute ventricular arrhythmia, anesthesia, relief post-herpetic neuralgia (patch)

## **Dose**

### Acute ventricular arrhythmia

Adult: slow **IV**(rate:1-2min) 50-100mg(1-2mg/kg), repeat dose after 5 or 10-20min; **max:300mg/hr**

### Injectable local anesthetic

Children and adult: varies with procedure, degree of anesthesia need; **max: 4.5mg/kg/dose**, do not repeat within 2 hrs

Pump spray: adults 1-5 spray; **max: 20spray**

Jelly/cream: individualized dosage

Patch: one patch < 12hrs, **max: 3 patch/day**

### **Adverse Reactions**

Cardiac arrest, malignant hyperthermia, seizure, sore throat, loss of voice, erythema, edema

### **Precautions**

1.2%, 400mg/20ml/vial 為多次使用劑型，開瓶後使用不可超過 3 天。

2.Spray: 清潔噴嘴可浸於水中煮沸 5 分鐘。

3.刺痛及灼熱感請移除貼片。

4.服用 Class I 抗心律不整藥物(如:Mexiletine)應小心使用，兩者毒性屬加乘作用及可能具協同作用。

5. Liprido cream® 450g/bot 僅供單位調撥領用

## **Lidocaine and Epinephrine**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Lidophrine® 20ml/vial (Lidocaine: epinephrine = 1:50000) <CLIDOC9>

### **Use**

Anesthesia

### **Dose**

#### Dental anesthesia

<10 yrs children: rarely exceed 10 ml

Adult: initial dose, 1-2 ml. Dosage depends on an individual basis; **max: 500 mg.**

### **Adverse Reactions**

Anxiety, restlessness, tremor, restlessness, confusion, hypotension,

### **Precautions**

本品需避光。

## **Ropivacaine**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Ropica® 10mg/ml, 20ml/vial <CROPIVA>

### **Use**

Anesthesia

### **Dose**

#### Surgical anesthesia

Lumbar epidural: 15-25ml of 0.75-1% soln

Lumbar epidural for cesarean section: 15-20ml of 0.75% soln

Thoracic epidural block: 5-15ml of 0.75% soln

#### Pain management

Post-OP: continuous infusion 6-14ml/hr of 0.2% soln

Field block: 1-100ml of 0.2% soln

Other : 10-20ml of 0.2% soln

**Max: 800mg/day**

### **Adverse Reactions**

Hypotension, nausea

### **Precautions**

1.與鹼性溶液混合 pH>6.0 時易產生沉澱

2.不含防腐劑，限單次使用。

## 2.3. Neuromuscular blockers

### Cisatracurium

**B<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Nimbex® 10mg/5ml/amp <CCISATR>

#### Use

Skeletal muscle relaxation, during surgery as adjunct to general anesthesia and to facilitate endotracheal intubation or mechanical ventilation in the ICU

#### Dose

##### Tracheal intubation

Children: **IV bolus** 0.1mg/kg, maintenance 0.02mg/kg

Adults: **IV bolus** 0.15mg/kg, maintenance 0.03mg/kg

##### Continus infusion

Children and adult: initial 3mcg/kg/min, maintenance 1-2mcg/kg/min

##### ICU administration

Adult: initial **IV bolus or IVF** 3mcg/kg/min, maintenance

0.5-10.2mcg/kg/min

#### Adverse Reactions

Bradycardia, hypotension, bronchospasm, rash

#### Precautions

1. 劑型為中效神經肌肉阻斷劑 (intermediate duration)。

2. 本品須冷藏。

3. 以 NS, D5W 稀釋，於 5-25°C 下可保存 24 小時。

### Pancuronium

**C<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Pancuronium® 4mg/2ml/amp <CPANCUR>

#### Use

Skeletal muscle relaxation, during surgery as adjunct to general anesthesia and to facilitate endotracheal intubation or mechanical ventilation in the ICU

#### Dose

Neonate: initial **IV** 0.03-0.04mg/kg, maintenance up to 0.02mg/kg

Children and Adult: initial **IV** 0.04-0.1mg/kg, maintenance 0.01-0.02mg/kg, 60-100 mins after initial dose if needed, repeat doses every 25-60 min as needed

#### Adverse Reactions

Bradycardia, hypotension, bronchospasm

#### Precautions

1. 劑型為長效神經肌肉阻斷劑 (long duration)。

2. 本品須冷藏。

### Rocuronium

**C<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Esmeron® 50mg/5ml/vial <CROCURO>

#### Use

Intubation, skeletal muscle relaxation

### Dose

#### Intubation

Initial **IV** 0.6-1.2mg/kg, maintenance 0.1-0.2mg/kg repeated as needed

#### Skeletal muscle relaxation

Initial bolus 0.6mg/kg, then continues **IV infusion** 0.01-0.012mg/kg/min

### Adverse Reactions

Injection site pain, change in vital signs, prolong neuromuscular block

### Precautions

1. 劑型為中效神經肌肉阻斷劑(intermediate duration)須避光冷藏。

2. 以 NS, D5W, D5W/NS, Diswater, Lactated ringers 稀釋為濃度 0.5mg/ml 或 2mg/ml。

3. 開封後，於冰箱中可存放一天；若在室溫下，開封後應立即使用。

## Succinylcholine

**C** Unknown

### Dosage Forms

Relaxin® 500mg/vial <CSUCCIN>

### Use

Muscle relaxation

### Dose

Children: **IV** 1mg/kg or **IM** 2-3mg/kg

Adult:

Divided administration: **IV** 10-60mg, have not produce skeletal muscle relaxation, increase dose until provide skeletal muscle relation

Continus infusion: 10-60mg **IVF** dilute with NS or D5W to 0.1-0.2% sol'n, with rate of 2.5mg/min

### Adverse Reactions

Increased intraocular pressure, prolonged muscle pain and stiffness, apnea, respiratory depression, malignant hyperthermia

### Precautions

1. 劑型為極短效神經肌肉阻斷劑(ultra-short duration)

2. 泡製後於冰箱中冷藏可保存 1 週。

### 3. ANTIMICROBIALS

#### 3.1. Aminoglycosides

##### Amikacin

D<sup>1</sup> Unknown<sup>1</sup>

##### Dosage Forms

Acemycin® 500mg/2ml/vial <CAMIK01>

##### Use

Serious infections due to organisms resistant to gentamicin and tobramycin including Pseudomonas, Proteus, Serratia and other G (-) bacilli

##### Dose

Neonate and infants: IV/IM initial 10mg/kg, then 7.5mg/kg q12h

Children and adults: IV/IM 7.5mg/kg q12h, max 1.5 g/day

##### Adverse Reactions

Ototoxicity (auditory and vestibular), nephrotoxicity

##### Precautions

1. 使用 0.9% NaCl, D5W, LR 稀釋，宜調配成 2.5-5mg/ml 之濃度，稀釋後於室溫下可存放 24 小時。
2. IV infusion over 30 min
3. 需依腎功能調整劑量。

##### Gentamicin

D<sup>1</sup> Safe<sup>1</sup>

##### Dosage Forms

Gentamycin® 80mg/2ml/vial <CGENTA2>

Oftalmolosa cusi® oph oint 0.3%, 5g/tube <WGENTA3> 參閱 p.271

Gentamicin® oph soln 0.3%, 5ml/bot <WGENTA2> 參閱 p.271

Gentermay® cream 0.1%, 15g/tube <WGARAMY> 參閱 p.134

##### Use

Susceptible bacterial infections, G (-) organisms including Pseudomonas, Proteus, Serratia and G (+) Staphylococcus

##### Dose

Infants and children < 5 yrs: IV/IM 2.5mg/kg q8h

Children > 5 yrs: IV/IM 1.5-2.5mg/kg q8h

Adults: IV/IM

Severe life-threatening infections: 2-2.5mg/kg q8h

Urinary tract infections: 1.5mg/kg q8h

Synergy for G (+) infections: 1mg/kg q8h

Once-daily doses: 5mg/kg

##### Adverse Reactions

Neurotoxicity, vertigo, ataxia, gait instability, nephrotoxicity, ototoxicity, auditory and vestibular

##### Precautions

1. IV infusion over 30 min

2. 需依腎功能調整劑量。

## Isepamicin

D<sup>3</sup> Unknown<sup>3</sup>

### Dosage Forms

Exacin® 200mg/2ml/amp <CISEPAM>

### Use

Infections due to some aminoglycoside-resistant infections and enterobacteriaceae, staphylococci infection

### Dose

#### Intermittent IV infusion

Infants < 16 days: 7.5mg/kg qd

Children >16 days-16 yrs: 7.5mg/kg bid

Adults:

Mild-moderate or localized infections: 8mg/kg qd

More severe infections: 15mg/kg qd

### Adverse Reactions

Headache, skin rash, ototoxicity, nephrotoxicity,

### Precautions

1. IV infusion over 30 min

2. 需依腎功能調整劑量。

## Neomycin

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Neomycin® 250mg/cap <KNEMOYC>

### Use

Diarrhea caused by E. Coli or prepare GI tract for surgery

Adjunct in the treatment of hepatic encephalopathy

### Dose

#### Hepatic encephalopathy therapy

Children: PO 625mg-1.75g/m<sup>2</sup> q6h × 5-6 days

Adults: PO 3g q6h × 5-6 days, max: 12g/day

#### Bowel preparation (pre-operative)

Children: PO 14.7mg/kg or 417mg/m<sup>2</sup> q4h × 3 days

Adults: PO 1g q1h × 4 dose, then 1g q4h for the balance of 24 hrs

### Adverse Reactions

Nausea, diarrhea, vomiting, ototoxicity, nephrotoxicity

## 3.2. Antifungals

## Amphotericin B

B<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Fungizone® 50mg/vial <CAMPHOT>

### Use

Infection by Basidiobolus, Conidiobolus, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, fungal infection of central nervous system, histoplasmosis

### Dose

Test dose: 1mg +20ml D<sub>5</sub>W **IVF** over 20-30 min

Maintenance 0.25-1.5mg/kg/day diluted in 500ml D<sub>5</sub>W **IVF** over 4-6 hrs

Cumulative dose: **IVF** 1-4g (usual duration: 4-12 wks)

#### Bladder irrigation(膀胱沖洗)

Intermittently or continuously 30-50 mg diluted in 20-1000 mL of sterile water via bladder irrigation for 2-14 days

#### **Adverse Reactions**

Fever, chills, headache, hypokalemia, nephrotoxicity

#### **Precautions**

1. 溶液配製限以 Diswater 或 D5W 溶液稀釋。

2. 開封後儲存：室溫 24 小時，冷藏 1 星期。

3. 需依腎功能調整劑量。

### **Anidulafungin**

**C<sup>5</sup> Unknown<sup>5</sup>**

#### **Dosage Forms**

Eraxis<sup>®</sup> 100mg/vial <CANIDUL>

#### **Use**

Candidemia, intra-abdominal or peritoneal candidiasis

#### **Dose**

**IVF** (1.4ml/min, >90min)

Loading 200mg on day 1, then 100mg qd

#### **Adverse Reactions**

Rash, urticaria, flushing, pruritus, dyspnea, hypotension

#### **Precautions**

1. 儲存於 2-8°C。

2. 以 30ml 注射用水溶解，再以 100ml D5W 或 NS 稀釋。

3. 乾粉溶解後於 25°C 可存放 24hrs，稀釋後於 25°C 可存放 48hrs。

4. 需依腎功能調整劑量。

### **Caspofungin**

**C<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Cancidas<sup>®</sup> 50mg/vial<CCASPOF>

#### **Use**

Antifungal

#### **Dose**

**IVF** 70 mg on day 1, then 50 mg daily; duration of therapy depends upon clinical response and microbiological response; continue for a minimum of 14 days beyond the first negative culture.

#### **Adverse Reactions**

Facial swelling, pruritus, rash, nausea, vomiting, increased liver enzymes, thrombophlebitis, headache, fever

#### **Precautions**

1. 不可使用含葡萄糖的稀釋液，且不可與其他藥品混合或同時輸注。

2. 調配方式：先將藥品回復到室溫，加入 10.5ml 的注射用水，輕輕的混合均勻，直到呈現澄清的溶液。將調配過之藥品加到 250ml 的靜

- 脈輸注液(NS 或 Lactated Ringer's solution)中，以約 1 小時的輸注時間緩慢靜脈輸注。
3. 調配後的溶液可以儲存在≤25°C，必須在 24 小時內使用完畢，如於 2-8°C 冷藏，必須於 48 小時內使用完畢。
  4. 需依腎功能調整劑量。

## **Fluconazole**

**D<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Diflucan® 100mg/50ml/vial <CFLUCON>  
 Flu-D® 50mg/cap <KFLUC01>  
 Flu-D® 150mg/cap <KFLUC02>

### **Use**

Candida infections

### **Dose**

#### **Fluconazole - Once-Daily Dosing IV, PO (Children)**

<b>Indication</b>	<b>Day 1</b>	<b>Daily Therapy</b>	<b>Duration of Therapy</b>
Oropharyngeal candidiasis	6mg/kg	3mg/kg	14 days
Esophageal candidiasis	6mg/kg	3-12mg/kg	21 days and for at least 2 wks following resolution of symptoms
Systemic candidiasis	-	6-12mg/kg	28 day
Cryptococcal meningitis Acute	12mg/kg	6-12mg/kg	10-12 wks after CSF culture becomes negative
Relapse suppression	6mg/kg	6mg/kg	N/A

#### **Fluconazole - Once-Daily Dosing IV, PO (Adults)**

<b>Indication</b>	<b>Day 1</b>	<b>Daily Therapy</b>	<b>Duration of Therapy</b>
Oropharyngeal candidiasis	200mg	100mg	14 days
Esophageal candidiasis	200mg	100mg	21 days and for at least 14 days following resolution of symptoms
Prevention of candidiasis in bone marrow transplant	400mg	400mg	7 day after neutrophils > 1000 cells/mm <sup>3</sup>
Candidiasis UTIs, peritonitis	-	50-200mg	N/A
Systemic candidiasis	800mg	400mg	28 days
Cryptococcal meningitis	-	400-800mg	10-12 wks after CSF culture becomes negative
Vaginal candidiasis	150mg	150mg	N/A

N/A = Not applicable

### **Adverse Reactions**

Nausea, headache, skin rash, elevated AST/ALT/alkaline phosphatase, hypokalemia

### **Precautions**

1. IV infusion over 1-2 hrs, don't exceed 200mg/hr
2. 需依腎功能調整劑量。

## **Flucytosine**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Flusine<sup>®</sup> 500mg/tab <KFLUCYT>

**Use**

Adjunctive treatment of systemic fungal infections (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of *Candida* or *Cryptococcus*

**Dose**

Usual dose: PO 50-150mg/kg/day divided q6h

Endocarditis

**PO** 100mg/kg/day divided q6-8h (with amphotericin B) for at least 4-6 weeks after valve replacement

Meningoencephalitis, cryptococcal

**PO** induction 100mg/kg/day divided q6h for at least 4 weeks, or if HIV-infected at least 2 weeks; if clinical improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole

**Adverse reactions**

Nausea, vomiting, abdominal pain, diarrhea, hallucinations

**Precautions**

1. 服藥期間需密切監測病人 CBC、liver function、renal function。

2. 腎功能不良需調整劑量。

**C<sup>1</sup> Unknown<sup>1</sup>**

**Itraconazole**

**Dosage Forms**

Sporanox<sup>®</sup> 100mg/cap <KITRACO>

**Use**

Superficial mycoses

**Dose**

Blastomycosis, histoplasmosis

Adult: **PO** 200mg qd, **max 400mg/day**

Aspergillosis

Adult: **PO** 200-400mg/day

Onychomycosis

Adult: **PO** 200mg qd for 12 wks

**Adverse Reactions**

Nausea, edema, headache, fever, abnormal liver function

**Precautions**

需依肝功能調整劑量。

**B<sup>5</sup> Unknown<sup>1</sup>**

**Liposomal Amphotericin B**

**Dosage Forms**

AmBil<sup>®</sup> 50mg/vial <CAMPHO1>

**Use**

Systemic fungal infection, cryptococcal meningitis of HIV infection.

**Dose**

Systemic fungal infection (aspergillosis, candidiasis, cryptococcosis)

**IVF** (>120min) 3-5mg/kg/day

## Cryptococcal meningitis of HIV infection

IVF (>120min) 6mg/kg/day

### **Adverse Reactions**

Chilly, diarrhea, nausea, vomiting, hypokalemia, hypomagnesemia

### **Precautions**

1.需冷藏於 2-8°C 。

2.配製方式:限以 12ml 無菌注射用水溶解(溶解濃度:4mg/ml

Amphotericin B)，並僅限以 D5W 溶液稀釋(成人稀釋濃度:1-2mg/ml;  
兒童稀釋濃度:0.2-0.5mg/ml)。

3.以注射用水溶解後，於 2-8°C 可存放 24 小時；以 D5W 稀釋後需於 6 小時內使用完畢。

## **Nystatin**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Mycostatin® 10 萬 U/ml, 24ml/bot <KNYSTAT>

Nystatin® 0.5MU/cap <KNYSTAT>

### **Use**

Fungal infections caused by the Candida species

### **Dose**

#### Candidiasis

Swish and swallow orally: infants: 200,000U qid or 100,000U to each side of mouth qid

Children and adults: 400,000-600,000U qid

#### Intestinal infections

Adults: PO 500,000-1,000,000U q8h

### **Adverse Reactions**

Nausea, vomiting, diarrhea, stomach pain, Stevens-Johnson syndrome

### **Precautions**

Suspension 加入 23ml 水，振搖後內容量為 24ml，配置後於室溫下可保存 7 天。

## **Posaconazole**

**C<sup>5</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Posanol® oral suspension 40mg/ml, 105ml/bot <KPOSACO>

### **Use**

Fungal infections caused by the Candida species

### **Dose**

#### Aspergillosis, invasive (treatment)

PO 400mg(10ml) twice daily; in patients unable to tolerate food or nutritional supplement, administer 200mg 4 times daily.

#### Aspergillosis, invasive (prophylaxis)

PO 200mg(5ml) 3 times daily; duration of therapy is based on recovery from neutropenia or immunosuppression.

#### Oropharyngeal candidiasis

PO 400mg(10ml) twice daily

### **Adverse Reactions**

Nausea, headache, thrombocytopenia, electrolyte imbalance, anorexia

### Precautions

- 1.具櫻桃口味之白色懸液，使用前振搖均勻，包裝為避光琥珀色玻璃瓶，內附量匙含兩種刻度(2.5ml 及 5ml)
- 2.每 5ml 懸液中約含 1.75g 葡萄糖，具葡萄糖-半乳糖吸收不良患者不可使用
- 3.藥品開封後室溫下可保存 4 週

## Terbinafine

**B** Unknown<sup>1</sup>

### Dosage Forms

Lamisil® 250mg/tab <KTERBIN>

### Use

Onychomycosis of the toenail or finger due to dermatophytes

### Dose

Children <20kg: **PO** 62.5mg qd

Children 20-40kg: **PO** 125mg qd

Children >40kg: **PO** 250mg qd

Adults

Fingernail(手指甲癬)

**PO** 250mg/day for up to 6 wks

Toenail(足趾甲癬)

**PO** 250mg/day for 12 wks

### Adverse Reactions

Abdominal pain, appetite decrease, headache, rash, muscle pain

### Precautions

1.應小心商品名易與 lamictal® (lamotrigine)混淆。

2.使用前應檢查 CBC 及 LFTs，使用超過 6 週應再檢查一次

3.需依肝腎功能調整劑量。

## Voriconazole

**D** Unknown<sup>1</sup>

### Dosage Forms

Vfend® 200mg/vial <CVORICO>

Vfend® 200mg/tab <KVORICO>

### Use

Invasive aspergillosis or serious fungal infections

### Dose

Injection:

2-12yrs: loading **IV** 9mg/kg q12h for 2 dose, maintenance 8mg/kg q12h  
>12yrs and adult: loading **IV** 6mg/kg q12h for 2 doses, maintenance 4 mg/kg q12h

Tablet:

2-12yrs: 9mg/kg q12h; max: 350mg/dose

≥40 kg: **PO** loading 400mg q12h for 2dose, maintenance 200mg q12h

<40 kg: **PO** loading 200 mg q12h for 2dose, maintenance 100mg q12h

### Adverse Reactions

Visual changes (photophobia, color changes, increased or decreased visual acuity, blurred vision)

#### Precaution

- 1.此藥僅建議大於 12 歲以上使用。
- 2.口服給藥建議於飯前 1 小時或飯後 1 小時。
- 3.針劑給藥速度建議 infusion 1-2 hrs ( rate not to exceed 3mg/kg/hr )
- 4.配置後，於冰箱冷藏可存放 24hr。
- 5.需依肝功能調整劑量; Clcr <50 mL/minute 建議使用口服劑型。

#### Contraindications

併用 CYP3A4 substrates, terfenadine, astemizole, cisapride, or quinidine，會造成 QT prolongation and torsade de pointes 的危險。

### 3.3. Antimalarials

#### Hydroxychloroquine

**C** **Safe<sup>1</sup>**

##### Dosage Forms

Plaquenil® 200mg/tab <KHYDR02>

##### Use

Suppresses and treatment of acute attacks of malaria, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA)

##### Dose

##### Chemoprophylaxis of malaria

Children: **PO** 6.5mg/kg once weekly, **max: 400mg/dose**

Adults: **PO** 400mg weekly on same day each wk, begin 2 wks before exposure; continue for 4 wks after leaving endemic area

##### RA

Children: **PO** avoid exceeding 6.5mg/kg/day

Adults: **PO** 400-600mg/day; usually after 4-12 wks dose should be reduced by 1/2 and maintenance 200-400mg/day

##### SLE

Children: **PO** avoid exceeding 6.5mg/kg/day

Adults: **PO** 400mg/day qd-bid until remission then 200 to 400 mg qd

##### Adverse Reactions

Agranulocytosis, leukopenia, aplastic anemia, ataxia

##### Precaution

尿液會呈黃棕色。

### 3.4. Antiparasitics

#### Levamisole

**C<sup>5</sup>** **Unknown<sup>3</sup>**

##### Dosage Forms

Decaris® 50mg/tab <KLEVAMI>

##### Use

An anthelmintic and immunomodulating agent

## Dose

Ascariasis (蛔蟲)/ankylostomiasis(鉤蟲)

Children <10kg: **PO** 25mg single dose

Children 10-20kg: **PO** 50mg single dose

Children 20-30kg: **PO** 75mg single dose

Children 30-40kg: **PO** 100mg single dose

Adults: **PO** 150mg single dose

Adjuvant treatment with fluorouracil in Dukes stage C colon cancer

**PO** initial 50mg q8h for 3 days, then 50mg q8h for 3 days every 2 wks

## Adverse Reactions

Edema, fatigue, nausea, diarrhea, fever

## Precautions

需依肝功能調整劑量。

## Mebendazole

**C<sup>4</sup>** **Safe<sup>1</sup>**

### Dosage Forms

Conquer® 100mg/tab <KMEBEND>

### Use

Pinworms, whipworms, roundworms and hookworms

### Dose

Pinworms(蟯蟲)

Children and adults: **PO** 100mg qd

Whipworm(鞭蟲), Roundworms(蛔蟲), Hookworms(鉤蟲)

Children and adults: **PO** 100mg bid for 3 consecutive days

## Adverse Reactions

Rash, headache, diarrhea, constipation, abdominal pain

## Precautions

Treatment should include family members in close contact with patient

## Praziquantel

**B<sup>1</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Kaicide® 600mg/tab<KPRAZIQ>

### Use

Anthelmintic

### Dose

Clonorchis sinensis (中華肝吸蟲)

**PO** 25mg/kg tid × 1day (at 4-6 hr intervals)

Schistosoma haematobium (埃及分體吸蟲)

**PO** 20mg/kg bid × 1day (at 4-6 hr intervals)

Schistosoma mansoni (曼氏分體吸蟲)

**PO** 40mg/kg qd × 1day

Schistosoma japonicum (日本分體吸蟲)

**PO** 20mg/kg tid × 1day (at 4-6 hr intervals)

Paragonimus westermani (衛氏並殖腺吸蟲)

**PO** 25mg/kg tid × 2day (at 4-6 hr intervals)

### Hymenolepsis nana (短小包膜條蟲), Diphyllobothrium latum

(闊節雙槽條蟲)

**PO** 25mg/kg qd×1day

### Taenia saginata & Taenia solium (牛肉條蟲及豬肉條蟲)

**PO** 10mg/kg qd×1day

Cysticercus cellulosae (豚囊蟲)

**PO** 25mg/kg tid ×4day (at 4-6 hr intervals)

#### **Adverse Reactions**

Dizziness, headache, somnolence, vomiting, diarrhea

## 3.5. Antituberculars

### **Ethambutol (EMB)**

**C<sup>4</sup> Safe<sup>1</sup>**

#### **Dosage Forms**

Ebutol® 400mg/tab <KETHAMB>

#### **Use**

Tuberculosis

#### **Dose**

Tuberculosis

Children and adults: **PO** 15-25mg/kg/day; **max: 2.5g/day**

Directly observed therapy (DOT)

Adults: **PO** 50mg/kg twice weekly; **max: 2.5g**

Disseminated Mycobacterium Avium Complex (MAC) with advanced HIV infection

Adults: **PO** 15mg/kg in combination with azithromycin 600mg/day

#### **Adverse Reactions**

Optic neuritis, headache, peripheral neuritis, confusion, rash, pruritis

#### **Precaution**

1. Regimen: INH/RIF/PZA/EMB for 2 months then INH/RIF±EMB for 4 months
2. 需定期進行視力檢查。
3. 服藥後可能發生急性痛風。
4. 兒童須小心使用。
5. 需依腎功能調整劑量。

### **Isoniazid (INH)**

**A<sup>4</sup> Safe<sup>1</sup>**

#### **Dosage Forms**

Isoniazide® 100mg/tab <KISONIA>

#### **Use**

Tuberculosis

#### **Dose**

Children: **PO** 10-15mg/kg/day; **max: 300mg/day**

Adult: **PO** 300mg qd

#### **Adverse Reactions**

Hepatitis, peripheral neuritis, hepatitis prodromal symptoms

## **Precaution**

- 1.Active or in remission alcoholism, hepatic function impairment
- 2.Pyridoxine (10-50mg/day) is recommended in individuals likely to develop peripheral neuropathies
- 3.需依肝功能調整劑量。

## **Pyrazinamide (PZA)**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Pyrazinamide<sup>®</sup> 500mg/tab <KPYRAZI>

### **Use**

Tuberculosis

### **Dose**

Children and adults: **PO** 15-30mg/kg/day, **max 2g/day**

Directly observed therapy (DOT)

**PO** 50-70mg/kg twice weekly, **max 4g/day**

### **Adverse Reactions**

Gout, malaise, vomiting, anorexia, hepatotoxicity

### **Precautions**

需依肝腎功能調整劑量。

## **Rifabutin**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Mycobutin<sup>®</sup> 150mg/cap <KRIFABU>

### **Use**

Prevention of Disseminated Mycobacterium Avium Complex (MAC)

禽結核分枝桿菌 in patients with advanced HIV infection

### **Dose**

Prophylaxis of Disseminated Mycobacterium Avium Complex

**PO** 300 mg qd

HIV infection - Tuberculosis combination

**PO** 450-600mg qd; 150-400mg qd 視併用抗病毒藥物決定

### **Adverse Reactions**

Vomiting, nausea, thrombocytopenia, leukopenia, myalgia, increased AST/ALT

### **Precautions**

需依腎功能調整劑量。

## **Rifampin (RIF)**

**C<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Rifampicin<sup>®</sup> 150mg/cap <KRIFAM1>

Rifampicin<sup>®</sup> 300mg/cap <KRIFAM3>

### **Use**

Tuberculosis, meningococci, G (+) infections and prophylaxis of Haemophilus influenzae type b infection

### **Dose**

Tuberculosis

Infants and children < 12 yrs: **PO** 10-20mg/kg qd, **max: 600mg/day**

Adults: **PO** 10mg/kg qd, **max: 600mg/day**

#### H. influenzae prophylaxis

Infants and children: **PO** 20mg/kg qd for 4 days, **max: 600mg/dose**

Adults: **PO** 600mg qd for 4 days

#### Meningococcal prophylaxis

Infants <1 mon: **PO** 10mg/kg q12h for 2 days

Infants  $\geq$  1 mon: **PO** 20mg/kg q12h for 2 days

Adults: **PO** 600mg q12h for 2 days

#### Synergy for Staphylococcus aureus infections

Adults: **PO** 600mg qd or 300-450**mg** q12h with other antibiotics

### **Adverse Reactions**

Anorexia, nausea, flu-like syndrome, elevated LFTs, discoloration of urine, sweat, tears, saliva

### **Precautions**

1. Periodic (baseline and every 2-4 wks) monitoring of liver function

2. Reddish coloration of the urine

3. 需依肝功能調整劑量。

## Rifater<sup>®</sup>

**C** **Unknown**

### **Dosage Forms**

1 tab: Rifampin 120mg+Isoniazid 80mg+ Pyrazinamide 250mg

<KRIFAM4>

### **Use**

Initial intensive phase of the short course treatment of tuberculosis (usually lasts 2 months)

### **Dose**

**PO** 1 tab/10kg, not exceeding 5 tab daily

$\geq$ 50kg: 5 tab; 40-49kg: 4 tab; 30-39kg: 3 tab

### **Adverse Reactions**

Hepatitis, diarrhea, thrombocytopenia, flu-like syndrome, hemolytic anemia

### **Precautions**

建議飯前給藥。

## Rifinah<sup>®</sup>

**C** **Unknown**

### **Dosage Forms**

1 tab: Rifampin 150mg+Isoniazid 100mg <KRIFAM2>

1 tab: Rifampin 300mg+Isoniazid 150mg <KRIFAM5>

### **Use**

Tuberculosis

### **Dose**

**PO** <50kg: 3 tab qd (Rifinah<sup>®</sup> 150);  $\geq$ 50kg: 2 tab qd (Rifinah<sup>®</sup> 300)

### **Adverse Reactions**

Hepatitis, diarrhea, thrombocytopenia, flu-like syndrome, hemolytic anemia

# **Streptomycin**

**D1 Safe**

## **Dosage Forms**

Streptomycin® 1g/vial <CSTRE02>

## **Use**

Combination therapy of active tuberculosis, streptococcal or enterococcal endocarditis, mycobacterial infections, plague, tularemia and brucellosis

## **Dose**

### Tuberculosis

Children:

Daily therapy: **IM 20-30mg/kg/day, max 1g/day**

Directly observed therapy (DOT)

Twice weekly: **IM 20-40mg/kg, max: 1g**

Adults:

Daily therapy: **IM 15mg/kg/day, max: 1g/day**

Directly observed therapy (DOT)

Twice weekly: **IM 25-30mg/kg, max: 1.5g**

### Enterococcal endocarditis

**IM 1g q12h for 2 wks, 500mg q12h for 4 wks in combination with penicillin**

### Streptococcal endocarditis

**IM 1g q12h for 1 wk, 500mg q12h for 1 wk**

## **Adverse Reactions**

Rash, urticaria, eosinophilia, facial paresthesia, drug fever

## **Precautions**

以注射用水或 NS 溶解至<250mg/ml

### 3.6. Anti- HIVs

#### 3.6.1. Integrase Inhibitor

Drug name	Dosage Forms	Dose	Adverse Reactions
Raltegravir	Isentress® 400mg/ F.C tab <KRALTEG>	400mg bid	Dizziness, diarrhea, nausea, fatigue

#### 3.6.2. Nucleoside Reverse Transcriptase Inhibitors (NRTI)

Drug name	Dosage Forms	Dose	Adverse Reactions
Combivir®	Lamivudine 150mg + Zidovudine 300mg/tab <KCOMBI>	1 tab bid	Headache, malaise, rash and fever
Kivexa®	Abacavir 600mg+Lamivudine 300mg/tab<KKIVEXA>	> 40 kg, 1 tab qd	Rash, lactic acidosis, joint pain, alopecia
Lamivudine (3-TC)	3-TC® 150mg/tab <KLAMIV2>	3mon-16yrs:4mg/kg bid Adults: 150mg bid	Fat redistribution, decreased appetite, nausea, vomiting, fatigue, headache
Zidovudine (AZT)	<b>Retrovir®</b> Oral Solution, 10mg/ml, 240ml/bot <KZIDOV1>  <b>Retrovir®</b> 10mg/ml, 20ml/vial <CZIDOVU>	300mg bid or 200mg tid 預防愛滋母子垂直感染母親：靜脈注射一劑 2 mg/kg，接著持續輸注 1 mg/kg/hr，直到生產。 嬰兒：口服 2 mg/kg q6h, 共 6 週	Anemia, headache, insomnia, malaise, anorexia, constipation, nausea, vomiting

### **3.6.2. Nucleoside Reverse Transcriptase Inhibitors (NRTI) *continue***

<b>Drug name</b>	<b>Dosage Forms</b>	<b>Dose</b>	<b>Adverse Reactions</b>
Tenofovir	Viread® 300mg/tab<KTENOFO>	300mg qd	Headache, dizziness, diarrhea, nausea
Truvada®	Emtricitabine 200mg+ Tenofovir 300mg/tab <KTRUVAD>	1 tablet QD	Diarrhea, nausea, fatigue, headache, dizziness

### 3.6.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Drug name	Dosage Forms	Dose	Adverse Reactions
Efavirenz	<b>Stocrin®</b> 600mg/cap <KEFAVIR>	>40 kg: 600mg qd	CNS side effects ) 52% ( Abnormal dreams, depression, dizziness, hallucinations, insomnia, impaired concentration, somnolence, rash, fat redistribution
Nevirapine	<b>Viramune®</b> 200mg/tab <KNEVIRA> <b>Viramune XR®</b> 400mg/tab <KNEVIRA>	initiate therapy with 200mg of immediate-release Nevirapine daily for the first 14 days, followed by 400mg of extended-release Nevirapine once daily.	Rash, headache, fatigue, diarrhea, nausea <註:持續釋放錠應整顆吞服，不可咀嚼、折斷或壓碎>
Rilpivirine	<b>Eduran®</b> 25mg/tab <KRILPIV>	25mg qd with meal	Depression, headache, insomnia, rash

### 3.6.4. Protease Inhibitors (PI)

Drug	Dosage Forms	Dose	Adverse Reactions
Kaletra®	Lopinavir 200mg+ Ritonavir 50mg/tab <KKALET1>	2 tab bid	Lipodystrophy, diarrhea, nausea, asthenia, headache <註：Kaletra 錠劑應整顆吞服，不可咀嚼、折斷或壓碎>
Atazanavir	<b>Reyataz®</b> 200mg/cap <KATAZAN> <b>Reyataz®</b> 150mg/cap <KATAZA1>	<u>For treatment-naïve and therapy-experienced patients</u> Reyataz 300mg + Ritonavir 100mg qd <u>For treatment-naïve patients who are unable tolerate Ritonavir</u> Reyataz 400mg qd	Rash, Abdominal pain, Diarrhea, Nausea, Unconjugated hyperbilirubinemia, Asymptomatic, Headache
Darunavir	<b>Prezista®</b> 600mg/tab <KDARUNA> <b>Prezista®</b> 400mg/tab <KDARUN1>	800mg qd or 600mg bid concomitantly with ritonavir 100mg qd or bid	Diarrhea, vomiting, abdominal pain, constipation, headache
Ritonavir	<b>Norvir®</b> 100mg/tab <KRITONA >	Adult: initial 300mg bid, then increase by 100 mg bid every 2 to 3 days, <b>max: 600mg bid</b> ≥2yrs Children: initial, 250 mg/m <sup>2</sup> bid, then increase by 50 mg/m <sup>2</sup> bid every 2 to 3 days, maintenance dose of 350 to 400 mg/m <sup>2</sup> ; <b>max: 600mg bid</b>	Nausea, headach, diarrhea, vomiting, abdominal pain, taste sense altered. <註：本品需冷藏儲存於 2-8°C，如置於室溫(25°C)下請於 30 天內使用完畢>

### **3.6.5. NNRTI + NRTI**

<b>Drug</b>	<b>Dosage Forms</b>	<b>Dose</b>	<b>Adverse Reactions</b>
<b>Atripla®</b>	Efavirenz 600mg+ Emtricitabine 200mg+ Tenofovir 300mg/tab <KATRIPL>	1 tablet QDAC or HS	Diarrhea, nausea, fatigue, depression

### 3.7. Anti-Cytomegalovirus (Anti-CMV)

#### Ganciclovir

C Unknown<sup>1</sup>

##### Dosage Forms

Cymevene® 500mg/vial <CGANCIC>

##### Use

Cytomegalovirus infection(巨細胞病毒感染症)

##### Dose

IV induction 5mg/kg q12h for 14-21 days, maintenance 5mg/kg qd × 7 days/wk or 6mg/kg qd × 5 days/wk

##### Adverse Reactions

Anemia, neutropenia, thrombocytopenia, fever, phlebitis, anorexia

##### Precautions

1. 不可快速靜脈注射，因血中濃度過高會增加毒性。
2. 不可使用含有 paraben 為保存劑的注射用水配製。
3. 肌肉或皮下注射可能導致嚴重的組織刺激。
4. 需依腎功能調整劑量。

#### Valganciclovir

C Unknown<sup>1</sup>

##### Dosage Forms

Valcyte® 450mg/F.C tab <KVALGA1>

##### Use

Cytomegalovirus retinitis(巨細胞病毒視網膜炎)

##### Dose

PO induction 900mg bid for 21 days, maintenance 900mg qd

##### Adverse Reactions

Anemia, neutropenia, diarrhea, nausea, pyrexia, fatigue

##### Precautions

1. 需依腎功能調整劑量。
2. 本學名與 Valaciclovir (Valtrex®) 極為相似請注意。

### 3.8. Anti-Herpetics

#### Acyclovir

B<sup>1</sup> Safe<sup>1</sup>

##### Dosage Forms

Virless® lyophilized 250mg/vial <CACYC02>

Virless® 200mg/tab <KACYC01>

Zovirax® susp 4%, 125ml/bot <KACYC03>

Aclovir® cream 5%, 5g/tube <WACYC05> 參閱 p.133

Devirus® oph oint 3%, 4.5g/tube <WACYC02> 參閱 p.274

##### Use

Herpes simplex (HSV-1 and HSV-2) infections, herpes zoster, genital herpes infection, varicella-zoster infections in healthy

## Dose

### Mucocutaneous HSV

**IV** 5mg/kg q8h × 5-10 days

### HSV encephalitis

**IV** 10mg/kg q8h × 10 days

### Genital herpes simplex virus infections

Adults: **PO** 200mg q4h × 10 days if initial episode, for 5 days if recurrence

### Varicella-zoster virus (chickenpox)水痘

Children: **PO** 10-20mg/kg qid for 5 days

Adults: **PO** 600-800mg q4h for 7-10 days or 1000mg q6h for 5 days

Children and Adults: **IV** 10mg/kg q8h for 7 days

### Herpes zoster infections 帶狀疱疹

Adults and Children: **PO** 800mg q4h (5 times/day) for 7-10days; **IV**

10mg/kg q8h

## Topical

Cream: q4h for 5-10 days

Oph oint: q4h

## Adverse Reactions

Diarrhea, nausea, vomiting, central nervous system effects, agitation, confusion, dizziness, hallucinations, somnolence, malaise, burning or stinging of the skin (topical), phlebitis (injection site), increased serum creatinine and BUN (IV infusion, transient)

## Precautions

1. 本學名與 Valaciclovir (Valtrex<sup>®</sup>)極為相似請注意。
2. 需依腎功能調整劑量。
3. 針劑以 10ml 注射用水或 NS 溶解配製，室溫下可保存 12 小時。
4. 健規：
  - (1) 使用療程以十天為限，疱疹性腦炎得使用 14-21 天。
  - (2) 口服、注射劑及外用藥膏擇一使用，不得合併使用。
  - (3) Herpes simplex 3 日內可使用 acyclovir 藥膏，每次以 5g 為限。

**B<sup>1</sup> Safe<sup>1</sup>**

## Valaciclovir

### Dosage Forms

Valtrex<sup>®</sup> 500mg/FC. tab <KVALACI>

## Use

Herpes zoster or herpes simplex infections

## Dose

### Herpes zoster (shingles)

Adult: **PO** 1g tid for 7 days

### Herpes simplex

Adult: **PO** 500mg bid for 5-10 days

## Adverse Reactions

Headache, nausea, vomiting

## Precautions

需依腎功能調整劑量。

### 3.9. Anti-Influenzas

#### Oseltamivir

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Tamiflu<sup>®</sup> 75mg/cap <KOSELTA>

##### Use

Treatment of influenza (A or B) infection

##### Dose

###### Treatment of influenza

Children <13yrs: ≤15kg PO 30mg bid; >15-23kg PO 45mg bid; >23-40kg

PO 60mg bid; >40kg PO 75mg bid

Children ≥13 yr and adult: PO 75mg bid for 5 days

###### Prevention of influenza

Children ≥ 13 yr and adult: PO 75 mg qd for at least 7 days

##### Adverse Reactions

Bronchitis, nausea, vomiting, insomnia, vertigo, severe dyspnea

##### Precautions

需依腎功能調整劑量。

##### Contraindications

<1yr: 不建議使用。

### 3.10. Antivirals

#### 3.10.1. Hepatitis

#### Adefovir dipivoxil

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Hepsera<sup>®</sup> 10mg/tab <KADEFON>

##### Use

Chronic hepatitis B viral infection

##### Dose

Adult 18-65yrs: PO 10mg qd

##### Adverse Reactions

Elevations in serum creatinine levels

##### Precautions

需依腎功能調整劑量。

#### Interferon Beta-1b

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Betaferon<sup>®</sup> 0.25mg/8MIU/vial <CINTER5>參閱 p.39

## Lamivudine

C Unknown

### Dosage Forms

Zeffix® 100mg/FC.tab <KLAMIV1>

3-TC® 150mg/FC.tab <KLAMIV2> 參閱 p.29

### Use

Chronic hepatitis B viral infection (Zeffix®), HIV infection(3-TC®)

### Dose

HBV infection (Zeffix)

Children 2-17 yrs: **PO** 3mg/kg qd; **max: 100mg/day**

Adults: **PO** 100mg qd

HIV infection (3-TC)

3 mon -16yrs children: **PO** 4mg/kg bid

Adults: **PO** 150mg bid or 300mg qd

### Adverse Reactions

Fatigue, headache, decreased appetite, nausea, vomiting, fat redistribution

### Precautions

需依腎功能調整劑量

## Entecavir

C Unknown

### Dosage Forms

Baraclude® 0.5mg/tab<KENTEC1>

Envir® 0.5mg/tab<KENTEC3>

### Use

Chronic hepatitis B

### Dose

Adult: **PO** 0.5-1 mg qd AC

### Adverse Reactions

Nausea, dizziness, headache, fatigue

### Precautions

1. 使用期限不得超過 2 年。

2. 需依腎功能調整劑量。

## Peginterferon Alfa-2a

C Unknown

### Dosage Forms

Pegasys® 135mcg/syringe <CPGIN1>

Pegasys® 180mcg/syringe <CPGIN2>

### Use

Chronic hepatitis C, chronic hepatitis B

### Dose

SC 135-180mcg/wk for 24-48 wks

### Adverse Reactions

Fatigue, fever, myalgia, headache, insomnia, alopecia, anxiety, irritability

### Precautions

1. 腎功能不良者(ESRD or HD)起始劑量為 135mcg。

2.須冷藏於 2-8°C 。

### Contraindications

自體免疫性肝炎患者、無代償機能之肝硬化患者、併有肝硬化且 Child-Pugh 分數 $\geq 6$  的 HIV-HCV 患者、新生兒及未滿 3 歲嬰兒。

### Peginterferon Alfa-2b

C Unknown

#### Dosage Forms

Peg-Intron® 80mcg/vial <CPEGIN4>  
Peg-Intron® 100mcg/vial <CPEGIN3>

#### Use

Chronic hepatitis C

#### Dose

Monotherapy: SC 0.5-1mcg/kg/wk for at least 6 mon

Combination: SC 1.5mcg/kg/wk with ribavirin 800-1200mg/day for 24-48wks

#### Adverse Reactions

Flu-like symptoms, injection site reactions, ophthalmologic disorders, bone marrow suppression, colitis, pancreatitis, psychiatric adverse events

#### Precautions

1.須冷藏2-8°C 。

2.調配後藥品須立即使用或在 2-8°C 保存不超過 24 小時。

3.需依腎功能調整劑量。

### Ribavirin

X Unknown

#### Dosage Forms

Ribarin® 200mg/cap <KRIBAVI>

#### Use

In combination with interferon alfa-2b for treatment of chronic hepatitis C in adult patients

#### Dose

Administration in two devided dose, in combination with interferon alfa-2b (3 MU tiw)

Adult $\leq$  75 kg: PO 1000mg/day (400mg qd + 600mg qn)

Adult $>$ 75 kg: PO 1200mg/day in 2 divided dose

#### Adverse Reactions

Fatigue, headache, anorexia, dyspepsia, nausea, rash, conjunctivitis, pancreatitis

#### Contraindications

Ccr (mL/min)  $<$  50 。

### Telbivudine

B Unknown

#### Dosage Forms

Sebivo® 600mg/tab <KTELBIV>

#### Use

Chronic hepatitis B viral infection

**Dose**

Adult and children ≥16 yr: **PO** 600mg qd

**Adverse Reactions**

Abdominal pain, finding of creatine kinase level (grade 3/4), headache, nasopharyngitis, upper respiratory infection, malaise and fatigue

**Precautions**

<16 yr不建議使用

### 3.10.2. Multiple Sclerosis

**Interferon Beta-1b****C<sup>1</sup> Unknown<sup>1</sup>****Dosage Forms**

Betaferon® 8MIU (0.25mg)/vial <CINTER5>

**Use**

Multiple sclerosis

**Dose**

Adult: **SC** 8 MIU(0.25mg) qod

**Adverse Reactions**

Flu-like symptoms, headache, local skin reactions, sweating, anaphylaxis, depression, mental disorders, elevated GOT/GPT levels, hypertension

**Precautions**

須冷藏於2-8°C。

### 3.11. Carbapenems

**Doripenem****B<sup>1</sup> Unknown<sup>1</sup>****Dosage Forms**

Finibax® 250mg/vial <CDORIPE>

**Use**

Complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis

**Dose**

Adult: **IVF** (rate: > 1 hr; critical ill patient > 4hrs) 500mg q8h

**Adverse Reactions**

Headache, nausea, diarrhea, phlebitis

**Precautions**

- 1.先加入 10ml 注射用水或 NS 溶解乾粉，再以 100mlNS 或 D5W 稀釋。
- 2.乾粉於 25°C 下儲存，乾粉經溶解後請於 1 小時內以稀釋液稀釋，經 NS 稀釋後於室溫下可儲存 12 小時，於 2-8°C 下可儲存 24 小時，經 D5W 稀釋後於室溫下可儲存 4 小時，於 2-8°C 下可儲存 24 小時。
- 3.勿與其他藥品混合施打。
- 4.需依腎功能調整劑量。

**Ertapenem****B<sup>1</sup> Unknown<sup>1</sup>**

## **Dosage Forms**

Invanz® 1g/vial <CERTAPE>

## **Use**

Complicated intra-abdominal infections, skin and skin structure infections, urinary tract infections, community acquired pneumonia, acute pelvic infections, septic abortion and postsurgical gynecologic infections

## **Dose**

Children 3 mon-12yrs: **IM/IV** 15mg/kg q12h for 3-14 days

Children ≥13 yrs and Adult : **IM/IV** 1g qd for 3-14 days

## **Adverse Reactions**

Diarrhea, nausea, vomiting, headache

## **Precautions**

- 1.不可與其他藥品混合或同時輸注，且不可使用含葡萄糖的稀釋液。
- 2.IV 注射的配製: 加入 10ml 的注射用水或 NS，充分搖動使藥品溶解並立刻以 50ml NS 稀釋，輸注的時間必須超過 30 分鐘。
- 3.IM 注射配製: 加入 3.2ml 的 1% 或 2% lidocaine HCl 注射液，充分搖動使藥品溶解。
- 4.稀釋後藥品必須在 6 小時內完成輸注，冷藏可保存 24 小時。
- 5.需依腎功能調整劑量。

## **Imipenem and Cilastatin**

**C** **Unknown**<sup>1</sup>

## **Dosage Forms**

Tienam® 500mg/vial <CIMIPE1>

## **Use**

Antibacterial activity includes pseudomonas aeruginosa, acinetobacter species, G(+) bacteria and anaerobes

## **Dose**

Children ≥3 mon: **IV** 15-25 mg/kg q6h; **max 2 g/day**

Adults: **IV** 250mg-1g q6-8h; **max 50mg/kg/day or 4g/day**

## **Adverse Reactions**

Diarrhea, nausea, vomiting, injection site pain, thrombophlebitis, seizures

## **Precautions**

- 1.Should be infused over 20-30 minutes for doses of 250-500mg
- 2.稀釋後於室溫下可貯放 4 小時，冷藏(4°C)可貯放 24 小時。
- 3.需依腎功能調整劑量。
- 4.Children less than 30kg with renal impairment, CNS infections or higher doses may increased seizure risk
- 5.不可與 Lactate 製品混合。

## **Meropenem**

**B** **Unknown**<sup>1</sup>

## **Dosage Forms**

Mepenem® 250mg/vial <CMEROPE>

## **Use**

Antibacterial activity includes pseudomonas aeruginosa, acinetobacter

species, G (+) bacteria and anaerobes, also indicated for bacterial meningitis in pediatric patients > 3 months of age caused by S. pneumoniae

### Dose

#### Intra-abdominal infections

Children: **IV** 20mg/kg q8h; **max 2g/dose q8h**

Adults: **IV** 0.5-1g q8h

#### Meningitis, bacterial

Children: **IV** 40mg/kg q8h; **max 2g/dose q8h**

Adults: **IV** 2g q8h

### Adverse Reactions

Diarrhea, nausea, headache, injection site inflammation, seizures (CNS disorders), toxic epidermal necrolysis, Steven-Johnson syndrome

### Precautions

1.不得使用注射用水稀釋。

2.以 $\geq$ 100ml 溶解，室溫下可存放 6 小時，5°C 可存放 24 小時。

3.需依腎功能調整劑量。

## 3.12. Cephalosporins

### 3.12.1. 1st Generations

#### Cefadroxil



#### Dosage Forms

Cefadroxil® 500mg/cap <KCEFADR>

#### Use

Susceptible G (+) bacterial infections, some G (-) bacilli

#### Dose

Children: **PO** 15mg/kg bid, **max: 2g/day**

Adults: **PO** 1-2g/day in 1-2 divided dose


#### Adverse Reactions

Diarrhea, nausea, vomiting, rash

#### Precautions

需依腎功能調整劑量。

#### Cefazolin



#### Dosage Forms

Stazolin® 1g/vial <CCEFA02>

#### Use

G (+) bacilli and cocci (except enterococcus), some G (-) bacilli including E. coli, Proteus and Klebsiella

#### Dose

Children: **IM/IV** 25-100mg/kg/day in 3-4 divided dose

Adults: **IM/IV** 1-2g q8h, depending on severity of infection, **max 12g/day**

## **Adverse Reactions**

Diarrhea, nausea, vomiting, pseudomembranous colitis

## **Precautions**

1.IV, slowly over 3-5min

2.靜脈注射可用 diswater、NS、D5W 稀釋，溶解後避光室溫下可保存  
48 小時，若使用 NS 溶解，請立即使用完畢。

3.需依腎功能調整劑量。

## **Cephalexin**

**B<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Ulex<sup>®</sup> 250mg/cap <KCEPHA1>

### **Use**

G (+) bacilli and cocci (except enterococcus), some G (-) bacilli including E. coli, Proteus and Klebsiella

### **Dose**

Children: **PO** 25-100mg/kg/day in 4 divided dose

Adults: **PO** 250mg-1g q6-12h

### **Adverse Reactions**

Abdominal pain, diarrhea, transient elevation in liver enzymes

## **3.12.2. 2nd Generations**

## **Cefmetazole**

**B<sup>1</sup> Unknown<sup>5</sup>**

### **Dosage Forms**

Cetazon<sup>®</sup> 500mg/vial <CCEFME1>

### **Use**

Infections caused by staphylococcus, streptococcus, pneumococcus, meningococcus

### **Dose**

Adults: **IV/IVF** 1-2g q8h; serious infection 2g q6h

### **Adverse Reactions**

Transient liver enzyme increases, rash, diarrhea, nausea, vomiting

### **Precautions**

1.乾粉可使用 Dis-water、NS、D5W 5ml 溶解。

2.需以 100ml 靜脈輸注時，請勿使用注射用蒸餾水稀釋。

3.稀釋後於室溫下可貯放 24 小時。

4.需依腎功能調整劑量。

## **Cefuroxime**

**B<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Cefuroxime<sup>®</sup> 750mg/vial <CCEFURO>

### **Use**

Infections caused by staphylococci, group B streptococci, H. influenzae, E. coli, Enterobacter, Salmonella and Klebsiella

### **Dose**

Children: **IM/IV** 30-100mg/kg/day in 3-4 divided dose

Infectious disorder of joint

Children ( $\geq$  3months): **IV** 50mg/kg q8h

Adults: **IM/IV** 750-1500mg q8-6h

**Adverse Reactions**

Local reactions at IV site, diarrhea, nausea

**Precautions**

1. Give IV bolus need over 3-5 minutes
2. 稀釋後溶液於室溫下可貯放24小時。
3. 需依腎功能調整劑量。

### 3.12.3. 3rd Generations

#### Cefixime

**B<sup>1</sup>** **Unknown<sup>1</sup>**

**Dosage Forms**

Cefiximycin<sup>®</sup> 100mg/cap <KCEFIXI>

**Use**

Urinary tract infections, otitis media, gonorrhea, respiratory infections due to susceptible organisms including S. Pneumoniae, S. pyogenes, H. influenzae and Enterobacteriaceae

**Dose**

Children 6 month-12 yrs: **PO** 8mg/kg/day in 1-2 divided dose

Adults: **PO** 100-400mg/day in 1-2 divided dose

**Adverse Reactions**

Abdominal pain, diarrhea, nausea, rash, urticaria, pruritus

**Precautions**

需依腎功能調整劑量。

#### Cefotaxime

**B<sup>1</sup>** **Safe<sup>1</sup>**

**Dosage Forms**

Claforan 2g/vial<CCFOT2>

**Use**

Most G(-) bacilli (not Pseudomonas) and G(+) cocci (not enterococcus), active against many penicillin-resistant pneumococci

**Dose**

Neonate<1wk: **IM/IV** 50mg/kg q12h

Neonate 1-4wks: **IM/IV** 50mg/kg q8h

Children 1month-2yrs and <50kg: **IM/IV** 100-200mg/kg/day in 4-6 divided dose

Adults: **IM/IV** 1-2g q6-8h, meningitis may require **IV** 2g q4-6h, **max 12g/day**

**Adverse Reactions**

GI effects ,diarrhea, nausea, vomiting, hypersensitivity, fever, pruritus rash,phlebitis and pain at injection site, Steven- Johnson syndrome, granulocytopenia, agranulocytosis.

## Precautions

1. 溶解後請儘速使用，稀釋後冷藏(2-8°C)可存放 24 小時。
2. 需依腎功能調整劑量。

## Ceftazidime

**B1** **Safe<sup>1</sup>**

### Dosage Forms

Tatumcef® 2g/vial <CCEFTA2>

### Use

Pseudomonas aeruginosa infection and infections due to other susceptible aerobic G (-) organisms

### Dose

Neonate ≥ 1 wk: **IV** 30-50mg/kg q8h

Neonate < 1 wk: **IV** 30mg/kg q12h

Children: **IV** 30-100mg/kg q8-12h, **max 6g/day** (meningitis 150mg/kg/day)

Adults: **IV/IM** 1-2g q8-12h, **max 6g/day**

### Adverse Reactions

Rash, diarrhea, injection site pain, phlebitis, seizures, encephalopathy, asterixis, neuromuscular excitability

### Precautions

1. 溶解後請儘速使用，稀釋後於室溫下可存放 18 小時，冷藏存放 7 天。
2. 需依腎功能調整劑量。

## Ceftriaxone

**B1** **Safe<sup>1</sup>**

### Dosage Forms

Sintrix® 1g/vial <CCEFTR1>

### Use

Lower respiratory tract infections, skin and skin structure infections, bone and joint infections, intra-abdominal and urinary tract infections, sepsis and meningitis due to susceptible organisms

### Dose

Children: **IV/IM** 25-37.5mg/kg q12h, **max 2g/day**; for serious infections 40-50 mg/kg q12h, **max 4g/day**; for meningitis **IV** 50mg/kg/day q12h, **max: 4g/day**

Adults: **IV/IM** 1-2g q12-24h; **max 4g/day**

### Adverse Reactions

Diarrhea, injection site pain, transient liver enzyme increases, rash, reversible gallbladder disease, immune-mediated hemolysis

### Precautions

1. 藥品乾粉使用 10ml 注射用水溶解，再以不含鈣溶液稀釋(0.9%NaCl, 0.45%NaCl+2.5 dextrose, D5W, D10W)。
2. 藥品配製後於 2-8°C 下可存放 48 小時，於 25°C 下可存放 24 小時。
3. 勿與 aminoglycoside 類抗生素混合或同時注射。
4. 不可與含鈣之溶液混合或併用；在注射 ceftriaxone 48 小時之後才能

再給予病患含鈣之溶液或其產品。

5. 需依腎功能調整劑量。

#### Contraindication

1. Hyperbilirubinemic neonates

2. ≤28 天的新生兒正在以靜脈注射方式接受含鈣藥品及營養品。

#### Flomoxef

**Unknown<sup>1</sup>**

#### Dosage Forms

Flumarin® 1000mg/vial <CFLOMO1>

#### Use

Respiratory tract infections, soft tissue infections, urinary tract infections, gynecologic infections

#### Dose

Children: **IV** 60-80mg/kg/day in 3-4 divided dose, for serious infection 150mg/kg/day in 3-4 divided dose

Adults: **IV** 1-2g q12h, for serious infection 4g/day in 2-4 divided dose

#### Adverse Reactions

Transient eosinophilia, thrombocytosis, slight reductions in erythrocyte count, Hb, Hct and leukocyte count, loose stool, stomatitis, numbness of tongue, rash

#### Precautions

1.配製後於室溫下可存放 6 小時，冷藏存放 24 小時。

2.對 penicillin 過敏者須審慎使用。

3.需依腎功能調整劑量。

### 3.12.4. 4th Generations

#### Cefepime

**B<sup>1</sup> Safe<sup>1</sup>**

#### Dosage Forms

Supecef® 500mg/vial <CCEFEPI>

#### Use

Treatment of urinary tract infections, monotherapy for febrile neutropenia, skin infections caused by Streptococcus pyogenes, moderate to severe pneumonia caused by pneumococcus, Pseudomonas aeruginosa and other G (-) organisms

#### Dose

Children >2 mon and ≤40 kg: 50 mg/kg q8h for 7-10 days; **max: 2 g q8h**

Children 1-2 month: 30 mg/kg q8 or 12h.

#### Mild to moderate UTI

Children >40 kg and adults: **IV/IM 0.5-1 g q12h;**

#### Mild to moderate infections other than UTI

Children >40 kg and adults: **IV/IM 1 g q12h;**

#### Severe infections other than UTI

Children >40 kg and adults: IV 2 g q12h;

#### Life-threatening infections:

Children >40 kg and adults: IV 2 g q8h.

#### Adverse Reactions

Headache, colitis, diarrhea, dyspepsia, local reactions, phlebitis, pain or inflammation, rash, encephalopathy, myoclonus, seizures

#### Precautions

1.稀釋後於室溫下可存放 24 小時，冷藏存放 7 天。

2.需依腎功能調整劑量。

### 3.13. Penicillins

#### 3.13.1. Natural Penicillins

##### Penicillin G Sodium

**B<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Penicillin<sup>®</sup> 3MU/vial [Na: 6mEq/vial]<CPENIC2>

#### Use

Infections caused by penicillin-sensitive organisms, eg: meningitis, pneumonia, endocarditis, GI, skin and soft tissue infection, syphilis, gonorrhea etc.

#### Dose

Infants and children: **IV/IM** 10-25MU/kg/day in 6 divided dose, **max 24MU/day**

Adults: **IV/IM** 12-24MU/day in 4-6 divided dose

#### Adverse Reactions

Convulsions, confusion, drowsiness, myoclonus, fever, rash, electrolyte imbalance, hemolytic anemia, thrombophlebitis, interstitial nephritis, anaphylaxis, Jarisch-Herxheimer reaction

#### Precautions

1.第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test。

2.需依腎功能調整劑量。

#### 3.13.2. Antistaphylococcal Penicillins

##### Dicloxacillin

**B<sup>1</sup>** Safe<sup>1</sup>

#### Dosage Forms

Ziefmycin<sup>®</sup> 250mg/cap <KDICLOX>

#### Use

Systemic infections such as pneumonia, skin and soft tissue infections, osteomyelitis caused by penicillinase-producing staphylococci

#### Dose

Children <40kg: **PO** 12.5-25mg/kg/day in 4 divided dose

Children ≥40kg and adults: **PO** 125-500mg q6h

#### Adverse Reactions

Nausea, diarrhea, abdominal pain

## Oxacillin

**B** **Safe<sup>1</sup>**

### Dosage Forms

Ocillina® 500mg/vial <COXACIL>

### Use

Susceptible bacterial infections such as osteomyelitis, septicemia, endocarditis, CNS infections due to susceptible strains of *Staphylococcus*

### Dose

Premature and neonates: **IV/IM** 25mg/kg/day

Children <40kg: **IV/IM** 12.5mg/kg q6h

Children ≥40kg and adults: **IV/IM** 250-2000mg q4-6h; **max:12g/day**

### Adverse Reactions

Fever, rash, nausea, diarrhea, vomiting, eosinophilia, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hepatotoxicity, increased AST, hematuria, acute interstitial nephritis, hematuria, serum sickness-like reactions

### Precautions

- 1.配製後溶液於室溫下可存放 3 天，冷藏存放 7 天。
- 2.第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test。

## 3.13.3. Aminopencillins

## Amoxicillin

**B** **Safe<sup>1</sup>**

### Dosage Forms

Amoxicillin® 250mg/cap <KAMOX01>

Amoxicillin® 500mg/cap <KAMOX02>

Amolin® powder suspension 3g/60ml/bot <KAMOXIC>

### Use

Otitis media, sinusitis, respiratory tract, skin, urinary tract infection, prophylaxis dental procedures, combination for eradication of *H. pylori*

### Dose

Children: **PO** 20-50mg/kg/day in 3 divided dose

Adults: **PO** 250-500mg q8h, **max 2-3g/day**, for *H. pylori* 1000mg bid

### Adverse Reactions

Agitation, anxiety, confusion, convulsions, dizziness, rashes, vasculitis, urticaria, nausea, vomiting, diarrhea, colitis, hemolytic anemia, hepatic cholestasis, eosinophilia, leucopenia, agranulocytosis, thrombocytopenia, elevated AST/ALT

### Precautions

- 1.液劑：先加入冷開水至箭頭處，貯存於冰箱，並在 7 天內使用。
- 2.需依腎功能調整劑量。

## Ampicillin

**B** **Safe<sup>1</sup>**

### Dosage Forms

Ampolin® 500mg/vial <CAMPI01>

### Use

Respiratory tract, GI infections, UTI, gonorrhea, septicemia, peritonitis, endocarditis, osteomyelitis, enteric fever

### Dose

Children <2 yrs: **IV/IM** 62.5-125mg q6h

Children 2-10 yrs: **IV/IM** 125-250mg/kg/day in 4 divided dose

Adults: **IV** 1-2g q4-6h or 50-250mg/day, **max 12g/day**

### Adverse Reactions

Rash, diarrhea, vomiting, candidiasis, abdominal cramps, allergic reaction

### Precautions

1.針劑：泡製後必須在 1 小時內用完；第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test。

2.需依腎功能調整劑量。

## Amoxicillin and Clavulanic acid

**B<sup>1</sup> Safe<sup>1</sup>**

### Dosage Forms

AmoClav® 600mg/vial, 1vial: Amoxicillin 500mg+ Clavulanic acid 100mg  
<CAUGM01>

AmoClav® 1.2g/vial, 1vial: Amoxicillin 1g+ Clavulanic acid 200mg  
<CAUGM02>

Curam® 1g/ tab, 1tab: Amoxicillin 875mg+ Clavulanic acid 125mg<KAUGM04>

Augmentin® Powder for syrup 457mg/5ml, 35ml/bot, 5ml: Amoxicillin 400mg+ Clavulanic acid 57mg <KAUGM02>

### Use

Otitis media, sinusitis, lower respiratory tract, skin and skin structure, urinary tract infection

### Dose

#### IV

Children 0-3 month: 25mg (amoxicillin)/kg q8-12h

Children 3 month-12 yrs: 25mg (amoxicillin)/kg q6-8h

Adults and children over 12yrs: 1g (amoxicillin) q6-8h

#### PO

Curam®: 1tab q12h

Syrup:

Children 2-6yrs: **PO** 2.5-5ml bid

Children 7-12yrs: **PO** 5-10ml tid

### Adverse Reactions

Diarrhea, colitis, rash, GI upset, candidiasis

### Precautions

1.Slow IV > 3-4 mins or IVF >30-40 mins and complete within 4 hrs

2.Curam 可撥半但不可咀嚼

3.Curam 不建議用於 12 歲以下兒童及腎絲球過濾率小於 30ml/min 的病患。

4.Syrup:將水加至瓶身上箭頭三分之二處，蓋上瓶蓋後充分振搖，確定溶解後將水加至箭頭處，配製後未使用完之藥液可於 2~8°C 下存

放 7 天。

- 5.針劑：第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test；泡製後須於 20 分鐘內使用完，稀釋後室溫下應於 4 小時內使用完畢，稀釋後於 5°C 下可儲存 8 小時。  
6.需依腎功能調整劑量。

## Subacillin® (Unasyn)

**B** **Safe<sup>1</sup>**

### Dosage Forms

1 vial: Ampicillin 1g+ Sulbactam 0.5g, 1.5g/vial < CUNASYN >

### Use

G (+) or G (-) including some anaerobes, acinetobacter infection

### Dose

Children >28day: **IM/IV** 25-75mg(ampicillin)/kg q6h

Adults: **IM/IV** 1-2g ampicillin (1.5-3g Subacillin) q6h; max: 8g/day  
ampicillin(12g/day Subacillin)

### Adverse Reactions

GI disturbances, skin rash, itching, blood disorders

### Precautions

1. IV/IM: 3.2ml Dis-water、NS、D5W、LR；配置後 1 小時內使用

2. 靜脈輸注：依據不同稀釋液及濃度使用期限如下表

稀釋液	Subacillin 濃度	使用期限(小時)	
		25°C	4°C
Dis-water	45mg/ml	8	48
	30mg/ml	-	72
NS	45mg/ml	8	48
	30mg/ml	-	72
D5W	15-30mg/ml	2	-
	3mg/ml	4	-
	30mg/ml	-	4
LR	45mg/ml	8	24

2. 第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test

3. 需依腎功能調整劑量。

## 3.13.4. Antipseudomonal Penicillins

### Piperacillin

**B** **Safe<sup>1</sup>**

### Dosage Forms

Picillina® 2g/vial (Na: 3.7mEq/vial) < CPIPER1 >

### Use

Susceptible infections such as septicemia, respiratory tract , skin and soft tissue and urinary tract infections due to susceptible strains of *Proteus*, *Pseudomonas*, *E. coli* and *Enterobacter*

### Dose

Neonates: **IV** 100-300mg/kg/day in 2-3 divided doses

Infants and children: **IV** 100-300mg/kg/day in 3-4 divided doses

Adults: **IV** 3-4g q4-6h, **max: 24g/day**, for UTI 2g q6h

#### Adverse Reactions

Diarrhea, colitis, rash, GI upset, candidiasis

#### Precautions

- 1.第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test。
- 2.需依腎功能調整劑量。

### **Tapimycin®**

**B<sup>1</sup> Safe<sup>1</sup>**

#### Dosage Forms

1vial: Piperacillin 4g+Tazobactam 0.5g [Na: 216mg/vial], 4.5g/vial  
<CPIPER3>

#### Use

Infections of lower respiratory tract, urinary tract, skin, gynecologic, bone and joint infections and activity of piperacillin to include beta-lactamase producing strains of S. aureus, H. influenza, bacteroides

#### Dose

Children ≥12 yrs and adults: **IV** 2.25-4.5g q6-8h, drip >30 mins

#### Adverse Reactions

Diarrhea, colitis, rash, GI upset, candidiasis

#### Precautions

- 1.第一次使用 penicillin 類之抗生素，建議執行 penicillin skin test。
- 2.稀釋後於室溫下可存放 24 小時，2-8°C 下存放 7 天。
- 3.需依腎功能調整劑量。

## 3.14. Quinolones

### **Ciprofloxacin**

**C<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Forms

Ciproxin® 200mg/100ml/bot <CCIPR1>

Cinolone® 250mg/tab <KCIPRO>

#### Use

Respiratory tract, ENT infections, cervicitis, uterine adnexitis, folliculitis, lymphangitis, mild to moderate skin and soft tissue infections

#### Dose

**IVF** 200-400mg q12h

**PO** 250-500mg q12h, for severe infection 750mg q12h

#### Adverse Reactions

Headache, restlessness, rash, nausea, diarrhea, vomiting, abdominal pain, elevated ALT/AST, elevated serum creatinine

#### Precautions

- 1.口服劑型避免與含鉛、鎂、鈣等制酸劑或鐵劑併用。
- 2.針劑移除外包裝後請於 3 天內使用完畢，開封後請立即使用。。
- 3.需依腎功能調整劑量。

## **Contraindication**

- 1.不建議使用於<18 yrs
- 2.併用 tizanidine

## **Levofloxacin**

**C Unknown<sup>1</sup>**

### **Dosage Forms**

Cravit® 250mg/50ml/vial <CLEVOFL>

Cravit® 500mg/tab<KKEVOFL>

Cravit® 0.5%, 5ml/bot <WLEVOFL> 參閱 p.271

### **Use**

Respiratory tract, ENT infections, intracterine infections, cervicitis, uterine adnexitis, folliculitis, lymphangitis, mild to moderate skin and soft tissue infectionsm,

### **Dose**

**IV/PO** 500-750mg qd

### **Adverse Reactions**

Dizziness, fever, headache, insomnia, nausea, vomiting, diarrhea, constipation

### **Precautions**

- 1.Should be infused slowly over 60 mins for doses of 250-500mg and over 90 mins for doses of 750mg
- 2.口服劑型避免與含鉛、鎂、鈣等制酸劑或鐵劑併用。
- 3.針劑移除外包裝後請於 3 天內使用完畢，開封後請立即使用。
- 4.口服可用於治療 chronic bacterial prostatitis (慢性細菌性前列腺炎)。
- 5.需依腎功能調整劑量。
- 6.健規：限用於成人(18 歲以上)之慢性支氣管炎的急性惡化、社區性肺炎、複雜性泌尿道感染。

## **Contraindication**

- 1.癲癇患者。
- 2.曾使用 Fluoroquinolones 有關的肌腱病變患者。
- 3.不建議使用於<18 yrs。
- 4.懷孕及哺乳女性。

## **Moxifloxacin**

**C Unknown<sup>1</sup>**

### **Dosage Forms**

Avelox® 400mg/250ml/bot <CMOXIFL>

Avelox® 400mg/tab <KMOXIFL>

Vigamox® 0.5%,5ml/bot<WMOXIFL> 參閱 p.272

### **Use**

Respiratory tract , skin and soft tissue infections and intra abdominal infections

### **Dose**

**IV/PO** 400mg qd for 5-14 days, depending on the specific infection

### **Adverse Reactions**

Dizziness, fever, headache, insomnia, nausea, vomiting, diarrhea

#### Precautions

1. IV infuse over 60 mins。
2. 口服劑型避免與含鉛、鎂、鈣等制酸劑或鐵劑併用。
3. 針劑開封稀釋後，在室溫下可貯存 24 小時。
4. 健規：限用於成人(十八歲以上)之慢性支氣管炎的急性惡化、社區性
5. 肺炎、複雜性腹腔內感染

#### Contraindications

1. 不建議使用於 <18 yrs。
2. 懷孕及哺乳女性。

### 3.15. Macrolides

#### Azithromycin

**B<sup>1</sup>** **Safe<sup>1</sup>**

##### Dosage Forms

Zithromax® 40mg/ml,15ml/bot <KAZIT02>

Zithromax® 250mg/tab <KAZIT01>

##### Use

Respiratory tract, skin and soft tissue infections, otitis media, uncomplicated genital infections due to Chlamydiatrachomatis and Neisseria gonorrhoeae

##### Dose

Children: **PO** 10mg/kg qd for 3 days

Adults: **PO** 500mg qd for 3 days

##### Adverse Reactions

Diarrhea, nausea, abdominal pain, vomiting

##### Precautions

健規：使用期間不得超過三日，每日最大劑量 500mg；禽結合桿菌(MAC)感染則不在此限。

#### Clarithromycin

**C<sup>1</sup>** **Unknown<sup>1</sup>**

##### Dosage Forms

Klaricid® XL 500mg/tab <KCLARIT>

##### Use

Respiratory tract, uncomplicated skin infection, eradication of H. pylori in patients with duodenal ulcer when used with omeprazole

##### Dose

Children>12 yrs and adults: **PO** 500mg qd, for H. pylori and MAC 500mg bid

##### Adverse Reactions

Dyscoordination, sedation, diarrhea, vomiting, headache, leukopenia, neutropenia, QT prolongation, thrombocytopenia, torsade de pointes

##### Precautions

1. 健規：使用期間不得超過 10 日，每日最大劑量 500mg。對於非結核分枝桿菌 (NTM) 感染患者，每日得使用 1000mg，且得持續使用 6 個月以上。
2. 服藥期間避免食用葡萄柚或葡萄柚汁。
3. 需依腎功能調整劑量。

## **Erythromycin**

**B<sup>1</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Erythrocin® lactobionate 500mg/vial < CERYTHR >

### **Use**

Infections due to G (+), G (-) cocci, G (+) bacilli including Legionella spp and Chlamydia

### **Dose**

#### Severe infection

Children: **IV** 15-50mg/kg/day administered by continuous infusion or q6h infusion 1-2 hrs, **max: 4g/day**

Adults: **IV** 1-4g/day

### **Adverse Reactions**

Diarrhea, nausea, abdominal pain, vomiting, oral candidiasis, dyspepsia, flatulence, anorexia, pancreatitis, eosinophilia, cholestatic jaundice

### **Precautions**

1. 注射劑建議 IVF 級藥，用 diswater 稀釋後，配製成 1-5mg/ml，溶液 >100ml 時輸注時間需超過 20-60 mins；不可以含 glucose 溶液稀釋。
2. 需依腎功能調整劑量。

## **3.16. Sulfonamides**

### **Sulfamethoxazole-Trimethoprim (SMZ-TMP)** **C<sup>1</sup> safe<sup>1</sup>**

### **Dosage Forms**

Sevtrim® 5ml/amp, 1amp: SMZ 400mg+TMP 80mg < CBAKTAR >

Chemix® 1 tab: SMZ 400mg+TMP 80mg < KBAKTA1 >

Sulfacotrim® susp 60ml/bot, 1ml: SMZ 40mg+TMP 8mg < KBAKTA2 >

### **Use**

Urinary tract infection, Pneumocystis carinii pneumonia, skin and genital infections

### **Dose**

**IV** 15-20mg TMP/kg/day q6-8h;

**PO** 2 tab q12h for 5 to 14 days

### **Suspension**

Children 6 wks-5 month: **PO** 2.5ml bid

Children 6 month-5 yrs: **PO** 5ml bid

Children 6-12 yrs: **PO** 10ml bid

**Adults:** **PO** 20ml bid

Prophylaxis of Pneumocystis carinii pneumonia (PCP)

**PO** 2 tab qd

Treatment of PCP

**IV/PO** 15-20mg TMP/kg/day tid-qid for 14-21days

#### **Adverse Reactions**

Hypoglycemia, anorexia, nausea, vomiting, diarrhea, Steven-Johnson syndrome, thrombocytopenia, jaundice, hepatitis, hyperkalemia

#### **Precautions**

1.需依腎功能調整劑量。

2.G6PD-deficiency 者應謹慎使用。

#### **Contraindications**

Neonate

### **3.17. Tetracyclines**

#### **Doxycycline**

**D<sup>1</sup>** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Doxymycin<sup>®</sup> 100mg/cap <KDOXYCY>

#### **Use**

Infections caused by susceptible Rickettsia, G (-) and G (+)

#### **Dose**

**PO** 100mg qd-q12h

#### **Adverse Reactions**

GI effects, photosensitivity, tooth discoloration

#### **Precautions**

1.Children <8 yrs, risk for permanent discoloration of teeth

2.避免與含鋁、鎂、鈣等制酸劑或鐵劑併用。

3.建議飯前 1 小時或飯後 2 小時服用避免與牛奶併服。

#### **Minocycline**

**D<sup>1</sup>** **Unsafe<sup>1</sup>**

#### **Dosage Form**

Borymycin<sup>®</sup> 100mg/cap <KMINOCY>

Mirosin<sup>®</sup> 100mg/vial <CMINOCY>

#### **Use**

Respiratory tract, soft tissue, acne vulgaris, ENT infection

#### **Dose**

**IV** initial 200mg then 100mg q12h

**PO** 100mg q12h

#### **Adverse Reactions**

GI disorders, tooth discolouration, photosensitivity

#### **Precautions**

1.Children <8 yrs, risk for permanent discoloration of teeth

2.避免與含鋁、鎂、鈣等制酸劑或鐵劑併用。

- 3.建議飯前 1 小時或飯後 2 小時服用避免與牛奶併服。
- 4.需依腎功能調整劑量。

### 3.18. Antimicrobial Miscellaneous

#### Clindamycin

**B<sup>1</sup>** **Safe<sup>1</sup>**

##### Dosage Forms

Clinclin® 300mg/2ml/vial <CCLINDA>

Tidact® 150mg/cap <KCLINDA>

Kolincin® acne gel 1%, 5g/tube <WCLIND1> 參閱p.131

##### Use

Aerobic and anaerobic streptococci (except enterococci), most staphylococci, pneumococci

##### Dose

###### Tablet

Children: **PO** 8-16mg/kg/day, more severe infections 16-20mg/kg/day

Adults: **PO** 150-300mg q6h, more severe infections 300-450mg q6h

###### Injection

Children: **IM/IV** 15-25mg/kg/day, more severe infections 25-40mg/kg/day in 3-4 divided dose

Adults: **IM/IV** 600-1200mg/day, more severe infections 1.2-2.7g/day in 2-4 divided doses, life-threatening infections 4.8g/day

##### Adverse Reactions

Diarrhea, urticaria, Stevens-Johnson syndrome, pseudomembranous colitis, nausea, vomiting, hypersensitivity, thrombocytopenia

##### Precautions

IM:一次劑量不可超過 600mg，而且必須深部注射。

IV:必須先經稀釋成濃度 12mg/ml 以下，然後再輸注投與。

#### Colistin

**C<sup>5</sup>** **Unknown<sup>1</sup>**

##### Dosage Forms

Colimycin® 2MU(colistin base 66.8mg)/vial<CCOLIST>

##### Use

Disease due to G(-) bacteria, P. aeruginosa, Enterobacter aerogenes, E. coli, and Klebsiella pneumoniae

##### Dose

**IM** 2.5-5mg colistin base/kg/day in 2-4 divided dose

**IV** (rate: over 3-5min)/**IVF** (rate: 5-6mg/hr) 2.5-5mg colistin base/kg/day in 2 divided dose

##### Adverse Reactions

Headache, GI upset, respiratory arrest, nephrotoxicity

##### Precautions

1.本品以 2ml 之滅菌注射用水或生理食鹽水溶解。

2.溶解後於室溫下可存放 7 天，冷藏可存放 14 天。

3. 本品以靜脈輸注方式投與，可用 NS, D5W/NS, D5W, D5W in 0.45% NaCl, D5W in 0.225% NaCl, LR 稀釋。
4. 稀釋後需於 24 小時內使用完畢。
5. 需依腎功能調整劑量，輸注速率須降低。

## Daptomycin

**B<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Cubicin® 500 mg/vial <CDAPTO1>

### Use

Bacteremia, endocarditi, infection of skin or subcutaneous tissue

### Dose

#### Complicated skin and skin structure infections

IVF (>30min) 4 mg/kg qd for 7-14 days.

#### Staphylococcus aureus bacteremia, including right-sided endocarditis

IVF (>30min) 6 mg/kg qd for 2-6 wks

### Adverse Reactions

Hypokalemia, constipation, diarrhea, injection site reaction

### Precautions

1. 本品輸注時間需大於 30 分鐘。
2. 本品需冷藏於 2-8°C，混合稀釋後室溫下可保存 12 小時，在 2-8°C 下可存放 48 小時。
3. 配製方法：將 7ml 之 NS 注射液加入藥瓶中，確定完全溶解後，靜置 10 分鐘，溶解後之 daptomycin 需以 NS 再稀釋，配製藥品時避免劇烈震動或搖晃藥瓶。
4. 需依腎功能調整劑量。
5. 可能導致 PT/INR 異常上升，如有此異常可於下次給藥前抽血監測。

## Fusidic acid

**B<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Fucidin® 250mg/tab <KFUSIDA>

Fusidic acid® cream 2%, 5g/tube <WFUSID1> 參閱 p.134

### Use

Osteomyelitis, skin and soft tissue infections due to Staphylococcus aureus

### Dose

PO 250-500mg tid

### Adverse Reactions

GI disturbances, jaundice, hypersensitivity reactions

### Precautions

1. 若發生黃疸時，應中止投藥直到血清內 bilirubin 值回復正常。
2. 應定期檢查肝功能。

## Linezolid

**C** Unknown<sup>1</sup>

### Dosage Forms

Zyvox® 600mg/300ml/bot <CLINEZO>

Zyvox® 600mg/tab <KLINEZO>

### Use

Methicillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant, Enterococcus faecium (VRE) infections, complicate or uncomplicated skin infection, nosocomial pneumonia, community acquired pneumonia (CAP),

### Dose

Children <11 yrs: **IVF/PO** 10mg/kg q8-12h for 10-14 days

Adults and ≥12 yrs: **IVF/PO** 600mg q12h for 10-14 day

### Adverse Reactions

Anemia, thrombocytopenia, leukopenia headache, chills, drug fever

### Precautions

1. IV infusion 級藥速率 30-120 分鐘。

2. 給予注射劑型時，請勿加入其他藥品。

3. 健規：骨髓炎(osteomyelitis)及心內膜炎(endocarditis)不建議使用。

## Metronidazole

**B** Unknown<sup>1</sup>

### Dosage Forms

SABS® 500mg/100ml/bot <CMETRON>

Frotin® 250mg/tab <KMETRON>

Free® gel(膚麗凝膠) 0.75%, 15gm/tube <WMETRO2> 參閱 p.135

Sutrol Gel-Vaginal® 7.5mg/g, 25g/tube <WMETRO1> 參閱 p.135

### Use

Anaerobic, protozoal, amebiasis, trichomoniasis pseudomembranous colitis, H. pylori

### Dose

#### Anaerobic infection

Children: **IV** 30mg/kg/day in 4 divided doses; **PO** 15-35mg/kg/day in 3 divided doses

Adults: **IV/PO** 500mg q6-8h

#### Amebiasis

Children: **PO** 35-50mg/kg/day q8h

Adults: **PO** 500-750mg q8h

#### Pseudomembranous colitis

Children: **PO** 20mg/kg/day in 3-4 divided doses

Adults: **PO** 250mg q6h or 500mg q8h

#### H. pylori

Adults: **PO** 500mg bid

### Adverse Reactions

Dizziness, headache, GI upset, loss of appetite, nausea, vomiting

### Precautions

需依腎功能調整劑量。

### Contraindications

SABS®:懷孕三個月內之婦女禁忌使用。

## Teicoplanin

Unknown<sup>1</sup>

## Dosage Forms

Targocid<sup>®</sup> 400mg/vial <CTEICO1>

## Use

Methicillin-resistant staphylococcus aureus (MRSA) or cephalosporin-allergic patients, prophylaxis for endocarditis

## Dose

### Moderate infections

Children < 14 yrs: **IM/IV** 10mg/kg q12h×3 doses, maintenance 6mg/kg qd

Adults: **IM/IV** loading 400mg (6mg/kg) single doses, maintenance 200mg (3mg/kg) qd

### Severe infections

Children <14 yrs: **IV** 10mg/kg q12h 3 doses, maintenance 10mg/kg qd

Adults: **IV** loading 400mg (6mg/kg) q12h×3 doses, maintenance 400mg (6mg/kg) qd; **max: 12mg/kg/day**

## Adverse Reactions

Local pain, allergic reactions, nausea, vomiting, diarrhea, eosinophilia, leukopenia

## Precautions

1.配製後應立即使用，未用完者應丟棄，但某些情況無法立即使用時，應於 2-8°C 保存，並於 24 小時內使用完畢。

2.需依腎功能調整劑量。

## Tigecycline

**D<sup>4</sup>** **Unknown<sup>1</sup>**

## Dosage Forms

Tygacil<sup>®</sup> 50mg/vial <CTIGECY>

## Use

Complicated skin and skin structure infections and complicated intra-abdominal infections

## Dose

**IV** 100 mg, followed by 50 mg q12h for 5-14 days

## Adverse Reactions

Abdominal pain, diarrhea, nausea, vomiting, thrombocytosis, headache

## Contraindications

18 歲以下病人安全性與療效評估尚未確立。

## Vancomycin

**C<sup>5</sup>** **Unsafe<sup>3</sup>**

## Dosage Forms

U-Vanco<sup>®</sup> 1g/vial <CVANCO1>

## Use

Methicillin-resistant staphylococcus aureus (MRSA) or cephalosporin-allergic patients, prophylaxis for endocarditis, pseudomembranous colitis

## Dose

Neonate and infant: **IV** initial 15mg/kg followed by 10mg/kg q8-12h

Children: **IV** 40mg/kg/day in 2-4 divided doses

Adults: **IV** 15mg/kg q12h

### Pseudomembranous colitis(PMC)

Children: **PO** 40mg/kg/day in 3-4 divided doses

Adult: **PO** 0.5-2g/day in 4 divided dose

### **Adverse Reactions**

Stomatitis, chills, drug fever, eosinophilia, thrombocytopenia, ototoxicity, renal failure, interstitial nephritis, Stevens-Johnson syndrome

### **Precautions**

1.給藥速率過快會造成 Red man syndrome 。

2.乾粉需先加入 20ml 滅菌注射用水溶解後，再以至少 200ml 5%

Dextrose 或 0.9% NaCl 稀釋，稀釋成 5mg/ml 溶液，給藥速率至少要 60 分鐘以上（或 <10mg/min）。

3.給藥速率：Adults :  $\geq 60\text{min}$  (或 <10mg/min) . Children、neonate & infant :  $\geq 60\text{min}$  。

4.乾粉以 20ml 注射用水溶解，可存放 14 天；稀釋後室溫下可存放 24 小時，冷藏可存放 96 小時。

5.需依腎功能調整劑量。

## 4. ANTINEOPLASTIC AGENTS

### 4.1. Chemo therapy

#### 4.1.1. Alkylating Agents

##### **Carboplatin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

##### **Dosage Forms**

Carboplatin<sup>®</sup> 150mg/15ml/vial <CCARB01>

##### **Use**

Ovarian cancer

##### **Dose**

IV total dose (mg): Target AUC (mg/ml/mimute) × (GFR[ml/min]+25)

##### **Adverse Reactions**

Myelosuppression, peripheral neuropathy, electrolyte disturbances, gastrointestinal disturbances

##### **Precautions**

- 1.需依肝腎功能調整劑量。
- 2.稀釋後於室溫下可保存 8 小時

##### **Contraindications**

禁用於曾對 cisplatin, 其他含鉑化合物, 或 mannitol 產生嚴重過敏反應的患者。

##### **Chlorambucil**

**D<sup>4</sup> Unsafe<sup>1</sup>**

##### **Dosage Forms**

Leukeran<sup>®</sup> 2mg/tab <KCHLOR1>

##### **Use**

Malignant lymphoma, follicular lymphomas

##### **Dose**

PO 0.1-0.2mg/kg/day for 3-6 wks then adjust for maintenance dose  
2mg/day

##### **Adverse Reactions**

Anemia, thrombocytopenia, gastrointestinal disturbances, Stevens-Johnson syndrome

##### **Precautions**

- 1.須避光冷藏。
- 2.本品刺激黏膜，不宜磨粉。

##### **Cisplatin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

##### **Dosage Forms**

Kemoplat<sup>®</sup> 50mg/50ml/vial<CCISP03>

##### **Use**

Bladder cancer, metastatic ovarian cancer, metastatic testicular cancer

##### **Dose**

Bladder cancer

IV 50-70mg/m<sup>2</sup> q3-4w

### Testicular cancer

IV 20mg/m<sup>2</sup>/day for 5 days q3-4w

### Ovarian cancer

IV 75-100mg/m<sup>2</sup> q4wks; **max: 120mg/m<sup>2</sup>**

### **Adverse Reactions**

Nephrotoxicity, ototoxicity, peripheral neuropathy, gastrointestinal disturbances, myelosuppression

### **Precautions**

- 1.需依肝腎功能調整劑量。
- 2.限用 0.3% 以上的含氯溶液稀釋。

## **Cyclophosphamide**

**D<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Syklofosfamid<sup>®</sup> 500mg/vial <CCYCL02>

Syklofosfamid<sup>®</sup> 50mg/tab <KCYCLOP>

### **Use**

Leukemias, lymphoma, multiple myeloma

### **Dose**

IV 40-50mg/kg for 2-5 days or 10-15mg/kg every 7-10 days or 3-5 mg/kg twice weekly; PO 1-5mg/kg/day

### **Adverse Reactions**

Alopecia, gastrointestinal disturbances, hemorrhagic cystitis, leukopenia

### **Precautions**

- 需依肝腎功能調整劑量。

## **Dacarbazine**

**C<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Form**

Dacarbazine<sup>®</sup> 200mg/vial <CDACARB>

### **Use**

Melanoma

### **Dose**

IV 250mg/m<sup>2</sup>/day for 5 days q3w

### **Adverse Reactions**

Myelosuppression, hepatotoxicity, gastrointestinal disturbances

### **Precautions**

- 需依肝腎功能調整劑量。

## **Estramustine**

**Unknown<sup>1</sup>**

### **Dosage Form**

Estracyt<sup>®</sup> 140mg/cap <KESTRA7>

### **Use**

Prostate cancer

### **Dose**

PO 560-1120mg (4-8 tab) bid-tid, recommended starting 560-840mg (4-6 tab)

## **Adverse Reactions**

Gastrointestinal disturbances, impotence, anemia, thromboembolism, angioneurotic edema

## **Precautions**

避免與牛奶或奶製品併服，建議空腹服用

## **Contraindications**

禁用於對 estradiol 和 nitrogen mustard 過敏的患者。

## **Ifosfamide**

**D****Unsafe<sup>1</sup>**

### **Dosage Form**

Holoxan® 2g/vial <CIFOSFA>

### **Use**

Bronchial carcinoma, testicular tumour, soft tissue sarcomas, malignant lymphomas, breast cancer, endometrial carcinoma, hypernephroma

### **Dose**

**IV** 1.2-2.4g/m<sup>2</sup>/day for 5 days, q3-4w

## **Adverse Reactions**

Hematuria, alopecia, nephrotoxicity, myelosuppression, nausea and vomiting

## **Precautions**

需依肝腎功能調整劑量。

## **Melphalan**

**D****Unsafe<sup>1</sup>**

### **Dosage Forms**

Alkeran® 2mg/tab <KMELPHA>

### **Use**

Multiple myeloma, ovarian cancer, polycythemia vera

### **Dose**

#### Multiple myeloma

**PO** 0.15mg/kg/day in divided doses for 4 days, q6w

#### Ovarian cancer

**PO** 0.2mg/kg/day for 5 days, q4-8w

#### Polycythemia vera

**PO** 6-10mg/day for 5-7 days, maintenance dose 2-6mg/wk

## **Adverse Reactions**

Myelosuppression, gastrointestinal disturbances, maculopapular rashes, hemolytic anemia, cystic fibrosis

## **Precautions**

1.需冷藏。

2.需依肝腎功能調整劑量。

## **Oxaliplatin**

**D****Unsafe<sup>1</sup>**

### **Dosage Forms**

Eloxatin® 50mg/10ml/vial <COXALI2>

### **Use**

Colorectal cancer, metastatic gastric cancer

## Dose

Colorectal cancer

IV 85mg/m<sup>2</sup> q2w

Metastatic gastric cancer

IV 130mg/m<sup>2</sup> q2w

## Adverse Reactions

Gastrointestinal disturbances, myelosuppression, alopecia, peripheral neuropathy, rash

## Precautions

1.需依肝腎功能調整劑量。

2.限用 D5W 稀釋。

## Temozolomide

**D** **Unsafe**

### Dosage Forms

Temodal® 20mg/cap <KTEMOZ1>

Temodal® 100mg/cap <KTEMOZ2>

### Use

Anaplastic astrocytoma

### Dose

Adults: PO 150-200mg/m<sup>2</sup>/day for 5 days, q4w

## Adverse Reactions

Gastrointestinal disturbances, myelosuppression, alopecia, headache, rash

## Contraindications

禁用於曾對 dacarbazine 產生過敏反應的患者。

## 4.1.2. Antimetabolites

### Capecitabine

**D** **Unsafe**

### Dosage Forms

Xeloda® 500mg/tab <KCAPECI>

### Use

Breast cancer, colorectal cancer, gastric cancer

### Dose

PO 2500mg/m<sup>2</sup>/day bid for 3 week cycle; 2 week on, 1 week off

## Adverse Reactions

Gastrointestinal disturbances, hand-foot syndrome, anemia, heart toxicity, peripheral neuropathy

## Precautions

1.需依肝腎功能調整劑量。

2.重大心臟疾病患者，治療時需小心謹慎。

### Cytarabine

**D** **Unsafe**

### Dosage Forms

Cytosar-U® 500mg/vial <CCYTAR3>

### Use

Leukemias

**Dose**

Acute non-lymphocytic leukemia

IV 100mg/m<sup>2</sup>/day continuous infusion for 7 days or every 12 hrs

Acute lymphocytic leukemia

IV 200mg/m<sup>2</sup>/day continuous infusion for 5 days

**Adverse Reactions**

Rash, neurotoxicity, peripheral neuropathy, gastrointestinal disturbances, myelosuppression

**Precautions**

需依肝腎功能調整劑量。

**D<sup>1</sup> Unsafe<sup>1</sup>**

**Fludarabine**

**Dosage Forms**

Fludara<sup>®</sup> 50mg/vial <CFLUDAR>

**Use**

Leukemia, non-Hodgkin's lymphoma

**Dose**

IV 25mg/m<sup>2</sup>/day for 5 days, repeated 28 days

**Adverse Reactions**

Myelosuppression, gastrointestinal disturbances, pneumonia, stomatitis, skin rash

**Precautions**

需依肝腎功能調整劑量。

**X<sup>4</sup> Unsafe<sup>1</sup>**

**Fluorouracil (5-FU)**

**Dosage Forms**

Fluoro-uracil<sup>®</sup> 1000mg/20ml/vial<CFLUOR5>

**Use**

Breast cancer, colorectal cancer

**Dose**

IV 0.5-1g or 10-20mg/kg qd or qod, total 8-15g

**Adverse Reactions**

Stomatitis, headache, alopecia, hand-foot syndrome, diarrhea

**Precautions**

需依肝腎功能調整劑量。

**D<sup>1</sup> Unsafe<sup>1</sup>**

**Gemcitabine**

**Dosage forms**

Gemmis<sup>®</sup> 200mg/6ml/vial <CGEMCIT>

**Use**

Pancreatic cancer, non-small-cell lung cancer, bladder cancer, metastatic breast cancer, ovarian cancer

**Dose**

Pancreatic cancer

IV 1000mg/m<sup>2</sup> qw, 7week on, 1 week off

### Non-small-cell lung cancer

**IV** 4-week schedule: 1000mg/m<sup>2</sup> at D1,D8,D15 repeated every 28 days  
3-week schedule: 1250mg/m<sup>2</sup> at D1,D8, repeated every 21 days

### Bladder cancer

**IV** 1000mg/m<sup>2</sup> at D1,D8,D15 repeated every 28 days

### Metastatic breast cancer

**IV** 1250mg/m<sup>2</sup> at D1,D8, repeated every 21 days

### Ovarian cancer

**IV** 1000mg/m<sup>2</sup> at D1,D8, repeated every 21 days

## **Adverse Reactions**

Proteinuria, flu-like symptoms, gastrointestinal disturbances, myelosuppression, rash

## **Precautions**

1. 需依肝腎功能調整劑量。
2. 限用 NS 稀釋。

## **Mercaptopurine (6-MP)**

**D<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Merpurine<sup>®</sup> 50mg/tab <KMERCAP>

### **Use**

Leukemia

### **Dose**

**PO** 2.5mg/kg/day may be increase up to 5mg/kg/day, maintenance 2.5mg/kg/day

## **Adverse Reactions**

Myelosuppression, gastrointestinal disturbances, jaundice

### **Contraindications**

Chronic lymphoid leukemia, Hodgkin's disease, malignant lymphoma 的患者禁止使用。

## **Methotrexate**

**X<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Methotrexate<sup>®</sup> 50mg/2ml/vial <CMETH01>

Methotrexate<sup>®</sup> 1g/10ml/vial <CMETH02>

Trexan<sup>®</sup> 2.5mg/tab <KMETHOT>

### **Use**

Trophoblastic neoplasms, leukaemia, lymphomas, psoriasis

### **Dose**

#### Trophoblastic neoplasm

**IM/PO** 15 to 30mg/day for 5 days; may repeat course 3 to 5 times with 1 or more week rest

#### Acute lymphoid leukemia

Induction: **IV** 3.3 mg/m<sup>2</sup>/day in combination with prednisone 60 mg/m<sup>2</sup>/day; maintenance: **IV** 2.5mg/kg every 14 days; **IM/PO** 30 mg/m<sup>2</sup>/week administered in 2 divided

#### Psoriasis

**IV/PO** initial 10 to 25mg/week or 2.5mg every 12 hour for 3 doses; **max:**

**30mg/day**

### **Adverse Reactions**

Ulceration stomatitis, leucopenia, gastrointestinal disturbances, neurotoxicity, Stevens-Johnson syndrome

### **Precautions**

1. 补充水份及鹼化尿液，以避免 methotrexate 及其代謝物在腎小管沉澱。
2. Calcium folinate 可中和 methotrexate 對造血器官的立即毒性。
3. 需依肝腎功能調整劑量。

## **Ufur®**

**D<sup>5</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

1 cap: Tegafur 100mg+Uracil 224mg <KTEGAFU>

### **Use**

Breast cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, lung cancer

### **Dose**

**PO** based on tegafur 500-800mg/day (300-350mg/m<sup>2</sup>/day) in 2-3 divided doses

### **Adverse Reactions**

Gastrointestinal disturbances, stomatitis, myelosuppression

## **Pemetrexed**

**D<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Alimta® 100mg/vial <CPMET1>

### **Use**

Non-small cell lung cancer, malignant mesothelioma

### **Dose**

**IV** 500 mg/m<sup>2</sup> on day 1, repeat cycle every 21-days

### **Adverse Reactions**

Gastrointestinal disturbances, peripheral neuropathy, rash, alopecia, pharyngitis, myelosuppression

### **Precautions**

1. 需依肝腎功能調整劑量。

2. 限用 NS 稀釋。

## **TS-1®**

**D<sup>5</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

1 cap: Tegafur 20mg+gimeracil 5.8mg+oteracil 19.6mg <KTS2>

### **Use**

Gastric cancer, pancreatic cancer

### **Dose**

**PO** Initial 40mg(tegafur)/dose for BSA<1.25, 50mg/dose for BSA 1.25-<1.5, 60mg/dose for BSA ≥ 1.5, twice daily, after breakfast and after the evening meal, for 28 consecutive days, followed by a 14-days rest.

**Maximum dose: 75mg/dose; minimum dose: 40mg/dose**

### **Adverse Reactions**

Leukopenia, neutropenia, decreased hemoglobin, anorexia, nausea

### **Precautions**

1.空腹會降低藥品之生體可用率，抗腫瘤效果，故須於飯後服用

2.建議兩週監測一次臨床檢查

### **Contraindications**

嚴重骨髓抑制、嚴重肝腎功能障礙、接受其他 fluoropyrimidine 類抗腫瘤劑、接受 flucytosine 治療、懷孕

## **4.1.3. Antibiotics**

### **Bleomycin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

#### **Dosage Forms**

Bleocin® 15mg/amp <CBLEOMY>

#### **Use**

Lymphoma, head-neck cancer, skin cancer, esophageal cancer

#### **Dose**

**IV/IM/IA/SC 10-20mg/m<sup>2</sup> 1-2 times/wk, max: 20mg/m<sup>2</sup>, max. cumulative: 400mg**

#### **Adverse Reactions**

Gastrointestinal disturbances, alopecia, fever, interstitial pneumonia, hyperpigmentation of skin

#### **Precautions**

需依肝腎功能調整劑量。

### **Doxorubicin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

#### **Dosage Forms**

Adriblastina® 10mg/vial <CDOXOR2>

#### **Use**

Leukemias, lymphomas, breast cancer, lung cancer, neuroblastoma, soft-tissue sarcomas-osteogenic

#### **Dose**

**IV 60-75mg/m<sup>2</sup> q3w; max cumulative: 550mg/m<sup>2</sup>**

#### **Adverse Reactions**

Cardiovascular disease, alopecia, nausea and vomiting, injection site extravasation

#### **Precautions**

1.需依肝腎功能調整劑量。

2.使用後 1-2 天尿液會呈紅色。

### **Doxorubicin liposomal**

**D<sup>4</sup> Unsafe<sup>1</sup>**

#### **Dosage Forms**

Lipo-Dox® 20mg/10ml/vial <CLIPODO>

#### **Use**

AIDS-related Kaposi's sarcoma, ovarian cancer, breast cancer, multiple

myeloma

### Dose

AIDS-related kaposi's sarcoma

**IV** 20mg/m<sup>2</sup> over 30 min q3w

Ovarian cancer, breast cancer

**IV** 50mg/m<sup>2</sup>/dose q4w.

Multiple myeloma

**IV** 40-60mg/m<sup>2</sup>/dose q3-4w.

### Adverse Reactions

Myelosuppression, cardiomyopathy, alopecia, stomatitis, palmar-plantar erythrodysesthesia

### Precautions

1.需依肝腎功能調整劑量。

2.限用 D5W 稀釋。(稀釋量: 90mg 以上用 500ml; 90mg 以下用 250ml)

## Epirubicin

**D**<sup>4</sup> **Unsafe**<sup>1</sup>

### Dosage Forms

Pharmorubicin<sup>®</sup> 10mg/vial <CEPIRU1>

Pharmorubicin<sup>®</sup> 50mg/vial <CEPIRU2>

### Use

Breast cancer, bladder cancer, malignant lymphoma, gastric cancer, lung cancer, ovarian cancer, soft-tissue sarcomas

### Dose

**IV** 60-90mg/m<sup>2</sup> q3w, **max. cumulative: 550-900mg/m<sup>2</sup>**

**Intravesically** 30-50mg qw for 8 wks

### Adverse Reactions

Breast cancer, bladder cancer, malignant lymphoma, gastric cancer, lung cancer, ovarian cancer, soft-tissue sarcomas

### Precautions

1.不可與 heparin 混合,在特定比例下二者混合會產生沉澱。

2.需依肝腎功能調整劑量。

## Hydroxyurea

**D**<sup>4</sup> **Unsafe**<sup>1</sup>

### Dosage Forms

Hydrea<sup>®</sup> 500mg/cap <KHYDR03>

### Use

Chronic myelogenous leukemia, cancer, malignant melanoma, ovarian cancer, sickle cell disease, radiation and for local control of the outer lip of the primary head and neck squamous cell carcinoma

### Dose

**PO** intermittent therapy: 80 mg/kg/day q3d; continuing therapy: 20-30 mg/kg/day qd

### Adverse Reactions

Myelosuppression, stomatitis, anorexia, nausea, vomiting, diarrhea, constipation, skin rash, Headache, dizziness

### Precautions

需依肝腎功能調整劑量。

## **Idarubicin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Zavedos® 5mg/vial <CIDARUB>

Zavedos® 5mg/cap <KIDARUB>

### **Use**

Acute non-lymphocytic leukemia(ANLL), acute lymphoblastic leukemia(ALL)

### **Dose**

IV 12mg/m<sup>2</sup>/day for 3 days; PO 15-30 mg/m<sup>2</sup>/day for 3 days;

### **Adverse Reactions**

Cardiotoxicity, myelosuppression, alopecia, stomatitis, hepatotoxicity, nausea, vomiting

### **Precautions**

1.尿液會呈紅色。

2.不可吸咬或咀嚼，使用本品應盡量避免開車或操作機器。

### **Contraindication**

針劑不可與 heparin 混合，會產生沉澱；也不建議與其他藥物混合。避免與任何鹼性溶液長時間接觸，會使本藥分解。

## **Mitomycin**

**D<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Mitomycin-C® 10mg/vial <CMITOM1>

### **Use**

Gastric carcinoma, bladder cancer, lung cancer, sarcoma, leukemia

### **Dose**

IV 10-20mg/m<sup>2</sup> q6-8w, max: 20mg/m<sup>2</sup>

Intravesically 20-40mg qw

### **Adverse Reactions**

Hemolytic uremic syndrome, nephrotoxicity, myelosuppression, nausea and vomiting, fever

### **Precautions**

需依肝腎功能調整劑量。

## **Mitoxantrone**

**D<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Mitoxantrone® 20mg/10ml/vial <CMITOXA>

### **Use**

Breast cancer,hepatoma,acute nonlymphocytic leukemia, multiple sclerosis

### **Dose**

Breast cancer and lymphomas

IV 14mg/m<sup>2</sup> q3w max: 14mg/m<sup>2</sup>

Non-lymphoblastic leukaemia

IV 12mg/m<sup>2</sup>/day for 5 days max: 14mg/m<sup>2</sup>

### **Adverse Reactions**

Myelosuppression, hepatotoxicity, vomiting, nausea, diarrhea, mucositis, alopecia

#### Precautions

- 1.投予期間必須監視心臟功能
- 2.投予後 24 小時候尿液呈藍綠色

### 4.1.4. Vinca Alkaloids

#### Docetaxel

D<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Nolbxol® 20mg/1ml/vial <CDOCET1>

#### Use

Breast cancer, non-small cell lung cancer, gastric cancer, head- neck cancer, prostate cancer

#### Dose

##### Breast cancer

IV 100mg/m<sup>2</sup> q3w

Non-small cell lung cancer, gastric cancer, head- neck cancer,

IV 75mg/m<sup>2</sup>

##### Prostate cancer

IV 75mg/m<sup>2</sup> q3w, repeat 4 cycles

#### Adverse Reactions

Neutropenia, GI disturbances, rash, peripheral neuropathy, systemic lupus erythematosus, Stevens-Johnson syndrome

#### Precautions

- 1.需依肝腎功能調整劑量。
- 2.建議稀釋後濃度 0.3-0.9 mg/ml，稀釋後於 25°C 下可保存 6 小時，若在非 PVC 輸注袋在 2-8°C 下可保存 48 小時。

#### Etoposide

D<sup>1</sup> Unsafe<sup>1</sup>

#### Dosage Forms

Vepesid® 50mg/cap <KETOPOS>

Fytosid® 100mg/5ml/vial <CTEOPOS>

#### Use

Small cell lung cancer, testicular cancer, Hodgkin's disease

#### Dose

##### Small cell lung cancer

IV 35mg/m<sup>2</sup>/day for 4 days or 50mg/m<sup>2</sup>/day for 5 days repeated 3-4 week

PO 100-200mg/m<sup>2</sup>/day for 1-5 days or 200mg/m<sup>2</sup>/day for 1<sup>st</sup>, 3<sup>rd</sup>, 5<sup>th</sup> days, repeated 3-4 week

##### Testicular cancer

IV 50-100mg/m<sup>2</sup>/day for 5 days

#### Adverse Reactions

Myelosuppression, alopecia, GI disturbances, anaphylaxis

#### Precautions

建議稀釋後濃度 0.2-0.4 mg/ml

## Paclitaxel

D<sup>1</sup> **Unsafe**<sup>1</sup>

### Dosage Forms

Formoxol® 150mg/25ml/vial <CPACLI3>

### Use

Breast cancer, ovarian cancer, nonsmall cell lung carcinoma, s-related kaposi's sarcoma, Breast cancer, ovarian cancer

### Dose

Ovarian cancer

**IV** 135-175 mg/m<sup>2</sup> over 3 hours q3w

Breast cancer

**IV** 175mg/m<sup>2</sup> over 3 hrs q3w

Nonsmall cell lung cancer

**IV** 135mg/m<sup>2</sup> over 3 hrs q3w

S-related Kaposi's sarcoma

**IV** 135 mg/m<sup>2</sup> over 3 hours q3w or 100 mg/m<sup>2</sup> over 3 hours q2w

### Adverse Reactions

Anemia, neutropenia, alopecia, myopathy, peripheral neuropathy, hypersensitivity reaction.

### Precautions

1.需依肝腎功能調整劑量。

2.不建議使用 PVC 塑膠容器及給藥組。

### Contraindications

禁用對於含 polyoxyl 35 篓麻油(純化)配方的藥品有嚴重過敏反應病史的患者

## Vinblastine

D<sup>1</sup> **Unknown**<sup>1</sup>

### Dosage Forms

Vinblastine® 10mg/10ml/vial <CVINBLA>

### Use

Hodgkin's disease, leukemias, malignant non-Hodgkin's lymphoma

### Dose

Adults: **IV** initial 3.7 mg/m<sup>2</sup>, usual dose 5.5-7.4 mg/m<sup>2</sup> every 7 days; **max: 18.5 mg/m<sup>2</sup>/dose**

### Adverse Reactions

Hypertension, alopecia, constipation , myelosuppression, malaise

### Precautions

1.For IV use only

2.需依肝腎功能調整劑量。

## Vincristine

D<sup>4</sup> **Unknown**<sup>1</sup>

### Dosage Forms

Vincristine® 1mg/1ml/vial <CVINCRI>

### Use

Acute lymphocytic leukaemia, malignant lymphomas, small cell lung cancer, Ewing's sarcoma, embryonal rhabdomyosarcoma,Wilm's tumour and retinoblastoma.

### Dose

Children  $\leq$  10kg or BSA  $>$  1m<sup>2</sup>: IV 0.05mg/kg qw  
Children  $<$  10kg or BSA  $\geq$  1m<sup>2</sup>: IV 1-2mg/m<sup>2</sup> qw  
Adults: 0.4-1.4mg/m<sup>2</sup> qwk; **max: 2mg/dose**

### Adverse Reactions

Alopecia, neuromyopathy, myelosuppression, nausea, vomiting

### Precautions

1. For IV use only
2. 需依肝腎功能調整劑量。

## Vinorelbine

**D<sup>1</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Navelbine® 20mg/soft cap <KVINORE>

### Use

Non-small cell lung cancer, metastatic breast cancer

### Dose

Monotherapy: PO 60mg/m<sup>2</sup>/week for 3 weeks then adjust for maintenance dose 80 mg/m<sup>2</sup>/week; **max: 120mg/week(60mg/m<sup>2</sup>);**

**160mg/week(80mg/m<sup>2</sup>)**

### Adverse Reactions

Myelosuppression, neuromyopathy, alopecia, pancreatitis, bronchospasm

### Precautions

1. 不宜以80mg/m<sup>2</sup>作為起始劑量，以免產生副作用。
2. 本品為軟膠囊(內容物為油狀，會刺激黏膜)必須整顆與冷開水服用，不可咀嚼或咬碎，並建議與食物同時併服。
3. 需冷藏。

### Contraindications

1. 避免與Phenytoin 或 CYP 450 inhibitor 併用。
2. 不建議與活體稀釋疫苗及 itraconazole 混合使用。

## 4.1.5. Proteasome Inhibitor Miscellaneous

## Asparaginase

**C<sup>4</sup> Unsafe<sup>4</sup>**

### Dosage Forms

Leunase® 10000KU(kallikrein unit)/vial(=10000U/vial) <CASPAR1>

### Use

Acute lymphocytic leukemia, lymphoma

### Dose

IVF 50-200ku/kg qd or qod

### Adverse Reactions

Fever, nausea and vomiting , anorexia, analphylaxis, pancreatitis

### Precautions

An intradermal skin test is recommended (1-10KU/0.1ml)

## All-trans-retinoic acid (Tretinoin)

**D<sup>1</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Vesanoid® 10mg/cap <KTRETIN>

**Use**

Acute promyelocytic leukemia (APL)

**Dose**

PO 45mg/m<sup>2</sup>/day bid

**Adverse Reactions**

Dry skin, mucous membrane dryness, rash, nausea, vomiting, skin irritation

**Precautions**

保持藥瓶密封，應避光及熱(不超過 30°C)。

**Contraindications**

治療時或停止治療一個月內可能懷孕之婦女禁用。

**Irinotecan**

**D<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Innocan® 100mg/5ml/vial <CIRINOT>

**Use**

Colorectal carcinoma

**Dose**

IV 350mg/m<sup>2</sup> q3w

**Adverse Reactions**

Diarrhea (early and late), alopecia, GI disturbances, neutropenia, cholinergic syndrome

**Precautions**

1.需依肝腎功能調整劑量。

2.即使患者在之前的治療週期曾經發生延遲性腹瀉也不可以預性的給予 loperamide。

3.建議稀釋後濃度 0.12-2.8 mg/ml，稀釋後於室溫下可保存 12 小時，在 2-8°C 下可保存 24 小時。

**Contraindications**

禁用於慢性發炎性腸道疾病或腸阻塞之患者。

**Topotecan**

**D<sup>4</sup> Unsafe<sup>1</sup>**

**Dosage Forms**

Topotecan® 4mg/vial <CTOPOTE>

**Use**

Small cell lung cancer, ovarian cancer, cervical cancer

**Dose**

Small cell lung cancer, ovarian cancer

IV 1.5mg/m<sup>2</sup> for 5 days, repeat 4 cycle

Cervical cancer

IV 0.75mg/m<sup>2</sup> for first 3days

**Adverse Reactions**

Alopecia, GI disturbances, myelosuppression, infection, anorexia, interstitial pneumonia

**Precautions**

1. 需依肝腎功能調整劑量。
2. 未開封需冷藏，以 D5W 或 NS 稀釋至 0.01-0.05mg/ml，冷藏可存放 24 小時。

### **Thalidomide**

**X** **Unsafe<sup>1</sup>**

#### **Dosage Forms**

Thado<sup>®</sup> 50mg/cap <KTHALID>

#### **Use**

Erythema nodosum leprosum (ENL), multiple myeloma

#### **Dose**

Erythema nodosum leprosum

**PO** initial 100-300mg 1 hr after dinner or at bedtime; **max: 400mg/day**

Multiple myeloma

**PO** 200mg qd; **max: 400mg/day**

#### **Adverse Reactions**

Dizziness, peripheral neuropathy, edema, hypocalcemia, leucopenia, deep venous thrombosis,

#### **Precations**

1. 簽署病患(男/女)同意書，了解此藥可能造成畸胎之危險性，服前後一個月期間應避孕。
2. 會加強 barbiturates、酒精、chlorpromazine 及 reserpine 的鎮靜作用。

## **4.2. Hormone Antagonists**

### **4.2.1 Antiandrogen**

#### **Bicalutamide**

**X** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Casodex<sup>®</sup> 50mg/tab <KBICALU>

#### **Use**

Metastatic prostate cancer (combination with GnRH analog)

#### **Dose**

**PO** 50mg qd

#### **Adverse Reactions**

Hot flashes, nausea, anemia, dizziness, hematuria, gynecomastia

#### **Precautions**

需依肝腎功能調整劑量。

#### **Cyproterone**

**B** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Androcur<sup>®</sup> 50mg/tab <KCYPR03>

#### **Use**

Prostatic carcinoma (palliative treatment)

#### **Dose**

**PO** initial 300mg/day bid-tid, maintenance 200-300mg/day

### **Adverse Reactions**

Hepatotoxicity, anemia, myocardial ischemia, edema, thromboembolic disease, impotence, gynecomastia

### **Flutamide**

**D<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Fugerel<sup>®</sup> 250mg/tab <KFLUTAM>

#### **Use**

Prostatic carcinoma (palliative treatment)

#### **Dose**

**PO** 250mg tid

#### **Adverse Reactions**

Hepatotoxicity, weight change, impotence, gynecomastia, anemia, hot flashes, fatigue

#### **Precautions**

1. 服用本藥前四個月需每月檢測肝功能。
2. 深色尿液(琥珀色或黃綠色)

## **4.2.2 Antiestrogens**

### **Tamoxifen**

**D<sup>4</sup> Unsafe<sup>1</sup>**

#### **Dosage Form**

Nolvadex<sup>®</sup> 10mg/tab <KTAMOXI>

#### **Use**

Metastatic breast cancer, adjuvant therapy after surgery for breast cancer

#### **Dose**

**PO** 10-20mg bid or 40mg qd

#### **Adverse Reactions**

Hot flashes, vaginal bleeding, genital itching, tumor flare, fluid retention

#### **Precautions**

停經前婦女使用本藥品，月經會受抑制

## **4.2.3. Gonadotropine-Releasing Hormone Analogs**

### **Goserelin**

**X<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Zoladex<sup>®</sup> Depot 3.6mg/syringe <CGOSERE>

#### **Use**

Prostate carcinoma, endometriosis, advanced breast cancer, thin endometrium before surgery and shrink uterine fibroids, assisted reproduction

#### **Dose**

**SC** 3.6mg every 28 days

#### **Adverse Reactions**

Headache, hot flashes, sexual dysfunction, bone pain, skin rash

### **Leuprorelin depot**

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Leuplin® Depot 3.75mg/syringe <CLEUPR2>

Leuplin® Depot 11.25mg/syringe <CLEUPR1>

### **Use**

Prostate carcinoma, endometriosis, central precocious puberty, premenopausal breast cancer, anemia(uterine leiomyoma, preoperatively)

### **Dose**

Leuplin 3.75mg/vial

#### Central precocious puberty

**SC** 0.03mg/kg q4w, titrated upward in 0.09mg/kg

Endometriosis, premenopausal breast cancer, prostatic cancer

**SC** 3.75mg q4w

Anemia(uterine leiomyoma, preoperatively)

**SC** 1.88-3.75mg q4w

Leuplin 11.25mg/syringe

#### Prostate cancer

**SC** 1 syringe every 3 month

#### Endometriosis

**SC** 1 syringe every 3 month up to 2 doses

#### Uterine leiomyomata

**SC** 1 syringe as a single injection

### **Adverse Reactions**

Amenorrhea, depression, pain, hot flashes, weight gain, nausea, vomiting, arrhythmias, edema, palpitation, dizziness, lethargy, insomnia, headache, rash

### **Precautions**

1.限 SC (IV 易引起血栓症)

2.定期監控病人之血糖及/或糖化血紅素 (HbA1c) 以及心血管疾病之相關徵兆。

3.注射部位應在上臂部、腹部、臀部的皮下區，且應每次變換，勿重覆注射同一部位。

## **Leuproreotide acetate**

X<sup>4</sup> Unknown<sup>1</sup>

### **Dosage Forms**

Leuproreotide acetate 5mg/ml, 2.8ml/vial<CLEUPRO>

### **Use**

Advanced prostate cancer (palliative treatment)

### **Dose**

**SC** 1mg (0.2 ml) single dose qd

### **Adverse Reactions**

Flushing, dizziness, headache, edema, nausea, vomiting

### **Precautions**

需冷藏或於 25°C 以下儲存。

## **4.2.4. Progestins**

## **Megestrol**

**X** **Unknown<sup>1</sup>**

### **Dosage Forms**

Megejohn® 160mg/tab <KMEGES2>

Megest Oral Suspension 40mg/ml, 120ml/bot <KMEGES3>

### **Use**

Tablet: Palliative treatment of breast and endometrial carcinomas

Suspension:後天免疫缺乏症候群患者及癌症患者的厭食症

### **Dose**

Tablet: **PO** 160mg qd

Suspension: **PO** 160-200mg/day (4-5ml); **max: 400mg/day (10ml)**

### **Adverse Reactions**

Allergic rash, headache, fever, diarrhea

## **4.2.5. Aromatase Inhibitors**

### **Anastrozole**

**D** **Unknown<sup>1</sup>**

### **Dosage Forms**

Anazo® 1mg/FC. tab <KANASTR>

### **Use**

Adjuvant treatment of postmenopausal early breast cancer

### **Dose**

**PO** 1mg qd

### **Adverse Reactions**

Headache, weakness, arthritis, bone pain, vaginal dryness, nausea, vomiting, diarrhea

### **Letrozole**

**D** **Unknown<sup>1</sup>**

### **Dosage Forms**

Femara® 2.5mg/FC. tab <KLETRO>

### **Use**

Breast cancer in postmenopausal women

### **Dose**

**PO** 2.5mg qd

### **Adverse Reactions**

Hot flushes, headache, fatigue, nausea, bone pain, back pain, cough, dyspnea

### **Exemestane**

**D** **Unknown<sup>1</sup>**

### **Dosage Forms**

Aromasin® 25mg/S.C tab <KEXEMES>

### **Use**

Breast cancer, advanced postmenopausal, following progression on tamoxifen therapy

### **Dose**

**PO** 25mg qd

### **Adverse Reactions**

Diaphoresis, hot flash, nausea, arthralgia, headache, insomnia, fatigue

## 4.3. Target therapy

### 4.3.1. Monoclonal Antibodies

#### Bevacizumab

C<sup>1</sup> **Unsafe<sup>1</sup>**

##### Dosage Forms

Avastin® 100mg/vial <CBEVACI>

##### Use

Metastatic colorectal cancer, metastatic breast cancer, glioblastoma  
nonsquamous non-small cell lung cancer

##### Dose

Metastatic colorectal cancer

**IV** first-line: 5mg/kg q2w; second-line 10mg/kg q2w or 15mg/kg q3w

Metastatic breast cancer

**IV** 10mg/kg q2w

Glioblastoma

**IV** 10mg/kg q2w or 15mg/kg q3w

Nonsquamous non-small cell lung cancer

**IV** 15mg/kg q3w

##### Adverse Reactions

Abdominal pain, proteinuria, hypertension, hemorrhage, asthenia

##### Precautions

限用 NS 稀釋(稀釋後濃度 1.4-16.5mg/ml)。

#### Cetuximab

C<sup>1</sup> **Unsafe<sup>1</sup>**

##### Dosage Forms

Erbixut® 100mg/20ml/vial<CCETUX2>

##### Use

Metastatic colorectal cancer, metastatic or recurrent squamous cell head  
and neck cancer

##### Dose

**IV** initial 400mg/m<sup>2</sup>, loading dose 250mg/m<sup>2</sup> weekly

##### Adverse Reactions

Acneiform eruption, hypomagnesemia, infusion-related reaction, increase  
in liver enzyme levels

##### Precautions

原液給藥，限用 NS flush set

#### Pertuzumab

D<sup>4</sup> **Unknown<sup>1</sup>**

##### Dosage Forms

Perjeta® 420mg/vial<CPERTUZ>

##### Use

Metastatic breast cancer, HER2 overexpression, first-line, in combination  
with trastuzumab and docetaxel

## Dose

IV initial 840mg (infusion time :60min), then 420mg q3w (infusion time: 30-60min)

## Adverse Reactions

Diarrhea, alopecia, neutropenia, nausea, fatigue, neuropathy

## Precautions

1. 本品需自費、需冷藏，由化療室調配
2. 以 250ml NS 溶液稀釋，禁用 D5W 溶液稀釋，配製後於 2-8°C 下可存放 24 小時。
3. 限以靜脈輸注給藥，不可靜脈推注或快速灌注給藥。
4. Pertuzumab、Trastuzumab、Docetaxel 應依序給藥，每次輸注後及任一藥物輸注前建議觀察 30-60 分鐘。

## Rituximab

**C<sup>4</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Mabthera® 100mg/10ml/vial <CRITUXI>

Mabthera® 500mg/50ml/vial <CRITUX5>

### Use

Non-Hodgkin's lymphoma(low-grade, diffuse and follicular B-cell,), chronic lymphoid leukemia, rheumatoid arthritis

### Dose

#### Non-Hodgkin's lymphoma

IV induction: 375mg/m<sup>2</sup> q3w for 4-8wks; relapsed or refractory: 375mg/m<sup>2</sup> weekly for 4-8 doses; maintenance: 375mg/m<sup>2</sup> every 8 weeks for 12doses

#### Chronic lymphoid leukemia

IV 375mg/m<sup>2</sup> and 500 mg/m<sup>2</sup> for all subsequent cycles (2 to 6)

#### Rheumatoid arthritis

IV 500-1000mg/day followed by a second 500-1000 mg 2 weeks later

## Adverse Reactions

Peripheral edema, pruritus, anemia, fever, infusion reaction

## Trastuzumab

**B<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

Herceptin® 440mg/vial <CTRASTU>

### Use

HER2 over expression: adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer

### Dose

IV loading dose is 4mg/kg, subsequent doses 2mg/kg qw; or loading dose is 8mg/kg, subsequent doses 4mg/kg q3w.

## Adverse Reactions

Gastrointestinal disturbances, neutropenia, infectious disease, infusion reaction, cardiomyopathy, pulmonary toxicity

## Precautions

限用 NS 稀釋。

### 4.3.2. Protein-Tyrosine Kinase Inhibitors

#### Afatinib

D<sup>5</sup> Unknown<sup>3</sup>

##### Dosage Forms

Giotrif 30mg/tab <KAFATI3>

Giotrif 40mg/tab <KAFATI4>

##### Use

Non-small cell lung cancer

##### Dose

PO 40mg QDAC; max:50mg/day

##### Adverse Reactions

Diarrhea, stomatitis, rash, decrease appetite, paronychia

##### Precautions

- 1.不可在服藥前 3 小時內進食或服藥後 1 小時內進食；需整粒吞服
- 2.無法吞服整粒錠劑，可將藥錠放入 100ml 飲用水(非碳酸類)中崩散，攪拌直到錠劑崩散成極小的顆粒(約 15 分鐘)後立即飲用，再以 100ml 水沖洗杯緣並喝下
- 3.治療期間及使用最後一劑藥物後至少兩週內應採取適當避孕措施
- 4.須曬太陽的病患建議穿著保護衣物或使用防曬乳

#### Axitinib

D<sup>5</sup> Unknown<sup>3</sup>

##### Dosage Forms

Inlyta<sup>®</sup> 1mg/tab <KAXITIN>

##### Use

Treatment of advanced renal cell carcinoma after failure of one prior systemic therapy

##### Dose

PO 5mg q12h; max:10mg q12h

##### Adverse Reactions

Diarrhea, hypertension, fatigue, decreased appetite, nausea

##### Precautions

- 1.欲進行手術，應停用 Inlyta 治療至少 24 小時
- 2.須依肝腎功能調整劑量

#### Crizotinib

D<sup>5</sup> Unknown<sup>3</sup>

##### Dosage Forms

Xalkori<sup>®</sup> 250mg/cap <KCRIZOT>

##### Use

Treatment of patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive

##### Dose

PO 250mg bid; max: 500mg/day

##### Adverse Reactions

Visual disturbance, vomiting, nausea, diarrhea, constipation

##### Precautions

1. 膠囊應整粒吞服，不可壓碎、溶解或打開。
2. 避免食用葡萄柚或葡萄柚汁，可能造成藥物濃度增加；避免使用聖約翰草，可能降低藥物濃度。
3. 需依肝腎功能調整劑量。
4. 治療期間應避孕，完成治療後亦應避孕至少 90 天。

## **Dasatinib**

**D<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Sprycel® 50mg/tab<KDASATI>

### **Use**

Chronic myeloid leukemia(blastic, accelerated, chronic phase), acute lymphoid leukemia, philadelphia chromosome-positive

### **Dose**

Chronic phase chronic myeloid leukemia

**PO** 100mg qd, escalate dose to 140mg/day

Chronic myeloid leukemia(blastic, accelerated phase)

**PO** 140mg qd, escalate dose to 180mg/day

Acute lymphoid leukemia

**PO** 140mg qd, escalate dose to 180mg/day

### **Adverse Reactions**

Abdominal pain, headache, musculoskeletal pain, dyspnea, body fluid retention, myelosuppression

### **Precautions**

1. 本品不可磨碎切割，整粒吞服

2. 與 CYP3A4 inducer 或 CYP3A4 inhibitor 併用會影響本品濃度。如需併用制酸劑，應在給與 dasatinib 之前或之後至少 2 小時給藥

### **Contraindications**

不建議與 H2 blocker 或 PPI 併用。

## **Erlotinib**

**D<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Tarceva® 150mg/tab <KERLOTI>

### **Use**

Non-small cell lung cancer

### **Dose**

Adults: **PO** 150mg qd AC

### **Adverse Reactions**

Rash, diarrhea, loss of appetite, nausea, vomiting, conjunctivitis, keratoconjunctivitis sicca, fatigue

### **Precautions**

1. 服藥期間避免食用葡萄柚或葡萄柚汁。

2. 需依肝腎功能調整劑量。

## **Gefitinib**

**D<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Iressa® 250mg/tab <KGEFITI>

**Use**

Non-small cell lung cancer

**Dose**

Adults: **PO** 250mg qd AC

**Adverse Reactions**

Anorexia, nausea, vomiting, acne, dry skin, pruritus, asthenia, diarrhea

**Precautions**

間質性肺病(ICD)應停用

**D<sup>4</sup> Unsafe<sup>1</sup>**

**Imatinib**

**Dosage Forms**

Glivec® 100mg/F.C tab <KIMATIN>

**Use**

Chronic myelogenous leukemia, gastrointestinal stromal tumors, dermatofibrosarcoma protuberans (DFSP)

**Dose**

**PO** 400-600mg qd, **max: 800 mg/day**

**Adverse Reactions**

Fluid retention, headache, fatigue, fever, rash, hypokalemia, nausea, vomiting, dyspepsia, abdominal pain, weight gain, hematologic toxicity

**Precautions**

需依肝腎功能調整劑量

**D<sup>4</sup> Unknown<sup>1</sup>**

**Lapatinib**

**Dosage Forms**

Tykerb® 250mg/tab <KLAPATI >

**Use**

Advanced or metastatic breast cancer, HER2 overexpression, in combination with capecitabine after prior

**Dose**

Combination with capecitabine

**PO** 1250mg/day (5table/day) AC

**Adverse Reactions**

Loss of appetite, depression of left ventricular systolic function, diarrhea, nausea, vomiting, rash, fatigue

**Precautions**

1.患者有間質性肺疾/肺炎症狀且 LVEF 功能下降至第 3 級時需停藥，兩週後待 LVEF 回復正常值時得以低劑量(1000mg/day)重新開始使用。

2.服藥期間應避免同時使用葡萄柚汁。

3.需依肝腎功能調整劑量。

**Unknown<sup>1</sup>**

**Pazopanib**

**Dosage Forms**

Votrient® 200mg/FC. tab <KPAZOPA>

## **Use**

Renal cell carcinoma

## **Dose**

PO 800mg QDAC (at least 1 hour before or 2 hours after a meal), max: 800mg/day

If a dose is missed, it should not be taken if it is less than 12 hours until the next dose

初次劑量調降時應調整為 400mg，接續的劑量減少或增加應根據個別患者的耐受性，每次調整 200mg，劑量不應超過 800 mg。

## **Adverse Reactions**

Diarrhea, hypertension, hair color changes, nausea, anorexia

## **Precautions**

1. 請勿壓碎藥錠
2. 治療期間頭髮或皮膚可能發生色素脫失
3. 如有眼白與皮膚泛黃、不尋常深色尿液、異常疲倦、右上腹疼痛等症狀時應立即通知醫療人員。

## **Regorafenib**

**D<sup>5</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Stivarga<sup>®</sup> 40mg/tab <KREGORA>

### **Use**

Metastatic colorectal cancer, gastrointestinal stromal tumor

### **Dose**

**PO** 160mg QD for the first 21 days of each 28-day cycle, continue until disease progression or unacceptable toxicity

## **Adverse Reactions**

Fatigue, hand-foot skin reaction, diarrhea, appetite decreased, hypertension

## **Precautions**

1. 藥品開封後請旋緊瓶蓋，開瓶 7 週後，請將瓶中未使用藥物丟棄。
2. 服用時請整粒吞服，並配合低脂飲食(脂肪含量低於 30%)。
3. 請勿為了補足前一天忘記服用藥量，於同一日服用兩倍劑量
4. 治療期間及治療完成後 2 個月以上，需採取有效避孕措施。

## **Sorafenib**

**D<sup>5</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

Nexavar<sup>®</sup> 200mg/cap<KSORAFE>

### **Use**

Liver carcinoma, renal cell carcinoma

### **Dose**

**PO** 400mg bid AC

## **Adverse Reactions**

Alopecia, hand-foot syndrome, rash, diarrhea, hypophosphatemia, abdominal pain, increased amylase or lipase level, fatigue

## **Precautions**

本品會導致 Doxorubicin 之 AUC 增加，併服時須謹慎小心。

## Sunitinib

D<sup>1</sup> **Unsafe**<sup>1</sup>

### Dosage Forms

Sutent® 12.5mg/cap <KSUNITI>

### Use

Gastrointestinal stromal tumor, renal cell carcinoma

### Dose

PO 50mg qd with a cycle of 4 weeks on followed by 2 weeks off

### Adverse Reactions

Left ventricular dysfunction, bleeding, thrombocytopenia, discoloration of skin, hypothyroidism

### Precautions

服藥期間避免食用葡萄柚或葡萄柚汁。

## 4.3.3. Proteasome Inhibitor

## Bortezomib

D<sup>1</sup> **Unsafe**<sup>1</sup>

### Dosage Forms

Velcade® 3.5mg/vial<CBORTEZ>

### Use

Multiple myeloma, mantle cell lymphoma

### Dose

IV 1.3 mg/m<sup>2</sup> twice a week(in day 1, 4, 8, 11, 22, 25, 29, and 32) for 1-4 cycles, followed by 1.3 mg/m<sup>2</sup> once a week(in day 1, 8, 22, 29, and 32) for 5-9 cycles; consecutive doses should be separated ≥72hr

### Adverse Reactions

Neuropathy, nausea, vomiting, thrombocytopenia, fever, weakness

### Precations

需依肝腎功能調整劑量；血液透析患者，洗腎後給藥。

## 4.3.4. mTOR Kinase Inhibitor

## Temsirolimus

D<sup>1</sup> **Unknown**<sup>4</sup>

### Dosage Forms

Torisel® 稀釋後：30mg/3ml/vial；<CTEMSIR>

未稀釋：含藥液 25mg/ml, 1.2ml/vial 及 稀釋液 1.8ml/vial

### Use

Renal cell carcinoma, mantle Cell Lymphom

### Dose

Renal cell carcinoma

IVF(over 30-60 min) 25mg weekly

Mantle Cell Lymphoma

IVF(over 30-60 min) 175mg weekly for 3 wks, followed by 75mg weekly.

### Adverse Reactions

Rash, asthenia, inflammatory disease of mucous membrane, hyperglycemia, serum cholesterol raised

### Precautions

- 1.投藥前須監測 ANC 及 platelet，開始使用後須每週監測，當病人 ANC<1000/mm<sup>3</sup> 且 platelet<75000/mm<sup>3</sup> 時需停藥。
- 2.需依肝腎功能調整劑量。
- 3.不建議使用 PVC 塑膠容器及給藥組。

### **Everolimus**

**D<sup>5</sup> Unknown<sup>1</sup>**

#### **Dosage Form**

Afinitor<sup>®</sup> 5mg/tab <KEVERO1>

Certican<sup>®</sup> 0.25mg/tab <KEVEROL> 參閱 p.99

#### **Use**

Treatment of advanced renal cell cancer (RCC) after sunitinib or sorafenib failure

#### **Dose**

**PO** 10mg qd

#### **Adverse Reactions**

Leukopenia, hyperlipidemia, anemia, edema, stomatitis, infections, asthenia, fatigue, cough, diarrhea

#### **Precautions**

- 1.須避光儲存，易吸濕須整粒吞服，不可壓碎或撥半，對於無法吞服患者，應將藥錠溶於一杯水(約 30ml)中，立即喝下。
- 2.治療期間應避免接受活疫苗注射或與接種活疫苗的人緊密接觸。
- 3.健保規定須經事前審查核准後使用。
- 4.肝功能不全應調整劑量。
- 5.高脂肪性食物會降低藥品濃度、葡萄柚汁易導致血中濃度增加。

## **4.4. Antineoplastic Miscellaneous**

### **Concentrated fermented soy milk**

**Unknown<sup>1</sup>**

#### **Dosage Forms**

Chemo young<sup>®</sup> oral solution 210ml/bot <KCHEMOY>

#### **Use**

Improve cancer patient's fatigue and anorexia

#### **Dose**

**PO** 8ml/day in 2 divided dose, before meal

#### **Adverse Reactions**

Constipation, diarrhea

#### **Precautions**

- 1.藥品以 100ml 溫開水稀釋後服用，使用後需多喝水
- 2.本品為精密濃縮液，瓶口或瓶底產生之固體結晶為自然現象，以溫開水沖泡即可飲用
- 3.藥品開封後可存放一個月

### **Drug eluting microsphere**

#### **Dosage Forms**

HepaSphere® 30-60um, 25mg/vial <CHEPAS1>

### Use

Embolisation of vessels supplying malignant hypervascularised tumour, delivery of a local, controlled, sustained dose of doxorubicin to the tumor.

### Dose

TACE 1 vial as order for loading doxorubicin, **max. concentration:**

**5mg/ml** (doxorubicin)

### Adverse Reactions

Non-target embolisation, ischaemic infarction, infection

### Precautions

3. 不可直接於乾燥狀態時使用、不可使用注射用水配置、勿使用 lipidol 或 ethiodol 還原栓塞微球體

4. 配置後如未立即使用，還原之栓塞微球體溶液應存放於 2-8°C，於 24 小時內使用。如加入顯影劑後微球體溶液則不繼續存放

### Contraindications

Vasospasm, hemorrhage, severe atheromatous disease, intracranial anastomosis or shunts

## Mesna

**B1 Unknown<sup>1</sup>**

### Dosage Forms

Uromitexan® 400mg/4ml/amp <CMESNA>

Siruta® 200mg/ml,3ml/amp <WMESNA> 參閱 p.326

### Use

Prevention of urothelial toxicity of oxazaphosphorines (ifosfamide or cyclophosphamide )

### Dose

IV ifosfamide, 20% of ifosfamide dose at the time of ifosfamide and at 4 hrs, 8 hrs after each dose of ifosfamide.

### Adverse Reactions

Nausea, vomiting, headache, pain in limb, fatigue

### Precautions

本品可能會引起 ketone bodies 呈現偽陽性。

## Polysaccharide-K (Kawartake)

### Dosage Forms

Krestin® 1g/sacket <KPOLYSA>

### Use

Digestive system cancer( gastric cancer, esophageal cancer, colon cancer, rectal cancer)

### Dose

PO 3g/day in divided doses

### Adverse Reactions

Nausea, vomiting, diarrhea, stomach cramping, constipation

## Picibanil® (OK-432)

### Dosage Forms

1 vial: Penicillin G potassium 13470U+Streptococcus pyogenes Su strain tx with PN G potassium 0.5mg, 5KE/vial <CPICIBA>

#### Use

Digestive organ cancer (gastric cancer, liver cancer, bile duct cancer, colorectal cancer), head and neck cancer (maxillary cancer, Laryngeal, cancer, pharyngeal cancer, tongue cancer), thyroid cancer, lung cancer

#### Dose

**IV** 0.2-1KE 2-3times per week and the dose should gradually increased stepwise; maintenance: 1-3KE 2-3 times weekly

**IM/SC** 0.2-0.5KE qd or qod at first then gradually increased stepwise after 3-5 time; maintenance: 1-5KE 1-3 times weekly

**Intratumor** 5-10KE daily or several days once

**Intracavitary** 5-10KE, 2-3 times/wk

#### Adverse Reactions

Leukocytosis, chest pain, headache, nausea, vomiting, skin abscess

#### Precautions

需冷藏儲存。

### Trastuzumab emtansine

**D<sup>1</sup>** **Unknown<sup>4</sup>**

#### Dosage Forms

Kadcyla<sup>®</sup> 100mg/vial <CTRAST1>

Kadcyla<sup>®</sup> 100mg/vial <CTRAST2>

#### Use

Breast cancer

#### Dose

IVF

3.6mg/kg every 3 weeks until disease progression or unacceptable toxicity;

**max. dose: 3.6 mg/kg**

#### Adverse Reactions

Nausea, fatigue, musculoskeletal pain, thrombocytopenia, increased serum transaminases

#### Precautions

1.首次輸注時間須超過 90 分鐘，後續輸注時間須超過 30 分鐘。

2.配製：5ml 或 8ml 注射用水加入 100mg/vial 或 160mg/vial 小瓶中，不可搖晃，配置後於 2-8°C 可保存 24 小時。

3.稀釋：不可使用 D5W，取出所需量將之加入 250ml 的 NS 輸注袋內，稀釋後於 2-8°C 可保存 24 小時。。

## 5. Biologic and Immunologic Agents

### 5.1. Vaccines-virus

**自費疫苗**

本院品項	Dosage Forms <藥品代碼>	Dose	備註
<b>Hepatitis A vaccine</b> VAQTA®	25U/0.5ml/vial <CHEPAT1>	<b>IM</b> 嬰幼兒/青少年：1st dose(0.5ml) at 12 to 23 months, the 2nd doses should be separated by 6 to 18 months >19yrs 成人：1ml with a booster dose, then 1ml to be given 6-18 months after primary immunization	懷孕分級:C <sup>4</sup> 哺乳: Unknown <sup>1</sup> Inactive vaccine
<b>Hepatitis B vaccine</b> Engerix-B®	20mcg/ml/vial <CHEPAT6>	<b>IM</b> in deltoid region, 3 dose at 0, 1, 6 month Children: 10mcg/dose >20yr Adults: 20mcg/dose	懷孕分級: C <sup>4</sup> 哺乳: Unknown <sup>3</sup> Inactive vaccine
<b>Influenza virus vaccine</b> Vaxigrip®	0.25ml/syringe <CINFLU1> 0.5ml/syringe <CINFLU2>	<b>IM</b> Children: 0.25ml/dose Adults: 0.5ml/dose	懷孕分級: C <sup>1</sup> 哺乳: Safe <sup>1</sup> Inactive vaccine
<b>Pneumococcal vaccine polyvalent</b> Pneumovax® 23	0.5ml/vial <CPNEUMO>	<b>IM/SC</b> Children>2 years and Adults: 0.5ml	懷孕分級: C <sup>1</sup> 哺乳: Unknown <sup>1</sup> Inactive vaccine

本院品項	Dosage Forms <藥品代碼>	Dose	備註
<b>Pneumococcal 13-valent conjugate vaccine Prevenar 13®</b>	0.5ml/vial <CPNEUM1>	<b>IM</b> Infant 2-6mon: 4 dose , 接種 4 劑 7-11mon: 3 dose , 接種 3 劑 12-23mon: 2 dose , 接種 2 劑 Children 2-5yrs: single dose , 接種 1 劑	懷孕分級: C <sup>1</sup> 哺乳: Unknown <sup>1</sup> Inactive vaccine 不可靜脈輸注
<b>Varicella virus vaccine Varilrix®</b>	0.5ml/vial <CVARICE1>	<b>SC</b> Children (12months to 12 years): 0.5ml Children (>12 years) and Adults: 2 dose of 0.5ml separated by 4-8 weeks	懷孕分級: C <sup>3</sup> 哺乳: Unknown <sup>1</sup> Live vaccine
<b>Zoster virus vaccine Zostavax®</b>	0.65ml/vial <CZOSTER>	<b>SC</b> Adults ≥50 years: 0.65 ml administered as a single dose	懷孕分級: Unknown <sup>5</sup> 哺乳: Unknown <sup>3</sup> Live vaccine
<b>Quadrivalent human papillomavirus Gardasil®</b>	0.5ml/vial <CHPV>	<b>IM</b> 0.5 mL × 3 doses at 0, 2, and 6months	懷孕分級: B <sup>1</sup> 9-26 歲女性之預防人類乳突病毒四型 (type 6,11,16,18)所引起子宮頸、陰道、外陰部癌前期或病變、生殖器疣 Inactive vaccine

本院品項	Dosage Forms <藥品代碼>	Dose	備註
<b>Human Papillomavirus Vaccine Types16/18 Cervarix®</b>	0.5ml/vial <CHPV1>	<b>IM</b> 0.5 ml/dose, three dose given on 0, 1, and 6 months	懷孕分級:Unknown <sup>1</sup> 哺乳:Unknown <sup>1</sup> 10 歲至 25 歲的女性預防致癌性人類乳突病毒(HPV)第 16 型與第 18 型所引起的偶發性及持續性感染、與子宮頸上皮內贅瘤、及癌前病變，從而預防子宮頸癌。 Inactive vaccine
<b>Rotavirus vaccine Rotarix®</b>	1.5ml/syringe <KROTA VI>	<b>PO</b> 1 ml × 2 doses at 6-24 weeks	本品於 6-16wks 接種第一劑，兩劑間隔至少 4wks，第二劑於 24wks 內完成。 Live vaccine
<b>Tetanus and diphtheria toxoids adsorbed vaccine Adacel®</b>	0.5ml/vial <CDPT03>	<b>IM</b> Children>4yrs and adult: 0.5ml	1.冷藏於 2-8°C，不可冷凍 2.三合一補追疫苗。 Inactive vaccine

肺炎球菌疫苗比較表格

學名/商品名	Pneumococcal 13-valent conjugate vaccine Prevenar 13®	Pneumococcal vaccine polyvalent Pneumovax® 23
Dosage Forms <藥品代碼>	0.5ml/vial <CPNEUM6>	0.5ml/vial <CPNEUMO>
衛生署核准適應症	預防莢膜血清型(1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 23F)的肺炎鏈球菌所引起的侵入性疾病	預防肺炎鏈球菌性肺炎及肺炎鏈球菌性菌血症
用法/用量	<b>IM</b> 2-6 個月大的嬰兒接種 4 劑，7-11 個月大的嬰兒接種 3 劑，12-23 個月大的嬰兒接種二劑，2-5 歲接種一劑	<b>IM</b> 大於 2 歲兒童及成人使用
備註	1. 2-8°C 冷藏 2.懷孕分級: C <sup>1</sup> , 哺乳: Unknown <sup>1</sup>	1. 2-8°C 冷藏 2.懷孕分級: C <sup>1</sup> , 哺乳: Unknown <sup>1</sup>

註：疫苗不可混合(加在一起)施打，且須於不同部位施打。

## 公費疫苗

疫苗種類		適合年齡	本院品項	Dosage Forms <藥品代碼>	Dose
<b>B型肝炎免疫球蛋白</b>		出生24小時內	<b>Hepatitis B immune globulin(HBIG)</b> HBIG®	0.5ml/vial <CHEPAT9>	<b>IM</b> 0.5ml
<b>B型肝炎疫苗</b>	第一劑	出生滿24小時內	<b>Hepatitis B vaccine</b> Engerix-B®	20mcg/ml/vial <CHEPAT11>常規 <CHEPAT12>高危險群追加	<b>IM</b> Children: 10mcg/dose
	第二劑	出生滿一個月			
	第三劑	出生滿六個月			
<b>卡介苗</b>	第一劑	出生滿五個月	<b>B.C.G vaccine</b> BCG® vaccine	0.1ml/dose <CBCG1>	<b>SC</b> 0.1ml
	追加	國小六年級普查測驗陰性之學童			
<b>白喉、百日咳、破傷風、不活化小兒麻痺混合疫苗</b>	追加	將進入國小就讀且滿5歲以上之兒童	<b>Diphtheria, Tetanus, Pertussis and Polio vaccine</b> Adacel®	0.5ml/vial <C4IN1>	<b>IM</b> 0.5ml
<b>麻疹疫苗</b>		出生滿九個月	<b>Measles vaccine (MV)</b> Rouvax®	0.5ml/vial <CMEASL1>	<b>SC</b> 0.5ml
<b>德國麻疹混合、腮腺炎、麻疹疫苗</b>		出生滿一年三個月	<b>Measles, Mumps and Rubella vaccine</b> MMR II®	0.5ml/vial <CMMR>	<b>SC</b> 0.5ml
<b>日本腦炎</b>	第一劑	出生滿一年三個月	<b>Japanese encephalitis vaccine (JE)</b> Japanese encephalitis vaccine®	1ml/amp < CJAPANE >	<b>SC</b> 1-3 yrs: 0.5ml ≥3yrs : 1ml
	第二劑	隔二週			
	第三劑	出生滿二年三個月			
	追加	國小一年級			

## 5.2. Toxoids

### Tetanus toxoid

C<sup>3</sup> Unknown<sup>1</sup>

#### Dosage Forms

Tetanus toxoid<sup>®</sup> 10LF/ml, 1ml/vial <CTETAN2>

#### Use

Selective induction of active immunity against tetanus in selected patients

#### Dose

IM/SC: 0.5ml × 2 times at 4-8 wks interval

Booster dose: 0.5ml every 6-12 months or in case of injury

#### Adverse Reactions

Fever, flushing, urticaria, tachycardia, hypotension, anaphylaxis, local redness

#### Precautions

需於 2-8°C 冷藏儲存，開封後於 24 小時內使用完畢。

## 5.3. Antitoxins and Antivenins

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

學名	商品名	藥品代碼	蛇毒屬性
Antivenin of A. acutus	抗百步蛇毒血清 1dose/vial	<CANTI03>	Hemorrhagic and Neurotropic
Antivenin polyvalent hemorrhagic	抗龜殼花、赤尾鯔蛇毒血清 1dose/vial	<CANTI04>	Hemorrhagic
Antivenin polyvalent neurotropic	抗雨傘節、飯匙倩蛇毒血清 1dose/vial	<CANTI05>	Neurotropic

#### Use

Treatment of snakebite

#### Dose

With systemic symptoms

**IM/IV/SC**

Children: double dose, repeated doses every 0.5-2hrs as needed until systemic symptoms improved

Adults: 1dose, repeated doses every 0.5-2hrs as needed until systemic symptoms improved

Bite time ≤ 2 hrs and no systemic symptoms

1/2 dose SC around wound, 1/2 dose IM

Bite time >2 hrs or with systemic symptoms

Majority of the dose administered by IV

(Note: First 1ml of IV dose should be given over 5 mins then followed with a infusion rate <1ml/min, remained dose administered by SC around wound)

#### Adverse Reactions

Anaphylaxis, chills, fever, urticaria, arthralgia, arthus reaction

#### Precautions

- 需於 2-8°C 冷藏儲存
- 血清過敏性檢查：以 NS 稀釋 100 倍之抗蛇毒血清 0.1ml SC 於前臂，30mins 後局部輪狀浮腫，周圍紅暈為陽性反應。

## 5.4. Immune Globulins

### Antithymocyte immunoglobulin (rabbit)

C<sup>3</sup> Unknown<sup>3</sup>

#### Dosage Forms

Thymoglobulin<sup>®</sup> 25mg/vial <CANTI02>

#### Use

Prophylaxis and treatment of transplant acute graft rejection, aplastic anemia

#### Dose

IVD (infusion rate  $\geq$  4hrs)

#### Prophylaxis of acute graft rejection

1-1.5mg/kg/day for 2-9 days after transplantation of kidney, pancreas or liver

1-1.5mg/kg/day for 5 days after heart transplantation.<br>

#### Treatment of acute graft rejection

1.5mg/kg/day for 3-14 days

#### Prophylaxis of acute and chronic graft versus host disease

2.5mg/kg/day 由移植前 4 天至移植前 2 或 1 天

#### Treatment of steroid-resistant, acute graft versus host disease

劑量依個體而定，usually between 2-5mg/kg/day for 5days

#### Aplastic anemia

2.5-3.5mg/kg/day for 5 consecutive days.

#### Adverse Reactions

Fever, chills, headache, rash, hyperkalemia, abdominal pain, diarrhea, leucopenia, thrombocytopenia, weakness, dyspnea, systemic infection, pain

#### Precautions

- 本品需於 2-8°C 冷藏儲存。
- 本品乾粉以 Dis-water 溶解，以 NS 或 D5W 稀釋，使輸注溶液體積達 50-500ml (通常 50ml/vial)。
- 稀釋後於 20°C 可存放 24 小時。
- Monitoring parameters: lymphocyte profile, CBC with differential and platelet count, vital signs during administration

### Cytomegalovirus immune globulin (human)

C<sup>3</sup> Unknown<sup>1</sup>

#### Dosage Forms

Cytotect<sup>®</sup> 2500IU/50ml/bottle <CCYTOME>

#### Use

Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, heart transplants

## Dose

### Prophylaxis

**IV** 1ml/kg single dose, total 6 single DS should be given q3w

### Treatment

**IV** 2ml/kg single dose qod until the clinical symptoms subside; **max infusion rate: 20 drops/min**

## Adverse Reactions

Flushing, fever, chills, nausea, vomiting, arthralgia, back pain, muscle cramps, wheezing

## Precautions

需於 2-8°C 冷藏儲存。

## Contraindications

Immunoglobulin A deficiency

## Hepatitis B immune globulin (HBIG)

**C<sup>1</sup> Unknown<sup>1</sup>**

## Dosage Forms

HyperHep B S/D® 0.5ml/vial <CHEPAT9>

HyperHep B S/D® 5ml/vial <CHEPAT4>

Hepatect® CP 500IU/10ml/vial <CHEPAT5>

## Use

Provide prophylactic passive immunity to hepatitis B infection

## Dose

HyperHep B S/D®

Postexposure prophylaxis of neonates born to HBsAg-positive

**IM** 0.5ml IM within 12 hrs after birth

Hepatitis prophylaxis, postexposure

**IM** 0.06 ml/kg IM within 24 hrs of percutaneous or permucosal exposure and within 14 days of sexual exposure

Hepatect® CP

## IVD

In the anhepatic phase: 10,000 IU (200 ml).

On OP days 1-7: 2,000 IU (40ml)/day. **Max:1 ml/kg/hr.**

## Adverse Reactions

Erythema at injection site, pain at injection site, headache, myalgias, malaise, nausea, vomiting, joint stiffness

## Precautions

需於 2-8°C 冷藏儲存

## Contraindications

Allergies to gamma globulin or anti-immunoglobulin antibiotics; allergies to thimerosal, IgA deficiency

## Immune globulin (Human) (IVIG)

**C<sup>1</sup> Unknown<sup>1</sup>**

## Dosage Forms

Human Immune globulin for intravenous® 3g/50ml/vial <CIMMU04>

## Use

Treatment of primary immunodeficiency syndromes, prevention of

bacterial infection in B-cell chronic lymphocytic leukemia (CLL), pediatric HIV infection, bone marrow transplant (BMT)

### Dose

#### Immunodeficiency disease

**IV** Children and adults: 200-400mg/kg once monthly

#### Idiopathic thrombocytopenia purpura

**IV** Children and adults: 400mg/kg/day for 5 days

#### Kawasaki disease

1-2g/kg for one dose

### Adverse Reactions

Flushing, angioedema, chills, lethargy, fever, urticaria, erythema, nausea, vomiting

### Precautions

需於 2-8°C 冷藏儲存。

**C<sup>3</sup> Safe<sup>1</sup>**

## Gammaglobulin

### Dosage Forms

Rho (D) Immune Globulin (Human) Hyperrho S/D Full Dose<sup>®</sup>

165mg/ml/syringe<CRHOD>

### Use

預防因配偶間 RH 因子不同而導致之流產及初生兒夭折

### Dose

#### Postpartum prophylaxis

**IM** 165mg preferably within 72 hrs of delivery

#### Antepartum prophylaxis

**IM** 165mg at 26-28 wks gestation and 165mg within 72 hrs after an Rh-incompatible delivery to prevent Rh isoimmunization during pregnancy

### Adverse Reactions

Hypotension, pallor, vasodilation, chills, dizziness, fever, headache, diarrhea somnolence, pruritus, rash, abdominal pain

### Precautions

需於 2-8°C 冷藏儲存。

### Contraindications

Not use in neonates

**C<sup>4</sup> Unknown<sup>1</sup>**

## Tetanus Immune Globulin (TIG)

### Dosage Forms

HyperTet S/D<sup>®</sup> 250U/syringe <CTETAN4>

### Use

Prophylaxis or treatment of tetanus

### Dose

Deep **IM** only

#### Prophylaxis

Adults and children  $\geq 7$  yrs: 250U as single dose

Children <7 yrs: 4 U/kg or 250U

#### Treatment

500-6000U as a single dose

### Adverse Reactions

Injection site pain, fever

### Precautions

1.本品須於 2-8°C 儲存。

2.不可以 IV 紿予。

## 5.5. Immunologic Agents

### Abatacept

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Form

Orencia® 250mg/vial <CABATAC>

#### Use

Rheumatoid arthritis, juvenile idiopathic arthritis(JIA)

#### Dose

##### Juvenile idiopathic arthritis(JIA)

6-17yrs children, and BW<75kg: 10mg/kg, repeat dose at 2 weeks and 4 weeks after initial infusion, and every 4 weeks thereafter

≥75-100kg: 750mg (3vial)

>100 kg: 1000 mg (4vial)

##### Rheumatoid arthritis

<60 kg: 500 mg (2vial)

60-100 kg: 750 mg (3vial)

>100 kg: 1000 mg (4vial)

Following the initial IV infusion, repeat dose at 2 weeks and 4 weeks after initial infusion, and every 4 weeks thereafter

### Adverse Reactions

Headache, upper respiratory tract infection, nasopharyngitis, nausea

### Precautions

1.不可與其他治療類風濕性關節炎之生物製劑同時使用

2.未開封需冷藏於 2-8°C

3.使用前需以 10ml 注射用水配製(使用內附之不含矽膠的注射筒)，再以 NS 稀釋至 100ml。配製後可於室溫或 2-8°C 下保存，並於 24 小時內使用完畢。

### Contraindications

嚴重或無法控制的感染，包括敗血症或伺機性感染、急性病毒性肝炎、肺結核、擴散性結核

### Adalimumab

B<sup>1</sup> Unsafe<sup>1</sup>

#### Dosage Form

Humira® 40mg/0.8ml/syringe, 2syringe/box <CADALIM>

#### Use

Rheumatoid arthritis, psoriasis with arthropathy

#### Dose

SC 40mg every other week

## **Adverse Reactions**

Hypertension, injection site reaction, rash, antibody development, antinuclear antibody positive, headache

## **Azathioprine**

**D<sup>1</sup> Unsafe<sup>2</sup>**

### **Dosage Form**

Asazipam<sup>®</sup> 50mg/tab <KAZATHI>

### **Use**

Rheumatoid arthritis, prophylaxis of kidney transplant rejection

### **Dose**

Prophylaxis of kidney transplant rejection

**PO** initial 3-5mg/kg/day, maintenance 1-3mg/kg/day

Rheumatoid arthritis

**PO** initial 1mg/kg/day qd-bid, maintenance 1-2.5mg/kg/day qd-bid

### **Adverse Reactions**

Nausea, vomiting, hepatotoxicity, infection, leukopenia, pancreatitis

### **Precautions**

Chronic immunosuppression increases risk of neoplasm, monitor hematologic function and mutagenicity, caution liver disease, renal impairment

## **Basiliximab**

**B<sup>2</sup> Unknown<sup>3</sup>**

### **Dosage Form**

Simulect<sup>®</sup> 20mg/vial <CBASILI>

### **Use**

Prophylaxis of acute organ rejection in renal transplantation

### **Dose**

**IVF**

Children <35 kg: 2 doses of 10mg each, first dose within 2 hrs prior to transplant, second dose 4 days after transplant; withhold second dose if complications occur

Children ≥35 kg and Adults: 2 doses of 20mg each, first dose within 2 hrs prior to transplant, second dose 4 days after transplant; withhold second dose if complications occur

### **Adverse Reactions**

Abdominal pain, vomiting, dizziness, asthenia, insomnia, candidiasis, cough, dyspnea, fever

### **Precautions**

本品泡製後溶液於 2-8°C 可保存 24hrs，常溫下可保存 4hrs。

## **Cyclosporine**

**C<sup>1</sup> Unsafe<sup>2</sup>**

### **Dosage Form**

Sandimmun<sup>®</sup> Inj. 50mg/1ml/amp <CCYCLOS>

Sandimmun Neoral<sup>®</sup> 25mg/cap <KCYCL01>

Sandimmun Neoral<sup>®</sup> 100mg/cap <KCYCL02>

Sandimmun Neoral Soln<sup>®</sup> 100mg/ml, 50ml/bot <KCYCL03>

Restasis<sup>®</sup> oph emulsion 0.05% 0.4ml/vial, 30vial/box <WCYCLOS>

參閱 p.283

### Use

Organ transplant rejection, rheumatoid arthritis, psoriasis

### Dose

Prophylaxis of rejection in kidney, liver or heart transplantation

**IV** 5-6mg/kg/day q4-12h before transplant continue same initial dose as daily dose until patient can tolerate oral formulation.

**PO** Initial 15mg/kg/day given 4-12 hrs before transplantation and continued for 1-2 wks. Taper the dosage by about 5% weekly to a maintenance dosage of 5-10mg/kg/day

Rheumatoid arthritis

**PO** 2-5mg/kg/day

Psoriasis

**PO** 2-5mg/kg/day

### Adverse Reactions

Ocular burning, hypertension, nephrotoxicity, headache

### Precautions

Dose-related raise of nephrotoxicity and hepatotoxicity, monitor blood pressure and serum creatinine after any cyclosporine dosage changes or addition, modification or deletion of other medications

**D<sup>5</sup>** **Unknown<sup>1</sup>**

### **Everolimus**

#### Dosage Form

Afinitor<sup>®</sup> 5mg/tab <KEVERO1> 參閱 p.85

Certican<sup>®</sup> 0.25mg/tab <KEVEROL>

### Use

Heart and kidney transplant rejection prophylaxis

### Dose

**PO** 0.75mg bid should be administered as soon as possible after transplantation. (level: 3-8ng/ml)

### Adverse Reactions

Leukopenia, hyperlipidemia, anemia, edema, stomatitis, infections, asthenia, fatigue, cough, diarrhea

### Precautions

- 須避光儲存，易吸濕須整粒吞服，不可壓碎或撥半，對於無法吞服患者，應將藥錠溶於一杯水(約 30ml)中，立即喝下。
- 治療期間應避免接受活疫苗注射或與接種活疫苗的人緊密接觸。
- 健保規定須需經事前審查核准後使用。
- 肝功能不全應調整劑量。
- 高脂肪性食物會降低藥品濃度、葡萄柚汁易導致血中濃度增加。

**B<sup>4</sup>** **Unknown<sup>4</sup>**

### **Golimumab**

#### Dosage Forms

Simponi<sup>®</sup> 50mg/0.5ml/syringe <CGOLIMU>

### Use

Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis

**Dose****SC**

50mg once a month (either alone or in combination with methotrexate or other nonbiologic DMARDs)

**Adverse Reactions**

Upper respiratory tract infection, injection site reaction, virus infection, GOT/GPT increase, hypertension

**Precautions**

1. 不建議接種活性疫苗
2. 應輪流使用不同注射部位，絕對不可注射在有觸痛、瘀傷、發紅或變硬等現象的皮膚區域
3. 2-8°C 冷藏避光儲存。

**Contraindications**

活動性肺結核或其他嚴重感染症、中度或重度心衰竭(NYHA class III/IV)

**Hydroxychloroquine**

<b>C</b>	<b>Safe<sup>1</sup></b>
----------	-------------------------

**Dosage Form**

Plaquenil® 200mg/tab <KHYDR02> 參閱p.23

**Leflunomide**

<b>X</b>	<b>Unsafe<sup>3</sup></b>
----------	---------------------------

**Dosage Form**

Arheuma® 20mg/tab <KLEFLU1>

**Use**

Rheumatoid arthritis

**Dose**

Adults: **PO** initial 100mg/day for 3 days, followed by 20mg/day; dosage may be decreased to 10mg/day in patients who have difficulty tolerating the 20mg dose

**Adverse Reactions**

Alopecia, rash, diarrhea, increased liver enzymes

**Precautions**

1. 服藥前及服藥後的前 6 個月，需每個月或較短的間隔檢測 ALT(GPT) 值，以後每隔 8 週檢測。
2. 若 ALT 值大於正常值二倍，則劑量需降低為 10mg/day，並持續或每週監控肝功能。

**Mycophenolate acid**

<b>D</b>	<b>Unknown<sup>2</sup></b>
----------	----------------------------

**Dosage Form**

Myfortic® 180mg/tab <KMYCOP1>

**Use**

Prophylaxis kidney transplants rejection

**Dose**

**PO** 720 mg bid initiated within 24 hr following renal transplantation.

**Adverse Reactions**

Hypertension, peripheral edema, headache, constipation, diarrhea, nausea, vomiting

### Precaution

避免與含鎂鋁成份制酸劑併服以免減少本品之吸收。

## Mycophenolate mofetil

D<sup>1</sup> Unknown<sup>2</sup>

### Dosage Form

Cellcept® 250mg/cap <KMYCOPH>

### Use

Prophylaxis heart, kidney, liver transplants rejection

### Dose

#### Renal transplant

Children (BSA 1.25-1.5m<sup>2</sup>) PO 750mg bid, (BSA >1.5m<sup>2</sup>) 1000mg bid

Adults: PO 1g bid

#### Cardiac and hepatic transplant

Adults: PO 1.5g bid

### Adverse Reactions

Hypertension, peripheral edema, headache, constipation, diarrhea, nausea, vomiting

### Precaution

1. Active serious digestive diseases

2. 建議飯前及整粒吞服。

## Palivizumab

C<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

Synagis® 50mg/vial <CPALIVI>

### Use

Prophylaxis respiratory syncytial virus infection

### Dose

IM 15mg/kg monthly; max: 6 dose

### Adverse Reactions

Injection site reaction, pyrexia

### Precautions

1. 冷藏保存。

2. 使用藥盒內所附之無菌注射用水稀釋，抽取 0.6ml 注射用水，沿玻璃瓶內壁緩慢加入，稀釋時應輕輕旋轉藥瓶，避免搖晃瓶體產生泡沫，調配後靜置 20 分鐘，直至溶液澄清。

## Penicillamine

D<sup>1</sup> Unsafe<sup>5</sup>

### Dosage Forms

Metalcaptase® 300mg/FC. tab <KPENIC1>

### Use

Rheumatoid arthritis, Wilson's disease, metal chelating agent

### Dose

#### Rheumatoid arthritis

PO initial 300mg/day, maintenance 300-600mg/day

### Acute and chronic metal poison

**PO** 900-1800mg/day

### Wilson's disease

**PO** 300mg qid

### **Adverse Reactions**

Anorexia, epigastric pain, nausea, myelosuppression, rash, taste disorders

### **Precautions**

建議飯前一小時或飯後兩小時服用。

## **Sirolimus**

**C<sup>2</sup> Unsafe<sup>2</sup>**

### **Dosage Form**

Rapamune® 1mg/tab <KSIROL2>

### **Use**

Renal transplant rejection prophylaxis

### **Dose**

Should be taken 4 hr after cyclosporine

Adults: **PO** loading dose 6mg, maintenance 2mg qd

Children ≥13 yrs or BW <40kg: **PO** loading dose: 3mg/m<sup>2</sup>, maintenance 1mg/m<sup>2</sup> qd

### **Adverse Reactions**

Anemia, thrombocytopenia, arthralgia, asthenia, headache, venous thromboembolism, hypercholesterolemia, hyperlipidemia, peripheral edema

### **Precautions**

Co-administration of sirolimus with strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein is not recommended, live vaccines should be avoided

## **Tacrolimus**

**C<sup>1</sup> Unsafe<sup>2</sup>**

### **Dosage Form**

Prograf® 0.5mg/cap <KTACR01>

Prograf® 1mg/cap <KTACR02>

Prograf® 5mg/cap <KTACR03>

Advagraf PR® 0.5mg/cap <KTACR04>

Advagraf PR® 1mg/cap <KTACR05>

Advagraf PR® 5mg/cap <KTACR06>

Protopic® oint. 0.1%, 5g/tube <WTACR03> 參閱 p.141

Protopic® oint. 0.03%, 5g/tube <WTACR04> 參閱 p.141

### **Use**

Atopic dermatitis (moderate/severe), liver and kidney transplant rejection prophylaxis

### **Dose**

**PO** 0.2mg/kg/day q12h

### **Adverse Reactions**

Tremor, headache, diarrhea, hypertension, nausea, renal dysfunction, hyperkalemia, hyperuricemia, hypomagnesemia, hyperglycemia, pleural effusion, abdominal pain, fever, back pain and peripheral edema

## Precautions

Concomitant administration of drugs or other substances that inhibit or induce CYP3A enzyme systems

## Tocilizumab

**B<sup>4</sup>** Unknown<sup>1</sup>

### Dosage Forms

Actemra® 200mg/10ml/vial <CTOCILI>

### Use

Rheumatoid arthritis, systemic juvenile idiopathic arthritis

### Dose

#### Rheumatoid arthritis

**IVF** initial 4mg/kg every 4 weeks; may be increased to 8mg/kg based on clinical response; **max: 800mg**

#### Systemic juvenile idiopathic arthritis

Children ≥2 years: **IVF>1hr** 12mg/kg every 2 weeks for BW<30 kg; 8mg/kg every 2 weeks for BW≥30kg

### Adverse reactions

Upper respiratory tract infection, nasopharyngitis, headache, hypertension, increase ALT

### Precautions

1. 需冷藏於 2-8°C
2. 限靜脈點滴給藥，輸注時間應大於 1 小時，不可靜脈推注(push or bolus)，不可與其他藥品共用注射管路
3. 限 NS 稀釋至 100ml，稀釋後需避光，2-8°C 或室溫可保存 24 小時。
4. 紿藥期間不可施打活性疫苗

## Ustekinumab

**B<sup>4</sup>** Unknown<sup>1</sup>

### Dosage Forms

Stelara® 45mg/0.5ml/syringe<CUSTEKI>

### Use

Plaque psoriasis, psoriatic arthritis, pediatric psoriasis

### Dose

#### Plaque psoriasis

≤100 kg: **SC** 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter  
>100 kg: **SC** 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

#### Pediatric Psoriasis (≥ 12 years)

<60 kg: **SC** 0.75 mg/kg at 0 and 4 weeks, and then every 12 weeks thereafter (or Dose may be calculated as BW (kg) x 0.0083 mL/kg)

≥60 kg to ≤100 kg: **SC** 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter

>100 kg: **SC** 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

#### Psoriatic arthritis

**SC** 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter

Moderate to severe plaque psoriasis and patients >100 kg: **SC** 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

### Adverse reactions

Nasopharyngitis, upper respiratory tract infection, headache, fatigue, diarrhea

#### **Precautions**

- 1.需冷藏於 2-8°C，僅供一次使用

#### **Contraindications**

活動性感染(如活動性結核)

## **5.6. Biologic and Immunologic Miscellaneous**

### **HTK solution**

#### **Dosage Form**

Custodiol<sup>®</sup> 1000ml/pk <WHTK1>

#### **Use**

移植器官保存用

#### **Dose**

As order

#### **Precautions**

- 1.保存在 2-8°C。
- 2.若需使用本品請事先通知藥劑部。

## 6. CARDIOVASCULAR

### 6.1. Cardiac Glycosides

#### Digoxin

**C** **Safe<sup>1</sup>**

#### Dosage Forms

Lanoxin® 0.5mg/2ml/amp <CDIGOX1>

Lanoxin® 0.25mg/tab <KDIGO02>

Cardiacin elixir® 0.05mg/ml, 60ml/bot <KDIGO01>

#### Use

Heart failure, atrial fibrillation, supraventricular arrhythmias

#### Dose

Age	Total Digitalizing Dose *		Daily Maintenance Dose (mcg/kg/day)	
	PO	IV/IM	PO	IV/IM
Preterm infant	20-30	15-25	5-7.5	4-6
Full-term infant	25-35	20-30	6-10	5-8
1 mon-2 yrs	35-60	30-50	10-15	7.5-12
2-5 yrs	30-40	25-35	7.5-10	6-9
5-10 yrs	20-35	15-30	5-10	4-8
> 10 yrs	10-15	8-12	2.5-5	2-3
Adults	0.75-1.5mg/d	0.5-1mg/d	0.125-0.5mg/d	0.1-0.4mg/d

\* Give one-half of the total digitalizing dose (TDD) in the initial dose, then give one-quarter of the TDD in each of two subsequent doses at 6- to 8-hour intervals.

#### Adverse Reactions

Anorexia, nausea, vomiting, diarrhea, headache

#### Precautions

1. Therapeutic serum level: CHF 0.5-0.9mcg/l; non CHF 0.5-2ng/ml

2. 需依腎功能調整劑量。

### 6.2. Antiarrhythmic Agents

#### 6.2.1. Class I-B

#### Lidocaine

**B<sup>1</sup>** **Safe<sup>1</sup>**

#### Dosage Forms

Lidocaine® 2%, 100mg/5ml/amp <CLIDOC1>

#### Use

Ventricular arrhythmias

#### Dose

Ventricular tachycardia or fibrillation

**IV** initial 1-1.5mg/kg, repeat 0.5-0.75mg/kg bolus may be given 3-5 mins after initial dose. Total dose should not exceed 200-300mg during a 1hr period or 3mg/kg total dose

## **Adverse Reactions**

Hypotension, nausea, heart block, cardiac dysrhythmia, seizure

### **Mexiletine**

**C** **Safe<sup>1</sup>**

#### **Dosage Forms**

Meletin<sup>®</sup> 100mg/cap <KMEXITI>

#### **Use**

Ventricular arrhythmias

#### **Dose**

**PO** initial 200mg q8h, maintenance 200-300mg q8h; **max: 1200mg/day**

## **Adverse Reactions**

Coordination difficulties, dizziness, lightheadedness, tremors, feeling nervous

### **Phenytoin (Diphenylhydantoin)**

**D** **Unsafe<sup>1</sup>**

#### **Dosage Forms**

Aleviatin<sup>®</sup> 250mg/5ml/amp <CPHENY1>

Dilantin<sup>®</sup> 100mg/cap <KPHENYT>

#### **Use**

Antiarrhythmic, anticonvulsant

#### **Dose**

##### Arrhythmia

100mg tid-qid

##### Status epilepticus

Neonates and children: **IV** loading 15-20mg/kg (rate ≤ 1-3mg/kg/min)

Adult: **IV** loading 10-15mg/kg (rate ≤ 50mg/min), then **IV/PO** 100mg q6-8h

##### Anticonvulsant

Children≤ 6yrs: **PO** 5 mg/kg/day bid-tid, usual maintenance dose is 4-8 mg/kg/day; **max: 300 mg/day**

Children > 6yrs: **PO** 100mg tid

Adult: **PO** maintenance 100 mg tid-qid; **max: 600mg/day** or loading 1000mg (300mg, 300mg, 400mg q2h) then maintenance dose after 24hrs

## **Adverse Reactions**

Morbilliform eruption, rash, constipation, gingival hyperplasia, nystagmus

## **Precautions**

限 NS 或 Sterile water 稀釋，避免使用 D5W，易產生結晶沉澱

## **Contraindications**

Sinus bradycardia, second and third degree AV block

## **6.2.2. Class I-C**

### **Propafenone**

**C** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Rytmonorm<sup>®</sup> 150mg/tab <KPROPAF>

#### **Use**

Ventricular arrhythmias

## Dose

Adults: **PO** 150-300mg tid; **max: 900mg/day**

## Adverse Reactions

Dizziness, proarrhythmic events, unusual taste

## 6.2.3 Class II

### Propranolol

**C<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Forms

Propranolol<sup>®</sup> 10mg/tab <KPROPRA1>

Cardolol<sup>®</sup> 40mg/tab <KPROPRA2>

#### Use

Hypertension, s, angina, migraine headache, tremor, anxiety, schizophrenia, prevention of bleeding esophageal varices

#### Dose

##### Angina

Adult: **PO** 10-20mg tid-qid, may titrate every 3 to 7 days to optimal response; **max: 320mg/day**

##### Arrhythmia

Children: **PO** 0.5-1mg/kg/day tid-qid for supraventricular tachycardia

Adult: **PO** 10-30mg tid-qid

##### Prophylaxis of migraine

Adult: **PO** initial 20mg qid, titrate to maintenance dose 160-240 mg/day in divided doses

##### Hypertension

Adult: **PO** initial 40mg bid, titrate to maintenance dose 120-240mg/day; **max: 640mg/day**

##### Thyrotoxicosis

Adult: **PO** 10-40 mg tid-qid

##### Pheochromocytoma

Adult: **PO** 20 mg tid for 3 days prior to surgery, with alpha-adrenergic blocker

#### Adverse Reactions

Dermatitis, pruritus, urticarial, dizziness, fatigue

#### Precautions

1.需依肝、腎功能調整劑量。

2.充血性心衰竭、糖尿病、氣腫或非過敏性支氣管炎、肝腎功能障礙、Raynaud's 症及其他末梢血管疾病患者應小心使用。

#### Contraindications

Bronchial asthma, cardiogenic shock, heart block (second or third degree), sick sinus syndrome, sinus bradycardia

## 6.2.4 Class III

### Amiodarone

**X<sup>4</sup> Unsafe<sup>1</sup>**

#### Dosage Forms

Cordarone<sup>®</sup> 150mg/3ml/amp <CAMIODA>

Cordarone<sup>®</sup> 200mg/tab <KAMIODA>

**Use**

Ventricular arrhythmias, supraventricular arrhythmia, atrial fibrillation/flutter, Wolff-Parkinson-White syndrome

**Dose**

**IV** loading 5mg/kg over 20-120mins, may be repeated 2-3 times/24hrs, maintenance 10-20mg/kg/24hr

**PO** loading 800-1600mg daily for 1 to 3 wks until initial therapeutic response occurs, maintenance 200-600mg/day

**Adverse Reactions**

Corneal deposit, increased liver enzymes, photosensitivity, prolonged QT interval

**Precautions**

- 1.針劑需以D5W稀釋，並建議使用非PVC材質之點滴，因本品會導致塑化PVC容器之DEHP成分釋出。
- 2.須避光儲存。

**D**<sup>1</sup> **Unsafe**<sup>1</sup>

**Dronedarone**

**Dosage Forms**

Multaq<sup>®</sup> 400mg/F.C tab <KDRONED>

**Use**

Paroxysmal or persistent atrial fibrillation,

**Dose**

**PO** 400mg bid

**Adverse Reactions**

Diarrhea, nausea, asthenia, rash, QT prolong

**Precautions**

重度肝功能不全不建議使用。

**Contraindications**

NYHA class IV CHF, HR<50 bpm, second and third degree AV block, sick sinus syndrome, QTc Bazett interval ≥500msce or PR interval > 280msec, concomitant use of QT-prolonging drugs, concomitant use of strong CYP3A inhibitor, severe hepatic impairment

## 6.2.5. Class IV

**C**<sup>1</sup> **Safe**<sup>1</sup>

**Diltiazem**

**Dosage Forms**

Diltisser<sup>®</sup> 30mg/tab <KDILT01>

**Use**

Angina pectoris, hypertension, arrhythmias

**Dose**

**PO** 30-60mg qid; **max: 360mg/day**

**Adverse Reactions**

Bradyarrhythmia, peripheral edema, headache, dizziness, fatigue

**Contraindications**

Sick sinus syndrome, second and third degree AV block, severe hypotension (SBP<90mmHg), acute MI or lung congestion

## Verapamil

**C** **Safe<sup>1</sup>**

### Dosage Forms

Verpamil® 5mg/2ml/amp <CVERAPA>

Cintu® 40mg/tab <KVERAP1>

### Use

Angina, hypertension, paroxysmal supraventricular tachyarrhythmias

### Dose

#### Angina

Adult: **PO** 80-120mg tid-qid

#### Atrial arrhythmia or paroxysmal supraventricular tachycardia

Children < 1 yrs: **IV** 0.1-0.2mg/kg over 2min, may repeat after 30 min

Children 1-13 yrs: **IV** 0.1-0.3mg/kg(max: 5mg) over 2min, may repeat dose after 30min(max: 10mg)

Adult: **IV** initial 5-10mg (0.075-0.15mg/kg) bolus over 2min, may give additional 10mg after 30min if no response; **PO** initial 240-320mg/day tid-qid, non-digitalized patients may require up to 480mg/day

#### Hypertension

Children: **PO** 3-4mg/kg tid; **max: 8mg/kg** up to **480 mg/day**

Adult: **PO** initial 80mg tid, may titrate at daily or weekly intervals to 360-480mg/day

### Adverse Reactions

Constipation, dizziness, edema, headache, hypotension

### Precautions

需依肝功能調整劑量。

### Contraindications

Severe LV dysfunction, hypotension(SBP<90mmHg), cardiogenic shock, second and third degree AV block, sick sinus syndrome

## 6.2.6 Antiarrhythmic Miscellaneous

## Adenosine

**C** **Unknown<sup>1</sup>**

### Dosage Forms

Adenocor® 6mg/2ml/vial <CADENOS>

### Use

Paroxysmal supraventricular tachycardia (PSVT), thallium-201 myocardial scintigraphy, diagnostic in narrow and broadcomplex tachycardias

### Dose

#### Paroxysmal supraventridulr tachycardia

Children < 50kg: **IV** initial 0.05-0.1mg/kg/dose (**max: 6mg/dose**) as a rapid bolus, repeat every 1-2 mins as needed; **max single dose: 0.3mg/kg**

Children ≥ 50kg and adult: **IV** initial 6mg over 1-2 sec, increase to 12mg every 1-2 mins as needed for 2 doses; **max: 12mg/dose**

#### Cardiac thallium 201 study

Adult: **IV** 140mcg/kg/min for 6min

**Adverse Reactions**

Chest discomfort, flushing, dyspnea, headache, abdominal discomfort

**Contraindications**

Sick sinus syndrome, second and third degree AV block

## 6.3. Calcium Channel Blocking Agents

### 6.3.1. Dihydropyridines

**Amlodipine**

C <sup>4</sup>	Unknown <sup>1</sup>
----------------	----------------------

**Dosage Forms**

Norvasc® 5mg/tab <KAMLODI>

**Use**

Hypertension, angina pectoris

**Dose**

Angina pectoris

**PO** 5-10mg/day

Hypertension

**PO** initial 2.5-5mg/day, usual dose 5mg/day; **max: 10mg/day**

**AdverseReactions**

Dizziness, fatigue, flushing, headache, palpitation, peripheral edema

**Contraindications**

不建議與葡萄柚汁一起併用。

**Amarel®**

D <sup>5</sup>	Unknown <sup>3</sup>
----------------	----------------------

**Dosage Forms**

1tab: Amlodipine 5mg + Benazepril 10mg/tab <KAMTREL>

**Use**

Hypertension

**Dose**

Adults: **PO** 1 tab qd

**AdverseReactions**

Headache, edema, cough, dizziness

**Precautions**

肝臟嚴重受損的病人服用本品時應特別注意。

**Contraindications**

嚴重腎功能不全不建議使用

**Caduet®**

X <sup>4</sup>	Unsafe <sup>1</sup>
----------------	---------------------

**Dosage Forms**

1tab: Amlodipine 5mg + Atorvastatin 10mg /tab <KCADUET>

**Use**

Hypertension and hyperlipidemia

**Dose**

**PO** 1-2 tab qd; **max: 2tab/day**

**AdverseReactions**

Flush, edema, fatigue, headache, palpitation, nausea, indigestion

### Precautions

1. 服用期間建議定期監測肝功能

2. 病患如出現肌肉疼痛、壓痛、肌肉無力等症狀時，請回診告知醫師。

## Exforge®

**D<sup>5</sup>** **Unknown<sup>3</sup>**

### Dosage Forms

1 tab: Amlodipine 5mg+Valsartan 80mg/tab <KEXFORG> 參閱 p.119

## Exforge HCT®

**X<sup>1</sup>** **Unsafe<sup>1</sup>**

### Dosage Forms

1 tab: Amlodipine 5mg+Valsartan 160mg+ Hydrochlorothiazide 12.5mg <KEXFORG> 參閱 p.119

## Lacidipine

**B<sup>5</sup>** **Unknown<sup>3</sup>**

### Dosage Forms

Lesyn® 6mg/F.C.tab <KLACID1>

### Use

Hypertension

### Dose

**PO** initial 2mg/day slow titrate 6mg/day (titrate time > 3-4 weeks)

### Adverse Reactions

Headache, flush, edema, dizziness, palpitation

### Contraindications

不建議與葡萄柚汁一起併用。

## Nicardipine

**C<sup>4</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Perdipine® 10mg/10ml/amp <CNICARD>

### Use

Hypertension

### Dose

**IV** (dilute to 0.1mg/ml) initial 5mg/hr, titrate 2.5mg/hr every 5-15 min;  
**max: 15mg/hr**; decrease to 3 mg/hr after reaching BP goal

### Adverse Reactions

Hypotension, peripheral edema, tachyarrhythmia, headache, nausea

## Nifedipine

**C<sup>4</sup>** **Safe<sup>1</sup>**

### Dosage Forms

Alat® 10mg/cap <KNIFED1>

Adalat OROS® 33mg/tab <KNIFED3>

### Use

Angina pectoris, hypertension

### Dose

**Cap: PO** initial 10mg tid, usual dose: 10-30mg tid; **max: 60mg/day**

**OROS: PO** initial 30mg qd; **max: 120mg/day**

### **Adverse Reactions**

Dizziness, flushing, headache, weakness, nausea, heartburn, peripheral edema

### **Precautions**

- 1.須避光儲存。
2. Adalat OROS® 不可剝半或磨粉。

### **Contraindication**

Cardiogenic shock、.不可與葡萄柚汁併服

## **Nimodipine**

**C** **Unknown<sup>1</sup>**

### **Dosage Forms**

Nimotop® 10mg/50ml/bot <CNIMODI>

Nimotop® 30mg/FC tab <KNIMODI>

### **Use**

Spasm following subarachnoid hemorrhage from ruptured intracranial aneurysms regardless of the patients neurological condition postictus (Hunt and Hess grades I-V)

### **Dose**

Injection

Adults: **IV** initial 1mg/hr(5ml/hr) or 15mcg/kg/hr for 2 hrs, if necessary, titrate up to 2mg/hr or 30mcg/kg/hr, therapy course should be maintained 5-14 days;

Adults <70kg or BP unstable patients: **IV** initial 0.5mg/hr (2.5ml/hr);

Tablet

**PO** 60mg q4h AC for 21 consecutive days (after the end of 5-14 days of treatment with nimodipine infusion the administration tablet is advisable for about 7 days)

### **Adverse Reactions**

Reduction blood pressure, nausea, diarrhea, abdominal discomfort

### **Precautions**

Cardiovascular surgery, hepatic impairment, hypotension

## **Sevikar®**

**D<sup>5</sup>** **Unknown<sup>3</sup>**

### **Dosage Forms**

1 tab: Amlodipine 5mg+ Omesartan 20mg/tab <KSEVIKA>

### **Use**

Hypertension

### **Dose**

**PO** 1 tab qd; **max: 2tab/day**

### **Adverse Reactions**

Edema, headache, dizziness, flushing, palpitation

### **Precautions**

不建議用於高血壓的起始治療。

### **Contraindications**

肝功能不全者。

### 6.3.2. Non-Dihydropyridines

**Diltiazem**

**C<sup>4</sup> Safe<sup>1</sup>**

**Dosage Forms**

Diltisser<sup>®</sup> 30mg/tab <KDILT01> 參閱 p.108

**Verapamil**

**C<sup>4</sup> Safe<sup>1</sup>**

**Dosage Forms**

Verpamil<sup>®</sup> 5mg/2ml/amp <CVERAPA> 參閱 p.109

Cintsu<sup>®</sup> 40mg/tab <KVERAP1> 參閱 p.109

## 6.4. Vasodilators

### 6.4.1. Organic Nitrates

**Isosorbide dinitrate**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Angidil<sup>®</sup> 10mg/10ml/amp <CISOS01>

**Use**

Angina pectoris, congestive heart failure

**Dose**

IV usual dose 2-7mg/hr up to 10mg/hr as needed

**Adverse Reactions**

Headache, hypotension, dizziness, lightheadedness, tachycardia

**Precautions**

不可直接注射，需以氯化鈉或葡萄糖溶液稀釋後給藥。

**Isosorbide -5- mononitrate**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Coxine<sup>®</sup> 20mg/tab <KISOS03>

**Use**

Angina pectoris

**Dose**

PO initial 1/4-1/2 tab twice daily in 1 and 2 day, maintenance 1 tab bid

**Adverse Reactions**

Headache, vertigo, hypotension, bradycardia

**Contraindications**

併用 Sildenafil、Tadalafil，會增強 nitrates 的降血壓作用而造成嚴重低血壓。

**Nitroglycerin**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Nitrostat<sup>®</sup> sublingual 0.6mg/tab <KNITRO1> <KNITRO3>

**Use**

Treatment of angina pectoris, congestive heart failure

### Dose

SL 1 tab every 5 min, if the pain continues after a total of 3 doses in 15 minutes, prompt medical attention is recommended

### Adverse Reactions

Hypotension, syncope, headache, dizziness, weakness, tachycardia

### Precautions

1. Nitrostat<sup>®</sup> 舌下錠宜存放於涼爽乾燥室溫中，避免高溫或陽光直射處；避免儲放於潮濕空間，開封後請將瓶蓋栓緊儲存，於正確保存方式下可持續使用至瓶外標示之保存期限。
2. 若藥品呈粉末狀或變質，請勿使用。
3. 急診病人若需帶回 1 瓶(25 顆)者，藥品代碼需輸入<KERNT03>。

### Contraindications

服藥期間避免服用 PDE-5 inhibitor (ex: viagra)。

## Nitroglycerin and 5% Dextrose

**C** **Unknown**

### Dosage Forms

N.T.G. Premixed<sup>®</sup> 0.2mg/ml, 250ml/bottle <CNITRO4>

### Use

Induction and maintenance hypotension during intraoperative, congestive heart failure

### Dose

IVF initial 5mcg/min, increased by 5mcg/min q3-5min to response

### Adverse Reactions

Hypotension, syncope, headache, dizziness, weakness, tachycardia

### Precautions

1. 此藥易被 PVC 吸著，建議使用短的輸注管以減少吸著程度
2. 開封後於 24 小時內使用完畢。

## 6.4.2 Peripheral Vasodilators

### Hydralazine

**C** **Safe**

### Dosage Forms

Aprelazine<sup>®</sup> 20mg/1ml/amp <CHYDRAL>

Stable<sup>®</sup> 10mg/tab <KHYDRA1>

Apoline<sup>®</sup> 25mg/tab <KHYDRA2>

### Use

Hypertension, congestive heart failure

### Dose

Children: PO initial 0.75mg/kg/day qid, titrate to max: **7.5mg/kg/day or 300mg/day** as needed

Adult: IM/IV 20-40mg/dose; PO initial 10mg qid for first 2-4 days, increase to 25mg qid for remainder of first week then increase to 50mg qid; max: **300mg/day**

### Adverse Reactions

Headache, palpitation, nausea, vomiting, tachycardia

### Contraindications

針劑忌以dextrose溶液稀釋。

## Minoxidil

C **Safe<sup>1</sup>**

### Dosage Forms

Loniten® 10mg/tab <KMINOXI>

PBF Minoxidil Solution® 2%, 60ml/bot<WMINOX3>參閱p.139

PBF Minoxidil Solution® 5%, 60ml/bot<WMINOX2>參閱p.139

### Use

Hypertension, alopecia, androgenetica (topical formulation)

### Dose

#### Hypertension

Children <12yrs: PO initial 0.2 mg/kg/day, **max: 5 mg**; maintenance 0.25-1.0 mg/kg/day; **max: 50mg/day**

Adult: PO initial 5mg qd-bid, maintenance 10-40mg/day qd-bid; **max:100mg/day**

### Adverse Reactions

Congestive heart failure, edema, tachycardia, hypertrichosis

## 6.4.3 Other vasodilators

## Nicorandil

**Unknown<sup>3</sup>**

### Dosage Forms

Sigmat® 5mg/tab <KNICORA>

### Use

Angina pectoris

### Dose

PO 5mg tid, adjust dose as need

### Adverse Reactions

Headache, aphthous ulcers, thrombocytopenia, palpitation, flushing

### Contraindications

服藥期間避免服用 PDE-5 inhibitor (ex: viagra) , 以免發生嚴重低血壓。

## 6.5. Antiadrenergics and Sympatholytics

### 6.5.1. Beta-Blockers

## Atenolol

D **Unknown<sup>1</sup>**

### Dosage Forms

Urosin® 50mg/tab <KATEN01>

Urosin® 100mg/tab <KATEN02>

### Use

Hypertension, angina pectoris

### Dose

PO 50-100mg qd; **max: 200mg/day**

### **Adverse Reactions**

Bradyarrhythmia, cold extremities, hypotension, fatigue, depression

### **Bisoprolol**

**C Unknown**

#### **Dosage Forms**

Concor® 1.25mg/tab <KBISOP1>

Bisol® 5mg/tab <KBISOPR>

#### **Use**

Hypertension, angina, congestive heart failure

#### **Dose**

Angina and hypertension

**PO 2.5-20mg qd; max: 20mg/day**

Congestive heart failure

**PO initial 1.25mg qd, titrate to maximum dose 10mg qd**

#### **Adverse Reactions**

Dizziness, headache, sleep disturbances, bradycardia, fatigue

### **Propranolol**

**C<sup>4</sup> Safe<sup>4</sup>**

#### **Dosage Forms**

Propranolol® 10mg/tab <KPROPRA1> 參閱 p.107

Cardolol® 40mg/tab <KPROPRA2> 參閱 p.107

## **6.5.2. Alpha and Beta Blocker Agents**

### **Carvedilol**

**C Unknown**

#### **Dosage Forms**

Syntrend® 6.25mg/tab <KCARV01>

Syntrend® 25mg/tab <KCAVE02>

#### **Use**

Hypertension and congestive heart failure

#### **Dose**

Hypertension

**PO initial 6.25mg bid for 1-2 wks, then 12.5mg bid for 1-2 wks, than increase to 25mg bid; max: 50mg/day**

CHF

**PO initial 3.125mg bid, it can be increased to 6.25mg bid; < 80kg:**

**maximum dose 25mg bid; >80kg: maximum dose 50mg bid**

#### **Adverse Reactions**

Dizziness, fatigue, hyperglycemia, weight gain, hypotension

### **Labetalol**

**C<sup>1</sup> Safe<sup>1</sup>**

#### **Dosage Forms**

Labtal® 200mg/tab <KLABETA>

Trandate® 25mg/5ml/amp <CLABETA>

#### **Use**

Mild to severe hypertension

#### **Dose**

**IV bolus** 50 mg, injection >1 min, every 5 mins repeat, total dose <200mg;  
**IVF** 50-200mg (rate: 2mg/min); **PO** 200-400mg bid; **max: 2.4g/day**

#### **Adverse Reactions**

Dizziness, nausea, hypotension, bradycardia

#### **Precautions**

- 1.注射液應避光儲存
- 2.稀釋後可儲存於室溫下 24 小時。

### **6.5.3. Alpha-adrenergic Blockers**

#### **Alfuzosin**

**B<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Xatral<sup>®</sup> XL 10mg/tab <KALFUZO> 參閱 p.302

#### **Doxazosin**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Doxaben<sup>®</sup> XL 4mg/tab <KDOXAZ2>

#### **Use**

Hypertension and benign prostate hypertrophy

#### **Dose**

##### Hypertension

**PO** initial 4mg qd; **max: 16mg/day**

##### BPH

**PO** 4-8mg qd; **max: 8mg/day**

#### **Adverse Reactions**

Dizziness, headache, hypotension, vertigo, edema, nausea, somnolence  
vertigo

#### **Precautions**

不宜磨粉。

#### **Silodosin**

**B<sup>5</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Urief<sup>®</sup> 4mg/cap <KSILODO> 參閱 p.303

#### **Tamsulosin**

**B<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Harnalidge<sup>®</sup> D 0.2mg/tab <KTAMSU1> 參閱 p.304

### **6.5.4. Alpha-2Adrenergic Agents**

#### **Clonidine**

**C<sup>5</sup> Unknown<sup>3</sup>**

#### **Dosage Forms**

Catapres<sup>®</sup> 75mcg/tab <KCLONID>

#### **Use**

Hypertension

#### **Dose**

**PO** 75-150mcg/day bid

**Adverse Reactions**

Dizziness, drowsiness, dry mouth, orthostasis, localized skin reactions

## 6.6. Angiotensin-Converting Enzyme Inhibitors

### Captopril

**D<sup>4</sup> Safe<sup>1</sup>**

**Dosage Forms**

Cabudan® 25mg/tab <KCAPTOP>

**Use**

Hypertension, congestive heart failure and diabetic nephropathy

**Dose**

**PO** initial 12.5-25mg bid-tid AC, may increase to 50mg bid-tid; **max: 450mg/day**

**Adverse Reactions**

Dry cough, hyperkalemia, rash, pruritus

**Precautions**

需依腎功能調整劑量

**Contraindications**

Bilateral renal artery stenosis

### Enalapril

**D<sup>4</sup> Safe<sup>1</sup>**

**Dosage Forms**

Synbot® 5mg/tab <KENALA1>

Synbot® 20mg/tab <KENALA2>

**Use**

Hypertension, congestive heart failure

**Dose**

Hypertension

Children: **PO** initial 0.08mg/kg qd, adjust dosage based on patient response

Adults: **PO** initial 2.5-5mg qd, than 10-40mg/day qd-bid

CHF

**PO** initial 2.5mg qd-bid, maintenance 5-20mg/day bid; **max: 40mg/day**

**Adverse Reactions**

Dry cough, hyperkalemia, dizziness, headache, hypotension, syncope, rash

### Fosinopril

**D<sup>4</sup> Unknown**

**Dosage Forms**

Fonosil® 10mg/tab <KFOSINO>

**Use**

Hypertension, congestive heart failure

**Dose**

**PO** initial 10mg qd , maintenance 20-40mg/day qd-bid

**Adverse Reactions**

Dry cough, hyperkalemia, dizziness, angioneurotic edema

**Precautions**

建議飯前服用。

## Amtral®

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

1 tab: Amlodipine 5mg + Benazepril 10mg/tab <KAMTREL> 參閱 p.110

## 6.7. Angiotensin II Receptor Antagonists

### Exforge®

D<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

1tab: Amlodipine 5mg+Valsartan 80mg/tab<KEXFORG>

### Use

Hypertension

### Dose

PO 1-2 tab daily, qd-bid; max: 2 tab/day

### Adverse Reactions

Peripheral edema, dizziness, upper respiratory infection, nasopharyngitis.

### Exforge HCT®

X<sup>1</sup> Unsafe<sup>1</sup>

### Dosage Forms

1tab: Amlodipine 5mg+Valsartan 160mg+ Hydrochlorothiazide 12.5mg<KEXFOR1>

### Use

Hypertension

### Dose

PO 1 tab qd; max: 2 tab/day

### Adverse Reactions

Dizziness, edema, headache, dyspepsia, fatigue

### Contraindications

Anuria, hypersensitivity to sulfonamide drug, grapefruit juice

### Hyzaar®

D<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

1 tab: Losartan 100mg + Hydrochlorothiazide 12.5mg/tab<KHYZAAR>

### Use

Hypertension

### Dose

PO 1tab qd

### Adverse Reactions

Dizziness, diarrhea, anaphylactic reaction, angioedema

### Irbesartan

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Aprovel® 300mg/tab <KIRBES1>

### Use

Hypertension, diabetic nephropathy

## Dose

### Hypertension

Adults: **PO** initial 150mg qd; **max: 300mg/day**

### Diabetic nephropathy

Adult: **PO** initial 150mg qd, target maintenance does 300mg qd

## Adverse Reactions

Diarrhea, dyspepsia, upper respiratory infection, headache, fatigue

## Precautions

1. 避免與 Aliskiren 併用於糖尿病患者。
2. 老年患者(>75yrs)起始劑量建議為 75mg。
3. 用於腎功能不全、因糖尿病腎病變引起明顯的蛋白尿及/或心衰竭患者時，應監測血鉀濃度。
4. 若有罕見遺傳性半乳糖不耐症、Lapp 氏乳糖缺乏或葡萄糖-半乳糖吸收不良症應避免使用。

## Contraindications

孕婦(易引起胎兒腎衰竭及頭骨發育不全)

## Olmesartan

**D<sup>4</sup>** **Unknown<sup>1</sup>**

### **Dosage Forms**

Olmetec® 20mg/tab <KOLMESA>

### **Use**

Hypertension

### **Dose**

**PO** 20mg qd, may titrate to 40 mg qd after 2 wks of initial treatment

## Adverse Reactions

Hypotension, diarrhea, dizziness, headache, fatigue

## Sevikar®

**D<sup>5</sup>** **Unknown<sup>3</sup>**

### **Dosage Forms**

1 tab: Amlodipine 5mg+ Omesartan 20mg/tab <KSEVIKA>參閱 p.112

## Valsartan

**D<sup>4</sup>** **Unknown<sup>1</sup>**

### **Dosage Forms**

Diovan® 160mg/tab <KVALSA1>

### **Use**

Hypertension, congestive heart failure

### **Dose**

#### Hypertension

**PO** 80-160mg qd; **max: 320mg/day**

#### CHF

**PO** 40mg bid; **max: 320mg/day**

## Adverse Reactions

Viral infection, neutropenia, postural hypotension, BUN and Scr raised

## 6.8. Direct Renin Inhibitor

## **Aliskiren**

**D** Unknown

### **Dosage Forms**

Rasilez® 150 mg/tab< KALISKI >

### **Use**

Hypertension

### **Dose**

**PO** initial 75-150mg once daily, may increase to 300mg/day.

### **Adverse Reactions**

Headache, hypotension, abdominal pain, hyperkalemia

### **Precautions**

1. 本品與利尿劑併用，建議起始劑量75mg。

2. Drug-Drug interaction: with furosemide reduced furosemide serum concentration; with cyclosporine increased aliskiren serum concentration that didn't suggest combination therapy

## **6.9. Alpha-adrenergic agonists**

### **Methyldopa anhydrous**

**B** Safe<sup>1</sup>

### **Dosage Forms**

Methyldopa® 250mg/tab< KMETHY3 >

### **Use**

Hypertension

### **Dose**

**PO** initial 250mg bid, maintenance 500-1000mg divide 2-3times

### **Adverse Reactions**

Asthenia, dizziness, disorder of ejaculation, impotence, reduced libido

### **Contraindications**

1. 急慢性肝炎及肝硬化活動期之患者。

2. 避免飯後使用及併用制酸劑服用。

## **6.10. Antihyperlipidemic Agents**

### **6.10.1. HMG-CoA Reductase Inhibitors**

#### **Atorvastatin**

**X** Unknown<sup>1</sup>

### **Dosage Forms**

Lipitor® 20mg/tab < KATORV1 >

### **Use**

Hyperlipidemias, secondary prevention of cardiovascular events

### **Dose**

Adults: **PO** initial 10-20mg qd; **max: 80mg/day**

### **Adverse Reactions**

Diarrhea, arthralgia, myalgia, pain in extremity, UTI, nasopharyngitis

### **Precautions**

1. Discontinue drug if markedly elevated CPK level or if myopathy is diagnosed or suspected
2. Concomitant statin therapy with fibrates should generally be avoided (risk of rhabdomyolysis)

## Caduet®

**X** **Unsafe<sup>1</sup>**

### Dosage Forms

1tab: Amlodipine 5mg +Atorvastatin 10mg /tab <KCADUET>參閱 p.110

## Fluvastatin

**X** **Unknown<sup>1</sup>**

### Dosage Forms

Lescol® XL 80mg/FC tab <KFLUVAS>

### Use

Elevated total cholesterol, LDL-C, TC, mixed dyslipidemia (type IIa and IIb) and primary hypercholesterolemia, atherosclerotic vascular disease

### Dose

PO 80mg hs

### Adverse Reactions

Insomnia, indigestion, nausea, headache, disorder of muscle

### Precautions

1.須整顆吞服，不可撥半或磨粉。

2.需依肝功能調降劑量。

### Contraindications

年紀<18 歲，活動性肝疾病。

## Linicor F.C.T®

**X** **Unsafe<sup>1</sup>**

### Dosage Forms

Niacin 500mg+ Lovastatin 20mg/tab <KLINICO>

### Use

Hyperlipidemias

### Dose

PO 1tab HS; max. dose: 2tab/day

### Adverse Reactions

Hot flashes, infection, headache, muscle pain, rhabdomyolysis

### Precautions

1.為緩釋劑型，不可弄破、壓碎或咀嚼

2.不建議空腹使用，可與低脂點心併服

3.服藥期間避免同時攝取酒精、熱飲或辛辣食物、食用葡萄柚或葡萄柚汁

### Contraindications

活動性肝病、懷孕、授乳婦

## Pravastatin

**X** **Unknown<sup>1</sup>**

### Dosage Forms

Mevalotin® 40mg/tab <KPRAVA1>

## **Use**

Hyperlipidemias, secondary prevention of cardiovascular events

## **Dose**

Adults: **PO** 10-40mg hs; **max: 80mg/day**

## **Adverse Reactions**

URI, nausea, vomiting, rash, musculoskeletal pain, headache

## **Rosuvastatin**

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Crestor® 5mg/F.C tab <KROSV1>

Crestor® 10mg/F.C tab <KROSVU>

## **Use**

Hypertriglyceridemia, hypercholesterolemia

## **Dose**

Adults: **PO** initial 5-10mg qd, maintained 5-20mg/day

## **Adverse Reactions**

Arthralgia, myalgia, headache, dizziness, headache, nausea

## **Precautions**

建議於開始治療及調高劑量後監測肝功能

## **Contraindications**

活動性肝病、懷孕、授乳婦

## **Vytorin®**

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

1tab: Ezetimibe 10mg+ Simvastatin 20mg /tab<KVYTORI>

## **Use**

Antilipemic agents (HMG-CoA reductase inhibitors +Cholesterol absorption inhibitor)

## **Dose**

**PO** 1tab/day , 晚間隨餐或空腹服用。

## **Adverse Reactions**

Headache, flatulence, abdominal pain, myalgia, liver enzyme elevated

## **Precautions**

1.嚴重腎功能不全 (CCR <30ml/min) , 應小心使用。

2.Drug-Drug interaction:與 CYP3A4 inhibitor , 及其他 fibrates 併用會增加肌病變/橫紋肌溶解症的危險性。

## **Contraindications**

中或重度肝功能不全

## **6.10.2 Fibric Acid Derivatives**

## **Choline fenofibrate**

**C<sup>4</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Trilipix® 135mg/cap <KFENOF2>

## **Use**

Hyperlipidemia (reducing triglyceride levels)

**Dose**

PO 1cap qd; max: 135mg/day

**Adverse Reactions**

Headache, back pain, upper respiratory tract infection, pain in extremity, nausea

**Precautions**

膠囊可撥開，剝開後小藥錠為持續釋放劑型，請勿磨粉

**Contraindications**

重度腎功能不全(Clcr<30ml/min)、活動性肝病及肝功能不全、膽囊疾病、以 fibrate 或 ketoprofen 治療曾發生光過敏或光毒性

**Fenofibrate**

**C** Unknown<sup>1</sup>

**Dosage Forms**

Lipanthyl supra<sup>®</sup> 160mg/tab <KFENOF1>

**Use**

Hyperlipidemia (reducing triglyceride levels)

**Dose**

PO 1tab qd

**Adverse Reactions**

Abdominal pain, nausea, liver function tests abnormal, backache, rhinitis

**Precautions**

需依腎功能調整劑量

**Contraindications**

Gallbladder disease, active liver disease (including primary biliary cirrhosis, unexplained persistent liver function abnormality), severe renal impairment

**Gemfibrozil**

**C** Unknown<sup>1</sup>

**Dosage Forms**

GEMD<sup>®</sup> 300mg/cap <KGEMFIB>

**Use**

Hyperlipidemia (reducing triglyceride levels)

**Dose**

Adults: PO 600mg bid AC

**Adverse Reactions**

Abdominal pain, acute appendicitis, indigestion, increased liver function test, rhabdomyolysis

**Contraindications**

肝腎功能不全患者禁用

### 6.10.4. Cholesterol Absorption Inhibitor

**Ezetimibe**

**X** Unknown<sup>1</sup>

**Dosage Forms**

Ezetrol<sup>®</sup> 10mg/tab <KEZETIM>

**Use**

Hypercholesterolemia

**Dose**

PO 10mg qd, can be administered at any time, with or without food

**Adverse Reactions**

Headache, abdominal pain, diarrhea, fatigue, increased liver enzymes

**Precautions**

1. Children <10yrs is not recommended。

2. 不建議與 Fibrates 類的藥物(如 Fenofibrate, Gemfibrozil)併用。

3. 中重度肝功能不良不建議使用。

**Vytorin®**

**X** **Unknown<sup>1</sup>**

**Dosage Forms**

1tab: Ezetimibe 10mg+ Simvastatin 20mg /tab<KVYTORI>參閱 p.123

## 6.11 Vasopressors

**Dobutamine**

**B** **Unknown<sup>1</sup>**

**Dosage Forms**

Gendobu® 250mg/20ml/vial <CDOBUTA>

**Use**

Congestive heart failure, increase cardiac output

**Dose**

IVF 2.5-10 mcg/kg/min; **max: 40mcg/kg/min**

Infusion rates of various dilutions of dobutamine

Rate (mcg/kg/min)	Infusion Rate (ml/kg/min)		
	250mg/L	500mg/L	1000mg/L
2.5	0.01	0.005	0.0025
5.0	0.02	0.01	0.005
7.5	0.03	0.015	0.0075
10.0	0.04	0.02	0.01
12.5	0.05	0.025	0.0125
15.0	0.06	0.03	0.015

**Adverse Reactions**

Tachyarrhythmia, hypertension, angina, headache, eosinophilic myocarditis

**Contraindications**

勿將 dobutamine hydrochloride 加到 5% Sodium Bicarbonate Injection、含有 Sodium Bisulfite、乙醇及其他強鹼溶液。由於可能的物理配伍禁忌，建議不要與其他藥物在同一溶液中互相混合。

**Dopamine**

**C** **Unknown<sup>1</sup>**

**Dosage Forms**

Dopamin® 200mg/5ml/amp <CDOPAMI>

**Use**

Shock, congestive heart failure

## Dose

Adults: **IVF** initial 1-5mcg/kg/min, and then increased by 1-4 mcg/kg/min at 10-15min interval.

Chronic refractory congestive heart failure

**IVF** initial 0.5~2mcg/kg/min

Occlusive vascular disease

**IVF** initial 1mcg/kg/min

Severely ill patients

**IVF** initial 5mcg/kg/min, and then increased by 5-10mcg/kg/min up to 20-50mcg/kg/min

## Adverse Reactions

Tachycardia, chest pain, dyspnea, headache, nausea, vomiting

## Precautions

勿添加Sodium bicarbonate 或其他鹼性靜脈輸注溶液。

## Ephedrine

**C<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Ephedrine<sup>®</sup> 40mg/ml/amp <CEPHED2>

### Use

Bronchial asthma, nasal congestion, acute bronchospasm, idiopathic orthostatic hypotension

### Dose

Children: **SC** 3mg/kg/day or 25-100mg/m<sup>2</sup>/day q4-6h; **IM/IV**(slow push) 0.2-0.3mg/kg/dose q4-6h slow push

Adults: **IM/SC** 25-50mg; **IV**(slow push) 5-25mg/dose, may repeat after 5-10 min then q3-4h as needed; **max: 150mg/day**

## Adverse Reactions

Hypertension, tachycardia, palpitations, nausea, vomiting, tremor

## Epinephrine

**C<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Adrenalin<sup>®</sup> 1mg/ml/amp <CEPINEP>

Bosmin<sup>®</sup> 0.1%, 500ml/bot <WEPINEP> 參閱p.326

### Use

Bronchospasms, anaphylactic reactions, cardiac arrest, added to local anesthetics to decrease systemic absorption

### Dose

#### Cardiac arrest

Children: **IV** 5-10mcg/kg, may repeat q3-5min as needed

Adults: **IV** 1mg, may repeat q3-5min as needed

#### Anaphylaxis

Children: **IM/SC** 10mcg/kg/dose q15min for 2 dose then q4h as needed; **max: 0.5mg/dose**

Adults: **IM/SC** 0.3-0.5mg, may repeat q10-15min as needed; **max: 1mg/dose**

#### Asthma

Children: **SC** 10mcg/kg/dose, may repeat q15-20min for 3-4 doses or q4h

as needed; **max: 0.5mg/dose**

Adults: SC 0.2-0.5mg, may repeat q20min for max 3 doses or q4h as needed

### Adverse Reactions

Tachycardia (parenteral), palpitations, nervousness, pallor, headache

### Precautions

1. IV infusion require an infusion pump
2. IM route is preferable to SC route during anaphylaxis

## Isoproterenol

**C Unknown**

### Dosage Forms

Proteranol-L® 0.2mg/1ml/amp < CISOPRO >

### Use

Adams-stokes syndrome, cardiac arrest, congestive heart failure, asthma

### Dose

#### Cardiogenic shock, congestive heart failure

Adult: **IVF** 0.5 to 5 mcg/min, if the heart rate >110 beats/min, it may be necessary to decrease or discontinue the infusion

#### Stokes-Adams syndrome, heart block

Adult: **IV bolus** initial 0.02-0.06mg followed by 0.01-0.2mg depending on response; **IVF** initial, 5 mcg/min, titrate to response

#### Asthma with status asthmaticus

Children: **IVF** initial 0.1mcg/kg/min; **max: 0.08-1.7mcg/kg/min**

### Adverse Reactions

Syncope, tachyarrhythmia, confusion, headache, tremor

### Precautions

1. Administration requires the use of an infusion pump
2. Prepare for infusion: 1mg isoproterenol to 500ml D5W, final concentration 2mcg/ml

## Norepinephrine

**C Unknown**

### Dosage Forms

Levophed® 4mg/4ml/vial < CNOREPI >

### Use

Cardiac arrest, acute hypotension

### Dose

Children: **IVF** initial 0.05-0.1mcg/kg/min, **max: 1-2mcg/kg/min**

Adults: **IVF** initial 8-12mcg/min, maintenance 2-4mcg/min

### Adverse Reactions

Bradyarrhythmias, hypertension, extravasation injury, nausea, vomiting

### Precautions

1. Levophed 應加在 1000ml D5W or D5W/NS 稀釋後使用(稀釋後濃度為 4mcg/ml),不可直接以 NS 稀釋。
2. 使用時維持適當的血容量，以預防由於藥物之血收縮作用導致組織缺血。
3. 儘可能注入大靜脈，並且要更換輸注部位以減少壞死之危險。

## 6.12. Cardiovascular Miscellaneous

### Alprostadil

C Unknown

#### Dosage Forms

Promostan® 20mcg/vial <CALPR01>

Caverject® 20mcg/vial <CALPR03>

Prostin VR® Pediatric 500mcg/ml/amp <CALPR02>

#### Use

Promostan®: peripheral obstructive arterial disease, Raynaud's phenomena, angina.

Caverject®: erectile dysfunction

Prostin VR Pediatric®: temporarily maintain patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed.

#### Dose

Peripheral vascular disease (Promostan®)

Adults: IVF 40-60mcg qd or q12h (rate: 0.005-0.01mcg/kg/min); IAF

10-15mcg via infusion pump (rate 0.0001-0.00015mcg/kg/min)

Erectile dysfunction(Caverject®)

Intracavernous(ICV)

Initial dose	Neurogenic etiology	Vasculogenic, psychogenic, or mixed etiology
Starting dose	1.25mcg	2.5mcg
Second dose	2.5mcg	Partial response: 5mcg No response: 7.5mcg
Third dose	5mcg	
增量至最佳劑量	5mcg	5-10mcg

Maintenance: once an appropriate dose has been determined, patient may self-administer injections at a frequency of no more than 3 times/week with at least 24hrs between doses.

Patent ductus arteriosus (Prostin VR® Pediatric)

Neonate: IVF initial 0.05-0.1mcg/kg/min, maintenance

0.01-0.4mcg/kg/min

#### Adverse Reactions

Prostin VR®: Flushing, fever, bradycardia, hypotension

Caverject®: Penile pain, haematoma, muscle spasms, erection increased, penis disorder

Promostan®: Injection site reaction, headache, cardiac arrest, edema

#### Precautions

1.投與時，注入部位偶有鈍痛、疼痛、腫脹，偶有發熱、發紅等症狀，發生此等症狀時應減慢投藥速度。

2.使用 infusion pump 時，注意請勿使氣泡混入袋內或針筒內。

3.Promostan®動脈內給藥時，20mcg/amp 以 5ml NS 溶解。

4.Prostin VR® Pediatric保存方式: 2-8 °C。

5.Caverject<sup>®</sup>:藥品配製後於 25 度下可保存 24 小時。

## Ivabradine

**Unsafe<sup>1</sup>**

### Dosage Forms

Coralan<sup>®</sup> 5mg/F.C. tab<KIVABRA>

### Use

Heart failure

### Dose

Initial **PO** 5mg BID with meal. After 2weeks, if resting heart rate >60 bpm, the dose can be increased to 7.5mg BID; if resting hear rate <50 bpm or in case of symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose can be decrease to 2.5mg BID

### Adverse Reactions

Phosphenes, blurred vision, headache, dizziness, bradycardia

### Precautions

- 1.可能造成光幻覺，駕駛或操作機械時應小心
- 2.75 歲以上老年人起始劑量應為 2.5mg BID
- 3.需依肝腎功能調整劑量
- 4.服用此藥期間避免飲用葡萄柚汁

### Contraindications

靜態心跳低於 60bpm、心因性休克、急性心肌梗塞、嚴重低血壓(<90/50mmHg)、嚴重肝功能不全、sick sinus syndrome、竇房阻斷、不穩定或急性心衰竭、使用心律調節器者、不穩定狹心症者、第 3 度 AV block 患者、懷孕及授乳婦女。

## Levosimendan

**Unknown<sup>1</sup>**

### Dosage Forms

Simdax<sup>®</sup> 12.5mg/5ml/vial< CLEVOSI>

### Use

Heart failure

### Dose

Initial **IV bolus** of 6-12mcg/kg delivered over 10 minutes, followed by a continuous **IVF** of 0.1mcg/kg/min. In patients receiving continuous infusions, doses of 0.05-0.2 mcg/kg/minute have been recommended

### Adverse Reactions

Headache, ventricular tachycardia, hypotension

### Precautions

- 1.不建議與血管擴張劑或強心劑併用
- 2.急性失代償性嚴重慢性心衰竭病人建議輸注時間為 24 小時
- 3.未開封需保存於 2-8°C，儲存期間濃縮液可能變為橘色，不影響藥效
- 4.使用前以 500ml D5W 稀釋至藥品濃度為 0.025-0.05mg/ml，稀釋後於 25°C 可保存 24 小時

### Contraindications

低血壓(SBP<100mmHg or DBP<60mmHg)、心跳過快、影響心室充填或外流或兩者皆有明顯之機械性阻塞、重度肝腎功能不全、Torsades

de pointes 病史

## Milrinone

C Unknown

### Dosage Forms

Primacor<sup>®</sup> 10mg/10ml/vial <CMILRIN>

### Use

Congestive heart failure (short-term intravenous)

### Dose

IV initial 0.05mg/kg over 10 mins, maintenance 0.59-1.13mg/kg/day,  
infusion rate: 0.375-0.75mcg/kg/min

### Adverse Reactions

Proarrhythmic events, chest pain, hypotension, headache

### Precautions

1. 以 0.45%NaCl, NS 或 D5W 稀釋後，於室溫下可貯放 72 hrs。

2. 需依腎功能調整劑量。

## 7. DERMATOLOGYS

### 7.1. Acne Preparations

#### Adapalene

**C** Unknown<sup>1</sup>

##### Dosage Forms

Tifforly® gel 0.1%, 15g/tube <WADAPAL>

##### Use

Acne

##### Dose

Children >12 yrs and adults: **Topical** use jelly at bedtime

##### Adverse Reactions

Dry skin, erythema, scaly skin,burning,stining

##### Precautions

- 1.Avoid contact with abraded, eczematous, or sunburned skin, mucous membranes, eyes, mouth
- 2.Use is associated with increased susceptibility/sensitivity to UV light; avoid sunlamps or excessive sunlight exposure

#### Benzoyl Peroxide

**C** Unknown<sup>1</sup>

##### Dosage Forms

Aczo® gel 5% 10g/tube <WBENZOY>

##### Use

Acne

##### Dose

**Topical** once daily

##### Adverse Reactions

Irritation, contact dermatitis, dryness, erythema, , stinging

##### Precautions

使用本品需做防曬。

#### Clindamycin

**B** Safe<sup>1</sup>

##### Dosage Forms

Kolincin® acne gel 1%, 20g/tube <WCLIND2>

##### Use

Acne

##### Dose

Children ≥ 12 yrs and adults: **Topical** qd-bid

##### Adverse Reactions

Dryness, burning, itching, scaliness, or peeling of skin

#### Isotretinoin

**X** Unknown<sup>1</sup>

##### Dosage Forms

Roaccutane® 10mg/cap <KISOTRE>

##### Use

Treatment of severe recalcitrant cystic and/or conglobate acne

## Dose

### Severe recalcitrant nodular acne:

Children (13-17 yrs): **PO** 0.5- 1mg/kg/day qd-bid for 15-20 wks

Adults: **PO** 0.5-2mg/kg/day qd-bid for 15-20 wks

## Adverse Reactions

Hypertriglyceridemia ,increased liver function test, arthralgia , backache, dry skin

## Precautions

1. Advise patient to use sunscreen and avoid sun and ultraviolet light
2. Instruct patient to take drug with food and to swallow capsules whole with a full glass of liquid
3. Instruct patient to avoid additional vitamin A supplementation during drug therapy, as this may increase the risk of toxicity
4. Children less than 12 yrs not established
5. 本品限皮膚科專科醫師使用。

## Contraindications

懷孕者禁止使用

## Tazarotene

**X<sup>6</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Zorac<sup>®</sup> cream 0.1%, 30g/tube <WTAZAR1>

## Use

Psoriasis, acne vulgaris

## Dose

### Acne vulgaris

Childern  $\geq$  12 yrs and adults: **Topical** after cleansing the face every evening

### Psoriasis

**Topical** once daily , use cream at evening

## Adverse Reactions

Dry skin,erythema, pain of skin, skin irritation, pruritus

## Precautions

During therapy, avoid exposing the treated areas to sunlight

## Contraindications

懷孕者禁止使用

## 7.2 Antiseptics and Germicides

## Povidone iodine

**C<sup>6</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Biodyne<sup>®</sup> oint 10%, 10g/tube <WPOVID8>

Sindine solution <sup>®</sup> 10% 不含Alcohol	Sindine solution <sup>®</sup> 10% 含Alcohol
30ml/bot <WPOVID5>	200ml/bot <WPOVID1>
200ml/bot <WPOVID4>	500ml/bot <WPOVID3>

**Use**

External antiseptic

**Dose**

**Topical** apply as needed for treatment and prevention of susceptible microbial infections

**Adverse Reactions**

Irritation, itching, burning

**Precautions**

Prolonged exposure to wet solution may cause irritation or rarely, severe skin reactions

## 7.3. Anti-Infective Agents

**Acyclovir**

**B<sup>1</sup> Safe<sup>1</sup>**

**Dosage Forms**

Virless® lyophilized 250mg/vial <CACYC02> 參閱 p.34

Virless® 200mg/tab <KACYC01> 參閱 p.34

Zovirax® susp 4%, 125ml/bot <KACYC03> 參閱 p.34

Aclovir® cream 5%, 5g/tube <WACYC05>

Devirus® oph oint 3%, 4.5g/tube <WACYC02> 參閱 p.274

**Use**

Herpes simplex infection

**Dose**

**Topical** q3h for 7 days

**Adverse Reactions**

Contact dermatitis

**Amorolfine**

**B<sup>6</sup> Unsafe<sup>1</sup>**

**Dosage Forms**

Loceryl® 5%, 3ml/bot <WAMOROL>

**Use**

Onychomycosis due to dermatophytes, yeasts and moulds

**Dose**

Qw-biw until clinical cure is achieved is recommended. Usual durations of therapy are 6 months in fingernail infections and 9-12 months in toenail infections.

**Adverse Reactions**

Slight, transient periungual burning sensation

**Biomycin®**

**C<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

1g: Neomycin 5mg+ Tyrothricin 0.5mg, oint 40g/tube <WBIOMYC>

**Use**

Prophylaxis and treatment of minor skin infections and dermal ulcers

**Dose**

**Topical** bid-qid

## **Butenafine**

**C** **Unknown<sup>1</sup>**

### **Dosage Forms**

Mentax® cream 1%, 10gm/tube <WBUTENA>

### **Use**

Superficial fungal infections

### **Dose**

Children>12 yrs and adults: **Topical** qd-bid

### **Adverse Reactions**

Contact dermatitis, erythema, itching, skin irritation

### **Precautions**

Advise patient to avoid contact with eyes, nose, mouth, and other mucous membranes

## **Clotrimazole**

**B** **Unknown<sup>1</sup>**

### **Dosage Forms**

Mycosten® cream 10g/tube <WCLOTR3>

Camazole® 100mg/vag. tab <WCLOTR4> 參閱 p.146

### **Use**

Candidal vulvovaginitis, Tinea cruris, Pityriasis versicolor,Candidiasis

### **Dose**

Childern≥12 yrs and adults: **Topical** bid (morning and evening) for 7 days

### **Adverse Reactions**

Burning, itch

## **Fradiomycin**

### **Dosage Forms**

Framycin® gauze dressing patch 10cm×10cm <WFRAMYC>

### **Use**

Treatment of infected burns, wounds, ulcers and graft sites

### **Dose**

**Topical** apply to the skin qd or more frequently

## **Fusidic acid**

**B** **Unknown<sup>1</sup>**

### **Dosage Forms**

Fucidin 250mg/tab<KFUSIDA> 參閱 p.56

Fusidic aicd® cream 2%, 5g/tube <WFUSID1>

### **Use**

Superficial dermatologic infections

### **Dose**

**Topical** tid-qid

### **Adverse Reactions**

Pain

## **Gentamicin**

**C** **Unknown<sup>1</sup>**

### **Dosage Forms**

Gentamycin® 80mg/2ml/vial<CGENTA2> 參閱 p.16

Gentermay® cream 0.1%, 15g/tube <WGARAMY>

Oftalmolosa® oint 0.3%, 5g/tube<WGENTA3>參閱 p.271

Gentamicin® oph sol'n 0.3%,5ml/bot<WGENTA2>參閱 p.271

**Use**

Susceptible bacterial infections, normally gram-negative organisms and gram-positive, skin and soft tissue infections

**Dose**

**Topical** tid-qid

**Adverse Reactions**

Erythema, pruritus

**C<sup>6</sup> Safe<sup>1</sup>**

**Ketoconazole**

**Dosage Forms**

Ketosone® cream 2%, 10g/tube <WKETOC1>

**Use**

Susceptible fungal infections

**Dose**

**Topical** qd-bid

**Adverse Reactions**

Local burning, pruritus, stinging

**B<sup>1</sup> Unsafe<sup>1</sup>**

**Metronidazole**

**Dosage Forms**

Free® gel 0.75%, 15g/tube <WMETRO2>

Sutrol Gel-Vaginal® 25g/tube<WMETRO1>

**Use**

Free® : Acne rosacea,

Sutrol Gel-Vaginal® : Bacterial vaginosis or vaginitis due to *Gardnerella*, *Mobiluncus*

**Dose**

Acne rosacea

**Topical** apply thin film to affected area twice daily (morning and evening)

Bacterial vaginosis or vaginitis due to Gardnerella, Mobiluncus

**Intravaginally** apply 5g gd-bid for 5 days,before bedtime if to be used once daily

**Adverse Reactions**

Free® : redness, mild dry skin, burning, skin irritation.

Sutrol Gel-Vaginal® : vaginal discomfort, vaginal candidiasis, vaginal irritation, gastrointestinal discomfort

**C<sup>6</sup> Unknown<sup>1</sup>**

**Pasca®**

**Dosage Forms**

1g: Tolnaftate 20mg+Methyl salicylate 20mg, oint 10g/tube <WTOLNAF>

**Use**

Tinea pedis, tinea cruris, tinea corporis, Tinea versicolor

**Dose**

**Topical bid**

**Adverse Reactions**

Pruritus and contact dermatitis

**Polyphenon E**

**C<sup>6</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Veregen<sup>®</sup> oint. 10%, 10g/tube <WPOLYPH>

**Use**

Condylomata acuminata

**Dose**

**Topical** 0.5cm ointment for all warts together, applied three times daily

**Adverse Reactions**

Redness, itching, irritation/burning, swelling, blisters

**Precautions**

- 1.不可塗抹於開放性傷口、患者生殖器或肛門周圍的區域應避免接觸陽光/紫外線
- 2.必須持續使用直到尖型濕疣完全清除為止，但療程不可超過 16 週
- 3.可能使衣物或寢具染色
- 4.開封後可保存 6 週

**Sulconazole**

**C<sup>6</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Exelderm<sup>®</sup> cream 1%, 5g/tube <WSULCO1>

**Use**

Superficial fungal infections of the skin, including tinea cruris (jock itch), tinea corporis (ringworm), tinea versicolor, possibly tinea pedis (athlete's foot-cream only)

**Dose**

Adults: **Topical** qd-bid

**Adverse Reactions**

Itching, pruritus, stinging, redness

## 7.4. Antipsoriatics

**Acitretin**

**X<sup>1</sup> Unsafe<sup>1</sup>**

**Dosage Forms**

Neotigason<sup>®</sup> 25mg/cap <KACITRE>

**Use**

Severe psoriasis, keratinization

**Dose**

Children: **PO** initial dose 0.5 mg/kg; **max: 35mg/day**

Adult: **PO** initial 25-30mg/day, maintenance dose: 25-50mg/day; **max: 75mg/day**

**Adverse Reactions**

Alopecia, cheilitis, disorder of nail, dry skin, peeling of skin

## **Precautions**

- 1.Avoid excessive exposure to sunlight or sunlamps
- 2.Abnormally elevated blood lipid levels hyperlipidemia

## **Contraindications**

Pregnant or intend on becoming pregnant, severe hepatic or renal dysfunction, chronically-elevated blood lipid levels

## **Calcipotriol**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Daivonex<sup>®</sup> oint 0.005%, 30g/tube <WCALCI01>

### **Use**

Plaque psoriasis

### **Dose**

**Topical** apply a thin film to the affected skin once or twice daily

### **Adverse Reactions**

Burning sensation, dermatitis, itching, rash, skin irritation, stinging

### **Precautions**

健規：用量以每星期不高於 30gm 或 30mL 為原則，如需使用超過 1 支，應於病歷詳細記載理由。

## **Betamethasone and Calcipotriol**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Daivobet<sup>®</sup> :Betamethasone 0.5mg+Calcipotriol 50mcg oint 30g/tub  
<WDAIVOB>

Xamiol<sup>®</sup> :Betamethasone 0.5mg+Calcipotriol 50mcg/g gel 30g/bot  
<WXAMIOL>

### **Use**

Plaque psoriasis

### **Dose**

Oint:**Topical** Once daily for up to 4 weeks; **max: 100g/week**

Soln:**Topical** apply to affected area of scalp ,once daily for up to 8 weeks;  
maximum recommended dose: 15g/day; **max: 100g/week**

### **Adverse Reactions**

Pruritus, erythema, irritation, scaly rash, burning sensation

### **Precautions**

使用前將Xamiol<sup>®</sup> gel瓶子搖一搖，為了獲得最佳效果，建議在使用後不要立刻洗頭髮。

### **Contraindications**

本品含 calcipotriol，禁用於高血鈣病患。

## **methoxsalen**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Sorialen-ultra<sup>®</sup> 10mg/FC tab <KMETHOX>

### **Use**

Severe, recalcitrant disabling psoriasis not responsive to other therapy,  
with long wave UV radiation for repigmentation of idiopathic vitiligo

## Dose

### Psoriasis

Adults: **PO** 10-70mg (based on weight; approximately 0.6mg/kg) 1.5-2 hrs before exposure to UV light, 2-3 times at least 48 hrs apart, dosage is based upon patient's body weight and skin type

Weight (kg)	Dose (mg)
<30	10
30-50	20
51-65	30
66-80	40
81-90	50
91-115	60
>115	70

### Vitiligo

Children >12 yrs and adults: **PO** 20mg 2-4 hrs before exposure to UVA light or sunlight, limit exposure to 15-40 min based on skin basic color and exposure

## Adverse Reactions

Nausea, erythema, pain of skin, pruritus

## Precautions

1. Avoid sun (including sun lamp) exposure for 8 hours after methoxsalen ingestion
2. Use caution with other (systemic or topical) photosensitizing drugs

## 7.5. Anti-Hemorrhoid Agents

### **Posuline®**

#### Dosage Forms

1 supp: Policosulen 100mg+ Cinchocaine 2.5mg/supp <WXYLMOL>

#### Use

Rectal for the treatment of hemorrhoids, anal fissures, pruritus ani, or similar conditions

#### Dose

Supp: **RECT** 1 supp bid-tid, then 1 supp qd if improved

#### Precautions

1. 儲存於 25°C 以下。
2. 案劑可能會變色以及包裝可能會破損，但不影響產品的有效性。
3. 使用於懷孕婦女可能的危險研究報告尚未提出，也仍未知主成分是否會在哺乳母親的乳汁中。

#### Contraindications

對 Cinchocaine 過敏者不可使用。

### **Xylmol®**

#### Dosage Forms

1g: Lidocaine 50mg + Aluminum acetate 35mg + Zinc oxide 180mg + Hydrocortisone 2.75mg oint, 15g/tube <WXYLMO1>

#### Use

Topical anti-inflammatory and anesthetic for skin disorders

#### Dose

Topical applicator tip should be gently inserted into the anal area, bid

#### Precautions

1. 兩歲以下兒童使用須詢問醫師或藥師
2. 蟲豆症患者請勿使用

## 7.6. Alopecias

### Finasteride

 Unknown<sup>1</sup>

#### Dosage Forms

Propecia® 1mg/tab <KFINAS1>  
Finta® 5mg/tab <KFINAS2> 參閱 p.208

#### Use

Male pattern alopecia

#### Dose

Adults: PO 1mg qd

#### Adverse Reactions

Abnormal ejaculation, Breast tenderness, Reduced libido

#### Precautions

1. Use with caution in patients with hepatic impairment
2. Not indicated for use in pediatric and female patients

#### Contraindications

Pregnant women or women trying to conceive should not handle the product

### Minoxidil

 Unsafe<sup>1</sup>

#### Dosage Forms

Loniten® 10mg/tab <KMINOXI> 參閱 p.115  
PBF Minoxidil Solution 2%, 60ml/bot <WMINOX3>  
PBF Minoxidil Solution® 5%, 60ml/bot <WMINOX2>

#### Use

2%: pattern baldness (alopecia androgenetica)

5%: alopecia androgenetica

#### Dose

2%: Topical 1ml bid; max: 2ml/day

5%: Topical 1ml twice a day .

#### Adverse Reactions

2%: leukoderma, pigmented contact dermatitis

5%: mild dermatitis, hypotension, hirsutism, body fluid retention, hypernatremia

#### Precautions

1.2%: Contact with eyes and mucous membranes should be avoided

2.5%: 禁用於 18 歲以下之患者。

## 7.7. Anti-Pruritus

### Sinbaby Lotion®

#### Dosage Forms

ZinO 100mg+Dihydroxyramine 5mg+Dibucane 1.5mg+Camphor 1.5mg+Benzalkonium 2.5mg+Silicone oil 10mg/120ml/bot <WCALAMI>

#### Use

Relieve the itching, pain and discomfort of minor skin irritations

#### Dose

**Topical** bid- tid

#### Precautions

1. Shake well before use

2. 蠶豆症患者禁止使用

### C.B.®

#### Dosage Forms

1g: Chlorpheniramine 10mg+Hexachlorophene 1mg+ Methyl salicylate 10mg+Menthol 10mg+Camphor 5mg+Lidocaine 30mg, oint 5g/tube <WCBO>

#### Use

Allergic skin disorders, insect bites, burns, wounds, corn

#### Dose

**Topical** apply to affected area several times daily

#### Precautions

1. 兩歲以下兒童使用需詢問醫師或藥師

2. 蠶豆症患者禁止使用

### Doxepin

**C<sup>1</sup> Unsafe<sup>1</sup>**

#### Dosage Forms

Ichderm® cream 0.5%, 15g/tube <WDOXEPI>

#### Use

Short-term (< 8 days) management of moderate pruritus in adults with atopic dermatitis

#### Dose

Adults: **Topical** apply a thin film 4 times/day (least 3-4 hrs interval)

#### Adverse Reactions

Stinging/burning

#### Precautions

健規：限成人使用，每次處方不超過 7 天。

## 7.8. Atopic Dermatitis

## Pimecrolimus

C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Elidel<sup>®</sup> cream 1%, 15g/tube <WPIMEC1>

### Use

Atopic dermatitis, Second-line therapy in adults and children over 2 yrs of age

### Dose

**Topical** application of a thin layer twice daily

### Adverse Reactions

Sensation of burning of skin, headache, at risk for viral infection

### Precautions

Infection at topical treatment sites, skin papillomas

### Contraindications

1. Continuous long-term use is to be avoided

2. Development of lymphadenopathy including in the presence of acute infectious mononucleosis; risk that it could be lymphoma

## Tacrolimus

C<sup>1</sup> Unsafe<sup>1</sup>

### Dosage Forms

Protopic<sup>®</sup> oint 0.1%, 5g/tube <WTACR03>

Protopic<sup>®</sup> oint 0.03%, 5g/tube <WTACR04>

### Use

Short-term and intermittent long-term therapy in moderate to severe atopic dermatitis

### Dose

Adults and children 2-15 yrs: **Topical** apply thin layer bid

### Adverse Reactions

Skin burning, pruritus, flu-like symptoms, skin erythema, headache

### Precautions

健規：限以 3 個月為一療程，若需繼續治療則每月限使用 30g。

## 7.9. Burn Preparations

## Silver sulfadiazine

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Siliverzine Cream<sup>®</sup> 1%, 20g/bot <WSILVE5>

Canflame Cream<sup>®</sup> 1%, 500g/bot <WSILVE4>

### Use

Prevention and treatment of infection in second and third degree burns

### Dose

**Topical** apply once or twice daily

### Adverse Reactions

Discoloration of skin, erythema multiforme, itching, photosensitivity

### Precautions

1. Use with caution in patients with G6PD deficiency, hepatic impairment,

- renal impairment.
- 2.因主成分物理特性關係，開封後藥品顏色會逐漸變深，屬正常現象。
- 3.金屬會加速藥品顏色變深，建議使用非金屬器具取藥。
- 4.開封後保存期限為1個月。

## 7.10. Corticosteroids

### 7.10.1 Single Preparations

#### Betamethasone

C<sup>6</sup> Unknown<sup>1</sup>

Ciprosone<sup>®</sup> cream 0.064%, 5g/tube <WBETA01> 【High potency】

##### Use

Psoriasis, inflammatory dermatoses

##### Dose

Topical bid-qid

##### Adverse Reactions

Acneiform eruptions, allergic dermatitis, burning, dry skin, erythema

##### Precautions

Discontinue if skin irritation or contact dermatitis should occur

#### Clobetasol

C<sup>6</sup> Unknown<sup>1</sup>

##### Dosage Forms

Beclosol<sup>®</sup> oint 0.05%, 7g/tube <WCLOB03> 【Very high potency】

##### Use

Short-term relief of inflammation of moderate to severe dermatosis, psoriasis

##### Dose

Topical bid; max: 50g/week

##### Adverse Reactions

Asteatotic eczema, burning sensation, dry skin

##### Precautions

1. Children <12 yrs of age have not been established
2. Hyperglycemia has been reported with systemic absorption of topical corticosteroids
3. Acne vulgaris, rosacea or perioral dermatitis; use not recommended

#### Clobetasone

C<sup>6</sup> Unknown<sup>1</sup>

##### Dosage Forms

Cloba<sup>®</sup> cream 0.05%, 5g/tube <WCLOB02> 【Very high potency】

##### Use

Non-infective inflammatory pathologies of the skin such as eczema, psoriasis, seborrhea

##### Dose

Topical bid

##### Adverse Reactions

Excessive dryness, allergic contact dermatitis

### **Precautions**

- 1.Application to facial, groin, and axillae areas (increased risk of side effects)
- 2.Uncontrolled or severe bacterial, viral, or fungal infection

## **Diflucortolone**

**Unknown<sup>1</sup>**

### **Dosage Forms**

Nerison® fatty oint 0.1%, 10g/tube <WDIFLUC> 【Very high potency】

### **Use**

Inflammatory and pruritic conditions of dermatologic diseases

### **Dose**

**Topical bid-tid**

### **Adverse Reactions**

Burning, itching, irritation, dryness, folliculitis

### **Precautions**

Application to facial, groin, axillae areas and children (increased risk of side effects)

## **Fluocinonide**

**C<sup>6</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Topsym® cream 0.05%, 5g/tube <WFLUOC1> 【High potency】

Topsym® lotion 0.05%, 10ml/bot <WFLUOC2> 【High potency】

### **Use**

Pruritus and inflammation, plaque-type psoriasis

### **Dose**

**Topical qd-tid**

### **Adverse Reactions**

Sensation of burning of skin

### **Precautions**

Topsym® lotion: 使用前請振搖

## **Fluticasone**

**C<sup>6</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Fluticosone® cream 0.05%, 5g/tube <WFLUT03> 【Intermidiate potency】

### **Use**

Atopic dermatitis

### **Dose**

**Topical qd-bid**

### **Adverse Reactions**

Dry skin, pruritu, rash, stinging of skin

## **Hydrocortisone**

**A<sup>6</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Solu-Tisone® 100mg/vial< CHYDROC >參閱 p.226

Cortema® enema 99.6mg/60ml/bot <WHYDR01>參閱 p.168

Cort. S<sup>®</sup> oint 1%, 50g/bot <WHYDR02> 【Low potency】

**Use**

Dermatoses

**Dose**

**Topical** qd-bid

**Adverse Reactions**

Acneiform eruptions, irritation, itching, secondary infection

**Contraindications**

- 1.皮膚結核病、單純性疱疹、水痘帶狀疱疹、種痘等疾病之患者禁用
- 2.患部潰瘍者禁用，如第2度以上之燙傷、凍傷

**Mometasone**

**C<sup>6</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Elisone<sup>®</sup> cream 0.1%, 5g/tube <WMOMET1> 【Intermidiate potency】

Nasonex<sup>®</sup> aqueous nasal spray 50mcg/dose, 140dose/bot <WMOMET3>

參閱 p.316

**Use**

Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

**Dose**

**Topical** qd

**Adverse Reactions**

Bacterial skin infection, burning, furunculosis, pruritus, skin atrophy

**Precautions**

Topical use of corticosteroids has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted

## 7.10.2. Mixed Preparations

**Flucort-F<sup>®</sup>**

**Dosage Forms**

**C<sup>6</sup> Unknown<sup>1</sup>**

1g: Fradiomycin (Neomycin) 3.5mg+ Fluocinolone 0.25mg, cream 0.025% 5g/tube <WFLUOR5>

**Use**

Relief of susceptible inflammatory dermatosis, dermatitis or psoriasis of the scalp, atopic dermatitis

**Dose**

**Topical** qd-tid

**Adverse Reactions**

Allergic contact dermatitis, secondary infection, irritation, itching

**Precautions**

避免長時間使用於廣範圍的皮膚熱傷或潰瘍

**Ecosone<sup>®</sup>**

**Dosage Forms**

1g: Econazole 10mg +Triamcinolone 1mg, cream 10g/tube <WECONA1>

**Use**

Dermal fungal infections of the skin

**Dose**

**Topical** bid

**Adverse Reactions**

Itching, pruritus, stinging, redness

## 7.11. Keratolytic Agents

**DuoFilm®**

C <sup>6</sup>	Unknown <sup>1</sup>
----------------	----------------------

**Dosage Forms**

1ml: Salicylic acid 16.7%+Lactic acid 16.7% w/w, solution 15ml/bot  
<WSALIC1>

**Use**

Keratolytic Agent

**Dose**

Adults: **Topical** apply to affected area (avoid applying to the surrounding normal skin) once or twice daily

**Adverse Reactions**

Burning and irritation at site of exposure on normal tissue, peeling, scaling

**Salicylic acid**

Unknown <sup>1</sup>
----------------------

**Dosage Forms**

Salic<sup>®</sup> oint 2.5%, 10g/tube <WSALIC2>

**Use**

Topically for its keratolytic effect in controlling seborrheic dermatitis or psoriasis of body and scalp, dandruff, other scaling dermatoses; also used to remove warts, corns, and calluses; acne

**Dose**

**Topical** apply a thin layer to affected area once or twice daily

**Adverse Reactions**

Burning sensation, erythema, pruritus, stinging of skin

**Ureson<sup>®</sup>****Dosage Forms**

1g: Hydrocortisone 10mg+Urea 100mg, cream 16g/tube <WURESON>

**Use**

Keratolytic effect, eczema

**Dose**

**Topical** apply thin film layer to affected area qd-bid

## 7.12. Scabicides and Pediculicides

**Benzyl benzoate**

B <sup>1</sup>	Unknown <sup>1</sup>
----------------	----------------------

**Dosage Forms**

B.B. lotion<sup>®</sup> 25%, 100ml/bot <WBENZYL>

**Use**

Treatment in lice and scabies infestations

**Dose**

Pediculosis capitis

Children and Adults: after washing the hair, apply 10ml on the hair and massage approximately 3 mins then washed off by water

Scabies

After shower, apply topically to the entire body from the neck down and washed off by water after 24hrs

Infants: diluted with water to 8.3%

Children: diluted with water to 12.5%

**Adverse Reactions**

Burning, stinging, hypersensitivity

**Precautions**

Avoid contact eyes and mucous membranes, do not use on broken or secondarily infected skin

**Ulex<sup>®</sup>**

**C<sup>6</sup> Unknown<sup>1</sup>**

**Dosage Forms**

1g: Crotamiton 10%+Hydrocortisone 0.25%, cream 10g/tube  
<WCROTAM>

**Use**

Pruritus, Scabies

**Dosage**

**Topical bid-tid**

**Adverse effects**

Contact dermatitis, pruritus, rash

## 7.13. Obstetrics Preparations

**Clotrimazole**

**B<sup>6</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Mycosten<sup>®</sup> cream 10g/tube <WCLOTR3> 參閱 p.134

Clomazole<sup>®</sup> 100mg/vag. tab <WCLOTR4>

**Use**

Fungal infections

**Dose**

**Topical** apply 1 tab hs for 7 days or 2 tab for 3 days.

**Dinoprostone (PGE2)**

**C<sup>3</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Prostin<sup>®</sup> E<sub>2</sub> 3mg/vag. tab <WDINOPR>

**Use**

Induction of labor

**Dose**

**Intravaginally** insert 3mg supp, 2<sup>nd</sup> tab may be inserted after 6-8 hrs; **max: 6mg/day**

### **Adverse Reactions**

Diarrhea , nausea,vomiting, Headache

### **Precautions**

1.需冷藏。

2.藉由藥物引產時，可能會增加分娩後引發血管內血液凝集的風險

**X<sup>1</sup> Safe<sup>1</sup>**

### **Estradiol**

#### **Dosage Forms**

Oestrogel® 30g/tube, 1g: Estradiol 0.6mg <WESTRA3>

#### **Use**

Vulvar and vaginal atrophy associated with menopause

#### **Dose**

**Topical** 2.5g/dose qd apply to the area of abdomen, inside of both thighs (3 wks on, 1 wk off)

### **Adverse Reaction**

Headache, vaginal bleeding, breast pain, endometrial carcinoma, abdominal pain

### **Precautions**

外用藥塗抹於前臂、手臂、兩肩或者完整大面積的皮膚上，勿塗抹於乳房、陰部或陰道黏膜。

### **Contraindications**

Breast cancer, liver dysfunction or disease, undiagnosed abnormal genital bleeding

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Estrogens conjugated**

#### **Dosage Forms**

Premarin® vaginal cream 14g/tube, 1g: Conjugated estrogens 0.625mg <WESTRO1>

#### **Use**

Atrophic vaginitis, post-menopausal atrophic urethritis

#### **Dose**

**Intravaginally** 0.5 to 2g daily

### **Adverse Reactions**

Breast pain , abdominal pain , Vaginitis weakness

### **Contraindications**

Arterial thromboembolic disease, deep vein thrombosis/pulmonary embolism, genital bleeding, hepatic dysfunction, Carcinoma of the breast; estrogen-dependent tumor

**Unknown<sup>1</sup>**

### **Policresulen**

#### **Dosage Forms**

Polinin® 90mg/vag. supp <WPOLICR>

#### **Use**

Local treatment of cervical and vaginal inflammatory

**Dose**

**Intravaginally** 1 supp qod-hs

**Adverse Reactions**

Local irritation, contact dermatitis

## 7.14. Dermatology Miscellaneous

**Antiscar<sup>®</sup>**

**Unknown<sup>5</sup>**

**Dosage Forms**

1g: Acexameric acid 50mg+Neomycin 4mg, cream 10g/tube <WCEXAM>

**Use**

Promotion the healing and prevention bacterial skin infection of ulcers and various other lesions

**Dose**

**Topical** qd-bid

**Cadexomeriodine**

**Unknown<sup>5</sup>**

**Dosage Forms**

Iodosorb<sup>®</sup> 3g/pack (碘粉) <WCADEX>

**Use**

Moist wounds including decubitus ulcers and chronic leg ulcers associated with venous disease

**Dose**

**Topical** sufficient powder should be applied to form a layer about 3 mm thick

**Adverse Reactions**

Transient smarting sensation, mild erythema

**Heparinoid**

**Unknown<sup>5</sup>**

**Dosage Forms**

Hirudoid<sup>®</sup> gel 20g/tube <WHEPARI>

**Use**

General care of the veins, superficial phlebitis and thrombosis, inflamed varicose veins, leg ulcers, various inflammatory processes, lymphadenitis, exudates, edema, hematomas, softening of hard scars, improved scars of injuries, burns, surgical operation

**Dose**

**Topical** take a length of cream (3-5cm) should be applied to or gently massaged into the affected area qd-qid

**Precautions**

Avoid open wounds or mucous membranes

**Hydroquinone**

**C<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Derma lightening<sup>®</sup> cream 7g/tube, 1g: Hydroquinone 40mg <WHYDROQ>

**Use**

Gradual bleaching of hyperpigmented skin condition

**Dose**

Children >12 yrs and adults: hs

**Adverse Reactions**

Burning, itching, stinging, erythema, localized contact dermatitis

**Precautions**

1.Avoid sun exposure, use protective sunscreen

2.Do not use in open wounds

3.使用完畢須立即將瓶口栓緊，瓶口外部氧化是正常現象，不影響藥品品質。

**Zinc oxide**

**Unknown<sup>5</sup>**

**Dosage Forms**

Zin<sup>®</sup> ointment 20%, 28.4g/tube <WZNO>

**Use**

Protective coating for mild skin irritations and abrasions; soothing and protective ointment to promote healing of chapped skin, diaper rash

**Dose**

**Topical** apply adequate amount to affected area several times a day

**Precautions**

需自費

## 8. GASTROENTEROLOGY

### 8.1. Antacids and Antiflatulents

#### Algital®

Unknown<sup>5</sup>

##### Dosage Forms

Chewable tab, 1 tab: Aluminum hydroxide dried gel 30mg+ Magnesium bicarbonate 40mg+Alginic acid 200mg <KTOPAAL>

##### Use

Antacid

##### Dose

Adults: PO 1- 2 tab tid-qid

##### Adverse Reactions

Abdominal distention, hiccups, constipation, diarrhea, nausea, vomiting

##### Precaution

1.請咀嚼後吞服。

2.腎衰竭病人長期服用含鋁胃藥可能導致或加重透析治療引起之透析性骨軟化症、透析性腦病變及低血磷血症

#### Aluzaine®

Unknown<sup>5</sup>

##### Dosage Forms

1ml: Aluminum hydroxide dried gel 61.2mg+Magnesium hydroxide 19.5mg+Oxethazaine 2mg, susp 360ml/bot < KALUM03 >

##### Use

Antacid

##### Dose

Adults: PO 5-10ml qid AC

##### Precautions

1. Shake well before use

2. 開封後請於 20 天內使用完畢。

3. 請勿與 tetracycline(四環素)及鐵鹽併服。

#### Dried Aluminum hydroxide Gel

Unknown<sup>5</sup>

##### Dosage Forms

Aluminum Hydroxide Dried Gel<sup>®</sup> 324mg/tab < KALUM02 >

##### Use

Antacid, hyperphosphatemia

##### Dose

Children( $\geq 12$  yrs) and adults: PO 2 tab tid-qid

Children(6-11 yrs): PO 1 tab tid-qid

Children(3-5 yrs): PO 0.5 tab tid-qid

##### Precautions

1. 請咬碎後吞服。

2. renal insufficiency

#### Dimethicone

C Unknown<sup>5</sup>

## Dosage Forms

Kascoal® 40mg/tab <KGASCO1>

Wilcon® 20mg/ml, 60ml/bottle < KGASCO2>

## Use

Flatulence, meteorism

## Dose

### Antiflatulent

Infants and Children <2 yrs or <11 kg: PO 20 mg 4 times/day, as needed

Children(>2yrs or >11kg): PO 40 mg 4 times/day, as needed

Adults: 40-360mg/day tid-qid

### Diagnostic aid (gastroscopy)

PO 40-80mg in 10ml of water, 15-40 min before diagnostic procedure

### Radiography

PO 120-240mg/day divided to 3 dose since 3-4 days before diagnostic procedure (驅除腸內氣體)

## Precaution

藥水開封後，應於 14 天內使用完畢。

## Lederscon®

Unknown<sup>5</sup>

## Dosage Forms

1 tab: Aluminum hydroxide dried gel 334mg+Magnesium hydroxide

166mg+ Antiform emulsion 36.7mg <KLEDERS>

## Use

Antacid

## Dose

PO 1 tab qid

## Precaution

請咀嚼後吞服。

## Magnesium oxide

B<sup>1</sup> Unknown<sup>1</sup>

## Dosage Forms

Magnesium oxide® 250mg/tab <KMAGNE2>

## Use

Antacid, laxative, mild hypomagnesemia

## Dose

### Antacid

PO 250-500mg tid-qid

### Laxative

PO 2-4g/day tid-qid

### Hypomagnesemia

PO 400-800mg/day, monitor serum magnesium response

## Adverse Reactions

Diarrhea, nausea, abdominal pain, hypermagnesemia

## Precautions

腎臟功能不佳者應小心使用。

## **Peichia®**

### **Dosage Forms**

1 tab: Aluminum dihydroxyallantoinate 50mg+Aluminum magnesium silicate 450mg <KPEICHI>

### **Use**

Antacid

### **Dose**

Adults: **PO** 1-2 tab tid-qid

### **Precautions**

請咀嚼後吞服。

## **Strocain®**

### **Dosage Forms**

1tab: Oxethazaine 5mg+Polymigel 244mg <KSTROCA>

### **Use**

Antacids

### **Dose**

Adults: **PO** 1-2 tab tid-qid

### **Adverse Reactions**

Anorexia, GI upset, constipation, dry mouth, vertigo, diarrhea

### **Precaution**

整粒吞服，勿咬碎。

## **8.2. Antidiarrheals**

### **Dioctahedral**

**Unknown<sup>5</sup>**

### **Dosage Forms**

Smecta® 3g/pack<KDIOCTA >

### **Use**

Acute and chronic diarrhea

### **Dose**

Children:

< 1yrs: **PO** 1 pack/ day, divide three times

1-2yrs: **PO** 1-2 packs/day, divide three times

> 2yrs: **PO** 2-3 packs/day, divide three times

Adult: **PO** 3 packs/day, divide three times

### **Adverse Reactions**

Constipation

### **Precautions**

1. 藥品可與 50ml 水混或是肉湯、果汁、菜泥、嬰兒食品混勻後使用。

食道炎病人需餐後服用，其餘病人宜於兩餐之間服用。

2. 本品的吸附作用可能干擾其他藥物的吸收與排除，應盡量避免與其他藥物同時，如需服用其他藥物，建議間隔一段時間。不宜與鹼性藥品(如 quinidine, disopyramide)併用。

### **Contraindications**

Fructose intolerance, glucose and galactose malabsorption, sucrase / somaltase deficiency

### Loperamide

**B<sup>1</sup>** **Safe<sup>1</sup>**

#### Dosage Forms

Lopedin<sup>®</sup> 2mg/cap <KLOPERA>

#### Use

Acute diarrhea, chronic diarrhea

#### Dose

Children: **PO** 0.08-0.24 mg/kg/day in 2-3 divided dose or

2-5yrs initial 1mg tid; 6-8yrs initial 2mg bid; 8-12yrs initial 2mg tid

Adults: **PO** initial 4mg; followed by 2 mg after each loose stool; **max: 16mg/day**

#### Adverse Reactions

Drowsiness, fatigue, dizziness, dry mouth, abdominal pain, constipation, nausea, vomiting, skin rash

### Nifuroxazide

**Unknown<sup>5</sup>**

#### Dosage Forms

Nirozide<sup>®</sup> 200mg/cap <KNIFURO>

#### Use

Acute diarrhea, chronic diarrhea, gastro-enteritis, colitis

#### Dose

Infant: **PO** 200-600 mg/day

4-8yrs Children: **PO** 600mg/day; 8-12yrs: 600-800 mg/day

>12yrs Children and adults: **PO** 800 mg/day

## 8.3. Antiemetics

### Aprepitant

**B<sup>1</sup>** **Unknown<sup>1</sup>**

#### Dosage Forms

Emend<sup>®</sup> 125mg/cap<KAPREP2>

#### Use

Antiemetics and antinauseants

#### Dose

**PO** 1cap 1 hr before chemotherapy then 1cap daily as a single dose for the next 2 days; should be used in combination with a corticosteroid and 5-HT3 receptor antagonist.

#### Adverse Reactions

Constipation, headache, hiccoughs, fatigue

#### Precautions

本品一盒1顆。

#### Contraindications

禁止與 fosaprepitant 及 cisapride 併用。

### Fosaprepitant

**B<sup>1</sup>** **Unknown<sup>1</sup>**

### **Dosage Forms**

Emend<sup>®</sup> 50mg/vial<CFOSAPR>

### **Use**

Antiemetics and antinauseants

### **Dose**

Prevention of nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy:

**IV** 150mg fosaprepitant on Day 1 only as an infusion over 20-30minutes initiated approximately 30 minutes prior to chemotherapy. No oral emend are administered on Days 2 and Days 3.

### **Adverse Reactions**

Infusion site erythema, pruritus, pain, ALT increased

### **Precautions**

1. 未開封時需儲存於 2-8°C 冷藏。
2. 將 5ml 生理食鹽水沿瓶壁注入小瓶。輕輕旋動小瓶，切勿用力震搖或將生理食鹽水直接注入小瓶。將小瓶中溶液抽出，轉注入裝有 145ml 生理食鹽水輸注袋中，如此即得總量 150ml 溶液，輕輕將輸注袋倒轉 2-3 次。
3. 配製後室溫下(25°C)可維持穩定 24 小時
4. 可能導致荷爾蒙避孕藥效果降低，治療期間及最後一次劑量使用後一個月內，應使用其他替代或輔助避孕方法
5. 限於化療第一天使用

### **Contraindications**

不可與 pimozide, terfenadine, astemizole 或 cisapride 同時使用，會導致藥物濃度升高，可能引發嚴重或危及生命的反應。

## **Diphenidol**

**Unknown<sup>5</sup>**

### **Dosage Forms**

Diphenidol<sup>®</sup> 25mg/tab <KDIPH02>

### **Use**

Nausea, vomiting, vertigo

### **Dose**

Children(> 23kg): **PO** 25mg q4h or 0.88mg/kg q4h; **max: 5.5mg/kg/day**

Adults: **PO** 25-50 mg q4h as needed; **max: 300 mg/day**

### **Adverse Reactions**

Hallucinations, confusion, disorientation, dry mouth

## **Meclizine**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Semper<sup>®</sup> 25mg/tab <KMECLIZ>

### **Use**

Motion sickness, vertigo

### **Dose**

Motion sickness

>12yrs Children and adults: **PO** 25-50mg 1 hr before travel, repeat dose

q24h if needed; **max: 50 mg/day**

### Vertigo

>12yrs Children and adults: **PO 25-100 mg/day in divided dose**

## **Granisetron**

**B<sup>1</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Grantron® 3mg/3ml/amp <CGRANIS >

### **Use**

Prevention of nausea and vomiting associated with chemotherapy, radiation and postoperative.

### **Dose**

IVP rate>30sec, IVF rate>5min

### Chemotherapy or radiation induced nausea and vomiting:

Adult:

Prophylaxis: **IV 1-3mg (10-40mcg/kg) single dose before therapy**

Treatment: **IV 1-3mg (10-40mcg/kg) single dose, additional infusions should be administered at least 10 min apart. max: 9mg/day**

Children (for chemotherapy induced nausea and vomiting):

Prophylaxis: **IV 10-40mcg/kg single dose before therapy, additional infusions should be administered at least 10 min apart. max: 3mg/day**

### Postoperative nausea and vomiting:

Adult: **IV 1mg (10mcg/kg) single dose; max:3mg/day**

### **Adverse Reactions**

Headache, constipation, rash, allergy reaction

### **Precautions**

1.本品使用 NS 或 D5W 稀釋，稀釋液體積成人加入 20-50ml，兒童加入 10-30ml。

2.稀釋後須於 24 小時內使用完畢。

3.健規：每次療程使用不得超過五日為原則。

## **Palonosetron**

**B<sup>1</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Aloxi® 0.25mg/5ml/vial <CPALONO>

### **Use**

Prevention of nausea and vomiting associated with chemotherapy

### **Dose**

**IV (>30sec.) 0.25mg as a single dose 30 min prior to the start of chemotherapy**

### **Adverse Reactions**

Headache, constipation, diarrhea, dizziness

### **Precautions**

1.不可與其他藥品混合，投與前後需以生理食鹽水沖洗管路。

2.健規：限於中、高致吐化療藥前使用

## **8.4. Antiulcers**

### 8.4.1.H<sub>2</sub>-Blockers

#### Cimetidine

**B<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Forms

Cimetidine<sup>®</sup> 200mg/2ml/amp <CCIMETI>

Tamedin<sup>®</sup> 200mg/tab <KCIMETI>

#### Use

Zollinger-Ellison syndrome, duodenal ulcers, gastric ulcers, reflux esophagitis

#### Dose

##### Duodenal and gastric ulcers

Children: **IVF** 20-40mg/kg/day individual dose

Adult: **IVF/IM** (>15-20min) 300mg q6-8h;

Tablet

**PO** 200-400mg tid or 400mg hs

##### Gastroesophageal reflux disease

Adulst: **PO** 800mg bid or 400mg qid for 12 wks

#### Adverse Reactions

Headache, dizziness, agitation, drowsiness, diarrhea, gynecomastia

#### Precautions

1.需依腎功能調整劑量

2.服藥期間避免食用葡萄柚或葡萄柚汁

3.靜脈輸注可加入 100ml D5W 稀釋

#### Famotidine

**B<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Forms

Famodine<sup>®</sup> 20mg/vial <CFAMOTI>

#### Use

Duodenal or gastric ulcer, reflux esophagitis, Zollinger-Ellison syndrome

#### Dose

##### Reflux esophagitis

>1yrs Children: **IV** 0.25-0.5mg/kg q12h, **max: 40mg/day**

Adults: **IV** 20mg q12h

##### Duodenal or gastric ulcer

>1yrs Children: **IV** 0.25-0.5mg/kg q12h; **max: 40mg/day**

Adults: **IV** 20mg q12h

#### Adverse Reaction

Rash, dizziness, headache, constipation, diarrhea

#### Precautions

需依腎功能調整劑量

#### Ranitidine

**B<sup>4</sup> UnSafe<sup>1</sup>**

#### Dosage Forms

Ranitidine<sup>®</sup> 150mg/tab <KRANITI>

#### Use

Duodenal or gastric ulcer, reflux esophagitis

## Dose

Duodenal ulcer

**PO** 2 tab HS

Gastroesophageal reflux disease

**PO** 1 tab BID

Zollinger-Ellison syndrome

**PO** 1 tab TID; max:6tab/day

## Adverse Reaction

Abdominal pain, constipation, diarrhea, headache

## Precautions

服藥期間避免食用葡萄柚或葡萄柚汁

## 8.4.2. Proton Pump Inhibitors(PPI)

### Esomeprazole

**B<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Nexium® 40mg/vial <CESOME>

Nexium® 40mg/tab <KESOME>

#### Use

Gastroesophageal reflux disease, NSAID-associated gastropathy,  
Prevention of rebleeding of peptic ulcer and duodenal ulcer, Helicobacter  
pylori with peptic ulcers (PO), Zollinger-Ellison syndrome(PO)

#### Dose

Gastroesophageal reflux disease

Adults:**IVF/IVD** 20 mg or 40 mg once daily in patients unable to take oral;

**PO** 20-40mg qd for 4-8 wks

NSAID-associated gastropathy

**IVF** 20mg qd in patients unable to take oral; **PO** 20mg qd for 4-8wks

Prevention of rebleeding of peptic ulcer and duodenal ulcer

**IV** initial 80mg (rate:30min), followed by 8mg/hr (5vial/day) infusion for  
72hrs

H. Pylori

Adults: **PO** 40mg qd for 7-14 days, requires combination therapy

Zollinger-Ellison syndrome

Adults: **PO** 40mg bid, adjust regimen to individual patient needs; **max:**  
**240mg/day**

#### Adverse Reactions

Headache, diarrhea, nausea, flatulence, abdominal pain, constipation

#### Precautions

1.錠劑請勿剝半或切開，如遇吞嚥困難的病患，可將藥錠置入半杯非  
碳酸類液體中攪拌溶解，並立即或在 30 分鐘內服用。

2.Safety and efficacy has not been established in pediatric

3.針劑以NS 100ml 調配,不可混其它藥品使用，調配後於 30°C 可以放置  
12 小時。

4.需依肝功能調整劑量

## Dexlansoprazole

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Dexilant® 60mg/DR cap <KDEXLAN>

### Use

Erosive esophagitis, maintenance of healed EE and symptomatic relief of heartburn, symptomatic GERD

### Dose

Erosive esophagitis

**PO** 60mg once daily for up to 8 weeks

Maintenance of healed EE and symptomatic relief of heartburn

**PO** 30mg once daily

Symptomatic GERD

**PO** 30mg once daily for 4 weeks

### Adverse Reactions

Diarrhea, abdomen pain, nausea, upper respiratory tract infection

### Precautions

必須整粒吞服，如無法整粒吞服，可打開膠囊服用：可將膠囊內藥粉顆粒灑入1湯匙食物(果醬)中，立刻吞服，勿咀嚼藥粉顆粒。

## Pantoprazole

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Pantyl® 40mg/vial <CPANTOP>

Pantoloc® 40mg/tab <KPANTOP>

### Use

Helicobacter pylori with peptic ulcers, duodenal, gastric ulcer, moderate and severe reflux esophagitis, Zollinger-Ellison syndrome

### Dose

Peptic ulcer

Adults: **IV** 40mg qd; **PO** 40 mg qd for 8 weeks

Gastroesophageal reflux disease

Adults: **IV** 40mg qd for 7-10 days

Adults: **PO** 40mg qd for 8-16 weeks

Zollinger-Ellison syndrome

Adults: **IV** 80mg q8-12h (IV over 2 mins or IV infusion over 15 mins)

Adults: **PO** 40mg bid up to 240 mg/day and over 2 yrs duration have been administrated

### Adverse Reactions

Headache, diarrhea, upper abdominal pain, skin rash, pruritus, dizziness

### Precautions

1. IV infusion diluted to 100ml, not to exceed 3mg/min

2. 鈎劑稀釋後 12hr 內用完

3. Safety and efficacy not established in children

4. 為腸溶膜衣錠，不可咀嚼或壓碎

## Rabeprazole

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Pariet® 20mg/tab <KRABEPR>

**Use**

Duodenal ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, Helicobacter pylori with peptic ulcers

**Dose**

Duodenal ulcer (active)

**PO** 20mg qd for 4-8 wks

Gastroesophageal reflux disease

**PO** 20mg qd for 4-8 wks, maintenance 20mg qd

H. pylori eradication

**PO** 20mg bid for 7 days (combination with Amoxicillin 1000mg plus Clarithromycin 500mg)

**Adverse Reactions**

Headache, nausea, diarrhea, dizziness, skin rash

**Precautions**

為腸溶膜衣錠故不建議磨粉。

### 8.4.3. Antiulcer Miscellaneous

#### Bismuth Subcarbonate

**C<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Bismuth Subcarbonate® 324mg/tab <KBISMU1>

**Use**

Gastric ulcer, diarrhea

**Dose**

Adults: **PO** 1- 2 tab tid-qid

**Adverse Reactions**

Pain, nausea and vomiting may occur during the early stages of treatment

**Precautions**

1. 會使糞便呈灰色。

2. 勿併服牛奶或制酸劑。

#### Misoprostol (PGE1)

**X<sup>1</sup> Unsafe<sup>1</sup>**

**Dosage Forms**

Cytotec® 200mcg/tab <KMISOPR>

**Use**

Prevention of NSAID-induced gastric ulcers, duodenal gastric

**Dose**

NSAID-induced gastric ulcer prophylaxis

**PO** 200mcg qid

Duodenal gastric

**PO** 800mcg/day bid-qid for 4 wks

Abortion

**PO** 400mcg 2 days after mifepristone dose of 600 mg

**Adverse Reactions**

Abdominal pain, diarrhea, nausea

**Precautions**

- 1.Antacids containing magnesium may increase risk of diarrhea
- 2.Cerebral vascular or coronary artery disease, epilepsy

## Sucralfate

**B<sup>6</sup> Safe<sup>1</sup>**

### Dosage Forms

Scrat<sup>®</sup> 1g/10ml/sachet <KSUCRA3>

### Use

Duodenal ulcer, gastric ulcers, gastroesophageal reflux disease, esophagitis, stress ulcer prophylaxis

### Dose

Adults: **PO** 1sachet qid AC

### Adverse Reactions

Constipation

### Precautions

1.飯前 30 分鐘服用

2.與制酸劑或減少胃酸分泌藥物併用，二者需間隔 30-60 分鐘

3.藥物含鋁鹽，腎衰竭病患長期服用需注意發生低血磷或 dialysis osteomalacia

## 8.5. Digestive Enzymes

## Biotase<sup>®</sup>

**Unknown<sup>5</sup>**

### Dosage Forms

1 tab: Biadiastase 30mg+Lipase 5mg+Newlase 10mg<KBIOTAS>

### Use

Digestants

### Dose

>12yrs Children and adult: **PO** 3tab tid

6-12yrs Children: **PO** 1.5tab tid

3-5yrs Children: **PO** 0.5tab tid

### Adverse Reactions

Nausea, abdomen pain, diarrhea

## Lactobacillus

**Safe<sup>1</sup>**

### Dosage Forms

Antibiophilus<sup>®</sup> 250mg/cap <KLACTOB>

### Use

Diarrhea, constipation, reestablish normal physiologic and bacterial flora of the intestinal tract

### Dose

>3yrs Children and adults: **PO** 2 cap bid-qid

## Pancrelipase

**C<sup>5</sup> Unknown<sup>5</sup>**

### Dosage Forms

Protease<sup>®</sup> 280mg/E.C. cap <KPANCRE>

## Use

囊腫性纖維化疾病、慢性胰臟炎、胰臟切除、胃腸鏡道手術及因腫瘤引發胰管式膽管阻塞等疾病所導致的胰液分泌不全

## Dose

PO 1 tab tid with food

## Adverse Reactions

Nausea, vomiting, abdominal discomfort, constipation

## Precaution

1. 服用時與三餐之食物或點心一起吞服，切勿於飯前或飯後及無食物之狀態下服用
2. 不可壓碎或咀嚼，也不可與酸鹼值 5.5 以上之食物混合，以免溶解腸溶膜衣而提早釋放出酵素，造成口腔粘膜之刺激及失去酵素之活性

## 8.6. Gastrointestinal Stimulants

### Domperidone

**B<sup>1</sup>** **Unknown<sup>1</sup>**

#### Dosage Forms

Domtoo<sup>®</sup> 10mg/tab <KDOMPER>

#### Use

Nausea, vomiting, dyspepsia

#### Dose

Children: PO 0.3-0.6mg/kg tid-qid

Adults: PO 10mg tid-qid 15-30 mins before meals and at bedtime, if required

#### Adverse Reactions

Dystonic reactions, arrhythmias, extrapyramidal effects, seizures, stomatitis galactorrhoea

#### Precautions

建議飯前服用。

#### Contraindications

Gastrointestinal hemorrhage, mechanical obstruction or perforation, prolactinoma

### Metoclopramide

**B<sup>1</sup>** **Safe<sup>4</sup>**

#### Dosage Forms

Promeran<sup>®</sup> 9.08mg/2ml/amp <CMETOCL>

Promeran<sup>®</sup> 3.84mg /tab <KMETOC1>

Aswell syrup<sup>®</sup> 60mg/60ml/bot <KMETOC3>

#### Use

Gastroesophageal reflux, prevention of nausea associated with chemotherapy

#### Dose

##### Gastroesophageal reflux

Children: PO 0.1-0.2mg/kg/dose qid, **max: 0.5mg/kg/day**

Adults: PO 1-2 tab tid AC

### Gastrointestinal hypomotility

Children: **IM/PO** 0.1mg/kg/dose qid, **max: 0.5mg/kg/day**

Adults: **PO** 1-2 tab qid AC for 2-8 wks; **IV** (severe symptoms) 10mg for 10 days

### Antiemetic (chemotherapy-induced emesis)

Children: **IV** 1-2mg/kg 30 mins before chemotherapy and q2-4h

Adults: **IV** 2mg/kg/dose q2-4h for 2-5 doses

### **Adverse Reactions**

Restlessness, drowsiness, diarrhea, weakness, breast tenderness, prolactin stimulation, xerostomia, extrapyramidal (high-dose)

### **Precautions**

1. Dosing adjustment in renal impairment

2. 建議飯前服用。

3. 藥水開封後室溫下可存放 2 個月。

### **Contraindication**

Gastrointestinal obstruction, perforation or hemorrhage, pheochromocytoma, history of seizure disorder

## **Mosapride**

**Unsafe<sup>3</sup>**

### **Dosage Forms**

Mozapry<sup>®</sup> 5mg/F.C. tab <KMOSAPR>

### **Use**

Diabetic gastroparesis, gastritis, gastroesophageal reflux disease, indigestion

### **Dose**

Adults: **PO** 5mg tid

### **Adverse Reactions**

Diarrhea, thirsty, tiredness

### **Precautions**

與心臟節律藥物併用時應監測其心電圖，如有心律不整之情形發生，應予減少劑量或停藥。

## **8.7. Laxatives**

### **Bisacodyl**

**B<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Dulcolax<sup>®</sup> 5mg/EC. tab <KBISACO>

Bisacodyl<sup>®</sup> 10mg/supp <WBISACO>

### **Use**

Constipation and bowel evacuation before procedures or surgery

### **Dose**

#### Constipation

#### Supp

<6yrs Children: **RECT** 0.5supp

>6 yrs Children and adults: **RECT** 1supp qd;

## Tablet

4-10yrs Children: **PO** 5mg qd

>10yrs Children and adults: **PO** 5-10mg qd

Bowel evacuation before procedures or surgery

Children ≥4yrs: **PO** 5mg hs and **RECT** 0.5 supp qd

Adults: **PO** 10-20mg hs and **RECT** 1supp qd

## Adverse Reactions

Abdominal cramps, abdominal pain, diarrhoea, nausea, haematochezia (blood in stool).

## Precautions

1. 口服錠劑建議空腹，不宜磨粉。

2. 避免服藥後一小時內飲用牛奶，牛奶可能導致腸衣錠提早胃中溶解，使藥品失效並對胃部產生刺激。

3. 案劑形體變形時，照原塑膠包裝型態浸入於溫水(40-50°C)中，軟化後再浸於冷水即可凝固。案劑如軟化或溶化時，浸於冷水即可凝固。

## Contraindications

Appendicitis, acute inflammatory bowel disease, intestinal obstruction, severe dehydration

## SlipFee<sup>®</sup>

**C<sup>6</sup> Unsafe<sup>3</sup>**

## Dosage Forms

Oral solution 1ml: Monobasic sodium phosphate 480mg+ Dibasic sodium phosphate 180mg, 45ml/bot <KFLEE1>

Fleet<sup>®</sup> enema 1ml: Monobasic sodium phosphate 160.2mg+Dibasic sodium phosphate 60mg, 133ml/bot <WFLEE1>

## Use

Bowel examination or surgery, constipation

## Dose

Bowel examination or surgery

**PO** 45ml bid

Constipation

Children: **PO** (5-9yrs) 7.5ml; (10-11yrs) 15ml;

>12yrs child and adults: **PO** 20- 45ml; **max: 45ml/day**

Enema:

≥12yrs child and adult: 1bot st.

## Adverse Reactions

Electrolyte imbalance, Acute phosphate nephropathy,Rash,Itching

## Precautions

1. 不建議使用於5歲以下兒童。

2. 一般在服用後30分鐘至6小時會產生排便。

3. 放入冰箱冷藏可增加口感，但不可冷凍。

4. 口服液開封後如未飲用完，於室溫下可存放7天。

4. Fleet enema 24小時內至多使用一瓶，若超量使用，可能引起傷害。

## Contraindications

鬱血性心衰竭、嚴重腎臟疾病者

## GI Klean powder®

C<sup>6</sup> Unknown<sup>4</sup>

### Dosage Forms

GI Klean powder® 68.6g/sachet <KKLEAN>

Each sachet contains:

Polyethylene glycol 3350.....	59 g
Sodium sulfate anhydrous.....	5.685 g
Sodium bicarbonate.....	1.685 g
Sodium chloride.....	1.465 g
Potassium chloride.....	0.7425 g

### Use

Bowel preparation before colonoscopy, colonic surgery, radiological examination and other related procedures

### Dose

Adults(include elderly): **PO** 1 sachet dissolved in 1 liter of water. 250 ml to be drunk rapidly every 10-15min until all the solution has been consumed. The procedure to be repeated with all 4sachets or until the rectal effluent is clear. The solution from all 4sachets should be drunk within 4-6hr

### Adverse Reactions

Nausea, abdominal fullness, bloating

### Precautions

1.配製後如未馬上服用應冷藏，並於 24 小時內使用完畢。

2.所有口服藥物均須於服藥前至少 1 小時使用。

### Contraindications

CHF (NYHA grades 3 and 4), weight<20kg, sever renal insufficiency

## Lactulose

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Duphalac® 300ml/bot, 1ml: Lactulose 666mg <KLACTUL>

Lactul® 60ml/bot, 1ml: Lactulose 666mg <KLACTU1>

### Use

Portal-systemic encephalopathy (PSE), chronic constipation

### Dose

#### Portal systemic encephalopathy

Adults: **PO** 30-45ml tid-qid

Children: **PO** 40-90ml/day

Infants: **PO** 2.5-10ml/day

**Rectal** 300ml is mixed with 700ml water or saline, retained for 30-60min, may be repeated q4-6h.

#### Chronic constipation

Adults: **PO** 15-30ml/day, up to 60ml/day

### Adverse Reactions

Flatulence, diarrhea (excessive dose), abdominal discomfort, nausea, vomiting, cramping

### Precautions

1.本品含少量 galactose 及 lactose，所以糖尿病患及半乳糖血症 (galactosemia)病患須小心謹慎給藥。

2. 在室溫良好條件下儲存，顏色變深並不影響療效。
3. 長期置於 30°C 以上或光直射時，易變成極深色及混濁，當此現象發生時，請勿再使用。
4. 如覺口味不適時，可與果汁、白開水、牛乳混合後使用。

## Magnesium citrate

**A<sup>4</sup>** **Safe<sup>1</sup>**

### Dosage Forms

Magvac® 250ml/bot <KMAGNE1>

1ml: Magnesium carbonate 42.9mg+Citric acid 78.3mg+Potassium bicarbonate 7.14mg

### Use

Laxative

### Dose

Constipation

**PO** 20-50ml hs

Bowel cleansing prior to GI exam

**PO** 250ml

### Adverse Reactions

Diarrhea, dizziness, weakness abdominal pain, nausea, vomiting

### Precautions

1. 每次服用時需併服大量水份或其他液體。
2. 口服本劑後不得飲用或食用牛奶或牛奶類食品。
3. 如發生變質或過期，不可再食用。

### Contraindications

Severe renal insufficiency

## Normacol®

**C** **Unknown<sup>1</sup>**

### Dosage Forms

1g: Sterculia 0.62g+Frangula 0.08g, 7g/pack <KNORMAC>

### Use

Laxative

### Dose

Children 6-12yrs: **PO** as directed by a doctor

Adult: **PO** 1-2 pack qd-bid

### Adverse Reactions

Abdominal distension, intestinal obstruction if overdosage or inadequate fluid intake

### Precautions

1. The granules should not be chewed or crushed and should be swallowed immediately with plenty of water.
2. Do not use when abdominal pain, nausea, or vomiting is present
3. 應飲用足量的水以避免腸阻塞。

### Contraindications

Intestinal obstruction, faecal impaction, total loss of muscle tone in the intestines.

## Sennoside A+B

**Unknown<sup>4</sup>**

### Dosage Forms

Sennapur® 12.5mg/tab <KSENNOS>

### Use

Constipation

### Dose

Children 3-5 yrs: 1/4 tab hs, 6-11 yrs: 1/2 tab hs

Adults: 1 tab hs

### Adverse Reactions

Excessive bowel activity, abdominal cramps, eruption, nausea, vomiting

### Precautions

Senna 類會使酸性尿呈黃、棕色，鹼性尿呈粉紅或紫紅

### Contraindications

Bowel obstruction, fecal impaction, patients with nausea, vomiting or other symptoms of appendicitis, undiagnosed abdominal pain

## 8.8. Antiobesity Agents

### Orlistat

**X<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

Xenical® 120mg/cap <KORLIST>

### Use

Management of obesity, indicated for obese patients with an initial body mass index (BMI)  $\geq 30\text{kg}/\text{m}^2$  or  $\geq 27\text{kg}/\text{m}^2$  in the presence of other risk factors

### Dose

Adults: PO 120mg tid; **max: 360mg/dose**

### Adverse Reactions

Fatty/oily stool, fecal urgency, flatus with discharge, oily evacuation, oily spotting, back pain, headache

### Precautions

1. 有時會有維生素 D,E 與貝他-胡蘿蔔素吸收減少。如有須補充綜合維生素時，應在服用完 Xenical 後兩小時服用或是睡前服用。

2. 食品藥物管理局提醒：使用含 Orlistat 成分藥品應謹慎監視肝功能。

### Contraindications

Chronic malabsorption syndrome or cholestasis

## 8.9. Spasmolytics

### Atropine

**C Unknown<sup>1</sup>**

### Dosage Forms

Atropine® 1mg/ml/amp <CATROPI>

Tropine® 0.3%,5ml/bot <WATRO3> 閱參p.277

### Use

Biliary colic, gastrointestinal tract spasm, organophosphate poisoning, pilocarpinism, mydriasis induction, premedication for anesthetic procedure, cycloplegic refraction

### Dose

#### Antispasmodic

Children: **SC** 0.01 mg/kg ; **max:0.4mg/dose**

Adults: **SC** 0.4-0.6 mg q4-6h.

#### Bradyarrhythmia

Children: **IV** 0.01-0.03mg/kg

Adults: **IV** 0.4-1 mg q1-2h; **max: 2 mg**

#### Cholinesterase inhibitor

Children: **IV** initial dose 1mg. 0.5-1mg titrated to response

Adults: **IV** 2-4 mg titrated to response

#### Premedication

Adults: **IM** 0.2-0.6mg 1-2hrs preoperation

### Adverse Reactions

Hot skin, impaired GI motility, constipation, dry throat, dry mouth, dry nose, diaphoresis, irritation at inject site

### Precautions

1.不建議加入大型溶液內

2.靜脈輸注應緩慢

### Contraindications

Narrow-angle glaucoma, tachycardia, thyrotoxicosis, obstructive GI tract disease, obstructive uropathy

## Hyoscyamine

**C<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

Buwecon® 0.125mg/tab <KHYOSCY>

### Use

GI tract disorders caused by spasm, adjunctive therapy for peptic ulcers, biliary colic, renal colic, bladder infection, vomiting of pregnancy, and dysmenorrheal

### Dose

Children (2-12 yrs): **PO** 0.0625-0.125mg q4h as needed; **max: 0.75mg/day**

Adults: **PO** 0.125-0.25mg q4h; **max: 1.5mg/day**

### Adverse Reactions

Dry mouth, urine retention, double vision, fast heartbeat, palpitations

### Precautions

含阿斯巴甜(Aspartame)賦形劑，苯酮尿症(Phenylketonurics)不宜使用。

### Contraindications

Glaucoma, obstructive uropathy, obstructive GI tract disease, myasthenia gravis, unstable cardiovascular status in acute hemorrhage

## Otilonium bromide

**Unknown<sup>3</sup>**

### Dosage Forms

Catilon® 40mg/tab<KOTILON>

**Use**

Irritable bowel syndrome

**Dose**

**PO** 40mg bid-tid; **max:** 240mg/day (6tab/day)

**Adverse Reactions**

Nausea, vomiting, upper abdominal pain, dizziness, headache

**Precautions**

青光眼、攝護腺肥大或幽門狹窄者需審慎使用

**Pinaverium**

**Unknown<sup>3</sup>**

**Dosage Forms**

Dicetel® 50mg/tab <KPINAVE>

**Use**

Gastric ulcer, duodenal ulcer, irritable bowel syndrome, colonitis, biliary tract dyskinesis syndrome

**Dose**

**PO** 50-100mg tid

**Adverse Reactions**

Dyspepsia

**Precautions**

為腸溶膜衣錠，不建議磨粉或剝半。

**Scopolamine bromobutylate**

**C<sup>1</sup> safe<sup>1</sup>**

**Dosage Form**

Butyscol® 20mg/ml/amp <CSOPOL>

**Use**

Intestinal colic, cholelithic colic and adjunct in the treatment of peptic ulcer disease

**Dose**

Adults: **IM/slow IV** 20mg bid-tid

**Adverse Reactions**

Dry mouth, headache, constipation

**Contraindications**

Narrow angle glaucoma, benign prostatic hyperplasia

## 8.10. Inflammatory Bowel Disease

**Hydrocortisone**

**C<sup>5</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Solu-Tisone® 100mg/vial <CHYDROC> 參閱 p.226

Cortema® enema 99.6mg/60ml/bot <WHYDR01>

Cort. S® oint 1%, 50g/bot <WHYDR02> 參閱 p.143

**Use**

Ulcerative colitis

**Dose**

**RECT** 100mg administered once daily at bedtime for 21 days.  
Treatment may be continued for 2-3 months. If used for longer than 3 wks, treatment should be gradually tapered over 2 or 3 wks

#### **Adverse Reactions**

Body fluid or electrolyte imbalance, wounds not easy to heal

#### **Contraindications**

Systemic fungal infections, enterostomy

**B<sup>4</sup> Unknown<sup>1</sup>**

### **Mesalazine**

#### **Dosage Forms**

Asacol® supp 500mg/supp <WMESALA>

Mezavant® XL 1200mg/tab <WMESALA>

#### **Use**

Active ulcerative colitis, proctosigmoiditis or proctitis

#### **Dose**

Mezavant:

Treatment of ulcerative colitis

**PO** 2.4-4.8g qd for up to 8 weeks; **max: 4.8g/day**

Maintenance of remission of ulcerative colitis

**PO** 2.4g qd

Asacol:

Adults: **RECT** 500mg-1000mg bid-tid × 3-6 wks

#### **Adverse Reactions**

Pain, abdominal pain, dyspepsia, constipation

#### **Precautions**

1. Asacol: 2 歲以下兒童、老年人須小心使用。

2.. 口服藥物建議與食物併服，不可咬碎或咀嚼。

#### **Contraindications**

Urea nitrogen or proteinuria, severe renal failure

**B<sup>4</sup> Unknown<sup>1</sup>**

### **Sulfasalazine**

#### **Dosage Forms**

Salazine® 500mg/E.C. tab <KSULFAS>

#### **Use**

Ulcerative colitis, rheumatoid arthritis

#### **Dose**

Ulcerative colitis

Children: **PO** 40-60 mg/kg/day in 3-6 divided doses

Adults: **PO** severe, 2-4 tab tid-qid; moderate, 2 tab tid-qid

Rheumatoid arthritis

Adults: **PO** 2 tab bid

#### **Adverse Reactions**

Headache, neutropenia, anorexia, nausea, vomiting, diarrhea, gastric distress

#### **Precautions**

1. 本品為腸溶錠不宜磨粉。

2. Hepatic or renal impairment, asthma or severe allergic reaction 須小心使用  
**Contraindications**

對水楊酸類，礦胺類賦形劑過敏者, acute intermittent porphyria,  
Glucose-6-phosphate dehydrogenase deficiency

## 8.11. Gastroenterology Miscellaneous

### Flopropione

**Unknown<sup>1</sup>**

#### Dosage Forms

Cospanon® 40mg/cap <KFLOPRO>

#### Use

Gallbladder tract spasms, cholecystitis, cholezystolithiasis, pancreatitis

#### Dose

Adults: **PO** 40-80mg tid

#### Adverse Reactions

Skin rash, flatulence, abdominal discomfort

### Gabexate mesilate

**Unknown<sup>3</sup>**

#### Dosage Forms

Foy® 100mg/vial <CGABEXA>

#### Use

Acute pancreatitis, acute exacerbation stage of chronic recurrent pancreatitis, disseminated intravascular coagulation (DIC)

#### Dose

##### Pancreatitis

Adults: **IVF** 100-300mg/day at a rate 8ml/min and decrease the dosage depending on the improvement of the symptoms

##### Disseminated intravascular coagulation

**IVF** 20-39mg/kg over 24 hrs

#### Adverse Reactions

Phlebitis, vascular pain, reddening and inflammatory at injection site, hypotension, nausea

#### Precautions

1.溶解後儘快使用

2.與抗生素、血液製劑混合時須注意可能產生混濁變化。

3.與胺基酸輸液，鹼性藥劑以及含亞硫酸鹽類藥劑配合使用時須注意可能產生分解變化。

#### Contraindications

Cerebral aneurysm or cerebrovascular hemorrhage, severe and uncontrolled hypertension, uncontrolled bleeding

### Glutathione

**C<sup>4</sup> Unsafe<sup>1</sup>**

#### Dosage Forms

Agifutol® 500mg/vial <CGLUTAT>

#### Use

Uses of exogenous GSH supplementation to protect against oxidant injury, detoxification, immunomodulatory activities

### Dose

Adults: **IM/IV** 100-200mg/dose

### Adverse Reactions

Anaphylaxis, nausea, vomiting

### Precautions

1. 避免與cefazolin, kanamycin 等注射劑混合使用，因會產生變化。
2. 與 Vitamin B6、Vitamin K、Cyanocobalamin 混合時，應於 3 小時內迅速注射。
3. 溶解後應立即使用，若分次使用藥品需冷藏，可存放 8 小時。

## Glycyrrhizin

**Unknown<sup>5</sup>**

### Dosage Forms

Stronger Neo-minophagen C<sup>®</sup> 40mg/20ml/amp <CGLYCYR>

### Use

Hepatic disease, drug or food allergy

### Dose

Drug or food allergy

Adult: **IV** 5-20ml qd

Chronic hepatic disease

**IV** 40-60ml qd; **max: 100ml/day**

### Adverse Reactions

Decrease in serum potassium, increase in blood pressure, flushing, edema

## Lanreotide Autogel

**C** **Unsafe<sup>3</sup>**

### Dosage Forms

Somatuline<sup>®</sup> 60mg/syringe<CLANREO>

### Use

Acromegaly, Carcinoid tumours

### Dose

Acromegaly

**Deep SC** 60-120mg every 28 days

Carcinoid tumours

**Deep SC** 90mg every 28 days during 2 months

### Adverse Reactions

Diarrhea, abdominal pain, cholelithiasis, flatulence, nausea

### Precautions

1. 會抑制胰島素及升糖激素分泌,故需監測血糖濃度。

2. 須儲存於2-8°C

3. 注射部位會有局部紅腫結塊此一反應為可逆。

### Contraindications

Complicated, untreated lithiasis of the bile ducts

## Octreotide

**B** **Unknown<sup>1</sup>**

### Dosage Forms

Sandostatin LAR® 20mg/vial <COCTRE2>

### Use

Acromegaly, Gastroenteropancreatic endocrine tumors

### Dose

#### Acromegaly

IM 20mg q4w for 3months, then dose adjustment depends on the response

#### Gastroenteropancreatic endocrine tumors

IM 20mg q4w for 3months, may increase to 30 mg per 4 wk based on clinical symptoms and biochemical parameters.

### Adverse Reactions

Hyperglycemia, sinus bradycardia, diarrhea, abdominal pain, flatulence, constipation, headache

### Precautions

1. 需避光冷藏。
2. 用於孩童的經驗非常有限。
3. Sandostatin LAR 注射用微粒用於單一劑量的容器，並不與其他產品做稀釋。
4. Octreotide 長效型注射劑，需事前審查後使用。

## Silymarin

**B<sup>5</sup>** Unknown<sup>3</sup>

### Dosage Forms

Siygen-H® 150mg/cap <KSILYMA>

### Use

Fatty degeneration of the liver, chronic hepatitis, chronic cirrhosis liver

### Dose

Adults: PO 150mg qd-tid

### Precautions

1. 肝庇護劑之使用，門診以口服一種為原則
2. 使用肝庇護劑應檢附肝功能報告，該報告有效期為三個月，逾期應再複查。

## Somatostatin

**B<sup>4</sup>** Unknown<sup>1</sup>

### Dosage Forms

Somatosan® 3mg/amp <CSOMATO>

### Use

Severe acute bleeding from esophageal varices, severe acute gastroduodenal ulcer bleeding, severe acute bleeding in acute erosive or hemorrhagic gastritis, prevention of postoperative pancreatic complication after pancreatic surgery

### Dose

Adults: IV initially 250 mcg IV bolus > 3-5 min, followed by a continuous infusion at the rate of 250 mcg/hr (3.5 mcg/kg/hr) for 24 hr

### Adverse Reactions

Nausea, dizziness, hot flashes, vomiting

### Precautions

1. 以生理食鹽水溶解藥品安定性可達 24 小時

2. 會抑制胰島素及升糖激素分泌，故需監測血糖濃度。
3. 預防胰臟手術後併發症，最長使用五天。
4. 胃、食道靜脈曲張出血，限三天。
5. 嚴重性急性消化性潰瘍出血，急性之糜爛或出血性胃炎之急性嚴重出血，經內視鏡處理同時經氫離子幫浦阻斷劑或乙型組織胺受體阻斷劑注射治療仍不能止血，且不適合外科手術者，得使用本品作為輔助治療三天。

## **Sulpiride**

**D<sup>5</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Sunpylon® 50mg/tab <KSULP01>

### **Use**

Psychosis, duodenal ulcer

### **Dose**

#### Duodenal ulcer

Adults: **PO** 50mg tid

#### Schizophrenia

**PO** 300-600mg/day in divided doses; **max: 1200mg/day**

#### Depression

**PO** 150-300mg/day in divided doses; **max: 600mg/day**

### **Adverse Reactions**

Leukocytosis, sedation, extrapyramidal symptoms, tardive dyskinesia

## **Terlipressin**

**X<sup>5</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

Terlissin® 1mg/vial <CTERLIP>

### **Use**

Bleeding esophageal varices, hepatorenal syndrome

### **Dose**

#### Bleeding esophageal varices(duration<5days)

**IV bolus** initial 2mg(<50kg:1mg) q4h, **max: 48hrs**; maintenance 1mg q4h, **max: 3days**

#### Type 1 hepatorenal syndrome

**IV** 3-4mg/day in divided 3-4 times, and treatment is continued until Scr<1.5mg/dl(130umol/L), or Scr decreased to 30%. If used for 3 days, treatment is ineffective that should be stopped the medicine.

The average of treatment duration about 10 days.

### **Adverse Reactions**

Increase blood pressure, abdominal cramps, headache

### **Precautions**

1. 本藥物不可與其他藥品相混合
2. 避光儲存，置於 25°C 以下
3. 溶解後的注射液須立即使用

### **Contraindications**

Acute coronary insufficiency, uncontrolled hypertension

respiratory insufficiency, asthma, renal insufficiency, septic shock

## **Ursodeoxycholic acid**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Genurso<sup>®</sup> 100mg/tab <KURSOD1>

### **Use**

Gallbladder stone dissolution, primary biliary cirrhosis

### **Dose**

Adults: **PO** 13-15mg/kg/day

### **Adverse Reactions**

Diarrhea, nausea, vomiting, constipation, abdominal pain

### **Precautions**

1. 肝庇護劑之使用，門診以口服一種為原則
2. 使用肝庇護劑應檢附肝功能報告，該報告有效期為三個月，逾期應再複查。

### **Contraindications**

Bile duct obstruction, severe hepatitis

## 9. HEMATOLOGYS

### 9.1. Anticoagulants

#### Dabigatran

C<sup>3</sup> **Unsafe<sup>1</sup>**

#### Dosage Forms

Pradaxa® 110mg/cap <KDABIG1>

Pradaxa® 150mg/cap <KDABIG2>

#### Use

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

#### Dose

PO 110~150mg bid

#### Adverse Reactions

Bleeding, dyspepsia, GERD, esophagitis, gastritis, GI ulcer

#### Precautions

1. ≥75 歲、CHADS 2 分數≥3、<50kg、胃腸出血病史、Clcr 30-50ml/min 等病患，建議劑量為 110mg bid
2. 膠囊建議整粒吞服，取出膠囊內藥粒服用會增加生理可用率達 75%
3. 侵入性檢查或手術前 1-2 天(Clcr≥50ml/min)或 3-5 天(Clcr<50ml/min)停用
4. 需依肝腎功能調整劑量

#### Contraindications

活躍的病理性出血、重度腎功能受損、出血性徵候、出血傾向、自發性或藥物性止血功能障礙、具出血風險之器質性病變

#### Heparin

C<sup>4</sup> **Safe<sup>1</sup>**

#### Dosage Forms

Hepac® 25000IU/5ml/vial <CHEPARI>

#### Use

Prophylaxis and treatment of thromboembolic disorders

#### Dose

##### Low dose prophylaxis

SC 5000IU 2 hrs before surgery and q8-12h for 7 days

##### Full dose therapeutic

SC initial 10000-20000IU, then 8000-10000IU q12h or 15000-20000IU q12h

##### **IV**

Children: initial 50IU/kg, then 50-100IU/kg q4h

Adults: initial 5000IU-10000IU, then 5000IU-10000IU q4-6h

##### **IVF**

Children: initial 50IU/kg, then 100IU/kg q4h

Adults: initial 5000IU, then 20,000-30,000 units/day at a rate of 10-30IU/kg/hr

#### Adverse Reactions

Allergic reaction, urticaria, thrombocytopenia, Bleeding, osteoporosis, fever

### Precautions

- 1.需依肝功能調整劑量。
- 2.不可IM；開封後於室溫下可保存 14 天；可用 NS、D5W 或 D10W 溶液稀釋，稀釋後可保存 48 小時。
- 3.解毒劑：protamine (注射 Heparin 15 分鐘內，10mg protamine 可中和 1000IU Heparin)
- 4.需監測APTT (建議可於最後一次 IV 5hr 後或最後一次 SC 12hr 後監測)。

### Contraindications

Severe thrombocytopenia, hypertension with a diastolic blood pressure > 105 mmHg, uncontrolled active bleeding, brain haemorrhage

## Rivaroxaban

**C<sup>4</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Xarelto® 10mg/FC. tab <KRIVARO>

Xarelto® 15mg/FC. tab <KRIVAR2>

Xarelto® 20mg/FC. tab <KRIVAR1>

### Use

Postoperative thromboprophylaxis in patients who have undergone hip or knee replacement surgery

### Dose

#### Arthroplasty of knee

Prophylaxis **PO** 10mg qd beginning at least 6 to 10 hours after surgery and continued for 2 weeks

#### Repair of hip

Prophylaxis **PO** 10mg qd beginning at least 6 to 10 hours after surgery and continued for 5 weeks

#### Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

**PO** 15~20mg qn; **max: 20mg/day**

#### Treatment of deep vein thrombosis and prevention of recurrent DVT and pulmonary embolism

**PO** 15mg bid for 21days (**max: 30mg/day**) then 20mg qd (**max: 20mg/day**)

### Adverse Reactions

ALT and AST increase, anemia, nausea, bleeding

### Precautions

1. 服用本品須監測出血徵狀
2. 本品含乳糖，患有罕見遺傳疾病，包含乳糖不耐症、乳糖酶缺乏症或葡萄糖-半乳糖吸收不良者不應服用本藥
3. 外科手術與介入治療：應於該治療的至少 24 小時前停用
4. 硬腦膜外導管應在服用本品最後一劑後的 18 小時之後再移除，導管取出後的 6 個小時之後才可再服用本品，如發生外傷性穿刺，則給藥時間應延後 24 小時

## Warfarin

**X** **Safe<sup>1</sup>**

### Dosage Forms

Cofarin® 1mg/tab <KWARFA1>

Mafarin® 5mg/tab <KWARFA2>

### Use

Prophylaxis and treatment venous thrombosis, pulmonary embolism and thromboembolic disorders, atrial fibrillation with risk of embolism and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction

### Dose

Adults: **PO** initial 2-5mg/day for 2-5 days, then 2-10mg/day according to PT or INR

### Adverse Reactions

Hemorrhage, edema, fever, skin lesions, alopecia, leukopenia

### Precautions

1. 監測PT及INR。

2. 解毒劑: Vit.K<sub>1</sub> (initial: 0.5-10mg, if necessary, increased to 25mg)

### Contraindications

anesthesia, aneurysms, bacterial endocarditis, blood dyscrasias, blood dyscrasias, pregnancy

## 9.2. Anticoagulants (low-molecular-weight heparin)

## Enoxaparin

**B** **Unknown<sup>1</sup>**

### Dosage Forms

Clexane® 60mg/0.6ml/syringe <CENOXAP>

### Use

Deep venous thrombosis(DVT), unstable angina, non-Q-wave myocardial infarction(MI)

### Dose

#### Prevention of DVT

**SC** 0.2-0.4ml/day q12h-q24h

#### DVT

**SC** 0.01ml/kg/dose q12h for  $\leq$  10 days

#### Unstable angina, non-Q-wave MI

**SC** 0.01 ml/kg/dose q12h for 2-8 days

### Adverse Reactions

Anemia, Fever, Increased liver function test, thrombocytopenia, nausea

### Contraindications

1. Active major bleeding, thrombocytopenia associated with positive antiplatelet antibody test in vitro induced by enoxaparin, severe renal dysfunction

2. 不可IM

## Tinzaparin

**B** **Unknown<sup>3</sup>**

### **Dosage Forms**

Innohep® 20000IU/2ml/vial <CTINZAP>

### **Use**

Deep venous thrombosis (DVT), prevention of post-op DVT in patients undergoing general & orthopedic surgery, prevention of clotting during hemodialysis

### **Dose**

#### DVT

**SC** 175 anti-Xa IU/kg qd once daily.

#### Prevention of post-op DVT (general surgery)

**SC** on the day of op 3500 anti-Xa IU 2 hr before surgery and post-op 3500 anti-Xa IU qd for 7-10 days.

#### Hemodialysis

Bolus into the arterial side of the dialyser (or **IV**) at the beginning of dialysis.

< 4 hr: 2000-2500 anti-Xa IU

> 4 hr: 2500 anti-Xa IU, followed by an infusion of 750 anti-Xa IU/hr

### **Adverse Reactions**

Erythema, hematoma, asymptomatic, local irritation symptom, local pain

### **Precautions**

Sulfite sensitivity, hemorrhagic stroke, elderly patients with renal insufficiency, severe and uncontrolled hypertension.

## **9.3. Antiplatelet Agents**

### **9.3.1. Aggregation Inhibitors**

#### **Anagrelide**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Agrylin® 0.5mg/cap <KANAGR>

### **Use**

Thrombocytosis

### **Dose**

**PO** initially, 0.5 mg qid or 1 mg bid for at least 1 wk, **max: 10mg/day or 2.5mg/dose**. The dose may be adjusted as needed but should not be increased by > 0.5 mg/day in any 1 wk.

### **Adverse Reactions**

Headache, palpitations, diarrhea, asthenia, edema

### **Precautions**

Abrupt stoppage of anagrelide therapy may increase platelet counts, usually within 4 days.

#### **Aspirin**

**D<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Bokey® 100mg/cap <KASPI01>

### **Use**

Prophylaxis myocardial infarction and thromboembolism

### Dose

Previous myocardial infarction or unstable angina

**PO** 75-325mg/day

Thromboembolic disorders

**PO** 160-325mg qd-bid

### Adverse Reactions

Nausea, vomiting, dyspepsia, gastrointestinal ulcers, Reye's syndrome

### Precautions

1.本藥會延長出血時間，欲接受手術之患者應於手術前一周停藥。

2.本品可剝開膠囊，但不宜磨粉。

### Contraindications

Children and teenagers with chickenpox or flu symptoms (risk of Reye's syndrome), asthma, rhinitis and nasal polyps

## Cilostazol

**C<sup>1</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Pletaal® 100mg/tab <KCILOS1>

### Use

Intermittent claudication

### Dose

**PO** 100mg bid AC

### Adverse Reactions

Headache, abdominal pain, diarrhea, dyspepsia, flatulence, nausea

### Contraindications

Congestive heart failure of any severity

## Clopidogrel

**B<sup>4</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Plavix® 75mg/tab <KCLOPID>

Pidogrel® 75mg/tab <KCLOPII>

### Use

Prophylaxis against thrombotic events (myocardial infarction, stroke, vascular deaths) or acute coronary syndrome (unstable angina/non-Q-wave MI)

### Dose

Recent MI, recent stroke or established arterial disease

**PO** 75mg qd

Acute coronary syndrome

**PO** loading dose 300mg, followed by 75mg qd

### Adverse Reactions

Abdominal pain, vomiting dyspepsia, gastritis and constipation

### Precautions

1.Risk of increased bleeding, severe liver disease and renal impairment

2.若病人需手術，預防出血時間延長的危險，可於手術前 7 天停藥。

### Contraindications

Active bleeding

## Dipyridamole

**B<sup>1</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Posintin® 10mg/2ml/amp <CDIPYRI> 參閱 p.194

Dipyridamole® 25mg/tab <KDIPY01>

### Use

Prophylaxis platelet aggregation, evaluation of coronary artery disease

### Dose

Prophylaxis platelet aggregation

**PO** 75-100mg/day qid

### Adverse Reactions

Chest pain, dizziness, headache, Abdominal discomfort, Flushing

## Ticagrelor

**C<sup>4</sup>** **Unknown<sup>4</sup>**

### Dosage Forms

Brilinta® 90mg/FC. tab < KTICAGR>

### Use

Acute coronary syndrome: Unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI)

### Dose

**PO** loading 180mg with 325mg aspirin, maintenance 90mg bid with 75-100mg aspirin

Patients who have received a loading dose of clopidogrel may be started on ticagrelor therapy

### Adverse Reactions

Dyspnea, bleeding, headache, cough, dizziness

### Precautions

1. 手術前 5 天建議停用
2. 忘記服藥應於下次服藥時間服用 1 顆 Ticagrelor，無須一次服用 2 顆
3. 健規；限用於已發作之急性冠心症(包括不穩定型心絞痛、非 ST 段上升型心肌梗塞或 ST 段上升型心肌梗塞)而住院的病人時，得與 acetylsalicylic acid (如 Aspirin) 合併治療，最長 9 個月。

### Contraindications

顱內出血病史(IICH)、活動性病理出血(消化性潰瘍或顱內出血)、嚴重肝功能不全

## Tirofiban

**B<sup>1</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Aggrastat® 12.5mg/50ml/vial <CTIROFI>

### Use

Acute coronary syndrome (relate thrombosis)

### Dose

Acute coronary syndrome (unstable angina, non-Q-wave MI)

**IVF** loading 0.4mcg/kg/min for 30 min, maintenance 0.1mcg/kg/min in

combination with aspirin and heparin for least 48 hrs, up to 108 hrs

#### Angioplasty or atherectomy

Initial 10mcg/kg **IV bolus** over 3 min, maintenance 0.15mcg/kg/min **IV** plus unfractionated heparin for 24-48 hrs after coronary intervention

#### **Adverse Reactions**

Bleeding, bradycardia, dizziness, thrombocytopenia

#### **Precautions**

1. 需避光儲存，使用前須先稀釋，以 50ml NS 或 D5W 稀釋(稀釋濃度: 50mcg/ml)。

2. 需依肝腎功能調整劑量。

#### **Contraindications**

Aortic dissection, bleeding, hemorrhagic stroke, severe hypertension

### **9.3.2. Antianemics**

#### **Ferric chloride hexahydrate**

**Unknown<sup>1</sup>**

#### **Dosage Forms**

Sucrofer<sup>®</sup> 2%, 5ml/vial (Trivalent iron 20mg/ml) <CFERRI1>

#### **Use**

Iron deficiency anemia

#### **Dose**

**IV** 1<sup>st</sup> day 2.5ml, 2<sup>nd</sup> day 5ml, 3<sup>rd</sup> day 10ml, followed 10ml twice weekly depending on Hb level

#### **Adverse Reactions**

Anaphylaxis

#### **Ferric hydroxide polymaltose**

**Unknown<sup>1</sup>**

#### **Dosage Forms**

Tedalin<sup>®</sup> (1 tab 含 100mg Fe)/chewable tab <KFERRI2>

Ferrum Hausmann<sup>®</sup> drops 30ml/bot (1 drops 含 2.5mg Fe) <KFERRI1>

#### **Use**

Prevention and treatment iron deficiency, iron deficiency anemia

#### **Dose**

Ferrum Hausmann<sup>®</sup> Drops

Infant: **PO** begin with 6 drops/day and gradually increase to 20 drops/day

Children: **PO** 20 drops qd-bid

Adults: **PO** 20 drops bid-tid

Tedalin<sup>®</sup> tab

Adults: **PO** 1 tab qd-bid

#### **Adverse Reactions**

GI disturbances, constipation

#### **Precautions**

1. Black stools

2. Drops may be mixed with vegetable juices or other liquids

#### **Folic acid**

**A<sup>4</sup> Safe<sup>1</sup>**

### **Dosage Forms**

Folacin® 5mg/tab <KFOLATE>

### **Use**

Pernicious anemia, Megaloblastic anemia, Pregnancy vitamin/iron prophylaxis

### **Dose**

Children <1 yr: **PO** 0.5mg/day, 1-5 yrs: 5mg/day, 6-12 yrs: 10mg/day

Adults: **PO** initial 5mg tid for 14 days, maintenance 5mg qd

### **Adverse Reactions**

Anorexia, nausea, allergic sensitization

**C<sup>6</sup> Safe<sup>1</sup>**

## **Hydroxocobalamin**

### **Dosage forms**

B-Red® 1mg/ml/amp <CHYDROXL>

### **Use**

Megaloblastic anemia due to vitamin B<sub>12</sub> deficiency, peripheral neuropathies

### **Dose**

**SC/IM** 1-2amp q12-24h

### **Adverse Reactions**

Headache, anxiety, dizziness, diarrhea, nausea, vomiting, itching

### **Precautions**

易受光線分解，使用時從避光器取出應立即使用，並避光保存 □

**C<sup>4</sup> Unknown<sup>1</sup>**

## **Leucovorin calcium (Calcium folinate)**

### **Dosage Forms**

Folina® 50mg/5ml/vial <CLEUCO1>

Folina® 15mg/tab <KCALC04>

### **Use**

Colorectal cancer (combination with 5-FU to prolong survival), rescue therapy after high-dose MTX, counteract overdosages of folic acid antagonists.

### **Dose**

#### Colorectal cancer

**IV** 200 mg/m<sup>2</sup> followed by 370-425mg/m<sup>2</sup> 5-fluorouracil IV daily for 5 days repeat course at 4 wks intervals for 2 courses then 4-5 wks intervals

#### Folic acid antagonist overdose

**IM/IV/PO** 15mg (10mg/m<sup>2</sup>) q6h until serum MTX level <10<sup>-8</sup>M, if serum MTX level >5×10<sup>-6</sup>M, increase dose to 100mg/m<sup>2</sup>/dose q3h until serum MTX level<10<sup>-8</sup>M

### **Adverse Reactions**

Rash, pruritus, erythema, urticaria, thrombocytosis

### **Precautions**

1. Rescue therapy should start within 24 hrs of MTX therapy

2. IV輸注速率不可超過160mg/min。

3.針劑須冷藏及避光。

4. Pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency.

## 9.4. Antihemophilic Agents

### 9.4.1. Antihemophilic Factors

**Antihemophilic factor VIII (recombinant)** C<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Advate<sup>®</sup> 500IU/5ml/vial <CANTIH1>

#### Use

Management of hemophilia A (deficiency in factor VIII)

#### Dose

##### Minor hemorrhage

10-20IU/kg q12-24h for 1-3 days until bleeding is resolved or healing achieved

##### Moderate hemorrhage

15-30IU/kg q12-24h for  $\geq 3$  days until pain and disability are resolved

##### Severe/life-threatening hemorrhage

30-50IU/kg q8-24h until threat is solved or loading 40-50IU/kg, then followed 20-25IU/kg q8-12h until threat is resolved

#### Adverse Reactions

Fever, headache, dizziness, nausea, disorder of taste

#### Precautions

1.須冷藏在 2-8°C 。

2.IU required = body weight (kg)  $\times$  desired factor VIII increase (%)  $\times$  0.5 IU/kg

3.室溫下(<30°C)可存放 6 個月，且移存於室溫後不可再重存於冷藏。

### 9.4.2. Heparin Antagonists

**Protamine**

C<sup>1</sup> Unknown<sup>1</sup>

#### Dosage forms

Protamine<sup>®</sup> 50mg/5ml/amp <CPROTAM>

#### Use

Heparin overdose

#### Dose

**Slow IV** loading 25-50mg, with the rest of the calculated dose over 8-16 hrs

Time Elapsed	Dose of Protamine (mg) to Neutralize 100IU of Heparin
Immediate	1-1.5
30-60 min	0.5-0.75
> 2 hrs	0.25-0.375

#### Adverse Reactions

Hypotension, bradycardia, dyspnea, hemorrhage, flushing

### 9.4.3. Warfarin Antagonists

#### Phytomenadione (Vitamin K1)

C<sup>4</sup> Safe<sup>1</sup>

##### Dosage Forms

Katimin 1<sup>®</sup> 10mg/ml/amp <CVITK1>

##### Use

Hemorrhage during severe hypoprothrombinemia, vitamin K deficiency or surgical operation, hemorrhage of newborn

##### Dose

###### Hemorrhage

Newborn: IM/IV/SC 1-2 mg

Adults: IM/IV/SC 10 -15mg (<1mg/min), rarely up to 50mg/day

###### Oral anticoagulant overdose

IM/IV/SC initial 5-10 mg, up to 20 mg

##### Adverse Reactions

Flushing, sweating, dyspnea, allergic skin reactions, chest pain and chest constriction

##### Precautions

不可急速靜脈注射。

##### Contraindications

G6PD deficiency

## 9.5. Hematopoietic Agents

### 9.5.1. Recombinant Human Erythropoietins

#### Darbepoetin alfa

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

NESP<sup>®</sup> 20mcg/0.5ml/syringe <CDARBE1>

##### Use

Anemia associated with chronic renal failure and chemotherapy

##### Dose

###### Anemia of chronic renal failure

IV/SC starting dose 0.45mcg/kg qw

###### Anemia of chemotherapy

SC starting dose 2.25mcg/kg qw

##### Adverse Reactions

Edema, abdominal pain, dyspnea, cough, cardiovascular events.

##### Precautions

冷藏儲存，如未冷藏於室溫下可存放 7 天。

##### Contraindications

Uncontrolled hypertension

#### Epoetin beta

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Recormon<sup>®</sup> 2000IU/0.3ml/syringe <CEPO1>

**Use**

Anemia associated with chronic renal failure and chemotherapy

**Dose**

Anemia associated with chronic renal failure

**IV/SC** initial 50-100IU/kg tiw, maintenance will maintain hematocrit (HCT) at the desired level (30-36%)

Anemia in cancer therapy

**SC** initial 150IU/kg tiw, up to 300IU/kg tiw

Reduction of allogenic blood transfusion in anemic surgery

**SC** 300IU/kg/day for 10 days prior to surgery or 600IU/kg qw, 21, 14 and 7 days prior to surgery

**Adverse Reactions**

Hypertension, fatigue, headache, fever

**Precautions**

冷藏在 2-8°C，室溫下可存放 3 天。

**Methoxypolyethylene (glycol-epoetin beta)**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Mircera<sup>®</sup> 50mcg/0.3ml/syringe <CEPO4>

**Use**

Anemia associated with chronic renal failure

**Dose**

**IVP/SC:** 50mcg q2w-q4w

**Adverse Reactions**

Nausea, vomiting, diarrhea, weight loss, anorexia

**Precautions**

冷藏在 2-8°C，若置於 25°C 下不可超過 30 天。

## 9.5.2. Colony Stimulating Factors

**Human granulocyte colony stimulating factor (G-CSF)**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Filgrastim<sup>®</sup> (rHG-CSF) 300 mcg/0.7ml/amp <CFILG02>

**Use**

Chemotherapy related neutropenia, severe chronic neutropenia, promotion of myeloid engraftment following bone marrow transplantation, mobilization of hematopoietic progenitor cells to peripheral blood

**Dose**

Chemotherapy related myelosuppressive neutropenia

**SC** 5mcg/kg qd

Bone marrow transplantation

**IV/SC** 10mcg/kg/day q4 or 24 hrs

Peripheral Blood Progenitor cell (PBPC) collection

**SC** 10mcg/kg/day

### Neutropenia

SC congenital: 6mcg/kg bid; idiopathic/cyclic: 5mcg/kg qd

### **Adverse Reactions**

Bone/skeletal pain, headache, Neutropenic fever, fever, alopecia

### **Precautions**

1.須冷藏在 2-8°C，室溫 15-30°C 下可存放 24 小時。

2.使用 D5W 或 NS 稀釋使用。

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Pegfilgrastim**

#### **Dosage Forms**

Neulasta® 6mg/0.6ml/syringe <CPEGFIL>

#### **Use**

Decrease the incidence of infection, in patients with nonmyeloid malignancies receiving myelosuppressive cancer chemotherapy associated with a clinically significant incidence of febrile neutropenia.

#### **Dose**

SC 6 mg once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy

### **Adverse Reactions**

Ostealgia, limb pain, splenic rupture, acute respiratory distress syndrome, anaphylaxis

### **Precautions**

未開封時需儲存於 2-8°C 冷藏；若放置於室溫超過 48 小時需丟棄。

## **9.6. Hemorrheologic Agents**

### **Cinnarizine**

**C<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage form**

Cinnazine® 25mg/tab <KCINNAR>

#### **Use**

Cerebral circulatory and balance disorder, motion sickness, peripheral circulatory disorder, Meniere's disease, urticaria

#### **Dose**

##### Cerebral circulatory and balance disorders

Adults: **PO** 25mg tid

##### Peripheral circulatory disorders

Adults: **PO** 50-75mg tid

##### Motion sickness

Children 5-12 yrs: half of adult dose

Adults: **PO** 25mg 30 mins before traveling and q6h

#### **Adverse reactions**

Drowsiness, allergic skin reactions, fatigue

#### **Precaution**

Parkinson's disease, elderly patients (possible accumulation)

## **Flunarizine**

**Unknown<sup>1</sup>**

### **Dosage Forms**

Fluzine® 5mg/tab <KFLUNAR>

### **Use**

Nausea, vomiting, prophylaxis migraine, peripheral vascular disease and motion sickness

### **Dose**

Prophylaxis migraine headache and peripheral vascular disease

Adults: **PO** 5-10mg qd-bid, maintenance 5mg hs

### Motion sickness

Adults: **PO** 10mg 30 mins before traveling

### **Adverse Reactions**

Sedation, drowsiness, weight gain, gingival hyperplasia

### **Precautions**

Extrapyramidal reactions, parkinsonism

## **Nicergoline**

**Unknown<sup>1</sup>**

### **Dosage Forms**

Seromin® 10mg/S.C. tab <KNICERG>

### **Use**

Cerebrovascular insufficiency (eye and ear) and peripheral vascular disease

### **Dose**

Adults: **PO** 5-15mg tid AC

### **Adverse Reactions**

Slight GI disturbances, flushing, drowsiness, insomnia

### **Contraindications**

Acute hemorrhage, arterial hypotension, concurrent use of alpha or beta receptor agonists, recent myocardial infarction, severe bradycardia

## **Piracetam**

**B<sup>1</sup> Unsafe<sup>5</sup>**

### **Dosage Forms**

Syntam® 2.4g/pack <KPIRAC1>

### **Use**

Improve dementia and other cerebrovascular disorders

### **Dose**

Cerebrovascular insufficiencies and age-associated intelligence disturbance

**PO** 1.2-2.4g/day qd-bid

### Cortical myoclonus

**PO** initial 7.2g/day bid-tid, increasing by 4.8g q3-4d; max: 24g/day

### **Adverse Reactions**

Hyperkinesia, weight gain, nervous, drowsiness, depression, impotent sense

### **Precautions**

1.可能影響開車及操作機械的能力，因此需小心注意。

2.先將顆粒倒入適量(約 50ml)水中溶解後服用，溶解後於 2-8°C冷藏可儲放 72 小時。

3.需依腎功能調整劑量。

#### Contraindications

腦內出血、ESRD

## 9.7. Hemostatics

### Pentoxifylline

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Pentop® 400mg/ S.R.F.C tab<KPENTOX>

#### Use

Intermittent claudication

#### Dose

Adults: PO 400mg bid-tid

#### Adverse Reactions

Dizziness, headache, nausea, vomiting, dyspepsia

#### Precautions

1.需依腎功能調整劑量。

2.不宜磨粉。

#### Contraindications

Patients with recent cerebral and/or retinal hemorrhage

### Tranexamic acid

B<sup>1</sup> safe<sup>1</sup>

#### Dosage Forms

Transamin® 5%, 250mg/5ml/amp <CTRANEX>

Tren® 250mg/cap <KTRANEX>

#### Use

Hemorrhage, abnormal bleeding

#### Dose

PO 3-8 cap/day tid-qid

IM/IV 250-500 mg/day qd-bid. Operation or post-op 500-25000 mg/dose

#### Adverse Reactions

Nausea, diarrhea, vomiting, thrombosis

#### Precautions

需依腎功能調整劑量。

#### Contraindications

Active intravascular clotting

## 9.8. Plasma Expanders

### Albumin

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Form

Plasbumin-25® 25%, 12.5g/50ml/vial <CALBU01>

#### Use

Hypovolemic shock, burn, hypoproteinemia with or without edema

## Dose

### Burn

**IVF** achieve plasma albumin level of approximately 2.5g/100ml (total plasma protein concentration of 5.2g/100ml)

### Hypoproteinemia

Children: **IVF** 0.5-1g/kg, repeat every 1-2 days; **max: 2g/kg/day**  
 Adults: **IVF** 200-300ml; **max: 2g/kg/day**

### Hypovolemic shock

Children: **IVF** 0.5-1g/kg, may repeat in 15-30 min; **max: 6g/kg/day**  
 Adults: **IVF** 200-300ml, may repeat in 15-30 min

## Adverse Reactions

Hypersensitivity (Shaking, chills, urticaria), hypervolemia, tachycardia, nausea, vomiting, pulmonary edema

## Contraindications

Severe anemia and cardiac failure

## Dextran low molecule 40

**C<sup>4</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Dextran 40<sup>®</sup> 10%, 500ml/bot (dextran 40 10%+dextrose 5%) <CDEXTRA>

### Use

Prevention and treatment of surgical shock due to trauma, burns, hemorrhage, plasma substitute for the treatment of acute hemorrhage

### Dose

#### Volume expansion/shock

Children: **IVF** total dose should not exceed 20ml/kg during first 24 hrs

Adults: **IVF** 500-1000ml (20-40ml/min); **max: 20ml/kg** for first 24 hrs; 10ml/kg/day thereafter, not continue beyond 5 days

#### Pump prime

Varies with the volume of the pump oxygenator, general dose of 1-2g/kg

#### Prophylaxis of venous thrombosis/pulmonary embolism

During surgical procedure 50-100g **IVF** on the day of surgery, then 50g (500ml) 2-3 days during the period of risk (up to 2 wks postoperatively), usual **max infusion rate** for nonemergency use **4ml/min**

## Adverse Reactions

Mild hypotension, tightness of chest, wheezing

## Precautions

1. Active hemorrhage, bowel surgery, thrombocytopenia

2. 肝腎功能不良者需小心使用。

## Contraindications

Severe bleeding disorders, pulmonary edema, renal disease with severe oliguria or anuria, severe congestive heart failure

## Tetraspan (HES)<sup>®</sup>

**C<sup>4</sup>** **Unknown<sup>3</sup>**

### Dosage Forms

商品名	Tetraspan <sup>®</sup>
規格<代碼>	10%, 500ml/bot <CTETRA1>

含量	Each 1000 ml solution contains: Poly starch (HES).....100 g Sodium chloride ..... 6.25 g Potassium chloride..... 0.30 g Calcium chloride 2H <sub>2</sub> O.....0.37 g Manesium chloride 6H <sub>2</sub> O..... 0.20 g Sodium acetate 3H <sub>2</sub> O..... 3.27 g Malic acid..... 0.67 g
----	--

**Use**

Therapy and prophylaxis of hypovolaemia

**Dose**

**IVF** 500ml qd; **max:** 30ml/kg/day

**Adverse Reactions**

Reduced hematocrit, decrease plasma protein, elevated serum  $\alpha$ -amylase concentrations

**Contraindications**

Renal failure with oliguria or anuria, fluid overload condition, severe hypernatremia or hyperchloremia, intracranial bleeding.

## 9.9. Thrombolytic Agents

**Alteplase, tissue plasminogen activator (t-PA)** **C<sup>4</sup>** **Unknown<sup>1</sup>**

**Dosage Forms**

Actilyse<sup>®</sup> 50mg/vial <CTPA>

**Use**

Management of acute myocardial infarction of thrombus in coronary arteries, acute ischemic stroke and acute massive pulmonary embolism

**Dose**Acute myocardial infarction

100mg over 1.5 hrs

**IV bolus** 15mg over 1-2 min; 50mg **IV infusion** 30 min (若BW>67kg: 0.75mg/kg, 不超過50mg); 35mg **IV infusion** 60 min (若BW ≤ 67kg: 0.5mg/kg, 不超過35mg)

Acute ischemic stroke

0.9mg/kg with in the first 3 hrs

**IV bolus** 0.09mg/kg, then **IV infusion** 0.81mg/kg over 60 min; **max: 90mg/dose**

Pulmonary embolism

100mg within 2 hrs, **IV bolus** 10mg over 1-2 min, then **IV infusion** 90mg

**Adverse Reactions**

Bleeding, reperfusion arrhythmias, intracranial hemorrhage, nausea, vomiting, hypotension, epistaxis, ecchymosis

**Precautions**

1. 未配製之藥品須避光儲存放於30°C 以下。

2. 調製後冷藏於可存放 24hrs，若於 30°C 下可放 8hrs。

## **Contraindications**

不可使用注射用水或含碳水化合物之輸注液稀釋，例如 dextrose。

## **Urokinase**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Urokinase<sup>®</sup> 60,000IU(60KIU)/vial <CUROKIN>

### **Use**

Thromboembolic disorders (pulmonary embolism, coronary occlusion in MI and arterio-venous thrombosis in the limb)

### **Dose**

#### Cerebral thrombosis

**IV** 60,000 IU once a day for about 7 days

#### Peripheral arterial-venous occlusion

**IV** 60,000-240,000 IU on first day of treatment followed by tapered dose for about 7 days)

#### Occluded catheter

**IV** 5000 IU in each lumen over 1-2 mins, leave in lumen for 1-4 hrs, then aspirate. May repeat with 10,000 IU in each lumen if 5000 IU fails to clear the catheter.

### **Adverse Reactions**

Hemorrhagic infarction, bleeding

### **Precautions**

1. 小兒使用安全性尚未建立。

2. 以 10ml NS, D5W 溶解乾粉，在用 NS, D5W 稀釋，藥品稀釋後應盡速使用。

## **Contraindications**

Active internal bleeding, recent intracranial or intraspinal surgery or trauma, intracranial neoplasm, aneurysm or arteriovenous malformation, known bleeding diathesis

## 10. DIAGNOSTIC AGENTS

### 10.1. Adrenocortical Insufficiencies

#### Cortisone

D<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Cortisone<sup>®</sup> 25mg/tab <KCORTIS>

#### Use

Adrenocortical insufficiency

#### Dose

PO 25mg tid-qid

#### Adverse Reactions

GI distress, growth depression, hypertension, increased skin of infection, Cushing's syndrome

#### Precautions

Cirrhosis, hypothyroidism, peptic ulcer

### 10.2. Liver Functions

#### Indocyanine green (ICG)

Unknown<sup>1</sup>

#### Dosage Forms

Diagnogreen<sup>®</sup> 25mg/vial (1 vial: 含碘3mg) <CINDOC>

#### Use

Liver function tests-general

#### Dose

Slow IV 25mg 稀釋成 2.5-5mg/ml 後，0.5mg/kg

#### Precautions

本品須先以蒸餾水溶解後，再以 N/S 稀釋後投予。

#### Contraindication

對碘過敏者應避免使用。

#### Gadoxetic acid

C<sup>5</sup> Unknown<sup>3</sup>

#### Dosage Forms

Primovist<sup>®</sup> 0.25mmol/ml, 10ml/syringe <CGADOXE >

#### Use

Contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions within focal liver disease

#### Dose

Adult: IV (rate:2ml/sec) 0.1ml/kg

#### Adverse reactions

Headache, blood pressure increase, vomiting, respiratory distress, rash, chest pain

#### Precutions

1.避免使用肌肉注射

2.使用後，靜脈留置針應用生理食鹽水沖洗

3. 腎功能不良 Clcr<30ml/min 需小心使用。

### 10.3. Myasthenia Gravis

#### Neostigmine

C Unknown

##### Dosage Forms

Vagostin® 0.5mg/ml/amp <CNNEOSTI>

##### Use

Abdominal distension, Myasthenia gravis

##### Dose

###### Abdominal distension

IM 0.25-0.5mg, repeat every 4 to 6 h for 2 to 3 days

###### Myasthenia gravis

IM 0.5mg

##### Adverse Reactions

GI effects, salivation, miosis, diaphoresis, muscle cramps, fasciculation, weakness

### 10.4. Skin Test

#### Penicillin skin test

##### Dosage Forms

10000IU/10ml/bot <CPENIC4>

##### Use

Testing for penicillin hypersensitivity

##### Dose

SC 0.1ml (100IU)

##### Precautions

需冷藏於 2~8°C，可存放 7 天。

#### Tuberculin Purified Protein Derivative (PPD) B<sup>5</sup> Safe<sup>3</sup>

##### Dosage Forms

Tuberculin PPD® 30T.U/1.5ml/vial <CTUBERC>

##### Use

Diagnostic agent for tuberculosis

##### Dose

###### 皮內診斷測試

SC 使用 0.1ml 在前臂三分之二處皮內注射，產生一圓形疙瘩且在約 10 分鐘後消失，注射後 72 小時判讀。

##### Adverse Reactions

Ulceration, necrosis, vesiculation, pain at injection site

##### Precautions

本品需冷藏，開封後 24 小時內須使用完畢。

### 10.5. Thyroid Functions

## **Thyrotropin alfa**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Thyrogen® 1.1mg/vial (0.9mg/ml reconstituted) <CTHYROT>

### **Use**

Thyroid cancer - diagnosis

### **Dose**

Children >16 yrs and adults: **IM** 0.9mg q24h ×2 doses or 0.9mg q72h ×3doses

### **Adverse Reactions**

Headache, nausea, asthenia, dizziness, flu-like syndrome, paresthesia, vomiting

### **Precautions**

本品需冷藏。

## **10.6. Thallium Myocardial Perfusion Scintigraphy**

### **Adenosine**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Adenocor® 6mg/2ml/vial <CADENOS>

### **Use**

Paroxysmal supraventricular tachycardias, diagnostic in narrow and broadcomplex tachycardias

### **Dose**

**Rapid IV bolus** initial 3mg over 2 seconds. If required, 2nd dose of 6mg and 3rd dose of 12mg at 1-2 min intervals may be given; **max: 12 mg/dose**

### **Adverse Reactions**

Chest pain or pressure, dyspnea, headache, lightheadedness, flushing, neck, throat or jaw discomfort

### **Dipyridamole**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Posintin® 10mg/2ml/amp <CDIPYRI>

Dipyridamole® 25mg/tab <KDIPY01> 參閱p.180

### **Use**

Thallium myocardial perfusion imaging for the evaluation of coronary artery disease

### **Dose**

**IV** 0.14mg/kg/min for 4 min; **max: 60mg**

### **Adverse Reactions**

Dizziness, electrocardiography changes, headache, exacerbation of angina pectoris

## **10.7. Radiopaque Contrast Agents**

### **10.7.1. Iodinated-Ionics**

## Sodium and meglumine ioxitalamate

### Dosage Forms

Telebrix 35<sup>®</sup> 100ml/vial (碘: 350 mg/ml) <XYTEL1>

### Use

Angiocardiography (ventriculography, coronary angiography), digital subtraction angiography, intravenous urography, computed tomography

### Dose

Ventriculography

**IV** 40 ml/dose

Coronary angiography

**IV** 4-8 ml/dose

Digital subtraction angiography

**IV** 0.6 ml/kg

Intravenous urography

**IV** 2 ml/kg

Computed tomography

**IV** 100 ml/dose

### Adverse Reactions

Sensation of heat

### Contraindications

Myelography

## 10.7.2. Iodinated-Non-Ionics

### Iodixanol

**B<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Visipaque<sup>®</sup> 100ml/vial (碘:320mg/ml)<CIODIXA>

### Use

Coronary angiography, arteriography of cerebral arteries, abdominal angiography

### Dose

**IV/IA/蜘蛛膜下腔注射/體腔注射** depending on the requirement for specific exam

### Adverse Reactions

Nausea, vomiting, pain, feelings of coldness, warmth.

### Precautions

1.對有過敏、氣喘史或曾對含碘對比劑有不知明反應者需特別注意。

2.含碘對比劑可能引發過敏性休克或高過敏反應，因此須隨時備有可立即治療嚴重反應之急救藥物。

3.使用前可加溫至 35-37°C 加溫後可存放 1 個月。

### Iohexol

Unknown<sup>1</sup>

### Dosage Forms

Omnipaque<sup>®</sup> 10ml/vial (碘: 300mg/ml)<CIOHEX>

Omnipaque<sup>®</sup> 100ml/vial (碘: 350mg/ml)<XYOMNI>

### Use

Myelography, angiography, contrast enhancement in CT and urography

#### Dose

IV/IA/IT/PO/RECT depending on the requirement for specific exam

#### Adverse Reactions

Feelings of coldness, warmth, nausea, vomiting.

#### Precautions

1. 接受抗痙攣劑之病人，應持續其治療。萬一發生癲癇發作時，建議

靜脈注射 diazepam 或 phenobarbital 治療。

2. 患有肝或腎嚴重障礙者、嚴重甲狀腺毒症者需謹慎使用。

3. 使用前可加溫至 35-37°C

#### Contraindications

明顯的甲狀腺毒素症。對 Iohexol 過敏者。

### Iopamidol

#### Dosage Forms

Iopamiro 370<sup>®</sup> 200ml/bot, 1 ml: Iopamidol 755.3 mg <CXIOP1>

#### Use

Angiography, urography

#### Dose

IV/IA/IT depending on the requirement for specific exam

#### Adverse Reactions

Nausea, vomiting, dizziness, headache, dyspnea.

#### Precautions

使用前可加溫至 35-37°C，加溫後可存放 1 個月。

### Iopromide

**Unknown<sup>1</sup>**

#### Dosage Forms

Ultravist 370<sup>®</sup> 50ml/bot (碘: 370mg/ml) <CIOVER1>

Ultravist 370<sup>®</sup> 100ml/bot (碘: 370mg/ml) <CIOVER2>

#### Use

Coronary arteriography, left ventriculography, visceral angiography, aortography

#### Dose

IV/IA/體腔注射 depending on the requirement for specific exam

#### Adverse Reactions

Nausea, vomiting, pain, feelings of coldness, warmth.

#### Precautions

1. 使用前可加溫至 40°C，加溫後可存放 6 個月。

2. 開瓶後 10 小時，未使用完藥品應丟棄。

### 10.7.3. Oily Contrast Mediums

### Ethiodized oil

**Unknown<sup>1</sup>**

#### Dosage Forms

Lipiodol<sup>®</sup> ultra-fluid 3.8%, 10ml/amp (碘: 480mg/ml) <CETHIOD>

#### Use

Lymphography, hysterosalpingography, tranarterial embolization of hepatoma

### Dose

#### Lymphography

Children and infants: **Intralymphatically** 1-6ml; **max: 6ml**

Adult: **Intralymphatically** 8ml

#### Hysterosalpingography

**Instilled into the uterus** 5ml

### Adverse Reactions

Cardiovascular collapse, thrombophlebitis, lipogranuloma, dermatitis, fever, iodism, abdominal pain, pelvic inflammatory disease, alveolar hemorrhage

## 10.7.4. Contrast Mediums for MRI

### Gadobenate dimeglumine

**C** **Unknown<sup>1</sup>**

#### Dosage Forms

Multihance® 20ml/vial <CXYMULT>

#### Use

Radiological contrast media

#### Dose

Central nervous system finding - Finding of lesion - Magnetic resonance imaging

**IV rapid bolus** 0.1mmol/kg(0.2 mL/kg) (成人 10ml/dose)

### Adverse Reactions

Nausea, taste sense altered, vomiting, xerostomia, Dizziness, headache

### Gadobutrol

**C** **Unknown<sup>1</sup>**

#### Dosage Forms

Gadovist 1.0® 604.72mg/ml, 15ml/vial<CXYGAD1>

#### Use

Contrast enhancement in cranial magnetic resonance imaging (MRI), contrast enhancement in Magnetic Resonance Angiography (CE-MRA)

#### Dose

##### Cranial and spinal MRI

>18 yrs: **IV** 0.1 ml/kg

##### CE-MRA

Imaging of one field of view: **IV** <75 kg: 7 ml; ≥ 75 kg: 10 ml

Imaging of more than one field of view: **IV** <75 kg: 10 ml; ≥ 75 kg: 15 ml  
**max: 15 ml/dose**

### Adverse Reactions

Feelings of coldness, warmth or pain, nausea, vomiting.

### Precautions

1.曾有過敏性休克情形，須小心。

2.須特別注意低癲癇發作閾值病患的使用狀況。

3.除非必要，懷孕期間不應使用本品。至少應間隔 24 小時後再繼續餵乳。

## **Gadodiamide**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Omniscan® 0.5mmol/ml, 20ml/vial <CGADODI>

### **Use**

MRI of cranial, spinal and general

### **Dose**

Children > 6 mon: **IV** 1ml/10kg/dose

Adults: **IV** 15ml/dose

**max: 20ml/total dose**

### **Precautions**

1. 嚴重腎功能不良之患者(GFR<30 mL/min)要特別謹慎。

2. 注射Omniscan 前，應停止哺乳；注射後 24hrs，方可再次哺乳。

## **Gadoxetic acid**

**C<sup>5</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Primovist® 0.25mmol/ml, 10ml/syringe <CGADOXE>

### **Use**

Contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions within focal liver disease

### **Dose**

Adult: **IV** (rate:2ml/sec) 0.1ml/kg

### **Adverse reactions**

Headache, blood pressure increase, vomiting, respiratory distress, rash, chest pain

### **Precautions**

1. 避免使用肌肉注射

2. 使用後，靜脈留置針應用生理食鹽水沖洗

3. 腎功能不良 Clcr<30ml/min 需小心使用。

## **10.8. Radiopaque Miscellaneous**

### **Fluorescein sodium**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Fluorescite® 10%, 5ml/vial <CFLUOR3>

### **Use**

Diagnostic agent for detecting corneal lesions and foreign bodies in the eye, for ocular angiography, determination of the circulation time

### **Dose**

Children: **IV** 7.7mg/kg

Adults: **IV** 500mg

### **Gonadorelin**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

LH-RH® 0.1mg/1ml/amp <CGONADO>

### **Use**

Diagnostic test to evaluate hypothalamic/pituitary gonadotropin function,

induce ovulation in primary hypothalamic amenorrhea

**Dose**

**IV/SC/IM** 0.1mg as a single injection

**Adverse Reactions**

Flushing, headache, lightheadedness, nausea, abdominal discomfort

**Precautions**

配製後室溫儲存可放24 小時。

**Patent blue-V**

**Unknown<sup>1</sup>**

**Dosage Forms**

Blue Patent V® 2.5%, 2ml/amp <CPATENT>

**Use**

Colour the lymph vessels,

**Dose**

Colour the lymph vessels for contrast medium

SC 1ml

Visualize the arterial bed for chemotherapy

IV 2.5% Patent blue V 40ml + 0.9% NaCl 80ml +1% Xylocaine 20ml

**Adverse Reactions**

Hypersensitivity reactions, shock, dyspnea, laryngeal spasm, edema, nausea, hypotension, tremor

**Precautions**

The bluish skin colour which may develop after injection usually disappears after 24 to 48 hrs

# 11. ENDOCRINE AND METABOLIC

## 11.1. Estrogens

### Estradiol

**X** **Safe<sup>1</sup>**

#### Dosage Forms

Estrade<sup>®</sup> (estradiol valerate) 2mg/tab <KESTRA5>

Oestrogel<sup>®</sup> 18mg/30g/tube <WESTRA3>

#### Use

Atrophic vaginitis, postmenopausal symptoms, hormone replacement therapy

#### Dose

##### PO

1-2mg/day, administration should be cyclic (3 weeks on, 1 week off)

##### Topical

2.5g/dose qd apply to the area of abdomen, inside of both thighs (3 weeks on, 1 week off)

#### Adverse Reactions

Breast tenderness, headache, dizziness, nausea, abdominal pain

#### Precautions

外用藥塗抹於前臂、手臂、兩肩或者完整大面積的皮膚上，勿塗抹於乳房、陰部或陰道黏膜。

### Estrogens conjugated

**X** **Safe<sup>1</sup>**

#### Dosage Forms

Estromon<sup>®</sup> 0.625mg/tab <KESTRO2>

Premarin<sup>®</sup> vaginal cream 14g/tube (1g: estrogens conjugated 0.625 mg) <WESTRO1>

#### Use

Atrophic vaginitis, postmenopausal symptoms, hormone replacement therapy, abnormal uterine bleeding

#### Dose

Tablet:

**PO** 0.625-3.75 mg/day

Vaginal cream:

##### Atrophic vaginitis

**Intravaginally** 0.5-2g vaginal cream/day, cyclically(e.g. 3wk on and 1wk off); **max: 4g/day**; reduce or discontinue dose at 3-6 month intervals

#### Adverse Reactions

Headache, dizziness, nausea, vomiting, weight change, edema

## 11.2. Selective Estrogen Receptor Modulators

### Raloxifene

**X** **Unsafe<sup>1</sup>**

#### Dosage Forms

Evista<sup>®</sup> 60mg/tab <KRALOXI>

**Use**

Prevention and treatment of osteoporosis in postmenopausal women

**Dose**

**PO** 60mg qd

**Adverse Reactions**

Hot sweats, leg cramp, arthralgia, flu syndrome, venous thromboembolism

## 11.3. Progestins

### Hydroxyprogesterone caproate

**B<sup>1</sup> Safe<sup>1</sup>**

**Dosage forms**

Progesteron depot<sup>®</sup> 125mg/1ml/amp <CPROGE1>

**Use**

Amenorrhea, uterine bleeding, infertility, abortion

**Dose**

**IM** 65-125mg once weekly

**Adverse Reactions**

Pain at injection site, swelling at injection site, preterm labor, urticaria

**Precautions**

注射時須注意：避開神經走位部位、如需連續使用請左右邊交互注射、確實觀察注射器反吸時無血液逆流現象

**Contraindication**

嚴重肝障礙及肝疾患者

### Levonorgestrel

**X<sup>3</sup> Safe<sup>3</sup>**

**Dosage Forms**

Mirena<sup>®</sup> 250mg/tab <CLEVONO>

**Use**

Contraception, menorrhagia, prophylaxis of endometrial hyperplasia

**Dose**

**Intrauterine device**

Mirena is inserted into the uterine cavity and is effective for five years.

Initially dissolution rate is approximately 20mcg/24hrs, and is reduced to 10mcg/24hrs after 5years. The mean release rate over 5 years is levonorgestrel 14 mcg/24hrs.

**Adverse Reactions**

Headache, depressed mood, nervousness, abdominal pain, nausea

**Precautions**

1. 可能影響病人葡萄糖耐受性，糖尿病患者應監測血糖。

2. 用於避孕或預防雌激素補充治療引起的子宮內膜增生之病人需自費。

**Contraindication**

懷孕、骨盆腔或下生殖道感染、產後子宮內膜炎、前3個月內曾發生感染性流產、子宮頸炎/瘤或發育異常、不明原因子宮不正常出血、急

性肝病或肝腫瘤、感染機率增高之狀況。

## Medroxyprogesterone

**Safe<sup>1</sup>**

### Dosage Forms

Provera® 10mg/tab <KMEDRO1>

### Use

Amenorrhea, hormone replacement therapy, endometrial carcinoma, breast cancer, prostate carcinoma

### Dose

#### Amenorrhea

**PO** 5-10mg/day for 5-10 days

#### Abnormal uterine bleeding

**PO** 5-10 mg/day for 5-10 days beginning on day 16 or 21 of the menstrual cycle

#### Endometrial hyperplasia, Estrogen-induced: Prophylaxis

**PO** 5 or 10 mg/day for 12-14 consecutive days per month, either beginning on day 1 or day 16 of the cycle

### Adverse Reactions

Weight gain, abdominal pain, headache, feeling nervous, amenorrhea

## Progesterone

**Safe<sup>1</sup>**

### Dosage forms

Progesterone® 25mg/ml/amp <CPROGES>

Promone® 100mg/soft cap <KPROGES>

Crinone® 8% 80mg/ tube<WPROGES>

### Use

Amenorrhea, hormone replacement therapy, uterine bleeding, infertility (vag gel)

### Dose

Capsule:

#### **PO**

200-300 mg/day (one in the morning and two at night) during 10 days/month, from 17-26th day of the cycle. The normal dose may vary from 1-4 caps per day.

#### **Intravaginally** (cap)

1-2 tab bid-tid.

Injection:

#### **IM**

5-10 mg/day qd-bid

Vaginal tube:

#### **Intravaginally**

Infertility due to inadequate luteal phase: One tube qd starting after documented ovulation or arbitrarily on the 18th-21st day of the cycle.

#### **In-vitro fertilisation**

If pregnancy occurs, one tube qd should be for 30 days

### Adverse Reactions

Dizziness, breast pain, headache, fatigue, abdominal pain, viral infection

## **Precautions**

Crinone<sup>®</sup>：本品需保存於 25°C 以下。

## **11.4. Estrogen and Progestin Combination**

### **Diane-35<sup>®</sup>**

**X<sup>5</sup> Unknown<sup>3</sup>**

#### **Dosage Forms**

1 tab: Cyproterone acetate 2mg+ Ethinylestradiol 0.035mg, 21 tab/box  
<KDIANE>

#### **Use**

Androgen-dependent diseases in women, contraceptives

#### **Dose**

PO 1 tab/day qd for 21 days, then a tablet-free interval of 7 days follows

#### **Adverse Reactions**

Nausea, abdominal pain, weight gain, headache, depression

### **Premelle Lite<sup>®</sup>**

**X<sup>5</sup> Unsafe<sup>3</sup>**

#### **Dosage Forms**

1 tab: Estrogens 0.3mg+ Medroxyprogesterone 1.5mg, 28 tab/box  
<KPREM03>

#### **Use**

Treatment of moderate to severe vasomotor symptoms associated with menopause, atrophic vaginitis, osteoporosis

#### **Dose**

PO 1 tab/day

#### **Adverse Reactions**

Headache, abdominal pain, breast enlargement, breast tenderness

### **Tibolone**

**X<sup>5</sup> Unsafe<sup>3</sup>**

#### **Dosage Forms**

Livial<sup>®</sup> 2.5/tabc<KTIBOLO>

#### **Use**

自然或手術後停經引起之症狀

#### **Dose**

PO 2.5 mg/day at the same time of day

#### **Adverse Reactions**

Headache, dizziness, edema, weight gain, abnormal vaginal bleeding

### **YAZ<sup>®</sup>**

**X<sup>4</sup> Unsafe<sup>3</sup>**

#### **Dosage Forms**

Ethinyl estradiol 0.02mg+ Drosipреноне 3mg/tab, 28 tab/box <KYAZ>

#### **Use**

Contraception, acne vulgaris

#### **Dose**

PO 1tab(pink) qd for 1-24 days, then take 1tab(white) qd for 25-28 days.

#### **Adverse Reactions**

Irregular Uterine bleeding, nausea, breast tenderness, headache

#### **Precautions**

1. 可於月經週期第一天或月經開始後第一個星期日開始服用
2. 執行大型手術前至少 4 週須停用，並於手術 2 週後開始服用

### **11.5. Ovulation Stimulants**

#### **Choriogonadotropin alfa ( $\gamma$ -hCG)** X<sup>4</sup> Unknown<sup>3</sup>

##### **Dosage Forms**

Ovidrel<sup>®</sup> 250mcg/vial <CHCG3>

##### **Use**

Primary ovarian failure, non-in vitro fertilization fertility

##### **Dose**

SC 250mcg one day following the last dose of follicle stimulating agent

##### **Adverse Reactions**

Injection site pain, headache, fatigue, nausea, vomiting, abdominal pain

##### **Precautions**

1. 儲存方式: 2-8°C；若於 25°C 可存放 30 天。

2. 一劑 250mcg 相當於 6500IU，但本品為 DNA 重組技術合作，效力應用於 ovulation induction 相當於 5000IU 尿液製成 hCG，若用於人工生殖促進濾泡成熟與引發早期黃體期時，250mcg 相當於 5000IU、10000IU HCG 尿液製劑。

#### **Clomiphene**

X<sup>4</sup> Unknown<sup>1</sup>

##### **Dosage Forms**

Clomid<sup>®</sup> 50mg/tab <KCLOMIP>

##### **Use**

Ovulatory dysfunction

##### **Dose**

PO 50-100mg/day for 5 days, if not effective, a second and third course may be given

##### **Adverse Reactions**

Ovarian enlargement, vasomotor flushing, abdominal discomfort, blurred vision

#### **Follitropin alfa**

X<sup>4</sup> Unknown<sup>1</sup>

##### **Dosage Forms**

Gonal-F<sup>®</sup> 75IU/amp <CFOLLIT>

##### **Use**

Assisted reproductive technologies, induction of ovulation

##### **Dose**

Assisted reproductive technologies

SC 150-225IU/day; max: 450IU/day

Ovulation induction

SC 75-150IU/day; max: 225IU/day

## **Adverse Reactions**

Ovarian hyperstimulation and multiple pregnancies, nausea, vomiting, weight gain, abdominal pain

## **Precautions**

須冷藏於2-8°C。

## **Follitropin beta**

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Puregon® 300IU/0.36ml/pen<CFOLLI1>

### **Use**

Female:

Anovulation (including polycystic ovarian disease, PCOD), controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs.

Male:

Deficient spermatogenesis due to hypogonadotropic hypogonadism.

### **Dose**

#### Anovulation

SC initial dose 50IU × 7days, if ovarian not response, gradually increased until follicle growth and plasma oestradiol level.

#### Medically assisted reproduction programs

SC initial dose 100-225IU × 4days, dose adjusted individually based upon ovarian response.

#### Deficient spermatogenesis

SC 450 IU/week divided in 3 dosages, concomitantly with hCG, for 3-4month.

## **Adverse Reactions**

Headache, bruising, pain, redness, swelling, and itching, abdominal pain

### **Precautions**

1. 2-8°C 冷藏；若於室溫 25°C 可放置 3 個月。

2. 若匣式包裝之橡皮鑲嵌物已被針頭戳過，請於 28 天內使用完畢。

3. Drug-drug interaction: Puregon 與 Clomiphene citrate 併用會使濾泡反應增強。

## **Gonadorelin**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

LH-RH® 0.1mg/1ml/amp <CGONADO>

### **Use**

Gonadotrophic function evaluation

### **Dose**

**IV/SC/IM** 0.1mg as a single injection

## **Adverse Reactions**

Flushing, headache, lightheadedness, nausea, abdominal discomfort

### **Precautions**

配置後室溫儲存可放置 24 小時。

## **Menopur<sup>®</sup>**

**X<sup>3</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

1 vial: FSH 75 IU+LH 75 IU <CMERION>

### **Use**

Stimulation of follicle maturation in infertile women

### **Dose**

#### Ovulation induction

**IM** initial 75-150 IU/day followed by hCG, 5,000-10,000 IU qd after the last dose; until indices of estrogen activity are equivalent to or greater than those of the normal individual.

#### Spermatogenesis induction

**IM** 75-150 IU tiw for > 10-12 wks.

### **Adverse Reactions**

Gastrointestinal symptoms, bloating, abdominal pain

### **Precautions**

1.須存放在25°C 以下，避光儲存。

2.配製後須立即使用。

## **11.6. Androgens**

### **Abiraterone**

**X<sup>3</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

Zytiga<sup>®</sup> 250mg/tab <KABIRAT>

### **Use**

Metastatic prostate cancer, Castration-resistant, in combination with prednisone

### **Dose**

**PO** 1000mg(4 tablet) qdac in combination with prednisolone 5mg bid

### **Adverse Reactions**

Joint swelling, myalgia, edema, hot flush, diarrhea

### **Precautions**

1.應整顆以水吞服，勿壓碎或嚼碎藥錠

2.建議治療前應先檢測 AST/ALT 及 Bilirubin，並於最初 3 個月治療期間每兩週檢測一次，之後亦應每月檢測一次

3.食物會導致藥物濃度增加，故需空腹，服用前應至少 2 小時不可進食或服用後至少 1 小時不可進食

4.須經事前審查核准後使用，每 3 個月需再次申請

### **Contraindication**

懷孕、嚴重肝功能不良(Child-Pugh Class C)

### **Methyltestosterone**

**X<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Methyltestosterone<sup>®</sup> 10mg/tab <KMETH03>

### **Use**

Hypogonadism

**Dose**

PO 10 mg qd-tid

**Adverse Reactions**

Gynecomastia, impotence, hirsutism, acne, nausea

**Precautions**

Hepatic disease, cardiac disease, renal disease, hypercalcemia

**Contraindications**

Prostate cancer

**X<sup>3</sup> Unsafe<sup>1</sup>**

**Testosterone**

**Dosage Forms**

Testosterone<sup>®</sup> 200mg/ml/amp <CTESTO1>

Nebido<sup>®</sup> 1000mg/4ml/amp<CTESTO3>

Androgel gel<sup>®</sup> 5g/sachets<WYY11>

**Use**

Androgen replacement therapy, inoperable breast cancer, male hypogonadism

**Dose**

Testosterone injection:

**IM** 200-400mg every 3-4 wks or 1000mg q10-12wks

Androgel gel

**Topical** 1 sachets qd; **max: 2 sachets/day**

**Adverse Reactions**

Acne, application site reactions, weight gain, hot flashes, polycythemia

**Precautions**

限肌肉注射需以極緩慢的速度施打，並避免注射到血管內

**Contraindications**

攝護腺癌、男性乳腺癌、惡性腫瘤伴隨高血鈣、罹患肝腫瘤之患者及女性

## 11.8. Antigonadotropics

**Ganirelix**

**X<sup>3</sup> Unsafe<sup>1</sup>**

**Dosage Forms**

Orgalutran<sup>®</sup> 0.25mg/0.5ml/syringe <CGANIRE>

**Use**

Female infertility

**Dose**

**SC** 0.25 mg, once daily

**Adverse Reactions**

Abdominal pain, injection site reaction

**Precautions**

1. Orgalutran 和濾泡刺素需同時給予，不可以混合使用，且需使用不同的注射部位。

2.體重50kg 以下及 90kg 以上之安全性及效力尚未確立，須小心使用。

### Contraindications

中度或重度肝或腎功能損傷者

### Gestrinone

X<sup>3</sup> **Unsafe<sup>3</sup>**

#### Dosage Forms

Gestrin<sup>®</sup> 2.5mg/cap <KGESTRI>

#### Use

Endometriosis

#### Dose

PO 2.5mg three times weekly; the first dose is taken on the first day of the menstrual cycle with the second dose taken three days later.

#### Adverse Reactions

Acne, weight gain, hot flushes, headache, gastrointestinal disturbances

#### Precautions

1.本品非避孕藥，不可作為避孕用途。

2.建議固定每週相同兩天服藥。

3.避孕藥、抗癲癇藥結核病藥物(Rifampicin)，可能會干擾本品作用。

## 11.9. Antiandrogen Hormones

### Dutasteride

X<sup>1</sup> **Unknown<sup>1</sup>**

#### Dosage Forms

Avodart<sup>®</sup> 0.5mg/cap <KDUTAST>

#### Use

Benign prostatic hyperplasia

#### Dose

PO 0.5mg qd

#### Adverse Reactions

Pruritus, Disorder of breast, gynecomastia, impotence, angioedema

### Finasteride

X<sup>3</sup> **Unknown<sup>1</sup>**

#### Dosage Forms

Propecia<sup>®</sup> 1mg/tab <KFINAS1> 參閱 p.139

Finta<sup>®</sup> 5mg/tab <KFINAS2>

#### Use

Male pattern hair loss, benign prostatic hyperplasia

#### Dose

Androgenetic alopecia

PO 1mg qd

Benign prostatic hyperplasia

PO 5mg qd

#### Adverse Reactions

Decreased libido, ejaculation disorder, erectile dysfunction, breast enlargement, breast tenderness, rash

## **Contraindications**

懷孕或可能懷孕之婦女不可接觸已壓碎或破損之 finasteride 錠劑，可能會對男性胎兒造成危險。

## **11.10. Growth Hormone**

### **Somatropin**

**C** **Unknown<sup>1</sup>**

#### **Dosage Form**

Omnitrope® 5mg/1.5ml/cart. <CSOMAT1>

#### **Use**

Growth hormone deficiency, prader-willi syndrome, turner syndrome, chronic renal insufficiency, children or adolescents born small for gestational age

#### **Dose**

##### Growth hormone deficiency

**SC** 0.025-0.035mg/kg/day or 0.7-1mg/m<sup>2</sup>/day

Prader-willi syndrome, children/adolescents born small for gestational age

**SC** 0.035mg/kg/day or 1mg/m<sup>2</sup>/day

##### Turner syndrome, chronic renal insufficiency

**SC** 0.045-0.05mg/kg/day or 1.4mg/m<sup>2</sup>/day

#### **Adverse Reactions**

Peripheral edema, stiffness in the extremities, arthralgia, myalgia, paraesthesia

#### **Precautions**

- 1.須冷藏於 2-8°C，開始使用後儲存於 2-8°C 可存放 28 天。
- 2.因含 benzyl alcohol,故不可用於早產或新生兒用,可能引起 3 歲以內幼兒有毒性及過敏反應。
- 3.需自費。

## **11.11. Abortifacients**

### **Dinoprostone (PGE2)**

**C** **Unknown<sup>1</sup>**

#### **Dosage Form**

Prostarmon-E® 0.5mg/tab <KDINOPR>

Prostin® E<sub>2</sub> 3mg/vaginal tab <WDINOPR>參閱 p.146

#### **Use**

Induction of labor

#### **Dose**

Tablet

**PO** 0.5mg q1h × 6 doses; **max: 3mg/day**

Vaginal tab:

#### **Adverse Reactions**

Abdominal cramps, nausea, vomiting, diarrhea, transient fever, headache

#### **Precautions**

陰道錠劑須冷藏於 2-8°C 。

### Mifepristone (RU486)

**X<sup>4</sup>** **Unknown<sup>1</sup>**

#### Dosage Forms

Aprost<sup>®</sup> 200mg/tab <KMIFEPR>

#### Use

Termination of pregnancy through 49 days of pregnancy

#### Dose

**PO** 600mg one dose, followed by misoprostol 400mcg if needed

#### Adverse Reactions

Vaginal bleeding and uterine cramping, nausea, vomiting, diarrhea

### Misoprostol (PGE1)

**X<sup>4</sup>** **Unknown<sup>3</sup>**

#### Dosage Forms

Cytotec<sup>®</sup> 200mcg/tab <KMISOPR> 參閱 p.159

## 11.12. Uterotonics

### Ergometrine

**C<sup>3</sup>** **Unknown<sup>1</sup>**

#### Dosage Forms

Ergometrine<sup>®</sup> 0.2mg/tab <KERGONO>

#### Use

Postpartum hemorrhage caused by uterine atony

#### Dose

**PO** 0.2-0.4mg bid-qid

#### Adverse Reactions

Dizziness, headache, hypertension, nasal congestion, nausea, vomiting

### Methylergometrine

**C<sup>4</sup>** **Safe<sup>1</sup>**

#### Dosage Forms

Methergine<sup>®</sup> 0.2mg/ml/amp <CMETH03>

#### Use

Postpartum and postabortion hemorrhage

#### Dose

**IM/IV** 0.2mg, may be repeated after 2-4 hrs if needed

#### Adverse Reactions

Tinnitus, dizziness, hypertension, nausea, vomiting, sweating

#### Precautions

須冷藏於 2-8°C 。

### Oxytocin

**C<sup>4</sup>** **Unknown<sup>1</sup>**

#### Dosage Forms

Oxocin<sup>®</sup> 10IU/ml/amp <COXYTOC>

#### Use

Induces of labor, postpartum bleeding

### Dose

#### Induction of labor

**SC/IM** 3 IU every 20-30 min

**Slow IVF** 10 IU added to 1000ml of infusion fluid, infusion rate 15 drops/min

#### Postpartum bleeding

**IVF** 0.6-2 IU added to 3-5ml 0.9% NaCl

### Adverse Reactions

Exceptionally, water intoxication symptoms, icterus neonatorum, nausea, vomiting

### Precautions

Oxytocin 稀釋在 NS 或 D5W，其效力至少可以維持 24 小時以上，而其它稀釋液的 24 小時安定性則尚未確定。

### Contraindications

Oxytocin should not be given after delivery of the placenta.

## 11.13. Uterine Relaxants

### Ritodrine

**B<sup>5</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Anpo<sup>®</sup> 50mg/5ml/amp <CRITODR>

Anpo<sup>®</sup> 10mg/tab <KRITODR>

#### Use

Prevention of preterm labor

#### Dose

**IV** initial 0.05mg/min, increase by 0.05mg/min every 10-15 min, continue for 12-48 hrs after contractions have stopped; **max: 0.35mg/min**

**IM** initial 10mg, followed by 10-20mg q2-6h for 12-48 hrs

**PO** Start 30-60 min before stopping IV infusion, 10mg q2h for 24 hrs, then 10-20mg q4-6h (usual dose: 80-120mg/day); **max: 120mg/day**

### Adverse Reactions

Increase maternal heart rate, palpitation, tremor, nausea, arrhythmia

## 11.14. Hyperprolactinemias

### Cabergoline

**B<sup>1</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Dostinex<sup>®</sup> 0.5mg/tab <KCABERG>

#### Use

Hyperprolactinemia, puerperal lactation inhibition

#### Dose

##### Puerperal lactation inhibition

**PO** 1 mg as a single dose on the first day after delivery

##### Interrupt lactation

**PO** 0.25 mg bid for 2 days

### Hyperprolactinemia

**PO** 0.25-0.5 mg, once or twice weekly

### **Adverse Reactions**

Dizziness, fatigue, headache, constipation, nausea, somnolence, depression

## **11.15. Bisphosphonates**

### **Clodronate**

**C<sup>5</sup> Unknown<sup>3</sup>**

#### **Dosage Forms**

Bonefos<sup>®</sup> 400mg/cap <KCLODRO>

#### **Use**

Osteolysis of malignant origin and malignant hypercalcemia

#### **Dose**

**PO** 1600 mg daily in single or 2 divided doses, **max: 3.2g/day**.於飯前 1 小時或飯後 2 小時服用

#### **Adverse Reactions**

GI disturbances (nausea, dyspepsia, diarrhea), hypocalcemia, nephrotoxicity, leukemia

#### **Precautions**

避免與含二價離子藥品、高酪酸胺(tyramine)食物併用。

### **Fosamax plus<sup>®</sup>**

**C<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

1 tab: Alendronate 70mg+ Colecalciferol 5600IU <KALEND1>

#### **Use**

Osteoporosis prevention and treatment in postmenopausal women, osteoporosis treatment in men

#### **Dose**

**PO** 70mg qw

#### **Adverse Reactions**

Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, headache

#### **Precautions**

1.早晨起床後以一整杯的白開水伴服，且病人在服藥後至少維持上半身直立 30 分鐘，並一直到吃過當天第一份食物之後才可躺下。

2.無法站立或坐直至少 30 分鐘者不建議使用。

### **Ibandronate**

**C<sup>5</sup> Unknown<sup>3</sup>**

#### **Dosage Forms**

Bonviva<sup>®</sup> 3mg/3ml/syringe <CIBANDR>

#### **Use**

Osteoporosis treatment in postmenopausal women

#### **Dose**

**IVP** (5-30sec) 3mg every 3 months

#### **Adverse Reactions**

Arthralgia, back pain, hypertension, abdominal pain, influenza-like illness

## Precautions

1. 限靜脈注射(請務必小心，若注入動脈或靜脈旁側可能導致組織損害)
2. 健規：不得併用其他骨質疏鬆症治療藥物。

## Contraindications

Scr >2.3mg/dl 或 Clcr <30ml/min 禁用

**D<sup>1</sup> Unknown<sup>1</sup>**

## Zoledronic acid

### Dosage Forms

Zodonic<sup>®</sup> 4mg/vial <CZOLEDR>

Aclasta<sup>®</sup> 5mg/100ml/vial<CZOLED1>

### Use

Zodonic<sup>®</sup> : Hypercalcemia of malignancy(HCM), osteolytic metastases

Aclasta<sup>®</sup> : Paget's disease, Postmenopausal osteoporosis

### Dose

Zodonic<sup>®</sup> : **IV** (>15 min)

Hypercalcemia of malignancy

4 mg as single dose. Wait at least 7 days before considering retreatment.

Multiple myeloma or metastatic bone lesions from solid tumors

4 mg q3-4 wks

Aclasta<sup>®</sup> : **IV infusion** (>15min)

Paget's disease

5 mg single dose

Postmenopausal osteoporosis

5 mg every year

### Adverse Reactions

Dermatitis, nausea, fever, anemia, neutropenia

### Precautions

1. 欲調製Zodonic<sup>®</sup> 輸注溶液，以 100ml 的 0.9%NaCl 或 5% Dextrose 溶液稀釋。
2. Zodonic<sup>®</sup> 調配後應保存於 2-8°C 的冰箱內並於 24 小時內使用完畢。
3. Aclasta<sup>®</sup> 開封後於 2-8°C 可儲存 24 小時。

### Contraindications

1. 不可與含鈣離子或其他二價離子之溶液混合。

2. 腎功能不全: Ccr<35ml/min, 不建議使用。

## 11.16. Antidiabetic Agents

### 11.16.1. Insulins

類型/外觀	藥品名	商品名	規格	藥物動力學			儲存方式	
				Onset	Peak	Duration	未開封	開封後
<b>Rapid- Short acting</b>								
速效筆型 (澄清液)	Insulin Aspart	NovoRapid® flexpen	300IU/3ml/flexpen	10-20 min	1-3 hr	3-5 hr	2-8°C	室溫(30°C)，下 存放4個星期
短效 (澄清液)	RI (Regular insulin, neutral)	Actrapid® HM	1000IU/10ml/vial	30 min	1.5-2hr	7-8 hr	2-8°C	室溫(25°C)，下 存放6個星期
<b>Intermediate-Acting</b>								
中效 (懸浮液)	NPH (Isophaneinsulin suspension)	Insulatard® HM	1000IU/10ml/vial	1.5hr	2-18hr	24 hr	2-8°C	室溫(25°C)，下 存放6個星期
中-長效筆 (澄清液)	Insulin detemir	Levemir Flex Pen®	300IU/3ml/pen	3-4hr	6-8 hr	24 hr	2-8°C	室溫(25°C)，下 存放6個星期
<b>Long-Acting</b>								
長效 (澄清液)	Insulin glargine	Lantus Solo Star®	100 IU/ml, 3ml/pen	4-6 hr	none	24 hr	2-8°C	室溫(25°C)，下 存放4個星期
<b>Combinations</b>								
速-中效筆型 (懸浮液)	Insulin aspart 30% + Protamin insulin aspart 70%	NovoMix® 30 flexpen	300IU/3ml/flexpen	10-20 min	1-4 hr	24 hr	2-8°C	室溫(25°C)，下 存放4個星期
速-中效筆型 (懸浮液)	Insulin lispro 50% + Protamin insulin lispro 50%	HumalogMix® 50 kwikpen	300IU/3ml/ kwikpen	15-30 min	0.8-4.8hr	14-24 hr	2-8°C	室溫(30°C)，下 存放4個星期

**Insulin 每日給藥分配表**

	早餐前	午餐前	晚餐前	睡前	備註
方法1	NPH : RI(2/3)	—	NPH : RI(1/3)	—	方便常用，但早餐前血糖不易控制
方法2	NPH : RI(2/3)	—	RI (1/6)	NPH(1/6)	可控制早餐前血糖
方法3	RI(1/4)	RI(1/4)	RI(1/4)	NPH(1/4)	多次給藥，控制效果佳

## **Humalog Mix<sup>®</sup> 50(Rapid-intermediate acting) B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Humalog Mix<sup>®</sup> 50: Insulin lispro 50%+Protamin insulin lispro 50%, 300IU/3ml/ kwikpen <CINSUL19>

### **Use**

Type 1, type 2 DM

### **Dose**

SC

Dosage should be determined by the physician, according to the requirement of the patient

### **Adverse reactions**

Hypoglycemia, redness, swelling, itching, edema

### **Precautions**

1. 不可靜脈注射
2. 若引起低血糖可能影響到患者注意力的集中及反應，若駕駛或操作機械需小心。
3. 未開封時需儲存於 2-8°C 冷藏；開始使用後儲存於 30°C 下可保存 28 天。
4. 由 insulin lispro(快速作用)與 insulin lispro protamine(中速作用)組成混合懸液，約 30-70 分鐘可達最高血中濃度。

## **Insulin aspart (Rapid-acting)**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

NovoRapid<sup>®</sup> flexpen 300IU/3ml/flexpen <CINSUL9>

### **Use**

Type 1 or type 2 DM

### **Dose**

SC 0.5-1IU/kg/day divided doses

Regularly adjust dose according to blood glucose

### **Adverse reactions**

Hypoglycemia, local reactions (redness, swelling, itching), lipodystrophy, weight gain, allergic skin reaction, hypokalemia

### **Precautions**

1. 本品為無色澄清液，可與中或長效型胰島素併用。
2. 級藥時間：飯前 5-10 分鐘。
3. 需依腎功能調整劑量。

## **Insulin detemir (Intermediate-acting)**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Levemir<sup>®</sup> Flex Pen 300IU/3ml/pen <CINSUL16>

### **Use**

Type 1 or type 2 DM

### **Dose**

SC individualized dose administered once or twice daily at the same time

every day

### Adverse Reactions

Allergic skin reactions, hypoglycemia, injection site pain, lipodystrophy, rash

### Precautions

- 1.本品為多次劑量的拋棄式注射筆。
- 2.勿加到點滴注射液裡。

**C<sup>1</sup> Safe<sup>1</sup>**

## Insulin glargine (Long-acting)

### Dosage Forms

Lantus® Solo Star 300 IU/3ml/pen <CINSUL17>

### Use

Type 1, type 2 DM

### Dose

SC individualized dose administered once daily at the same time every day

### Adverse Reactions

Allergic skin reactions, hypoglycemia, injection site pain, lipodystrophy, rash

### Precautions

- 1.本品不可與其它胰島素混合或稀釋。
- 2.本品為無色透明溶液，使用前不需要振搖。
- 3.開啟後保存期限是 4 週，建議將首次使用之日期標示於注射筆標籤上。
- 4.使用期間勿儲存在高於 25°C 的環境，開封後的注射筆不要放入冰箱
- 5.本品為多次劑量的拋棄式注射筆。

## NovoMix® 30 flexpen(Rapid-intermediate acting)B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Insulin aspart 30%+Protamin insulin aspart 70%, 300IU/3ml/flexpen  
<CINSUL10>

### Use

Type 1, type 2 DM

### Dose

SC

#### Type 1 DM

0.5-1.2 IU/kg/day in divided dose

#### Type 2 DM

Adults: A total insulin dose: 5-10IU/day or 0.7-2.5IU/kg/day in divided dose

Regularly adjust dose according to blood glucose

Adjustment of the initial dose is based on fasting and postprandial BG conc.

### Adverse reactions

Hypoglycemia, local reactions (redness, swelling, itching), lipodystrophy weight gain, allergic skin reaction

### Precautions

- 1.白色混濁懸浮液，使用前應振搖成均勻的混濁或牛奶樣方可使用。
- 2.給藥時間：飯前 5-10 分鐘。

## NPH (Isophane insulin suspension) (Intermediate-acting)

**B<sup>4</sup>Safe<sup>1</sup>**

### Dosage Forms

Insulatard® HM, NPH 1000IU/10ml/vial <CINSUL14>

### Use

Type 1, type 2 DM

### Dose

Adults: SC 0.5-1.0IU/kg/day divided doses and before meal

Regularly adjust dose according to blood glucose

### Adverse Reactions

Hypoglycemia, local reactions (redness, swelling, itching), lipodystrophy, weight gain, allergic skin reaction

### Precautions

- 1.白色混濁懸浮液，使用前應振搖成均勻的混濁或牛奶樣方可使用。

- 2.可與短效型 (actrapid)胰島素併用。

- 3.給藥時間：飯前 30-60 分鐘。

- 4.開封後於室溫(25°C)下可使用達 6 個星期。

## Regular Insulin (Neutral) (Short-acting)

**B<sup>4</sup>Safe<sup>1</sup>**

### Dosage Forms

Actrapid® HM 1000IU/10ml/vial <CINSUL02>; 1 IU/dose <CINSUL13>

### Use

Type 1 or type 2 DM, gestational DM

### Dose

#### Type 1 DM

SC 0.5-1.0IU/kg/day divided doses

#### Type 2 DM

SC initial 0.5-1.0IU/kg/day divided doses, maintenance increased

5-10IU/wk until SMBG reach 120ml/dL

#### Obesity and insulin resistance

SC 80-100IU/day or more to achieve control level

#### Gestational diabetes mellitus

A combination of short and intermediate actino insulin is generally used

Initial SC 0.7IU/IBW (1<sup>st</sup> trimester); 0.8IU/IBW (2<sup>nd</sup> trimester); 0.9IU/IBW (3<sup>rd</sup> trimester)

Adjustment of the initial dose is based on fasting and postprandial BG conc.

### Adverse Reactions

Hypoglycemia, local reactions (redness, swelling, itching), lipodystrophy, weight gain, allergic skin reaction, hypokalemia

### Precautions

- 1.本品為無色澄清液，可與中效或長效型胰島素併用。

2. Type 1 及 type 2 DM 級藥時間：飯前 30 分鐘。
3. 需依腎功能調整劑量。

## 11.16.2. Sulfonylureas

**Amaryl M<sup>®</sup>**

**C<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

1 tab: Glimepiride 2mg +Metformin 500mg <KAMARYL>

### Use

Type 2 DM

### Dose

PO 1 tab once or twice per day before or with meals.

### Adverse Reactions

Hypoglycemia, dizziness, nausea, flatulence, lactic acidosis

### Precautions

1. 含碘顯影劑會增加 metformin 引起乳酸中毒的危險，應先暫停使用 metformin 48 小時。

2. ACEI 可能會暫時性的增加 insulin 的敏感度，併用降血糖藥會有低血糖的危險。

**Gliclazide**

**B<sup>5</sup> Unknown<sup>1</sup>**

### Dosage Forms

Gliclax<sup>®</sup> 30mg/SR tab <KGGLICL2>

### Use

Type 2 DM

### Dose

Initial PO 30mg qd AC, maintenance 30-120mg; **max: 120mg/day**

### Adverse Reactions

Hypoglycemia, dizziness, nausea, vomiting, abdominal pain, weight gain

**Glimepiride**

**C<sup>5</sup> Unknown<sup>1</sup>**

### Dosage Forms

Amaryl<sup>®</sup> 2mg/tab <KGGLIMEP>

### Use

Type 2 DM

### Dose

Initial PO 1-2mg qd AC, maintenance 1-4mg qd AC; **max: 8mg/day**

### Adverse Reactions

Hypoglycemia, dizziness, nausea, vomiting, abdominal pain, weight gain

**Glipizide**

**C Unknown<sup>1</sup>**

### Dosage Forms

Glidiab<sup>®</sup> 5mg/tab <KGGLIPIZ>

### Use

Type 2 DM

### Dose

Adults: initial **PO** 5mg qd AC, increase by 2.5-5mg/day; **max: 40mg/day**

Elderly or hepatic impairment patient: initial **PO** 2.5mg qd AC

#### **Adverse Reactions**

Hypoglycemia, dizziness, nausea, vomiting, abdominal pain, weight gain

### **11.16.3. Meglitinides**

#### **Repaglinide**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Repaglinide<sup>®</sup> 1mg/tab <KREPAGL>

#### **Use**

Type 2 DM

#### **Dose**

Initial **PO** 0.5 mg taken 1-30 min before meals. The starting dose of patients transferred from another oral hypoglycemic agent is 1 mg. Dosage adjustments should be made at intervals of at least 1 wk or more; **max: 16 mg/day.**

#### **Adverse Reactions**

Hypoglycemia, nausea, diarrhea, constipation, vomiting, dyspepsia

#### **Precaution**

1.需依腎功能調整劑量。

2.本品須於用餐前服用，未進食則不需服藥，避免低血糖。

### **11.16.4. Alpha-Glucosidase Inhibitors**

#### **Acarbose**

**B<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Glucobay<sup>®</sup> 100mg/tab <KACARB1>

#### **Use**

Type 2 DM

#### **Dose**

Initial **PO** 50mg tid with meal, **max: 200mg tid with meal**

#### **Adverse Reactions**

Abdominal pain, diarrhea, flatulence, elevated liver enzymes

#### **Precautions**

治療初期應監測肝功能。

#### **Contraindications**

CrCl <25ml/min, age <18 yrs, colon ulcerations, cirrhosis, diabetic ketoacidosis, bowel obstruction

### **11.16.5. Biguanides**

#### **Actosmet<sup>®</sup>**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

1 tab: Pioglitazone 15mg+ Metformin 850mg/tab <KACTOSM> 參閱 P.220

#### **GalvusMet<sup>®</sup>**

**Unsafe<sup>3</sup>**

## Dosage Forms

1tab: Metformine 500mg+ vildagliptine 50mg/tab <KGALVU1> 參閱 p.221

## Metformin

**B<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Loditon<sup>®</sup> 500mg/tab <KMETFOR>

### Use

Type 2 DM, polycystic ovary syndrome (unlabeled use)

### Dose

#### Type 2 DM

Adults: initial **PO** 500mg qd-bid, maintenance 500-2500mg/day in divided dose; **max: 2500mg/day**

#### Polycystic ovary syndrome (PCOS)

**PO** 500mg tid

### Adverse Reactions

Diarrhea, nausea, vomiting, flatulence, anorexia, lactic acidosis

### Precautions

進行放射線性檢查須注射顯影劑者應先停藥 48 小時。

### Contraindications

腎不全患者, CHF, acute and chronic metabolic acidosis, including diabetic ketoacidosis and conditions

## 11.16.6. Thiazolidinediones

## Actosmet<sup>®</sup>

**C<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

1 tab: Pioglitazone 15mg+ Metformin 850mg/tab <KACTOSM>

### Use

Type 2 DM

### Dose

**PO** 1table qd-bid; **max: 3 table/day**

### Adverse Reactions

Upper respiratory infection, diarrhea, edema, headache

### Precaution

進行放射線性檢查須注射顯影劑者應先停藥 48 小時。

### Contraindications

腎不全患者、正罹患肝臟疾病或 ALT 濃度超過正常上限 2.5 倍

## Pioglitazone

**C<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Glitos<sup>®</sup> 30mg/tab <KPIOGLI>

### Use

Type 2 DM

### Dose

Initial **PO** 15-30mg qd; **max: 45mg/day**

### Adverse Reactions

Anemia, edema, myalgia, upper respiratory tract infection, weight gain

### Precaution

Active liver disease (transaminases >2.5 times), CHF (class I-II), edema, rapid weight gain, dyspnea, diabetic ketoacidosis

### Contraindications

NYHA class III or IV CHF

## 11.16.7. Antihypoglycemics

### Glucagon

**B<sup>1</sup>** Unknown<sup>1</sup>

### Dosage Forms

Glucagen<sup>®</sup> 1mg/vial <CGLUCAG>

### Use

Hypoglycemia, GI radiography

### Dose

Hypoglycemia

**IM/IV/SC**

Children: weight <20kg: 0.5mg/dose, weight ≥20kg: 1mg; **max: 1mg/dose**

Adults: 1mg, may repeat in 20 min if necessary

Radiologic examinations

Adults: 0.2-2mg **IV** 1 min before procedure or 1-2mg **IM** 5-15 min before procedure

### Adverse Reactions

Nausea, rash, vomiting

## 11.16.8. Dipeptidyl Peptidase 4 Inhibitors

### GalvusMet<sup>®</sup>

**Unsafe<sup>3</sup>**

### Dosage Forms

1tab: Metformine 500mg+ vildagliptine 50mg/tab < KGALVU1>

### Use

Type 2 DM

### Dose

**PO** 1 tab bid; **max: 2tab/day**

### Adverse Reactions

Hypoglycemia, tremor, headache, dizziness, nausea

### Precautions

1. 使用含碘顯影劑：含 metformin 成分，應在檢測前停用，且在完成後 48 小時內不可重新使用。

2. 手術：含 metformin 成分，如需以全身麻醉進行非急需性手術，應在 48 小時前停止治療，且通常不可在手術完成後 48 小時內恢復使用

### Contraindications

糖尿病酮酸血症、糖尿病性昏迷、肝腎功能不全、可能影響腎功能之急性病症(心衰竭、呼吸衰竭、近期心肌梗塞、休克、經血管注射含碘顯影劑)、急性酒精中毒、酗酒

## **Linagliptin**

**B<sup>5</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Trajenta® 5mg/FC. Tab < KLINAGL >

### **Use**

Type 2 DM

### **Dose**

**PO** 5mg qd

### **Adverse Reactions**

Hypoglycemia, nasopharyngitis, cough

### **Precautions**

可能引起低血糖需小心

### **Contraindications**

不可用於治療第一型糖尿病及糖尿病酮酸中毒

## **Sitagliptin**

**B<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Januvia® 100mg/tab <KSITAGL>

### **Use**

Type 2 DM

### **Dose**

**PO** 100mg qd

### **Adverse Reactions**

Hypoglycemia, headache, nasopharyngitis, upper respiratory infection

### **Precautions**

需依腎功能調整劑量，Clcr<50ml/min: 0.5tab qd, Clcr<30ml/min: 0.25tab qd

## **Saxagliptin**

**B<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Onglyza® 5mg/FC. tab <KSAXAGL>

### **Use**

Type 2 DM

### **Dose**

**PO** 2.5-5mg qd

### **Adverse Reactions**

Peripheral edema, hypoglycemia, headache, nasopharyngitis

### **Precautions**

需依腎功能調整劑量，Clcr<50ml/min: 0.5# qd

## **Vildagliptin**

**C<sup>5</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Galvus® 50mg/F.C tab <KVILDAG>

### **Use**

Type 2 DM

### **Dose**

**PO** 50mg qd-bid; **max:100mg/day**

## **Adverse Reactions**

Tremor, headache, dizziness, asthenia, weight increase, hypoglycemia

## **Precaution**

- 1.與 sulfonylurea 併用時僅能 1tab qd
- 2.需依腎功能調整劑量，Clcr<50ml/min: 1tab qd

## **Contraindications**

中重度腎功能不全或接受血液透析之患者、ALT 或 AST 大於正常值 2.5 倍以上之患者。

## **11.16.9. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist**

### **Exenatide**

**C<sup>s</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Byetta<sup>®</sup> 10mcg/dose, 2.4ml/prefilled pen <CEXENA2>

#### **Use**

Type 2 diabetes mellitus

#### **Dose**

Initial SC 5mcg bidAC (within 60min before the meal) for 1 month, may increase to 10mcg bidAC

## **Adverse Reactions**

Nausea, vomiting, diarrhea, dizziness, headache

## **Precautions**

- 1.兩次注射時間需間隔 6 小時以上
- 2.本品為澄清無色液體，如有顆粒或混濁請勿使用
- 3.未開封時需儲存於 2-8°C，開封後於 25°C 下可存放 30 天
- 4.病患已進食者勿補打
- 5.健規:不得與 insulin、DPP-4 抑制劑(如 sitagliptin 成分)等藥物併用。

## **Contraindications**

末期腎疾病或嚴重腎功能不足之患者(Clcr<30ml/min)

### **Liraglutide**

**C<sup>s</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Victoza<sup>®</sup> 18mg/3ml/pen <CLIRAGL>

#### **Use**

Type 2 diabetes mellitus

#### **Dose**

Initial SC 0.6mg once daily for 1 week, maintenance 1.2mg/day; **max: 1.8mg/day**

## **Adverse Reactions**

Nausea, vomiting, diarrhea, constipation, upper respiratory infection

## **Precautions**

- 1.不可用於第一型糖尿病或糖尿病酮酸血症
- 2.未開封時需儲存於 2-8°C 冷藏；開始使用後需儲存於 30°C 下或冷藏 2-8 °C 下可保存 30 天
- 3.健規:不得與 insulin、DPP-4 抑制劑(如 sitagliptin 成分)等藥物併用

### **Contraindications**

甲狀腺髓樣癌、第 2 型多發性內分泌腫瘤綜合症

## **11.16.10. Sodium-Glucose Cotransporter 2(SGLT2) inhibitor**

### **Dapagliflozin**

**C<sup>5</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Forxiga® 10mg/tab <KDAPAGL>

#### **Use**

Type 2 diabetes mellitus

#### **Dose**

**PO** initial 5mg once daily in the morning, the dose can be increased to 10mg once daily

#### **Adverse Reactions**

Genital mycotic infection, nasopharyngitis, urinary tract infection, back pain, increased urination

#### **Contraindications**

嚴重腎功能不全、末期腎病、透析患者

### **Empagliflozin**

**C<sup>5</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Jardiance® 10mg/tab <KEMPAG1>

Jardiance® 25mg/tab <KEMPAG2>

#### **Use**

Type 2 diabetes mellitus

#### **Dose**

**PO** 10mg once daily in the morning, the dose may be increased to 25mg/day

#### **Adverse Reactions**

Genital mycotic infection, urinary tract infection, hypotension, impairment in renal function, hypoglycemia, increase LDL

#### **Contraindications**

嚴重腎功能不全、末期腎病、透析患者

## **11.17. Adrenocortical Steroids**

### **Cortisone**

**D<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Cortisone® 25mg/tab <KCORTIS>

#### **Use**

Management of adrenocortical insufficiency

#### **Dose**

**PO** 25mg tid-qid

#### **Adverse Reactions**

GI distress, growth depression, hypertension, increased skin of infection  
Cushing's syndrome

## **Contraindications**

Systemic fungal infections, cirrhosis, hypothyroidism, peptic ulcer

## **Dexamethasone**

**C Unknown<sup>1</sup>**

### **Dosage Forms**

Dexamethasone® 5mg/ml/amp <CDEXAME>

Decone® 0.5mg/tab <KDEXA01>

Dorison® 4mg/tab <KDEXA02>

Zine® orabase 0.1%, 5g/tube <WDEXA02> 參閱p.328

### **Use**

Systemically and locally for chronic inflammation, allergy, autoimmune diseases, cerebral edema, septic shock, antiemetic

### **Dose**

#### Cerebral edema

Injection:

initial 10mg **IV** followed by 4mg q6h **IM** until symptoms subside

Tablet

**PO** 2mg bid-tid

#### Allergic disorder (acute)

First day: 4-8mg **IM**; second and third days: 1.5mg bid **PO** each day;

fourth day: 0.75mg bid **PO**; fifth and sixth days 0.75mg/day **PO**

#### Shock

**IV** 2-6mg/kg repeated in 2-6 hrs if shock persist

#### Antiemetic

Children: **IV** 10mg/m<sup>2</sup> before chemotherapy, then 5mg/m<sup>2</sup> q6h as needed;

**max: 20mg**

Adults: **IV** 20mg before chemotherapy, then 8mg (IV/PO) bid for 3 days after chemotherapy

#### Inflammatory conditions

Children: **PO/IM/IV**, 0.08-0.3mg/kg/day or 2.5-10mg/m<sup>2</sup>/day q6-12h

Adults: **PO** 0.75-9mg/day or **IM/IV** initial 0.5-9mg/day

Oral paste : Apply to the affected area once to several times daily

### **Adverse Reactions**

GI distress, growth depression, hypertension, increased skin of infection

Cushing's syndrome

### **Precautions**

Cirrhosis, hypothyroidism, peptic ulcer

### **Contraindications**

Systemic fungal infections

## **Fludrocortisone**

**C Unknown<sup>1</sup>**

### **Dosage Forms**

Florinef® 0.1mg/tab <KFLUDRO>

### **Use**

Chronic adrenocortical insufficiency in Addison's disease, salt-losing adrenogenital syndrome

### **Dose**

### Minerocorticoid insufficiency

Children: **PO** 0.05-0.1mg/day

Adults: **PO** 0.1 mg, 3 times/wk to 0.2 mg/day

### Adrenogenital syndrome

Adults: **PO** 0.1-0.2mg/day

### **Adverse Reactions**

Edema, muscle weakness, peptic ulcer, impair wound healing, convulsions

### **Precautions**

Cirrhosis, hypothyroidism, peptic ulcer, diabetes mellitus, electrolyte abnormalities, renal insufficiency.

### **Contraindications**

Systemic fungal infections

**C<sup>5</sup> Unknown<sup>1</sup>**

## **Hydrocortisone**

### **Dosage Forms**

Solu-Tisone<sup>®</sup> 100mg/vial <CHYDROC>

Cortema<sup>®</sup> enema 99.6mg/60ml/bot <WHYDR01> 參閱 p.168

Cort. S<sup>®</sup> oint 1%, 50g/bot <WHYDR02> 參閱 p.143

### **Use**

Adrenocortical insufficiency, inflammation of dermatoses, ulcerative colitis

### **Dose**

### **IV/IVD/IM**

Children: >25mg/day; **max: 15mg/kg**

Adults: 100-500mg q6h

### **Adverse Reactions**

GI distress, musculoskeletal weakness, negative protein balance due to protein catabolism, headache, osteoporosis

### **Precautions**

1.Cirrhosis, hypothyroidism, peptic ulcer, measles, chickenpox and other infections, myasthenia gravis

2.以 2ml 注射用水溶解，以 50-1000ml D5W, NS 溶液稀釋，配置後溶液可存放 4 小時。

### **Contraindications**

Systemic fungal infections, live or live attenuated vaccines  
(immunosuppressive doses)

**C<sup>1</sup> Unknown<sup>1</sup>**

## **Methylprednisolone**

### **Dosage Forms**

Methylprednisolone<sup>®</sup> 40mg/vial <CMETH04>

Solu-Medrol<sup>®</sup> 500mg/vial <CMETH05>

### **Use**

Adrenocortical insufficiency, immunosuppression and inflammatory conditions, multiple sclerosis (MS), nephrotic syndrome, acute spinal cord injury

### **Dose**

### Asthma

**IV** 40-80mg/day in 1-2 divided until severe symptoms have been controlled

### Systemic lupus erythematosus

Pulse doses: 1 g **IV** daily for 3 days

### Multiple sclerosis(MS)

160 mg/day **IV** for 1 wk followed by 64 mg qod for 1 month

### Acute spinal cord injury (Solu-Medrol®)

Administered within 8 hours of the incident 30mg/kg **IV** over 10-20 min, then 5.4mg/kg/h for 23 hrs

### **Adverse Reactions**

Euphoria/depression, GI distress, peptic ulcer, elevations in liver function tests, growth depression, hypertension, sodium and fluid retention

### **Precautions**

1.Cirrhosis, hypothyroidism, peptic ulcer, measles, chickenpox and other infections, myasthenia gravis

2. Methylprednisolone® 乾粉以 2ml 注射用水溶解。

### **Contraindications**

Systemic fungal infections, live or live attenuated vaccines (immunosuppressive doses)

**C<sup>4</sup> Safe<sup>1</sup>**

### **Prednisolone**

#### **Dosage Forms**

Donison® 5mg/tab <KPREDNI>

Pred Forte® oph 1%, 5ml/bot <WPREDN1> p.273

Kidsolone® oral solution 60mg/60ml/bot, 1ml:Prednisolone 1.344mg <KPREDN1>

#### **Use**

Asthma (uncontrolled), endocrine disorders, hematologic disorders, multiple sclerosis exacerbations, allergic and nonrheumatic inflammatory disorders

#### **Dose**

##### **PO**

##### Asthma

7.5-60mg/day tid-qid (Long-Term Therapy)

##### Endocrine disorders, hematologic disorders, multiple sclerosis

##### exacerbations, allergic and nonrheumatic inflammatory disorders

5-60mg/day tid-qid

### **Adverse Reactions**

Euphoria, depression, GI distress, peptic ulcer, growth depression, skin atrophy

### **Precautions**

Cirrhosis, hypothyroidism, peptic ulcer, measles, chickenpox and other infections, myasthenia gravis

### **Contraindications**

Systemic fungal infections, live or live attenuated vaccines (immunosuppressive doses)

## Triamcinolone

C Unknown

### Dosage Forms

Shincort® 40mg/ml/amp <CTRIAM2>

Nincort® oral paste 0.1% 6g/tube <WTRIAM3> 參閱 p.329

Nasacort® nasal spray 55mcg/puff, 120puffs/bottle <WTRIAM4> 參閱 p.316

### Use

Arthritic disorders and dermatologic lesions

### Dose

#### Intra-articular (IA)

Up to 10 mg for smaller area and up to 40 mg for larger areas.

Single injections into several joint for multiple locus involvement, up to a total of 80 mg.

#### IM

Children 6-12yrs: initial 40mg, adjustment

Adults: initial 60mg, usual dose 40-80mg

Topical: apply to the affected area qd-tid

### Adverse Reactions

Euphoria, depression, GI distress, peptic ulcer, growth depression, skin atrophy, rhinitis, headache, pharyngitis, epistaxis, nasal irritation

### Precautions

Local viral, fungal or bacterial infections, cirrhosis, hypothyroidism, peptic ulcer, measles, chickenpox and other infections, myasthenia gravis, ulcerative colitis, renal insufficiency

### Contraindications

禁用 静脈注射。

## 11.18. Gout Related Agents

## Allopurinol

C Unknown

### Dosage Forms

Allopurinol® 100mg/tab <KALLOPU>

### Use

Prevention of gout arthritis, antineoplastic-induced hyperuricemia and urate stone

### Dose

#### Gout

Adults: PO 100-300mg/day qd-tid; max: 800mg/day

#### Antineoplastic-induced hyperuricemia

Children 6-10 yrs: PO 100mg tid or 300mg qd

Adults: PO 600-800mg/day, 12 hrs to 3 days prior to initiation of chemotherapy

#### Urate stone(抗尿酸結石)

PO 100-200mg qd

### Adverse Reactions

Rash, pruritus, renal failure, renal insufficiency, Stevens-Johnson

syndrome, nausea, vomiting

### Precautions

1. Allopurinol should be discontinued at the first appearance of a rash or other sign of hypersensitivity
2. Do not use to treat asymptomatic hyperuricemia
3. 需依腎功能調整劑量

## Benzbromarone

C<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

Beenrone<sup>®</sup> 50mg/tab <KBENZBR>

### Use

Hyperuricemia and gout

### Dose

Adults: PO 50-150mg/day

### Adverse Reactions

Diarrhea, nausea, urticaria, allergic conjunctivitis

### Precautions

Hepatic disease (開始服用後需定期監測肝功能)

### Contraindications

Acute gout attack, severe renal disease(GFR<20ml/min), nephrolithiasis

## Colchicine

D<sup>4</sup> Unknown<sup>3</sup>

### Dosage Forms

Colchicine<sup>®</sup> 0.5mg/tab <KCOLCHI>

### Use

Treatment and prevention of acute gouty arthritis attacks

### Dose

#### Gouty arthritis(acute attacks)

Adults: PO initial 0.5-1mg, then 0.5mg q1-2h or 1mg q2h until relief or GI side effects occur; max: 8mg/day (increase dose <1.8mg/hr)

#### Gout (prophylaxis)

Less than 1 acute attack/yr, PO 0.5-0.6mg/day 3-4 times/wk; more than 1 acute attack/yr, 0.5-1.5mg/day

### Adverse Reactions

Nausea, vomiting, diarrhea, abdominal pain

### Precautions

需依腎功能調整劑量。

### Contraindications

Blood dyscrasias (granulocytopenia, thrombocytopenia), hepatic failure, severe (cardiac, gastrointestinal renal) disease

## Febuxostat

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Feburic<sup>®</sup> 80mg/tab <KFEBUXO>

### Use

Chronic management of hyperuricemia in patients with gout

**Dose**

PO initial 40mg qd, increased to 80mg qd if sUA  $\geq$  6mg/dl after 2 weeks

**Adverse Reactions**

Liver enzymes abnormal, rash, nausea, arthralgia, gout attack(during initial treatment)

**Precautions**

開始使用後，由於血清尿酸濃度改變導致尿酸鹽從組織沉積移轉，痛風可能會發作，故建議併用 NSAIDs 或 Colchicine 以預防痛風發作，預防性治療效益達 6 個月；治療過程若痛風發作無需停用 Feburic

**Contraindications**

正在使用 Azathioprine 或 Mercaptopurine 的患者、無症狀高尿酸血症禁用

## 11.19. Thyroid Agents

### 11.19.1. Thyroid Hormones

**Levothyroxine**

A <sup>1</sup>	Unknown <sup>1</sup>
----------------	----------------------

**Dosage Forms**

Eltroxin® 50mcg/tab <KTHYRO1>

**Use**

Supplemental therapy in hypothyroidism

**Dose**

Adults: initial **PO** 50-100mcg/day, maintenance 100-200mcg/day

**Adverse Reactions**

Anginal pain, cardiac arrhythmia, palpitation, tachycardia, diarrhea,

**Precautions**

1. Cardiovascular disease, diabetes mellitus, pituitary myoedema, adrenocortical deficiency

2. 需飯前服用。

### 11.19.2. Antithyroid Drugs

**Methimazole**

D <sup>1</sup>	Unsafe <sup>1</sup>
----------------	---------------------

**Dosage Forms**

Lica® 5mg/tab <KMETHIM>

**Use**

Management of hyperthyroidism

**Dose**

Children: initial **PO** 0.4mg/kg/day tid, maintenance 0.2mg/kg/day tid

Adults: initial **PO** 15mg/day, maintenance 5-15mg/day; **max: 60mg/day**

**Adverse Reactions**

Rash, leukopenia, agranulocytosis, drowsiness, nephrotic syndrome

**Precautions**

Bleeding disorders or easy bruising, liver disease, signs of infection,

surgery

## Propylthiouracil

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Procil® 50mg/tab <KPROPYL>

### Use

Management of hyperthyroidism

### Dose

Children 6-10 yrs: PO 50mg/day q8h, upward titration should occur carefully based on the patient's clinical response as well as their TSH and free T4 levels.

Adults: PO initial 300-400mg/day q8h, maintenance 100-150mg/day q8-12h, server 600-900mg/day.

### Adverse Reactions

Drug fever, skin rash, leukopenia, dizziness, nausea, vomiting

### Precautions

1. Hepatic function impairment (開始使用後六個月內需監測肝功能)

2. 腎功能不良者須調整劑量。

### Contraindications

Not established in children  $\leq 6$  yrs

## 11.19.3. Iodine Products

### Lugol's solution

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

複方碘稀釋溶液 60ml/bot (1ml: Iodine 5mg+Potassium Iodine 10mg)

<KLUGOL>

### Use

Disinfection, suppress hyperthyroidism, thyrotoxicosis, thyroid disorder due to iodine deficiency, induce thyroid involution before thyroidectomy

### Dose

Before subtotal thyroidectomy, thyrotoxicosis

PO 1-3ml tid

### Adverse Reactions

Skin rash, fever, salivary gland swelling or tenderness, diarrhea, nausea

## 11.20. Posterior Pituitary Hormones

### Desmopressin (DDAVP)

B<sup>4</sup> Safe<sup>1</sup>

### Dosage Forms

Minirin® 4mcg/ml/amp <CDESM01>

Minirin® 0.1mg/tab <KDESM01>

Minirin® nasal spray 250mcg/25puffs/2.5ml/bot <WDESM0>

### Use

Treatment of diabetes insipidus and controlling bleeding in mild

hemophilia, Von Willebrand disease (VWD), thrombocytopenia (eg, uremia), primary nocturnal enuresis

### Dose

Central diabetes insipidus

**Intranasal**

Children > 12 yrs: 5-10mcg/day qd-bid

Children  $\geq$  12 yrs and adults: 10-20mcg/day qd-bid

**IV/SC**

Children  $\geq$  12 yrs and adults: 2-4mcg/day bid

**PO**

Children  $\geq$  4 yrs and adults: 0.1-1.2mg/day bid-tid

Primary nocturnal enuresis (PNE)

**PO** 0.2-0.6mg hs

Therapeutic control of bleeding , bleeding prophylaxis in Haemophilia A, type 1 VWD

**IV** 0.3mcg/kg (dilute in 0.9% NaCl 50-100 ml) over 15-30 mins, may be repeated 1-2 times intervals of 6-12 hrs

### Adverse Reactions

Flushing, headache, nausea, hyper- or hypotension, palpitations,

### Precautions

1. Hypertension, coronary artery insufficiency, patients predisposed to thrombus formation

2. 鈎劑及鼻噴劑需冷藏。

### Contraindications

Type IIB or platelet-type Von Willebrand disease, desmopressin injection in children under 3 months of age with hemophilia A, type 1 VWD

## Vasopressin

**C<sup>1</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Pitressin® 20IU/1ml/amp <CVASOPR>

### Use

Diabetes insipidus, prevention and treatment of postoperative abdominal distention, esophageal varices bleeding (EV bleeding)

### Dose

Diabetes insipidus

Children: **IM/SC** 2.5-10IU 2-4 times/day

Adults: **IM/SC** 5-10IU 2-3 times/day

Abdominal distension, prophylaxis-postoperative complication

**IM** 5IU postoperatively, increase to 10IU at subsequent injections repeated at 3-4 hrs intervals if necessary

GI bleeding (EV bleeding)

Dilute in 100-200 ml D5W, initial **IVF** 0.1-0.2IU/min, then titrate dose as needed, may repeat 1-2 hours.

### Adverse Reactions

Arrhythmias, myocardial infarction, fever, vertigo, urticaria, bronchial constriction, hyponatremia

## 11.21. Calcitonin-Salmon

### Calcitonin

C Unknown<sup>1</sup>

#### Dosage Forms

Miacalcic® 100IU/ml/amp <CCALC01>

#### Use

Treatment of Paget's disease of bone (osteitis deformans), adjunctive therapy for hypercalcemia, postmenopausal osteoporosis and osteogenesis imperfecta

#### Dose

##### Paget's disease

Adults: **IM/SC** 100IU/day to start, 50IU/day or 50-100IU every 1-3 days as maintenance dose

##### Hypercalcemia

Adults: **IM/SC** initial 4IU/kg q12h, **max: 8IU/kg q6-12h**

##### Osteogenesis imperfecta

Adults: **IM/SC** 2IU/kg 3 times/wk

##### Postmenopausal osteoporosis

**IM/SC** 100IU/day

#### Adverse Reactions

Facial flushing, nausea, diarrhea, anorexia, edema at injection site, polyuria, back or joint pain, nasal bleeding/crusting, dyspnea

#### Precautions

Administration of calcitonin possibly could lead to hypocalcemic tetany, in relapse of Paget's disease, a dosage increase beyond 100IU/day does not improve response

## 11.22. Parathyroid Hormone Analogues

### Teriparatide

C Unknown<sup>1</sup>

#### Dosage Forms

Forteo® 750mcg/3ml/syringe <CTERIPA>

#### Use

Postmenopausal osteoporosis, primary or hypogonadal steoporosis

#### Dose

**SC** 20 mcg qd

#### Adverse Reactions

Arthralgia, leg cramp, dizziness, orthostatic hypotension

#### Precautions

1.本品須冷藏，每 syringe 開封後使用期限不得超過 28 天。

2.健規：本品不得併用 biphosphonates、calcitonin、raloxifene 及活性

Vit D3 等藥品。

## 11.23. Endocrine and Metabolic Miscellaneous

## **Strontium**

**[Unsafe<sup>3</sup>]**

### **Dosage Forms**

Protos<sup>®</sup> granule 2g/sachet <KSTRONT>

### **Use**

Osteoporosis

### **Dose**

PO 1pk QDAC or HS

### **Adverse Reactions**

Nausea, diarrhea, headache, dermatitis

### **Precautions**

1. 加一杯水泡製成懸浮液服用，泡製後室溫可存放 24 小時。
2. 每日需同時補充鈣(1500mg)及維生素 D(400IU~800IU)
3. 鈣片、制酸劑、牛奶、食物會影響本品吸收，建議至少間隔 2 小時
4. 易與 tetracycline 及 quinolone 類抗生素螯合，因此使用抗生素期間應暫停使用本品
5. 需依腎功能調整劑量。

### **Contraindications**

現有或曾有靜脈血栓栓塞(VTE)病史之病人，及暫時或永久無法行動者。

## **Denosumab**

**C<sup>5</sup> [Unknown<sup>3</sup>]**

### **Dosage Forms**

Prolia<sup>®</sup> 60mg/ml/syringe <CDENOSU>

Xgeva<sup>®</sup> 120mg/1.7ml/vial <CDENOS1>

### **Use**

Prolia<sup>®</sup>: Postmenopausal osteoporosis

Xgeva<sup>®</sup>: Prevention of skeletal-related events in bone metastases from solid tumors

### **Dose**

Prolia<sup>®</sup>: SC 60mg once every 6 months

Xgeva<sup>®</sup>: SC 120mg once every 4 weeks

### **Adverse Reactions**

Prolia<sup>®</sup>: Back pain, limb pain, musculoskeletal pain, hypercholesterolemia, cystitis

Xgeva<sup>®</sup>: Fatigue, asthenia, hypophosphatemia, nausea, hypocalcemia, osteonecrosis

### **Precautions**

1. 每日需補充 1000mg 鈣質及 400IU 維生素 D。

2. 需儲存於 2-8°C，自冰箱取出後不可超過 25°C，並於 14 天內使用完畢。

3. Xgeva 需使用 27 號針頭抽取及注射，每四週一次於上臂、大腿或腹部皮下注射

# 12. NEUROLOGYS

## 12.1 Anticonvulsants

### Carbamazepine

D<sup>1</sup> Safe<sup>1</sup>

#### Dosage Forms

Tegretol<sup>®</sup> 200mg/CR.tab <KCARB02>

#### Use

Epilepsy, trigeminal neuralgia, bipolar disorder, glossopharyngeal neuralgia

#### Dose

##### Epilepsy

Children ≤4yrs: initial **PO** 20-60mg/day, increased by 20-60mg/day; >4yrs: initial **PO** 100mg/day, increased by 100mg/day

Children 0-1yrs: maintenance **PO** 100-200 mg/day; 1-5 yrs **PO** 200-400 mg/day; 6-10 yrs **PO** 400-600 mg/day; 11-15 yrs **PO** 600-1000 mg/day

Adults: initial **PO** 100-200 mg/day qd-bid, increased by 200 mg/day at weekly intervals, up to 1600-2000 mg/day.

##### Trigeminal neuralgia

Adults: **PO** initial 200-400 mg/day, maintenance 100 mg tid-qid.

##### Bipolar disorder

**PO** 400-1600 mg/day divided in 2-3 doses.

##### Glossopharyngeal neuralgia

Initial **PO** 100 mg q12h, increase by 200 mg/day (divided into 2 doses) as needed for pain control (max dose 1200 mg/day)

#### Adverse Reactions

Leucopenia, dizziness, nausea, vomiting, stevens-johnson syndrome

#### Precautions

1.服藥後發生皮膚，口腔黏膜處發紅，起疹或水泡建議立刻就醫。

2.不建議磨粉。

#### Contraindications

Tricyclic antidepressant or MAO inhibitor use, bone marrow depression, AV block

### Clonazepam

D<sup>1</sup> Unsafe<sup>1</sup>

#### Dosage Forms

Clonopam<sup>®</sup> 0.5mg/tab <KCCLON01>

Clonopam<sup>®</sup> 2mg/tab <KCCLON02>

#### Use

Seizure

#### Dose

Children <10 yrs or 30kg: initial **PO** 0.01-0.03mg/kg/day, maintenance 0.05-0.1mg/kg/day tid

Children >10 yrs or 30kg: initial **PO** 1-2mg /day, maintenance 1.5-3mg/day

Adults: initial **PO** 0.5mg tid, maintenance 2-4mg/day, **max: 20mg/day**

#### Adverse Reactions

Problem behavior, somnolence, ataxia, dizziness, fatigue

### Precautions

1. 突然停藥可能會導致重積性癲癇(status epilepticus)
2. 應定期做血液學檢查及肝功能檢查。

### Contraindications

Severe liver disease, narrow-angle glaucoma

## Diazepam

**D<sup>1</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Dianlin® 10mg/2ml/amp <CDIAZ01>

### Use

Anxiety, alcohol withdrawal symptoms, skeletal muscle spasm, status epilepticus

### Dose

#### Anxiety

Adults: **IM/IV** 2 to 10 mg every 3 to 4 hr if needed depending on symptom severity; **IM** 10 mg before surgery

#### Alcohol withdrawal symptoms

Adults: **IV/IM** 10 mg , may give 5 to 10 mg in 3 to 4 hr if necessary

#### Skeletal muscle relaxation or anxiety

Children < 5 yrs: **slow IV/IM** 5-10mg q3-4h

Adults: **IM/IV** 2-10mg, may repeat in 3-4 hrs if needed

#### Status epilepticus

Children 30 days-5 yrs: **slow IV/IM** 0.2-0.5mg/dose q2-5min, repeat every 2 to 4 hr as necessary, **max:5mg/dose**

Children > 5 yrs: **slow IV/IM** 1mg q2-5min, repeat every 2 to 4 hr as necessary, **max: 10mg/dose**

Adults: **IM/IV** 5 to 10 mg every 10 to 15 min as necessary, may repeat in 2 to 4 hr if needed , **max: 30 mg/dose**

### Adverse Reactions

Hypotension, muscle weakness, ataxia, somnolence, respiratory depression

### Precautions

1. 年老及體弱病人,幼童,肝病或低血清蛋白病人,對本藥的中樞神經系統抑制作用較為敏感

2. 肌肉注射時應注射至三角肌深部。

### Contraindications

Severe hepatic insufficiency, myasthenia gravis, acute narrow-angle glaucoma

## Levetiracetam

**C<sup>1</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Kepra® 500mg/5ml/vial <CLEVETI>

Kepra® 500mg/FC. tab <KLEVETI>

Kepra solution® 100mg/ml, 300ml/bot<KLEVET1>

### Use

Partial seizures, myoclonic seizure, tonic-clonic seizure

## Dose

Injection

### Monotherapy

>16yrs adolescent and adult: **IV** initial 250mg/dose twice daily, increase to 500mg/dose twice daily after 2 weeks; **max: 1500mg/dose twice daily**

### Add-on therapy

12-17yrs (BW≥50kg) adolescent and adult: **IV** initial 500mg/dose twice daily, may increase every 2 weeks by 1000mg/day (500mg/dose); **max: 1500mg/dose twice daily**

4-11yrs children and BW<50kg adolescent: **IV** 10mg/kg/dose twice daily, may increase every 2 weeks by 20mg/kg/day (10mg/kg/dose); **max: 30mg/kg/dose twice daily**

Tablet

**PO** initial 500mg bid, increased by 1000mg/day every 2 wks; **max: 3000mg/day**

Solution

<11 y/o or <50 kg: **PO** initial dose 10mg/kg/bid; **max: 30mg/kg/bid**

>18 y/o or >50 kg: **PO** initial dose 500mg/bid; increased by 1000 mg/day at 2-4 weekly, **max: 3000mg/day**

## Adverse Reactions

Somnolence, asthenia, dizziness, headache

## Precautions

1.需依腎功能調整劑量。

2.Abrupt withdrawal of therapy may increased risk of seizure frequency

3.針劑限靜脈注射(注射時間需大於 15 分鐘)，不建議連續使用超過 4 天

4.針劑可使用 100ml NS、LR 或 D5W 稀釋，稀釋後於室溫 15-25°C 下可存放 24 小時

5.針劑與口服均可直接轉換，不需漸段式增減劑量，每日總劑量及使用頻率需維持不變

## Contraindications

4 歲以下兒童、pyrrolidone 衍生物過敏

## Oxcarbazepine

C<sup>4</sup> Unknown<sup>1</sup>

## Dosage Forms

Trileptal® 300mg/FC. tab <KOXCARB>

Trileptal® oral suspension 6%, 60mg/ml, 100ml/bot <KOXCAR1>

## Use

Partial seizures and trigeminal neuralgia

## Dose

Children: **PO** initially 8-10mg/kg/day in 2 divided dose, **max:**

**60mg/kg/day**

Adults: **PO** initially 600 mg/day (8-10mg/Kg/day) in 2 divided doses, **max: 2400mg/day**

Conversion to monotherapy: **PO** 2400mg/day

## Adverse Reactions

Dizziness, somnolence, headache, nausea, vomiting

### Precautions

- 1.服藥後發生皮膚，口腔黏膜處發紅起疹或水泡建議立刻就醫。
- 2.需依腎功能調整劑量。
- 3.Suspension:請於開封後室溫儲存 7 週內使用完畢。

## Phenytoin (Diphenylhydantoin)

**D<sup>4</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Aleviatin® 250mg/5ml/amp <CPHENY1>  
Dilantin® 100mg/cap <KPHENYT>

### Use

Control of generalized tonic clonic and complex partial seizures, prevention and treatment of seizures occurring during or after neurosurgery

### Dose

#### Status epilepticus:

Infant and children: loading dose **IV** 15-20mg/kg in a single or divided dose, maintenance 5 mg/kg/day in 2 divided doses .

Adults: loading doses **IV** 15-20mg/kg; **max rate: 50mg/min**

#### Anticonvulsant:

Children: initial **PO** 5 mg/kg/day in 2-3 divided doses, maintenance 4-8mg/kg/day divided 2-3 doses; **max: 300mg/day**

Adults: initially **PO** 100mg tid, maintenance 300 mg/day

### Adverse Reactions

Nystagmus, ataxia, gingival hyperplasia, Stevens-Johnson syndrome,

### Precautions

- 1.服藥後若黏膜出現變化(腫脹,潰瘍)或出現皮疹請立即就醫
- 2.突然停藥可能會導致重積性癲癇(status epilepticus)
- 3.應定期做血液檢查

### Contraindications

Sinus bradycardia, SA block, second and third degree AV block and Adams-Stokes syndrome (intravenous phenytoin only)

## Phenobarbital

**D<sup>4</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Phenobital® 100mg/ml/amp <CPHENO>  
Phenobarbital® 30mg/tab <KPHEOB>

### Use

Sedative, hypnotic, generalized tonic-clonic (grand mal) and partial seizures

### Dose

#### Sedation

Children: **PO** 2mg/kg tid

Adults: **IM/PO** 30-120mg/day bid-tid

#### Hypnotic

Children: **IM/SC** 3-5mg/kg hs

Adults: **IM/SC/PO** 100-320mg hs

### Anticonvulsant(status epilepticus)

IM 1-3mg/kg/day

### **Adverse Reactions**

Somnolence, hallucinations, syncope, dizziness, lightheadedness

### **Precautions**

- 1.服用本藥應避免飲用含有酒精之飲料，因為可能引起昏睡。
- 2.停藥時應逐漸進行以免產生戒斷症狀。
- 3.注射劑限皮下或肌肉注射，嚴禁靜脈注射。

## **Valproic acid**

**X** **Safe<sup>1</sup>**

### **Dosage Forms**

Depakine® 400mg/vial <CVALPRO>

Depakine® 200mg/EC. tab <KVALPR1>

Depakine® Chrono (1 tab: Sodium valproate 333mg+Valproic acid 145mg)

500mg/FC. tab <KVALPR2>

Depakine® 8000mg/40ml/bot <KVALPR3>

### **Use**

Epilepsy and mania

### **Dose**

#### Seizures disorders

Children: **PO** (suggest take oral solution) 30mg/kg/day in 2-3divided dose

Adults:

**IV** initially 15 mg/kg **bolus** over 5 min, then 1 mg/kg/hr continuous **IVD** maintenance 20-30mg/kg in 2-4 divided doses.(administer as a 60 minute infusion)

**PO** initial 10-15mg/kg, maintenance 20-30mg/kg in 2-4 divided doses;  
**max: 60mg/kg/day**

#### Mania

Adults: **PO** initial, 750mg/day, in divided doses;may increase dose to achieve desired clinical response or desired range of plasma concentrations;  
**max: 60mg/kg/day**(or less with a therapeutic serum range of 50 to 125 mcg/mL)

### **Adverse Reactions**

GI disturbance, asthenia, dizziness, somnolence, tremor, alopecia

### **Precautions**

- 1.可能引起嚴重肝病或胰臟癌
- 2.不建議與 lamotrigine or carbapenem 併用
- 3.治療前應進行肝功能監測,並在初期 6 個月中定期追蹤

### **Contraindications**

Acute and chronic hepatitis,hepatic porphyria

## **12.2. Adjuvant Anticonvulsants**

### **Gabapentin**

**C** **Unknown<sup>1</sup>**

### **Dosage Forms**

Neurontin® 100mg/cap <KGABA01>

### Use

Partial seizures, postherpetic neuralgia

### Dose

#### Anticonvulsant

Children 3-12 yrs: **PO** initial 10-15mg/kg/day tid, titrate to effective dose over 3 days; 3-4 year: effective dose 40mg/kg/day tid; ≥5-12 years: effective dose: 25-35 mg/kg/day tid

Children <12 yrs and adults: **PO** initial 300mg tid; if necessary the dose may be increased up to 1800mg/day tid.

#### Postherpetic neuralgia

Adults: initial **PO** 300mg tid, may be titrate up to 1800mg/day

### Adverse Reactions

Somnolence, dizziness, ataxia, fatigue, viral infection

### Precautions

1. Avoid abrupt withdrawal, may precipitate status epilepticus, discontinue gradually over a minimum of 1 week

2. 需依腎功能調整劑量

3. 與含 Mg, Al 制酸劑需間隔 2 小時

## Pregabalin

**C<sup>5</sup>** **Unknown<sup>3</sup>**

### Dosage Forms

Lyrica® 75mg/cap < KPREGAB>

### Use

Neuropathic pain associated with diabetic peripheral neuropathy or with spinal cord injury, postherpetic neuralgia, adjunctive therapy for partial-onset seizure disorder, fibromyalgia

### Dose

#### Postherpetic neuralgia, Diabetic peripheral neuropathy

**PO** 75-150mg bid, **max: 300mg/day**

#### Partial-onset seizures (adjunctive therapy)

**PO** 150-600mg/day bid-tid, **max:600mg/day**

#### Fibromyalgia

**PO** initial 75mg bid, increased to 300mg/day within 1 week based on tolerability and effect; **max: 450mg/day**

#### Spinal cord injury induce neuropathic pain

**PO** initial 75mg bid, increased to 150-600mg/day twice daily within 1 week based on tolerability and effect; **max: 600mg/day**

### Adverse Reactions

Dizziness, somnolence, ataxia, asthenia, blurred vision, edema

### Precautions

1. 需依腎功能調整劑量。

2. 駕駛或操作機械時需小心。

## Lamotrigine

**C<sup>4</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Lamictal® 5mg/chewable tab <KLAMOT1>

Lamictal® 50mg/tab <KLAMOT2>

Lamictal® 100mg/tab <KLAMOT3>

### Use

Primary generalized tonic-clonic seizure, partial seizures, bipolar I disorder, Lennox-Gastaut syndrome

### Dose

Children 2-12yrs: initial **PO** 0.15mg/kg qd for 2wks, then 0.3mg/kg qd for 2wks. Maintenance 1-5mg/qd/day qd-bid. **Max:200mg/day**

Monotherapy of seizure, bipolar disorder and Lennox-Gastaut syndrome

Children >12 yrs and adults: initial **PO** 25mg qd for 2 wks, then 50mg qd for 2wks, maintenance 100-200mg qd-bid

### Adverse Reactions

Somnolence, ataxia, dizziness, fatigue, headache

### Precautions

1.併用 valproic acid 可能會增加 stevens-Johnson syndrome 的危險

2.服藥後若出現皮疹建議盡速就醫

3. Pediatric patients (2 to 16 years of age) ,higher rate of serious rash

## Topiramate

**D** **Unknown<sup>1</sup>**

### Dosage Forms

Topamax® 25mg/tab <KTOPIR1>

Topamax® 100mg/tab <KTOPIR2>

### Use

Monotherapy or Adjunctive therapy for partial onset seizures and primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome, migraine (Prophylaxis)

### Dose

Epilepsy. monotherapy

Children  $\geq$  10 yrs and adult: **PO** 25mg bid, may increase weekly by 50mg/day up to 100mg bid. **max:200mg bid**

Epilepsy. adjunctive therapy

Children 2-16yrs: initial **PO** 25mg, may be increase in increments of 1-3mg/kg/day at 1-2weekly to a total daily dose of 5-9mg/kg/day.

Children  $\geq$  17yrs and adults: initial **PO** 25-50mg/day bid for 1 week, increase at weekly intervals by 25-50mg/day until response; maintenance 100-200mg bid

Migraine Prophylaxis

Adult: initial **PO** 25mg/day, titrate at weekly intervals in 25mg increments, up to 100mg/day bid

### Adverse Reactions

Somnolence, dizziness, nervousness, fatigue, loss of appetite

### Precautions

肝腎功能不良須小心使用

## Vigabatrin

**C** **Unknown<sup>1</sup>**

**Dosage Forms**

Sabril® 500mg/tab &lt;KVIGABA&gt;

**Use**

Adjunctive therapy for epilepsy

**Dose**Adults: usual **PO** 2-3g/day qd-bid; **max: 3g/day**Children: initial **PO** 40mg/kg/day, maintenance dose base on p't weight

Body Weight (kg)	Dose (g/day bid)
10-15	0.5-1
15-30	1-1.5
30-50	1.5-3
>50	2-3

**Adverse Reactions**

Visual field defects, drowsiness, fatigue, acute psychosis, dizziness

**Precautions**

1.治療期間建議每半年進行一次眼科檢查

2.老年人與腎功能不全者應考慮調整劑量或服用頻次

## 12.3. Skeletal Muscle Relaxants

**Baclofen****C<sup>4</sup> Safe<sup>1</sup>****Dosage Forms**

Befon® 5mg/tab &lt;KBACLO5&gt;

**Use**

Cerebral origin spasticity , Spinal cord spasticity

**Dose**Children: initial **PO** 5mg/day qd-bid,

maintenance dose:12-15 yrs 5-25mg/day bid-tid; 7-11 yrs 5-20mg/day bid-tid; 4-6 yrs 5-15mg/day bid-tid

Adults: initial **PO** 5-15mg/day qd-tid; maintenance 30mg/day bid-tid.**max:80 mg/day.****Adverse Reactions**

Poor muscle ton, dizziness, somnolence, nausea, headache

**Precautions**

Seizure disorder, impaired renal function

**Methocarbamol****C<sup>4</sup> Safe<sup>1</sup>****Dosage Forms**

Bolaxin® 500mg/tab &lt;KMETHOC&gt;

**Use**

Muscle spasm associated with acute painful musculoskeletal conditions

**Dose**Intial **PO** 500mg qid for 2-3days, then 1000mg qid**Adverse Reactions**

Dizziness, headache, lightheadedness, somnolence, leukopenia

## Tizanidine

C Unsafe<sup>3</sup>

### Dosage Forms

Tizaflex® 2mg/tab <KTIZANI>

### Use

Skeletal muscle relaxant used for treatment of muscle spasticity

### Dose

Adults: PO 2-4mg tid-qid, **max: 36mg/day**

### Adverse Reactions

Hypotension, sedation, daytime drowsiness, somnolence, xerostomia

### Precautions

1.需依肝腎功能調整劑量

2.Hypotension, cardiac disease , bleeding

### Contraindications

嚴重肝功能不良者

## 12.4. Migraines

## Dihydroergotamine

X Unsafe<sup>1</sup>

### Dosage Forms

Digalo® 1mg/tab <KDIHYD6>

### Use

Migraine

### Dose

PO 1mg tid

### Adverse Reactions

Rhinitis, dizziness, nausea, vomiting, diarrhea

## Sumatriptan

C Safe<sup>1</sup>

### Dosage Forms

Imigran® FDT50mg/tab <KSUMAT1>

Imigran® nasal spray 20mg/spray, 2spray/box <WSUMATR>

### Use

Acute treatment of migraine with or without aura

### Dose

PO

Initial dose 25-50mg, may repeat after 2 hrs

Usual dose 50-100 mg as a single dose; **max: 300mg/day**

### Intranasal

20mg prn in one nostril, may repeat after 2 hr as needed; **max: 40 mg/day**

### Adverse Reactions

Bad taste, nausea, vomiting, tingling, paresthesias, dizziness, fatigue

### Precautions

1.不建議使用於 65 歲以上病患

2.健規:每月限用 4 次，口服劑型每次用量不超過 100mg，每月不超過 400mg,鼻噴劑型每次用量不超過 1 劑(10mg 或 20mg)，每月不超過四

劑(10mg 或)20mg。

#### Contraindication

- 不可與含有 ergotamine 或 methylsergide 製劑併用。
- 不可與 MAOI 同時投予，也不可在 MAOI 停藥後 2 星期內使用。

### 12.5. Parkinsonian Agents

#### Amantadine

C Unknown

##### Dosage Forms

Enzil® 100mg/tab <KAMANTA>

##### Use

Prophylaxis and treatment influenza A virus infection and parkinsonism, drug-induced extrapyramidal symptom (EPS)

##### Dose

###### Influenza A virus infection

Children 1-9 yrs: **PO** 4-8mg/kg/day in 2 divided dose; **max: 150mg/day**

Children >9 yrs and adults: **PO** 100mg bid; treatment for 5-7days, prophylaxis for 7-10days

###### Parkinsonism

**PO** initial 100mg qd then 100mg bid after 5-7days.

###### Drug-induced EPS

**PO** 100mg bid, up to 300mg/day in divided dose.

##### Adverse Reactions

Nausea, orthostatic hypotension, peripheral edema, agitation, dizziness

#### Biperiden

C Unknown

##### Dosage Forms

Bipiden® 5mg/ml/amp <CBIPERI>

Akinfree® 2mg/tab <KBIPERI>

##### Use

Neuroleptic-induced extrapyramidal reactions, adjunctive therapy in Parkinson's disease

##### Dose

###### Drug induced extrapyramidal reactions

Children: **IM/IV** <1yrs: 1mg/dose, <6yrs: 2mg/dose, <10yrs: 3mg/dose, may repeat after 30 mins as needed; **max: 4 doses/day**

Adults: **IM/IV** 2.5-5mg/dose, may repeat q30min until resolution of symptoms; **max: 20mg/day**

Adults: **PO** 2mg qd-tid

###### Parkinson's disease

Adults: **PO** 2mg tid-qid; **max: 16mg/day**

##### Adverse Reactions

Constipation, xerostomia, somnolence, blurred vision, urinary retention

##### Precautions

Cardiac arrhythmia, epilepsy, prostatism, manifest glaucoma

##### Contraindication

Bowel obstruction, megacolon, narrow angle glaucoma

## Entacapone

C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Comtan® 200mg/FC. tab <KENTACA>

### Use

Adjunct to Levodopa/Benserazide or Levodopa/Carbidopa therapy  
idiopathic Parkinson's disease

### Dose

Adults: PO 200mg/does; **max: 2000mg/day**

### Adverse Reactions

Nausea, dyskinesia, diarrhea, abdominal pain, dry mouth

### Precautions

Levodopa/carbidopa dosage must be reduced by 10-30%

### Contraindication

1. Concomitant use of non-selective MAOI (eg, phenelzine, tranylcypromine) should generally be avoided, 如需轉換需間隔 2 週。
2. Hepatic impairment, non-traumatic rhabdomyolysis, 抗精神病藥惡性症候群(neuroleptic malignant syndrome)。

## Levodopa and Benserazide

C<sup>4</sup> Unsafe<sup>1</sup>

### Dosage Forms

Madopar® 250, 1 tab Benserazide 50mg+Levodopa 200mg <KMADOP2>

Madopar® HBS, 1 cap Benserazide 25mg+Levodopa 100mg <KMADOP3>

### Use

Parkinson's disease

### Dose

Initial PO 25-50mg benserazide and 100-200mg levodopa bid-qid; **max: 200mg benserazide and 800mg levodopa/day**

### Adverse Reactions

Anorexia, nausea, vomiting, thrombocytopenia, orthostatic hypotension

### Precautions

1. Severe hepatic, active peptic ulcer, bone marrow, heart disease, severe hyperthyroidism, tachycardia or pheochromocytoma, osteomalacia
2. 可能會引起嗜睡或突然睡著反應，應避免駕駛或操作機械
3. 尿液可能會變紅色，靜置後由淡轉暗。

### Contraindication

Narrow-angle glaucoma, MAO inhibitor drug, melanoma

## Carbidopa and Levodopa

C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Sinemet® 125, 1 tab: Carbidopa 25mg+Levodopa 100mg <KSINEM1>

Sinemet® 275, 1 tab: Carbidopa 25mg+Levodopa 250mg <KSINEM2>

Sinemet® 250 CR, 1 tab: Carbidopa 50mg+Levodopa 200mg <KSINEM3>

### Use

Parkinson's disease

## Dose

Adults: initial **PO** 25/100mg bid-qid; **max: 200/2000mg/day**

Elderly: initial **PO** 25/100mg bid

## Adverse Reactions

Dystonic, choreiform, nausea, dyskinesia, neuroleptic malignant syndrome

## Precautions

1. Sever cardiovascular disease, sever pulmonary disease hepatic disease, renal disease
2. May cause or exacerbate preexisting dyskinesia; may require dose reduction
3. 尿液顏色變深。

## Contraindication

Narrow-angle glaucoma, nonselective MAOI, malignant melanoma

## Levodopa and Carbidopa and Entacapone C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Stalevo® FC/tab: Carbidopa 25mg + Entacapone 200mg + Levodopa 100mg <KSTALEV>

### Use

Parkinson's disease

### Dose

**PO** 1tab tid-qid, individualized with titration based on clinical response.

## Adverse Reactions

Dyskinesia, nausea, urine discolouration, insomnia, diarrhea, fatigue

## Precautions

1. 與 MAO inhibitor 併用時，須至少停用 MAOI 兩週後才可開始服用
2. 易引起嗜睡、突然睡著、暈眩、姿勢性低血壓，開車或操作機械需小心。
3. 建議長期治療之患者，定期追蹤評估肝臟、造血、心血管及腎臟功能。

## Contraindications

18 歲以下、嚴重肝功能受損、隅角狹窄型青光眼、嗜鉻細胞瘤、藥物引起的椎體外症狀。

## Trihexyphenidyl C<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

B.H.L.® 2mg/tab <KTRIHEX>

### Use

Adjunctive treatment of Parkinson's disease and drug-induced extrapyramidal symptoms(EPS)

### Dose

#### Parkinson's disease

Adults: initial **PO** 1-2mg/day increase by 2mg increments at intervals of 3-5 days, maintenance 5-15mg/day tid-qid

#### EPS

initial **PO** 1mg/dose increase as necessary to usual range 5-15 mg/day in 3-4 divided doses

### **Adverse Reactions**

Nausea, xerostomia, dizziness, blurred vision, feeling nervous

### **Precautions**

對尿滯留、心臟血管疾病、肝或腎損害等，應避免突然的停止治療。

### **Contraindication**

Glaucoma

## **Rasagiline**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Rakinson® 1mg/tab <KRASAGI>

### **Use**

Parkinson's disease

### **Dose**

Mono-therapy: **PO 1mg qd; max: 1mg/day**

Adjunctive therapy with levodopa: **PO initial 0.5mg qd, may increase to 1 mg qd based on response and tolerability; max: 1mg/day**

### **Adverse Reactions**

Headache, musculoskeletal pain, depression, flu-like symptoms, rhinitis

### **Precautions**

健規：單獨使用每日最高劑量 1mg，與 levodopa 併用每日最高劑量 0.5mg，且不可與 levodopa 以外抗帕金森氏症治療藥品併用。

### **Contraindication**

Severe hepatic dysfunction

## **12.6. Dopaminergics**

## **Pramipexole**

**C<sup>4</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Mirapex® 0.25mg/tab <KPRAM01>

Mirapex® 1mg/tab <KPRAM02>

### **Use**

The sign and symptoms of idiopathic Parkinson's disease, depression, restless legs syndrome (RLS)

### **Dose**

Parkinson's disease

Adults: initial **PO 0.375mg/day given in 3 divided doses increase gradually by 0.125mg/dose every 5-7 days, range 1.5-4.5mg/day; max. 4.5mg/day**

### RLS

Initial **PO 0.125mg/day hs, increase gradually by 0.125mg/dose every 4-7 days; max: 0.5mg/day**

### **Adverse Reactions**

Dizziness, insomnia, constipation, nausea, dyskinesia, hallucinations

### **Precautions**

1.需依腎功能應調整劑量

2.Use with caution in patients with myasthenia gravis.

## Ropinirole

C<sup>4</sup> **Unsafe<sup>3</sup>**

### Dosage Forms

Requip<sup>®</sup> 0.25mg/F.C tab <KROPIN1>  
Requip PD<sup>®</sup> 2mg/P.R tab <KROPIN4>  
Requip PD<sup>®</sup> 4mg/P.R tab <KROPIN5>

### Use

Idiopathic parkinson's disease, primary restless legs syndrome

### Dose

#### Parkinson's disease

Requip<sup>®</sup> :Initial **PO** 0.25mg tid increase gradually by 0.25mg/dose every 7 days; **max: 24mg/day**

週	1	2	3	4
單一劑量(mg)	0.25	0.5	0.75	1.0
每日總劑量 (mg)	0.75	1.5	2.25	3.0

Requip PD<sup>®</sup>: **PO** 2mg qd increase gradually by 2mg/day every 7-14 days; **max:24mg/day**

#### RLS

Requip<sup>®</sup> : Initial **PO** 0.25mg/day hs increase gradually by 0.25mg/dose every 4-7 days; **max: 4mg/day**

### Adverse Reactions

Postural hypotension, dizziness, nausea, headache, hallucinations, dyskinesias, somnolence

### Precautions

1. Requip PD<sup>®</sup>為持續釋放膜衣錠，需整粒吞服，切勿咀嚼，壓碎或剝半服用。

2. 會抑制乳汁分泌，不建議用於哺乳婦女。

### Contraindications

ClCr<30ml/min,嚴重肝功能損害之患者。

## Rotigotine

C<sup>5</sup> **Unsafe<sup>3</sup>**

### Dosage Forms

Neupro<sup>®</sup> 4mg/24hr, 9mg/patch <WROTIKO>

### Use

Idiopathic parkinson's disease

### Dose

#### Transdermal

Early-stage: initial 2mg qd, may increase weekly by 2mg to 4mg qd;  
**max:8mg qd**

Advanced-stage: initial 4mg qd, may increase weekly by 2mg; **max: 8mg qd**

### Adverse Reactions

Application site reaction, somnolence, dizziness, nausea, orthostatic hypotension

### Precautions

1. 本品儲存於 2-8°C
2. 貼片應貼在潔淨、乾燥、沒有損傷的皮膚表面，避免在 14 天內重複黏貼在同一個部位。
3. 當貼片脫落，應換用一張新的貼片。
4. 賦形劑含亞硫酸鹽(sulfite)，氣喘患者需小心使用。
5. 治療期間開車、操作機械或在高處工作應小心。
6. 健規：限用於原發性帕金森氏症，每日限用一片，且不得併用其他 dopamine agonist 之口服藥。

#### **Contraindications**

進行核磁共振造影(MRI)或心臟電擊

### **12.7. Myasthenias**

#### **Pyridostigmine**

**C<sup>4</sup> Safe<sup>1</sup>**

#### **Dosage Forms**

Mestinon® 60mg/tab <KPYRID1>

#### **Use**

Improve muscle strength in patients with myasthenia gravis

#### **Dose**

Children: **PO** 7mg/kg/day in 5-6 divided doses

Adults: **PO** 60-1500mg/day, usually 600mg/day divided into 5-6 doses

#### **Adverse Reactions**

Nausea, vomiting, diarrhea, increased salivation, sweating, weakness

### **12.8. Amyotrophic lateral sclerosis (ALS)**

#### **Riluzole**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Rilutek® 50mg/tab <KRILUZO>

#### **Use**

Amyotrophic lateral sclerosis (ALS)

#### **Dose**

Adults: **PO** 50mg bidAC; **max: 100mg/day**

#### **Adverse Reactions**

Asthenia, elevation of serum transaminases, worsening of spasticity, astrointestinal symptoms and blood pressure elevations

#### **Precautions**

1. 需依肝腎功能調整劑量(ALT>5 備以上須停藥)。

2. 健規：經兩位神經專科醫師診斷為運動神經元疾病(ALS/MND)，且未經氣管切開或使用人工呼吸器之病患。

### **12.9. Neuromuscular blockers**

## **Botulinum Toxin Type A**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Botox® 100U/vial <CBOTULL>

Dysport® 500IU/vial <CBOTUL2>

### **Use**

Strabismus and blepharospasm associated with dystonia (including benign essential blepharospasm or VII nerve disorders in patients ≥12 yrs); cervical dystonia (spasmodic torticollis) in patients ≥16 yrs

### **Dose**

Doses for other indications will be determined by clinical experience

#### Strabismus

**IM** 1.25-5 U

#### Blepharospasm

**IM** 1.25-2.5 U without electromyographic guidance

#### Glabellar lines

**IM** 4 U into each of 5 sites for a total dose of 20 IU

#### Primary axillary hyperhidrosis

**IM** 50 U per axilla, evenly distributed in multiple sites

### **Adverse Reactions**

Injection site pain, chest pain, tenderness, bruise

### **Precautions**

1. Botox 儲存：2-8°C，開封混合後置冷藏室可存放 6 個禮拜。
2. 與 aminoglycoside 類抗生素或干擾神經肌肉傳導藥物併用須小心
3. 以 2.5ml 之 NS 調配，調配至 200IU/ml 濃度，避免氣泡或劇烈振盪
4. Dysport:於 2-8°C 冷藏，配製後於 2-8°C 可存放 8 小時。

## **12.10. Alzheimer's Disease**

## **Donepezil**

**C<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Aricept® 5mg/FC. tab <KDONEPE>

Aricept® 10mg/FC. tab <KDONEP1>

### **Use**

Alzheimer's disease- Dementia

### **Dose**

**PO** 5mg hs, dose may be increased to 10mg hs following 4-6 weeks of clinical assessment

### **Adverse Reactions**

Headache, nausea, diarrhea, anorexia, muscle cramps

### **Precautions**

1. 胃潰瘍病史或同時併服非類固醇抗發炎藥物(NSAID)之病患應小心觀察是否有急性或隱藏性胃腸道出血。
2. 氣喘及阻塞性肺病之病患應小心給藥。

## **Memantine**

**B<sup>1</sup> Unknown<sup>1</sup>**

### Dosage Forms

Exmem<sup>®</sup> 10mg/tab <KMEMANT>

### Use

Moderate-to-severe dementia of the Alzheimer's type

### Dose

Initial PO 5mg qd, titration by 5mg/day, maintenance 10mg bid

### Adverse Reactions

Constipation, dizziness, headache, hypertension, pain

### Precautions

1. Use caution with seizure disorder or severe hepatic impairment
2. 需依腎功能調整劑量
3. 避免使用會使尿液呈鹼性藥品，(例 carbonic anhydrase inhibitor 或 sodium bicarbonate)，會導致藥品清除率明顯降低。

## Rivastigmine

**B1** Unknown<sup>1</sup>

### Dosage Forms

Exelon<sup>®</sup> 1.5mg/cap <KRIVAS1>

Exelon<sup>®</sup> 3mg/cap <KRIVAS2>

Exelon<sup>®</sup> 4.5mg/cap <KRIVAS3>

Exelon<sup>®</sup> patch 9mg/5cm<sup>2</sup>/patch, 4.6mg/24hrs <WRIVAST>

### Use

Mild to moderate dementia of the Alzheimer's type

### Dose

#### Tablet

Initial PO 1.5mg bid, may increase to 3mg bid after 2 wks, maintenance 1.5-6mg bid; **max: 6mg bid**

#### Patch

1 patch qd (switch from oral to patch 已使用 3mg Exelon<sup>®</sup> bid 若耐受性良好且情況穩定達四週以上可轉換為 Exelon<sup>®</sup> patch 一天一片)

### Adverse Reactions

Dizziness, headache, nausea, vomiting, diarrhea, anorexia, abdominal pain

### Precautions

1. 建議每天變換部位黏貼，以避免對皮膚產生刺激，相同的點 14 天內不宜重複黏貼。貼片應每 24 小時更換一片且每日黏貼時間應一致
2. 貼片不可剪裁或摺疊。
3. 健規：使用 rivastigmine 貼片劑(如 Exelon Patch)，每日限用一片，且不得併用同成分之口服藥品。

## 12.11. Antivertigo Preparations

### Bethistine

**Unknown<sup>1</sup>**

### Dosage Forms

Ecycle<sup>®</sup> 16mg/tab <KBETAH1>

### Use

Meniere's disease and other audiovestibular disorders

**Dose**

PO 24-48mg in divided dose

**Adverse Reactions**

Gastrointestinal disturbances, headache, sedation

**Precautions**

Phaeochromocytoma, asthma, peptic ulcer disease, liver disease

**Cinnarizine**

**C<sup>1</sup> Unknown<sup>1</sup>**

**Dosage form**

Cinnazine<sup>®</sup> 25mg/tab <KCINNAR> 參閱 p.186

**Diphenidol****Dosage Forms**

Diphenidol<sup>®</sup> 25mg/tab <KDIPH02> 參閱 p.154

**Flunarizine**

**Unknown<sup>1</sup>**

**Dosage Forms**

Fluzine<sup>®</sup> 5mg/tab <KFLUNAR> 參閱 p.187

**Meclizine**

**B<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Semper<sup>®</sup> 25mg/tab <KMECLIZ> 參閱 p.154

## 13. NUTRIENTS AND NUTRITIONAL AGENTS

### 13.1. Electrolytes

品項	規格	代碼	Dextrose(g/L)	Na <sup>+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl(mEq/L)	Ca <sup>2+</sup> (mM/L)	Lactate(mM/L)	mOsm/Kg
5% Dextrose	250ml/pack	CDEXT02	50						278
	500ml/pack	CDEXT04							
	500ml/P.P	CDEXT10							
10% Dextrose	500ml/pack	CDEXT09	100						556
50% Dextrose	20ml/amp	CDEXTR2	500						2778
	500ml/pack	CDEXT05							
0.9% NaCl+5% Dextrose	500ml/pack	CNSD511	50	154		154			559
	1000ml/pack	CNSD512							
0.225% NaCl+5% Dextrose	500ml/pack	CNSD502	50	34		34			330
0.45% NaCl	20ml/amp	CNAC452		77		77			154
	500ml/pack	CNAC451							

品項	規格	代碼	Dextrose (g/L)	Na <sup>+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl(mEq/L)	Ca <sup>2+</sup> (mM/L)	Lactate (mML)	mOsm/Kg
0.45% NaCl+2.5% Dextrose	500ml/pack	CNSDE25	25	77		77			
0.9% NaCl	20ml/amp	CNAC903							
	100ml/pack	CNAC904							
	250ml/pack	CNAC905							
	250ml/P.P.	CNA905G		154		154			308
	500ml/pack	CNAC901							
	500ml/P.P	CNA901G							
	1000ml/pack	CNAC902							
	500ml/bot	WNAC901							
0.9% NaCl irrigation	1000ml/bot	WNAC902							
	2000ml/pack	WNACL2							
3% NaCl	500ml/pack	CNACL3		513		513			1026
23.5% NaCl	200ml/bot	CNAC235		4000		4000			
Lactated Ringer	500ml/pack	CLACTA1		130	4	109	3	28	274
	1000ml/pack	CLACTA2							
Water for injection	20ml/amp	CWATER1							
	1000ml/pack	CWATER2							

品項	規格	代碼	Dextrose (g/L)	Na <sup>+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl <sup>-</sup> (mEq/L)	Ca <sup>2+</sup> (mM/L)	Lactate (mML)	mOsm/Kg
Sterile water for irrigation	2000ml/bot	WH2O1							
	1000ml/bot	WH2O2							
	500ml/bot	WH2O3							

註：1.5% Dextrose 500ml/PP建議用於稀釋amiodarone, etoposide, oxaliplatin 等針劑。

2.50%Dextrose 500ml/pack 因滲透壓高，不建議週邊靜脈注射使用。

3.23.5%NaCl限TPN 調配用。

4.Lactated Ringer 用於燒傷、體液流失病患之酸中毒。

5.0.9%NaCl 100ml/pack 及 250ml/P.P.限化療調配用。

## TAITA

品名	NAKO (No.2)	NAKO (No.4)	NAKO (No.5)
代碼	CTAITA2	CTAITA4	CTAITA5
規格	500ml/bot	500ml/bot	500ml/bot
成份			
mEq/L	Na	40	110
	K	12	20
	Mg	-	-
	Cl	26	102
	Ca	-	-
	SO <sub>4</sub>	-	-
	Acetate	20	16
	Gluconate	-	-
nM/L	(PO <sub>4</sub> ) <sup>3-</sup>	6	12
g/L	Glucose	33	8
	Kcal/L	132	32
	pH	5.5	5.5
	mOsm/L	287	300
適應症	高張性下痢及小兒下痢之水份、電解質、養份補充；成人維持液	等張性下痢、腸液損失之病人其水份、電解質、養份補充； DM 病人磷之補充	手術前後及未能進食之水份、電解質、養份補充
特色		DM 病人磷補充	非 DM 病人磷補充

## Calcium chloride

C Unknown<sup>1</sup>

### Dosage Forms

Vitacal® 2%, 20ml/amp (1ml: Ca<sup>2+</sup> 0.272mEq+Glucose 100mg)  
<CCALC04>

### Use

Hemorrhagen, nutrition, hypocalcemia

### Dose

#### Hypocalcemia

Pediatric: 2.7 to 5mg/kg, IV every 4 to 6hours; **max rate: 1mL/min**

Adults: 200mg to 1g, IV every 1 to 3days; **max rate: 1mL/min**

### Adverse Reactions

Burning sensation, vasodilatation, necrosis vomiting

## Calcium polystyrene sulfonate

C Unknown<sup>1</sup>

### Dosage Forms

Kalimate® 5g/pack <KCALC05>

### Use

Acute and chronic renal insufficiency associated with hyperkalaemia

### Dose

**PO** 15-30 g, 1-3 times daily, slurry in water

**Rectal** 30g suspended in 100 ml water or 2 % methylcellulose soln.

### Adverse Reactions

Constipation, anorexia, nausea

## Precautions

1. Not mixed with fruit juices having K content
2. 服用此藥需注意病人是否發生便祕之現象。

## Magnesium sulfate ( $\text{MgSO}_4$ )

A<sup>1</sup> Safe<sup>1</sup>

### Dosage Forms

Magnesium sulfate<sup>®</sup> 10%, 20ml/amp (1ml: 0.81mEq  $\text{Mg}^{2+}$ = 9.84mg  $\text{Mg}^{2+}$ )  
<CMAGNE1>

### Use

Hypomagnesemia, eclampsia, pre-eclampsia, uremia

### Dose

#### Hypomagnesemia

Pediatrics: IV 25-50mg/kg (rate > 30min); **max 2g/dose**

Adults: mild hypomagnesemia IM 1 g q6h for 4doses; severe hypomagnesemia, IM > 250mg/kg in 4hours or 5g (40mEq) (rate>3hrs)

#### Treatment and prophylaxis eclampsia

Adults: IV initial, 4-5g , maintenance 1-2g/hr/day until paroxysms cease or IM 4-5g q4h as needed; **max: 30-40g/day**

### Adverse Reactions

Decreased heart rate, facial flushing, hypotension, muscle weakness

## Potassium chloride

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

KCl<sup>®</sup> 15%, 10ml/amp ( $\text{K}^+$ : 2mEq/ml) <CPOTASS>

### Use

Treatment or prevention of hypokalemia

### Dose

#### Normal daily requirement

#### IV

Children: 2-3mEq/kg/day

Adults: 1-2mEq/kg/day

#### Hypokalemia

#### IV

Pediatric: 0.5 -0.75 mEq/kg (infused >1-2 hrs), **max:40 mEq/dose**;

Adults: serum K < 2 mEq/L(rate >40 mEq/hr) ; **max 400 mEq/day**; K > 2.5 mEq/L(rate < 10 mEq/hr); **max 200 mEq/day** ;

### Adverse Reactions

Hyperkalemia, electrocardiogram changes, nausea, abdominal pain, diarrhea, indigestion, flatulence, vomiting

### Precautions

1. 限稀釋後使用，稀釋濃度為週邊輸注 40 mEq/L 及中央輸注 80 mEq/L，需監測心電圖
2. 成人最大輸注速率為 40 mEq/hr。

## Potassium chloride solution (ready-to-use)

C<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

0.298% KCl 20mEq+ 0.9% NaCl Injection<sup>®</sup> 500ml/bot<CPOTAS2>  
0.149% KCl 10mEq+ 0.9% NaCl Injection<sup>®</sup> 500ml/bot<CPOTAS3>  
0.149% KCl 10mEq+ 5% Dextrose/0.33%NaCl  
Injection<sup>®</sup> 500ml/bot<CPOTAS10>  
0.298% KCl 20mEq+5%Dextrose Injection<sup>®</sup> 500ml/bot<CPOTAS11>  
KCl 20mEq+ 0.9% NaCl Injection<sup>®</sup> 100ml/bag<CPOTAS8>  
KCl 20mEq+ 0.45%NaCl Injection<sup>®</sup> 500ml/bag<CPOTAS6>

### Use

Treatment or prevention of hypokalemia

### Dose

#### Normal daily requirement

Children: **IVF** 2-3mEq/kg/day

Adults: **IVF** 1-2mEq/kg/day

#### Hypokalemia

**IVF** 0.5-1mEq/kg/dose

Infusion rate 10-20mEq/hr; K<2mEq/L 20-40mEq/hr; **max: 400mEq/day**

### Adverse Reactions

Hyperkalemia, abdominal pain/discomfort, diarrhea, flatulence

### Precautions

1. 投與藥物前需檢查是否混濁或混合後產生沉澱
2. 藥廠之商業配方若使用幫浦給藥，於藥液快用完或可能有空氣栓塞時，需停止幫浦。若未以幫浦給藥要避免過度擰扭施壓(>300mmHg)導致容器變形，會損壞容器。
3. 藥劑部製劑室配置之 KCl 20mEq+ 0.9%NaCl 100ml/bag 與 KCl 20mEq + 0.45%NaCl 500ml/bag，於室溫可保存 14 天

### Contraindications

對玉米製品過敏者、有鈉滯留現象的腎衰竭、少尿或尿毒症、無尿、Crush syndrome、嚴重溶血反應、腎上腺功能不足、急性脫水、遺傳性偶發無力、手術後初期少尿狀態等

## Potassium gluconate

**C<sup>4</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

Radi-K<sup>®</sup> 595mg/tab (K<sup>+</sup>: 2.54mEq/tab) <KPOTAS5>

### Use

Treatment or prevention of hypokalemia

### Dose

Adults: **PO** 3-9 tab/day divided 2-3 dose (1tab=2.54 mEq k+)

### Adverse Reactions

Nausea, vomiting, diarrhea, abdominal pain, constipation

## Potassium phosphate

**C<sup>6</sup>** **Unknown<sup>1</sup>**

### Dosage Forms

K<sub>3</sub>PO<sub>4</sub><sup>®</sup> 20ml/amp (K<sup>+</sup>: 4.4mEq/ml, P: 3.0mmol/ml) <CPOTAS1>

K<sub>3</sub>PO<sub>4</sub>+ 0.9% NaCl<sup>®</sup> 250ml/pk (K<sup>+</sup>: 17.6mEq+ P: 12mmol+ 0.9% NaCl 250ml /pk) <CPOTAS7>

## Use

Treatment and prevention of hypophosphatemia

## Dose

Children: **IVF** (rate <0.2mmol/kg/hr) 0.15-0.33mmol (P)/kg over 6 hrs

Adults: **IVF** (rate< 0.24mmol/kg/day) 0.08-0.16mmol (P)/kg over 6 hrs

## Adverse Reactions

Bradycardia, hypocalcemia, hypomagnesemia, hyperphosphatemia, dyspnea, weakness, hypotension

## Precautions

- 1.給藥速度過速會引起心律不整
- 2.配製後室溫下可存放 3 天
- 3.藥劑部製劑室配製之磷酸鉀溶液基於用藥安全退藥一律不再使用
- 4.血中 K 值>4 meq/L 時，應謹慎使用，避免產生高血鉀

## Contraindications

- 1.禁用 IV push
- 2.禁止與含鈣溶液混合

## Sodium bicarbonate

 **Safe<sup>1</sup>**

## Dosage Forms

Rolikan® 7%, 20ml/amp (Na<sup>+</sup>: 0.8mEq/ml) <CNAHCO>

Sodium bicarbonate® 300mg/tab (Na<sup>+</sup>: 3.6mEq/tab, bicarbonate: 3.6mEq/tab) <KNAHCO1>

## Use

Metabolic acidosis, Diabetic ketoacidosis

## Dose

### Metabolic acidosis

Adult: **PO** initial 600mg 3times daily; maintain serum bicarbonate  $\geq 23$  mmol/L

### Diabetic ketoacidosis

Pediatric: **IV** 1 to 2mmol/kg ( 60minutes)

Adault: **IV** 100mmol in 400mL Dis-water + 20mEq KCl (rate 200mL/hr, 2 hours until venous pH >7; if pH remains < 7, q2h repeat until pH > 7)

## Adverse Reactions

Cellulitis, injection site extravasation, skin ulcer, tissue necrosis metabolic alkalosis

## Precautions

- 1.與鈣離子會產生沉澱，勿與鈣製劑混合使用。
- 2.為鹼性溶液，當與其它藥物配合使用時須注意。

## Trace element®

## Dosage Forms

1 ml: Zn 1.5mg+Copper 0.5mg+Mn 0.2mg+Cr 0.005mg+ I 0.028mg,  
10ml/vial <CTRACE>

## Use

Supplement of trace elements, diluted in TPN solution

## Dose

## **IVF**

<3 kg Preterm Neonates: 0.02ml/kg/day

>3 kg Term Neonates: 0.02ml/kg/day

<20 kg Children: 0.02ml/kg/day

>20 kg Children: 0.04ml/kg/day

Adult: 1-2ml/day

### **Precautions**

1. 儲放於 TPN 室；為低張溶液，稀釋液體積至少要 250ml 以上，未經稀釋，不可直接由末梢靜脈注射。
2. 藥品開封後需冷藏，可存放 2 週。

## **13.2. Amino Acids**

### **Alanyl-glutamine**

**Unknown<sup>1</sup>**

#### **Dosage Forms**

Dipeptiven® 20g/100ml/bot <CALANYL>

Each 100ml contain N(2)-L-alanyl-L-glutamine 20g (=8.2g L-alanine + 13.64g L-glutamine)

#### **Use**

Part of an IV parenteral nutrition regimen as a supplement to amino acid solution (hypercatabolic and/or hypermetabolic)

#### **Dose**

Adults: IVF 1.5-2 ml (0.3-0.4 g)/kg/day; 稀釋後週邊最大輸注速率為 2.5ml/kg/hr

#### **Adverse Reactions**

Peripheral edema, fever, abnormal liver function

#### **Precautions**

1. 每日量不應超過氨基酸總量的 20%；請勿使用超過 3 週。
2. 為高濃度溶液，若為原液，則應由中央靜脈輸注；若為稀釋液，建議以氨基酸溶液、N/S 或 D5W 稀釋(ex: Dipeptiven 100ml+400ml 稀釋液) 後由週邊靜脈輸注。

#### **Contraindications**

Clcr< 25ml/min、嚴重肝功能不全、嚴重代謝性酸血症。

### **Cerebrolysin**

**Unknown<sup>3</sup>**

#### **Dosage Forms**

Cerebrolysin® 10ml/amp <CYY04>

#### **Use**

Amino acid supplementation

#### **Dose**

IM/IV 2ml qd at initial stage, then extend the interval to 2ml qod-q3d

IVD(high doses) 5-40ml/day slowly IV drip

可依據病況使用，較輕的症狀每一治療過程需 10-15amp，較重的症狀視需要可加長至數個治療過程。

## **Adverse Reactions**

If injected too quickly, mild flush may result

## **Precautions**

- 1.以 NS 250ml 稀釋，緩慢點滴輸注，輸注時間應在 60-120 分鐘以上。
- 2.藥品稀釋後可保存 24 小時。

## **Contraindications**

嚴重腎功能不全禁用

## **Clinimix N9G15E®**

**C<sup>5</sup> Unknown<sup>3</sup>**

### **Dosage Forms**

Amino acid 2.75%+ Glucose 7.5% 20g/100ml/bot <CCLINIM>

### **Use**

Electrolytic, caloric, and water balance

### **Dose**

Dosage is individualized. IVD > 8 hr after mixing the two compartments;  
max: 40ml/kg/day or 2400-2800ml/day

## **Adverse Reactions**

Hypertonic solutions may cause venous irritation. Hyperglycaemia,  
Glycosuria & Hyperosmolar syndrome may occur.

## **Precautions**

- 1.配製後 25°C 下儲存 48 小時, 2-8°C 下可儲存 7 天，不可冰凍
- 2.本品需避光(勿直接曝曬於陽光及烤燈下)。

## **Contraindications**

未進行透析之腎臟衰竭患者、嚴重肝疾病患者、代謝性酸中毒、高乳酸血症、氨基酸代謝不良者、腎上腺功能不良者、肺水腫脫水及代償性心臟功能不良、高血鉀與高血鈉患者不應使用。

## **Ketosteril®**

**Unknown<sup>3</sup>**

### **Dosage Forms**

Ketosteril® 67mg/tab <KKETOST>

成份	含量
Calcium-3-methyl-2-oxo-valerate	67mg
Calcium-4-methyl-2-oxo-valerate	101mg
Calcium-2-oxo-3-phenylpropionate	68mg
Calcium-3-methyl-2-oxo-butyrate	86mg
Calcium-DL-2-hydroxy-4-butyrate	59mg
L-Lysine-acetate	105mg
L-Threonine	53mg
L-Tryptophan	23mg
L-Histidine	38mg
L-Tyrosine	30mg
Total nitrogen content/tablet	36mg
Calcium/table	1.25mmol =0.05g

### **Use**

Chronic renal insufficiency amino acid supplement

**Dose**

4-8 tab tid with meals

**Adverse Reactions**

Hypercalcemia

**Precautions**

1.須於餐中服用。

2.應定期監測血清鈣含量。

3.使用於 GFR 5-15ml/min，且蛋白質攝取< 40g/day 之病患。

4.健規：用於 Scr>6mg/dl，**max:6tab/day**

**Oliclinomel N4-550E® emulsion**

**Unknown<sup>1</sup>**

**Dosage Forms**

Premix: 5.5% Amino acid 600ml+ 20% Glucose 600ml+ 10% fat 300ml, 1500ml/bag

Mix: 2.2% Amino acid+ 8% Glucose+ 2% fat/1500ml/bag <CPPN2>

**Use**

Electrolytic, caloric, and water balance

**Dose**

**IVF** (central or peripheral) 1 bag q12-24h

Children > 2yrs: **max 100ml/kg/day**

Adult: **max 40ml/kg/day**

**Adverse Reactions**

Hyperthermia, excessive sweating, tremors, nausea, headaches, dyspnoea

**Precautions**

1.混合後 2~8°C 可存放 7 天，拿出冰箱後於 25°C 可保存 48 小時；但下方輸注 set 如拆開則需立即使用。

2.勿直接於軟袋上使用簽字筆寫字，會導致墨水滲入軟帶內。

**Contraindications**

未滿 2 歲下兒童、對蛋或黃豆類蛋白質過敏者、無法進行透析之嚴重腎功能不良者、高血糖(insulin>6IU/hr)。

## Amino acid

品項	10% Moriamin-SN	7.4% Amiyu	7.1% Aminopoly-H	10% Aminosteril-infant	5% Aminoplasmal
規格	200ml/bot	200ml/bot	500ml/bot	100ml/bot	500ml/bot
代碼	CAMIN01	CAMIN05	CAMIN03	CAMIN06	CAMIN02
成份	含有量(w/v %)				
<b>必須氨基酸</b>					
L-Isoleucine	0.560	0.720	0.920	0.8	0.25
L-Leucine	1.250	1.125	0.945	0.13	0.37
L-Lysine				0.851	0.33
L-Lysine acetate	1.240	1.155	0.395	0.12	0.215
L-Methionine	0.350	1.125	0.065	0.312	0.225
L-Phenylalanine	0.935	1.125	0.030	0.375	0.255
L-Threonine	0.650	0.515	0.300	0.440	0.22
L-Tryptophan	0.130	0.255	0.070	0.201	0.1
L-Valine	0.450	0.820	0.890	0.9	0.31
<b>非必須氨基酸</b>					
L-Alanine	0.620		0.840	0.93	0.7
L-Arginine	0.790		0.920	0.75	0.45
L-Aspartic acid	0.380		0.020		
L-Cysteine	0.100		0.020	0.052	
L-malic acid				0.262	
L-Glutamic acid	0.650				
L-Histidine	0.600	0.560	0.310	0.476	0.15
L-Proline	0.330		0.530	0.971	0.506
L-Serine	0.220		0.260	0.767	0.325
L-Tyrosine	0.035		0.060	0.42	
Glycine			0.540	0.415	0.5
Taurine				0.04	0.01
L-Acetyltyrosine					1.038
L-Ornithine aspartate					0.23
L-Aspartic acid			0.020		
Aminoacetic acid	1.070				
Na <sup>+</sup>	<1mEq/200ml	13mEq/L	15-16mEq/L		
Cl <sup>-</sup>	0 mEq/L		0 mEq/L		
CH <sup>3</sup> COO <sup>-</sup>		56mEq/L			
EAA/NEAA			1.04		
<b>Total amino acid</b>	<b>10.36 w/v %</b>	<b>7.4 w/v %</b>	<b>7.115 w/v %</b>	<b>10 w/v %</b>	<b>5 w/v %</b>
Osmotic	924 mosm/L	616mosm/ L	770 mosm/L	885 mosm/L	483mosm/L
總氮量	15.2mg/ml	9.0mg/ml	12.1mg/ml	14.9 mg/ml	7.75mg/ml
PH	5.5-5.6	7.0-7.8	6.8-7.8	5.5-6.0	5.0-7.5
適應症	嚴重創傷/ 火傷/骨折/ 手術前後蛋白質補給	腎功能不全氨基酸補給	肝昏迷氨基酸補給	嬰幼兒部分腸外營養	周邊靜脈營養液
用法用量	200 ml IVF for 20 min	200-400ml IVF 120-180ml n	500ml加 D50W 80ml 混合，於 2-3 小時緩慢滴注	IVF <u>最大輸注速率</u> ： 0.1g/kg/hr =1.0ml/kg/hr <u>Max dose</u> ： <1歲:1.5-2.5g/kg >1歲:1.5 g/kg	IVF 1-1.25ml/kg/hr <u>Max dose</u> ： 2g/kg/day

### 13.3. Lipids

品項	10% MCT/LCT Lipofundin	20% MCT/LCT Lipovenes MCT
規格	100ml/bot	250ml/bot
代碼	CFAT03	CFAT02
<b>成份</b>		<b>每1000ml乳劑中含有</b>
Soya-bean oil	50g	100g
Medium-chain Triglycerides	50g	100g
Essential fatty acids	24-29g	
Linoleic acid	2.5-5.5g	
Theoretical osmolarity	345mOsm/L	273mOsm/L
pH	6.5-8.8	6.5-8.7
<b>熱量提供</b>		
Kcal/bot	約110Kcal/bot	約500Kcal/bot
Caloric value	1022kcal/L	1950Kcal/L
<b>劑量</b>	1-2g/kg/day(10-20ml/kg/day)	1-2g/kg/day(5-10ml/kg/day) 最大劑量2g/kg/day
<b>注射速率</b>	最初15分不宜>0.05g-0.1g/kg/hr (0.5-1ml/kg/hr)	最初15分不宜>0.05g-0.1g/kg/hr (0.25-0.5ml/kg/hr)
<b>最大注射速率</b>	1)不可>0.15g/hr/kg(1.5ml/hr/kg) ;不可>0.5滴/kg/min 2)營養不良及兒童應調降注射速率,每天輸注速率>16hrs	不可>0.15g/kg/hr (0.625ml/kg/hr)
<b>注射方式</b>	可經週邊靜脈或中央靜脈	
<b>貯放方式</b>	避光存放於25°C以下,避免冷凍;未用完者應立即丟棄。	

### 13.4. Vitamins

#### Alinamin-F® 50

##### Dosage Forms

1 tab: Thiamine tetrahydrofuryl disulfide 50mg+Vitamin B<sub>2</sub> 5mg  
< KALIN02 >

##### Use

Neuralgia, neuritis, eye's fatigue, nervous cystitis, postoperative intestinal paralysis, vitamin B<sub>1</sub> deficiency

##### Dose

**PO** 1-3 tab/day

Critical neuritis

**PO** 300mg/day

##### Precautions

造成尿液顏色變黃。

#### Alpha-Tocopherol acetate (Vitamin E)

A<sup>4</sup> Unknown<sup>1</sup>

**Dosage Forms**

Vitamin E<sup>®</sup> 50mg/tab (1mg=1IU) <KVITE>

**Use**

Prevention and treatment vitamin E deficiency, premenstrual symptoms

**Dose**

Prevention and treatment vitamin E deficiency

Adult: **PO** 32-50mg/day,max 300mg/day

Premature or low-birth-weight neonates: **PO** 25 to 50 units/day

Premenstrual symptoms

Adult: **PO** 400 IU/day

**C**  
**Safe<sup>1</sup>**

**Ascorbic acid (Vitamin C)****Dosage Forms**

Vitacicol<sup>®</sup> 100mg/2ml/amp <CASCORB>

Pannobel<sup>®</sup> 5g/20ml/amp <CASCOR1>

**Use**

Ascorbic acid deficiency

**Dose**

Ascorbic acid deficiency

Children: **IM/IV/SC** 100 mg 3 times/day

Adult: **IM/IV/SC** mild to moderate 100- 250 mg; severe 1- 2 g/day

Scurvy

**IM/IV/SC** 100-250mg qd-bid for at least 2 wks

Urinary acidification

**IM/IV/SC** 500mg q6-8h

Dietary supplement

**IM/IV/SC** 50-200mg/day; **max: 2g/day**

**Adverse Reactions**

Hyperoxaluria with large doses

**C**  
**Unknown<sup>1</sup>**

**Calcitriol (Vitamin D<sub>3</sub>)****Dosage Forms**

Cacare<sup>®</sup> 2mcg/ml/amp <CCALC02>

U-Ca<sup>®</sup> 0.5mcg/soft cap <KCALC06>

**Use**

Management of hypocalcemia in patient undergoing chronic renal dialysis

**Dose**

Hypocalcemia - Renal dialysis

Adult: **IV** 1mcg -2mcg 3times/wks, the dose may be increase by 0.5-1mcg at2-4 wk interval

Adult: **PO** initial 0.25mcg qd or qod, increased by 0.25 mcg/day at 2-4 wk intervals as needed. Maintenance: 0.5-1 mcg/day

**Adverse Reactions**

Hypercalcemia, weakness, bone pain, metallic taste

**C**  
**Safe<sup>1</sup>**

**Mecobalamin (Vitamin B<sub>12</sub>)****Dosage forms**

Mecobal<sup>®</sup> 500mcg/amp <CMETHYL>  
Methylcobal<sup>®</sup> 500mcg/cap <KMETHY4>

### Use

Vitamin B<sub>12</sub> deficiency, anemia

### Dose

#### Vitamin B<sub>12</sub> deficiency

Children: **IM/IV** 30-50 mcg/day for 2 or more wk; then 100 mcg/ mon mantance dose 1000 mcg/day; **PO** 1000 mcg/day

Adult: **IM/IV** 500mcg/day, 3-4 times/week; **PO** 1000 mcg/day

### Adverse Reactions

Headache, anxiety, dizziness, diarrhea, nausea, vomiting, itching

### Precautions

1.若發生過敏症狀時，請停止使用。

2.本劑易受光線分解，使用時，從避光器取出應立即使用，並避光保存。

## Multivitamins

**C** Unknown<sup>1</sup>

### Dosage Forms

商品名	注射: Lyo-Povigent <sup>®</sup>	
規格	CVITAM2	
<代碼>	PART I	PART II
含量	Vitamin E (IU).....10 Vitamin K1 (mg).....2 Thiamin Hydrochloride(B1, mg)....3.9 Riboflavin-5-phosphate sodium(B2, mg)...4.6 Cyanocobalamin (B12 ,μg)...5 Niacinamide (B3 ,mg)...40 Folic acid (B9 , μg).....400 Biotin (μg).....60 Ascorbic acid (mg).....100	Vitamin A .....3300IU Vitamin D.....200IU Pyridoxine Hydrochloride.....4.9mg D-Pantheno.....14mg

### Use

Vitamin supplementation

### Dose

Children>11 yrs and adults: **IV** 1盒(part I+part II)

### Precautions

1.注射劑 Lyo-Povigent<sup>®</sup> 應儲存於 2-8°C，每次輸注需同時將 part I+part II 混合溶解後加入輸液稀釋後才可使用。

2. part I+part II 混合溶解後應儲存於 2-8°C，必須 72 小時內使用完畢。

## Phytomenadione (Vitamin K<sub>1</sub>)

**C** Safe<sup>1</sup>

### Dosage Forms

Katimin 1<sup>®</sup> 10mg/ml/amp <CVITK1>參閱 p.184

## **Pyridoxal phosphate (Vitamin B<sub>6</sub>) A Safe<sup>1</sup>**

### **Dosage Forms**

Pyridoxine<sup>®</sup> 50mg/tab <KVITB61>

### **Use**

Prevents and treats vitamin B<sub>6</sub> deficiency, pyridoxine-dependent seizures in infants, adjunct to treatment of acute toxicity from isoniazid, cycloserine or hydralazine overdose

### **Dose**

#### Pyridoxine-dependent

Infant: **PO** 2-100 mg/day

#### Drug-induced neuritis

Children: **PO** 10-50mg/day, prophylaxis: 1-2mg/kg/day

Adults: **PO** 100-200mg/day, prophylaxis: 25-100mg/day

### **Adverse Reactions**

Sensory neuropathy, headache, nausea, decreased serum folic acid secretions

## **Vitamin B complex C Unknown<sup>1</sup>**

### **Dosage Forms**

商品名	Combeplex <sup>®</sup>	Vitamin B-complex <sup>®</sup>
規格<代碼>	1ml/amp <CVITBC>	Cap <KVITAB>
含量	Thiamin(Vit B <sub>1</sub> ).....100mg Riboflavin (Vit B <sub>2</sub> ).....5mg Pyridoxine (Vit B <sub>6</sub> ).....5mg Nicotinamide..... 50mg Sod. Pantothenate..... 5mg Benzyl alcohol..... 20mg	Thiamin(Vit B <sub>1</sub> ).....5mg Riboflavin (Vit B <sub>2</sub> ).....2mg Pyridoxine(Vit B <sub>6</sub> ).....1mg Cyanocobalamin(Vit B <sub>12</sub> ).....1μg Cal. Pantothenate..... 2.75mg Nicotinamide..... 10mg

### **Use**

Supply vitamin B complex

### **Dose**

#### Vitamin B deficient

**IM/SC** 1-2ml qd until symptom disappeared.

**PO** 1-3 cap/day

#### Vitamin B supplement before surgical operation

**IM/SC** 1ml/day qd-bid

## **13.5. Minerals**

## **Bio-Cal<sup>®</sup>**

## **C Unsafe<sup>1</sup>**

### **Dosage Forms**

1 chewable tab: Tricalcium phosphate 802mg (equivalent Ca<sup>2+</sup>=300mg) + Cholecalciferol 62.5IU (1.56mcg) <KCALC01>

### **Use**

Treatment and prevention of calcium deficiency

### **Dose**

2-4 tab/day

### Adverse Reactions

Hypercalcemia, hypervitaminosis D

## Calcium acetate

C Safe<sup>1</sup>

### Dosage Forms

Caphos® 667mg/tab (equivalent Ca<sup>2+</sup> =169mg=8.45mEq) <KCALC02>

### Use

Control of hyperphosphatemia in ESRD

### Dose

Adults: 2-4 tab with each meal

### Adverse reaction

Nausea, hypercalcemia

## Calcium carbonate

C Safe<sup>1</sup>

### Dosage Forms

A-CAL® 500mg/tab <KCALC03>

### Use

Calcium deficiency, hyperphosphatemia, antacid, hyperparathyroidism

### Dose

Calcium supplement

**PO** 500mg bid-tid

Antihyperphosphatemia in uremia

Adults: **PO** 2.5g/day; **max:** 8g/day

Osteoporosis

Adult>51yrs: **PO** 1.2g/day

Antacid

**PO** 0.5-1g; **max:** 7g/day

Hyperparathyroidism

**PO** 1-2g tid, until calcium conc. to arrive at normal range.

### Adverse Reactions

Hypophosphatemia, hypercalcemia

### Precautions

腎功能不全(Clcr<25ml/min)需調整劑量。

## Lanthanum carbonate hydrate

C Unsafe<sup>1</sup>

### Dosage Forms

Fosrenol® chewable tablets 750mg/tab<KLANTHA>

### Use

A phosphate binder agent for use in hyperphosphatemia therapy

### Dose

Adults: Initial 1500mg/day in divided doses with meals, increase 750mg every 2-3 weeks, maintenance 1500-3000 mg/day in divided doses with meals.

### Adverse Reactions

Abdominal pain, Diarrhea, Nausea, Vomiting.

### Precautions

錠劑必須咬碎，不可整粒吞服

### **Sevelamer carbonate**

**C Safe<sup>1</sup>**

#### **Dosage Forms**

Renvela<sup>®</sup> powder 800mg/pack <KSEVELA>

#### **Use**

Phosphate Binder

#### **Dose**

**PO** 5.5mg/dl < P < 7.5mg/dl: 800mg tid with meal; P ≥ 7.5mg/dl:

1600mg tid with meal

#### **Adverse Reactions**

Vomiting, nausea, diarrhea, dyspepsia, abdominal pain

#### **Precautions**

1. 800-1600mg 以 30ml 白開水混合服用，用力攪拌(本品不會溶解)並於 30 分鐘內喝完

2. 可能會降低維生素 D,E,K 或葉酸的吸收，建議隨餐服用並適量補充維生素

#### **Contraindications**

低血磷、腸阻塞

### **Zinc gluconate**

**A Unknown<sup>1</sup>**

#### **Dosage Forms**

Zinga<sup>®</sup> 78mg/tab (equivalent zinc=10mg) <KZINCGL>

#### **Use**

Zinc supplementation

#### **Dose**

Infants and children: 0.5-1mg equivalent zinc/kg/day qd-tid

Adults: 25-50mg equivalent zinc/day qd-tid

#### **Adverse Reactions**

Vomiting, neutropenia, jaundice, pulmonary edema

#### **Precautions**

Coffee reduces zinc absorption by up to 50%

## **13.6. Nutritional Agents Miscellaneous**

### **All-right calcium suspension<sup>®</sup>**

#### **Dose Forms**

1ml: Tribasic calcium phosphate 103 mg+Cholecalciferol 160 IU+Vitamine A 1600 IU, 180ml/bot <KCALC07>

#### **Use**

Vitamin A, D and calcium supplement

#### **Dose**

Infants: 2.5ml/day, children: 15 ml/day

Adults: 10-15 ml/day, pregnancy: 15 ml/day

#### **Precautions**

1. 本品顏色為白-淡黃，使用前須先振搖。
2. 本品含活性 Vit D3，不建議與 Biphosphonate 類、Teriparatide 併用。

## 14. OPHTHALMOLOGYS

### 【注意事項】

- 1.若要使用兩種以上眼藥水，則不同眼藥水點藥時間須間隔 5 分鐘，若同時須使用眼藥水與眼藥膏，請先點完眼藥水後再點眼藥膏，並間隔 5 分鐘，若使用兩種眼藥膏時，兩者至少隔 10 分鐘。
- 2.開封後置於室溫乾燥處且避光，一個月內若未用完則丟棄。
- 3.點眼藥水後，眼睛儘量張開，不眨眼數秒，再輕輕閉上眼睛二到三分鐘，擦掉流到臉上的多餘眼藥水。
- 4.手指可輕按壓眼角處的上下淚小管至少兩分鐘，防止藥水流進鼻淚管進入喉嚨。

### 14.1. Antibacterials

#### **Chloramphenicol**

**C<sup>1</sup> Unsafe<sup>1</sup>**

##### **Dosage Forms**

Chloramphenicol<sup>®</sup> oph drop 0.25%, 5ml/bot <WCHLOR1>

##### **Use**

Treatment of bacterial eye infection due to E coli, H influenza, Staph aureus, Strep hemolyticus, Morax Axenfeld bacillus

##### **Dose**

1-2 drops 4-8 times a day

##### **Precautions**

開瓶後可保存 1 個月，儲存以不超過 25°C 為主。

#### **Gentamicin**

**C<sup>1</sup> Unknown<sup>1</sup>**

##### **Dosage Forms**

Gentamicin<sup>®</sup> oph soln 0.3%, 5ml/bot <WGENTA2>

Oftalmolosa cusi<sup>®</sup> oph oint 0.3%, 5g/tube <WGENTA3>

##### **Use**

Superficial bacterial infection of the eye

##### **Dose**

Soln: 2 drop tid-qid; Oint: tid-qid

#### **Levofloxacin**

**C<sup>1</sup> Unknown<sup>1</sup>**

##### **Dosage Forms**

Cravit<sup>®</sup> oph slon 0.5%, 5ml/bot <WLEVOFL>

##### **Use**

Corneal ulcers, conjunctivitis

##### **Dose**

1-3drop qd-tid

##### **Adverse reactions**

Eye irritation, eye itching, corneal lesion, blepharitis

##### **Precautions**

1.用於結膜炎治療不建議超過 2 週

2.點眼時注意藥瓶瓶口勿觸及眼睛

3.健規：限用於角膜潰瘍或嚴重角膜炎病例，其餘眼科疾病列為第二線用藥

## Moxifloxacin

C<sup>1</sup> **Unsafe<sup>1</sup>**

### Dosage Forms

Vigamox® oph solution 0.5% 5ml/bot <WMOXIFL>

### Use

Treatment of bacterial conjunctivitis due to susceptible organisms

### Dose

1drop tid for 7days

### Adverse Reactions

視覺敏銳度降低、眼睛乾澀、角膜炎、眼部不適、充血、疼痛、搔癢、結膜下出血及流淚。

### Precautions

儲存於2-25°C。

## Sulfamethoxazole

C<sup>1</sup> **Unsafe<sup>1</sup>**

### Dosage Forms

Sinomin® eye drops 4%, 15ml/bot <WSULFAM>

### Use

Trachoma or inclusion conjunctivitis

### Dose

1-2 drops qid

### Adverse Reactions

Irritation, pain, stinging and burning

### Precautions

使用本品後15分鐘才可戴隱形眼鏡。

### Contraindications

Sulfonamide allergy, G6PD dysfunction

## Tetracycline

D<sup>1</sup> **Safe<sup>1</sup>**

### Dosage Forms

Tetracycline® oph oint 1%, 5g/tube <WTETRAC>

### Use

Superficial ocular infections, post-op infections, conjunctivitis

### Dose

bid-qid

## Tobramycin

D<sup>1</sup> **Unknown<sup>1</sup>**

### Dosage Forms

Tobrex® oph oint 0.3% 3.5g/tube <WTOBRA1>

### Use

Palpebitis, sty, conjunctivitis, keratitis

### Dose

Mild to moderate: bid-tid

Severe: instill q3-4h until symptoms improved

## 14.2. Antibacterials and Corticosteroids

### Tobradex®

C Unknown<sup>1</sup>

#### Dosage Forms

Oint 3.5g/tube: Dexamethasone 0.1%+Tobramycin 0.3% <WTOBRA3>

Susp 5ml/bot: Dexamethasone 0.1%+Tobramycin 0.3% <WTOBRA4>

#### Use

Inflammatory ocular conditions with bacterial infection

#### Dose

3-4 times a day

#### Adverse Reactions

Hypersensitivity, lid itching and swelling, conjunctival erythema

## 14.3. Corticosteroids

### Fluorometholone (FML)

C Unknown<sup>1</sup>

#### Dosage Forms

Foxone® oph susp 0.02%, 10ml/bot <WFLUOR6>

Viscone® eye drops, 5ml/bot <WFLUOR2>

#### Use

Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eye

#### Dose

1-2 drops bid-qid

#### Contraindications

遮蔽或加重急性化膿性眼睛發炎、單純性疱疹角膜炎、濾過性病毒角膜炎、黴真菌之眼疾。

### Prednisolone

C Safe<sup>1</sup>

#### Dosage Forms

Donison® 5mg/tab <KPREDNI> 參閱 p.227

Pred Forte® oph 1%, 5ml/bot <WPREDN1>

Kidsolone® oral solution 60mg/60ml/bot, 1ml:Prednisolone 1.344mg

<KPREDN1> 參閱 p.227

#### Use

Steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of globe

#### Dose

1-2 drop bid-qid

#### Contraindications

遮蔽或加重急性化膿性眼睛發炎、單純性疱疹角膜炎、濾過性病毒角膜炎、黴真菌之眼疾。

## 14.4. Antivirals

### Acyclovir

**B<sup>1</sup> Safe<sup>1</sup>**

#### Dosage Forms

Virless® lyophilized 250mg/vial <CACYC02> 參閱 p.34

Virless® 200mg/tab <KACYC01> 參閱 p.34

Zovirax® susp 4%, 125ml/bot <KACYC03> 參閱 p.34

Devirus® oph oint 3%, 4.5g/tube <WACYC02>

Aclovir® cream 5%, 5g/tube <WACYC05> 參閱 p.133

#### Use

Herpes simplex keratitis

#### Dose

q4-q6h

#### Adverse Reactions

Transient mild stinging, superficial punctuate keratopathy, local irritation

#### Precautions

1. Herpes simplex 3 日內可使用 acyclovir 藥膏，每次以 5g 為限。

2. 口服、注射、外用藥膏擇一使用，不得合併使用。

## 14.5. Glaucomas

### 14.5.1. Beta-Blockers

#### Levobunolol

**C<sup>4</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Bunolgan® oph soln 0.5%, 5ml/bot <WLEVOBU>

#### Use

Open-angle glaucoma, ocular hypertension

#### Dose

Adults: 1 drop qd-bid

#### Adverse Reactions

Transient ocular burning, stinging, itching, dizziness, headache

#### Precautions

嚴重 COPD 、 asthma 、 CHF 、 AV-block 等病人不建議使用。

### 14.5.2. Alpha-2-Agonists

#### Brimonidine

**B<sup>1</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Alphagan® P oph soln 0.15%, 5ml/bot <WBRIMO1>

#### Use

Open-angle glaucoma, ocular hypertension

#### Dose

1 drop tid

#### Adverse Reactions

Oral dryness, ocular hyperemia, burning, headache

#### Precautions

儲存於25°C 以下。

### 14.5.3. Carbonic Anhydrase Inhibitors

#### Azarga®

C<sup>5</sup> Unknown<sup>3</sup>

#### Dosage Forms

1ml: Brinzolamide 10mg+Timolol 5mg, oph suspension 5ml/bot  
<WAZARGA>

#### Use

Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma

#### Dose

1 drop bid

#### Adverse Reactions

Blurred vision, pain in eye, eye irritation, taste sense altered

#### Precautions

1. 使用前需先搖勻。
2. 不可在戴隱形眼鏡時使用，至少間隔 15 分鐘以上。
3. 開封後可保存 4 週，不可冷藏。
4. 健規：限單一降眼壓藥物治療，眼壓控制不良之青光眼第二線用藥，每月以處方一瓶為原則。

#### Contraindications

氣喘、心因性休克、心跳徐緩、高血氯性酸中毒、腎功能 Clcr<30ml/min。

#### Brinzolamide

C<sup>1</sup> Unknown<sup>1</sup>

#### Dosage Forms

Azopt® oph slon 1%, 5ml/bot <WBRINZO>

#### Use

Intraocular hypertension, open-angle glaucoma

#### Dose

1 drop bid-tid

#### Adverse Reactions

Abnormal taste in mouth, bitter, headache, blurred vision

#### Precautions

開封後 4 週內使用完畢。

#### Contraindications

Sulfonamide 過敏者禁用。

#### Combigan®

C<sup>5</sup> Unknown<sup>3</sup>

#### Dosage Forms

1ml: Brimonidine 0.2%+ Timolol 0.5% oph solution 5ml/bot <WCOMBI1>

#### Use

Glaucoma

#### Dose

1 drop bid

### Adverse Reactions

Blurred vision, pain in eye, eye irritation, taste sense altered

### Precautions

1. 使用前需先搖勻。

2. 不可在戴隱形眼鏡時使用，至少間隔 15 分鐘以上。

3. 開封後可保存 4 週，不可冷藏。

4. 健規：限單一降眼壓藥物治療，眼壓控制不良之青光眼第二線用藥，每月以處方一瓶為原則。

### Contraindications

氣喘、心因性休克、心跳徐緩、高血氯性酸中毒、腎功能 Clcr<30ml/min。

## 14.5.4. Prostaglandin Agonists

### Bimatoprost

C<sup>5</sup> Unknown<sup>3</sup>

### Dosage Forms

Lumigant<sup>®</sup> oph soln 0.01%, 3ml/bot <WBIMAT1>

### Use

Reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension

### Dose

1 drops in the affected eye(s) in the evening; **max: 1drop/day**

### Adverse Reactions

Conjunctival hyperemia, growth of eyelashes, ocular pruritus

### Precautions

1. 開封後 28 天內應丟棄。

2. 使用前應先取下隱形眼鏡，滴入 15 分鐘後再重新戴上。

3. 避免讓瓶口碰觸到眼睛及其周圍結構、手指或任何其他表面，以避免造成眼睛感染。

4. 使用後可能發生永久性的虹膜棕色色素沉著增加，以及停藥後可逆轉的眼瞼皮膚變深和睫毛或柔毛變化。

5. 健規每月處方一瓶為原則。

### Contraindications

嚴重乾眼症及小於 16 歲的病患不建議使用。

### Travoprost

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Travatan<sup>®</sup> oph soln 0.004%, 2.5ml/bot <WTRAVOP>

### Use

Glaucoma and ocular hypertension

### Dose

1 drop in the affected eye once a day in the evening

## 14.5.5. Miotics

**Carbachol****C Unknown<sup>1</sup>****Dosage Forms**

Miostat® oph soln 0.01%, 1.5ml/vial &lt;CCARBAC&gt;

**Use**

Intraocular use for miosis during surgery

**Dose**

Instilled 0.5ml into anterior chamber of the eye before or after securing sutures

**Adverse Reactions**

Headache, blurred vision, burning sensation in eye, eye irritation, night blindness

**Pilocarpine****C Unknown<sup>1</sup>****Dosage Forms**

Salagen® 5mg/tab &lt;KPILOCA&gt; 參閱p.329

Isopto® Carpine oph drop 2%, 15ml/bot &lt;WPILOC2&gt;

**Use**

Control of intraocular pressure

**Dose**

2 drops tid-qid

**Adverse Reactions**

Slight ciliary spasm, conjunctival vascular congestion, temporal or supraorbital headache

## 14.6. Mydriatics and Cycloplegics

**Atropine sulphate****C Unknown<sup>1</sup>****Dosage Forms**

Atropine® 1mg/ml/amp &lt;CATROPI&gt; 參閱p.166

Tropine® oph soln 0.3%, 5ml/bot &lt;WATRO3&gt;

**Use**

Cycloplegic refraction

**Dose**

Children: 1 drop tid

Adults: 2 drops tid

**Adverse Reactions**

Dryness of the mouth, blurred vision, sensitivity to light, local irritation

**Precautions**

Children who have previously had severe systemic reaction to atropine (ophthalmic formulation)

**Contraindications**

Glaucoma, or a predisposition to narrow anterior chamber angle glaucoma

**Cyclopentolate****C Unknown<sup>1</sup>****Dosage Forms**

Cyclogyl® oph soln 1%, 5ml/bot <WCYCL01>

**Use**

Mydriasis and cycloplegia induction

**Dose**

1-2 drops, may repeat in 5-10 min as needed

**Adverse Reactions**

Increased intraocular pressure, burning, photophobia, blurred vision, irritation

**Precautions**

Children with spastic paralysis or brain damage; Down's syndrome; predisposition to angle-closure glaucoma

**Contraindications**

Narrow-angle glaucoma or anatomical narrow angles

**Mydrin-P®**

**Dosage Forms**

1ml: Phenylephrine 5mg+Tropicamide 5mg, 10ml/bot <WTROP01>

**Use**

Mydriasis and cycloplegia for diagnosis

**Dose**

Mydriasis for diagnosis

1-2 drops q3-5min for 2 doses

Cycloplegia

1 drop q3-5min for 2-3 times

**Adverse Reactions**

Transient sting, dry mouth

**Phenylephrine**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Phenylephrine® oph soln 10%, 5ml/bot <WPHENYL>

**Use**

Induce mydriasis to facilitate ocular surgery and allow exam of intraocular structures, adjunctive treatment of anterior uveitis

**Dose**

1 drop to each eye, may repeat once only, after 1 hr

**Adverse Reactions**

Irritation, photophobia, decreased vision

**Precautions**

Contact lens users

**Contraindications**

Anatomical narrow-angle, narrow angle glaucoma

**Tropicamide**

**C<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Mydriacyl® oph drop 1%, 5ml/bot <WTROP03>

**Use**

Mydriasis, cycloplegia for diagnostic procedures

**Dose****Refracts**

1-2drops repeated 15-20 min prior to exam.

**Adverse Reactions**

Blurred vision, headache, ocular irritation

**Precautions**

Increased intraocular pressure, infants and children, may cause central nervous system disturbances

**Contraindications**

Primary glaucoma or a tendency toward glaucoma

## 14.7. Cataracts

**Azapentacene****Dosage Forms**

Quinax<sup>®</sup> oph soln 0.015%, 15ml/bot <WAZAPEN>

**Use**

Senile and traumatic cataract

**Dose**

2 drops 3-5 times/day

## 14.8. Ocular Decongestants and Anti-Allergys

**Cromolyn**

**B<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Cromo<sup>®</sup> eye drops 20mg/ml, 10ml/bot<WCROM01>

Allergocrom<sup>®</sup> nasal spray, 100sprays/15ml/bot<WCROM04> 參閱 p.318

**Use**

Prevention and relief of the ocular symptoms that appear with allergic conjunctivitis

**Dose**

1 drop qid

**Adverse Reactions**

Stinging, irritation

**Contraidcations**

1.懷孕前三個月禁用。

2.治療期間不配戴隱形眼鏡。

**Cyanocobalamin (Vitamin B<sub>12</sub>)**

**C<sup>4</sup> Safe<sup>1</sup>**

**Dosage Forms**

Sancoba<sup>®</sup> oph soln 0.02%, 5ml/bot <WCYANOC>

**Use**

Allergic conjunctivitis, vitamin B12 deficiencies

**Dose**

1 drop 3-5 times/day

**Emedastine****B** Unknown<sup>1</sup>**Dosage Forms**

Emadine® oph soln 0.05%, 5ml/bot &lt;WEMEDAS&gt;

**Use**H<sub>1</sub>-blocker for allergic conjunctivitis**Dose**

1 drop qid

**Adverse Reactions**

Headache

**Olopatadine****C** Unsafe<sup>1</sup>**Dosage Forms**

Patanol® oph soln 0.1%, 5ml/bot &lt;WOLPAT&gt;

**Use**H<sub>1</sub>-blocker for allergic conjunctivitis**Dose**

1 drop bid

**Adverse Reactions**

Headache, blurred vision, xerophthalmia

## 14.9. Dry Eye Products

**Carbomer****Dosage Forms**

Ginpol® gel 20mg/10g/tube &lt;WCARBOM&gt;

**Use**

Substitute for lacrimal fluid in deficiency of tear or dry eye

**Dose**

Instil 1 drop into conjunctival sac 3-5 times daily or more frequently during the day and before retiring at night

**Adverse Reactions**

Transient blurring in vision

**Duratears®****Dosage Forms**

1g: Anhydrous liquid lanolin 30mg+Mineral oil 30mg+Methylparaben 0.5mg+Propylparaben 0.1mg, artificial tears oph oint 3.5g/tube &lt;WDURATE&gt;

**Use**

Ocular lubricant

**Dose**

Apply a small ribbon under the lower lid or to the affected area

**Optive®****Dosage Forms**

1ml: Carboxymethylcellulose sodium 0.5% + Glycerin 0.9% oph soln

15ml/bot <WOPTIVE>

**Use**

Dry eyes, exposure to wind or sun, protectant against further irritation

**Dose**

1-2 drops in the affected eye(s) as needed

**Precautions**

開封後需在 180 天內使用完畢。

## **Propylene glycol**

**Dosage Forms**

Systane® 10ml/bot<WSYSTAN>

**Use**

Ocular lubricant

**Dose**

1-2 drops in the affected eye(s) as needed

**Precautions**

開瓶後在 25°C 下可保存 30 天。

## **Tears naturale®**

**Dosage Forms**

1ml: Hydroxypropyl methylcellulose 3mg+Dextran 70 1mg+ Borax 3.5mg+ NaCl 6mg+ KCl 1.2mg+ Polyquaternium-1 solution 0.001% , 15ml/bot <WARTIO2>

**Use**

Dry eye

**Dose**

1-2 drops as required

**Adverse Reactions**

Irritation

**Precautions**

開瓶後請於 30 天內使用完畢。

**Contraindications**

配戴軟式隱形眼鏡時請勿使用。

## **Tears naturale® Free**

**Dosage Forms**

1ml: 0.3% Hydroxypropyl methylcellulose+ 0.1% Dextran 70, artificial tears oph drop 1ml/vial (32vial/box) <WTEARS1>

**Use**

Dry eye

**Dose**

1-2 drops as required

**Adverse Reactions**

Irritation

**Precautions**

開瓶後請於 12 小時內使用完畢。

## **14.10. Ophthalmology Miscellaneous**

### **Aflibercept**

#### **Dosage Forms**

Eylea 4mg/0.1ml/vial <CAFLIB1>

#### **Use**

Neovascular(wet) age-related macular degeneration(AMD), macular edema following retinal vein occlusion(RVO) and Diabetic retinopathy (DR) in patients with Diabetic macular edema (DME)

#### **Dose**

##### Age-related macular degeneration(AMD)

**Intravitreal injection (IVI)** 2 mg (0.05 mL) every 4 weeks for 12 weeks, then once every 8 weeks

##### Macular edema following retinal vein occlusion(RVO)

**IVI** 2 mg (0.05 mL) once every 4 weeks

##### Diabetic retinopathy (DR) in patients with Diabetic macular edema (DME)

**IVI** 2 mg (0.05 mL) once every 4 weeks for the first 5 injections, then 2 mg (0.05 mL) every 8 weeks

#### **Adverse Reactions**

Conjunctival hemorrhage, pain in eye

#### **Precautions**

1. 冷藏保存，使用前於室溫(25°C)可存放 24 小時，僅供單次使用

2. 進行眼內手術，應於之前或之後 28 天暫時停用藥物

3. 治療期間應避孕，直到最後一劑注射後至少 3 個月

### **BSS®**

#### **Dosage Forms**

1ml: NaCl 6.4mg+KCl 0.75mg+CaCl<sub>2</sub> 0.48mg+MgCl<sub>2</sub> 0.3mg+Na acetate 3.9mg+Na citrate 1.7mg, balanced salt soln 15ml/bot <WBSS>

#### **Use**

For irrigation during various surgical procedures of the eye, ear, nose or throat

#### **Adverse Reactions**

When the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy

#### **Precautions**

不含防腐劑，開封後請一日內使用完畢，如有變色或混濁時，請勿繼續使用。

### **BSS® plus**

#### **Dosage Forms**

Balanced salt soln 480ml (Part I)/bot+20ml(Part II)/vial <WBSSPLU>

Part I 1ml: NaCl 7.14mg+KCl 0.38mg+Dibasic sodium phosphate 0.42mg+ NaHCO<sub>3</sub> 2.1mg

Part II 1ml: CaCl<sub>2</sub> · 2H<sub>2</sub>O 0.154mg+MgCl<sub>2</sub> · 6H<sub>2</sub>O 0.2mg+Dextrose 0.92mg+ Glutathione disulfide 0.184mg

### Use

For irrigation during various surgical procedures of the eye, ear, nose or throat

### Adverse Reactions

When the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy

### Precautions

- 1.不得做為注射劑或靜脈輸注之用。
- 2.混合液配置後 6 小時內使用完畢，剩餘部份應予丟棄。

## Cyclosporine

**C<sup>1</sup> Unknown<sup>2</sup>**

### Dosage Form

Restasis® oph emulsion 0.05% 0.4ml/vial, 30vial/box <WCYCLOS>

### Use

Anti-inflammatory

### Dose

1 drop q12h

### Adverse Reactions

Burning, conjunctival hyperemia, eye pain, epiphora, blurring

### Precautions

- 1.本品須經事先審查核准後方可使用。
- 2.使用前需先振搖數次，形成均勻白色不透明乳液後方可使用。
- 3.每盒 30 小瓶，每小瓶限單次使用，開封後須立即使用，未使用完之藥液需丟棄。
- 4.使用時勿配戴隱形眼鏡，待投藥 15 分鐘後才可重新戴上隱形眼鏡。

## Proparacaine

**C<sup>1</sup> Unknown<sup>1</sup>**

### Dosage Forms

Alcaine® oph soln 0.5%, 15ml/bot <WOXYBUP>

### Use

Corneal anesthesia of short duration (tonometry, gonioscopy, removal of corneal foreign bodies, for short corneal and conjunctival procedures)

### Dose

1 drop q5-10 min for 5-7 doses

### Adverse Reactions

Local irritation and stinging

### Precautions

須冷藏

## Ranibizumab

**C<sup>1</sup> Unknown<sup>1</sup>**

### Dosage Forms

Lucentis® 10mg/ml, 0.23ml/vial <CRANIBI >

### Use

Exudative age-related macular degeneration

**Dose****IVI**

0.3-0.5mg(0.03-0.05ml) once monthly

**Adverse Reactions**

Intraocular inflammation, eye pruritus, blepharitis, headache, arthralgia

**Precautions**

- 1.需儲存於 2~8°C
- 2.本品須經事先審查後方可使用

**Contraindication**

眼睛周圍或眼內發炎。

# 15. PSYCHIATRYS

## 15.1. Antidepressants

### 15.1.1. Tricyclic-Tertiary Amines (TCA)

#### Amitriptyline

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Trynol® 25mg/tab <KAMITRI>

#### Use

Relief of symptoms of depression

#### Dose

**PO** initial 75 milligrams/day in divided doses, maintain 50-100mg/day in divided dose; max: 300mg/day

#### Adverse Reactions

Weight gain, constipation, drowsiness, dizziness, headache

#### Imipramine

D<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Fronil® 25mg/tab <KIMIPRA>

#### Use

Various forms of depression, childhood enuresis

#### Dose

##### Depression

Outpatient initial 75mg/day **PO** in divided doses; **max: 200mg/day**

Inpatient initial 100mg/day **PO** in divided doses; **max: 300mg/day**

#### Adverse Reactions

Weight gain, constipation, bloating, blurred vision, dizziness

#### Precautions

1. 使用 MAOI 二者投藥時間需至少間隔 14 天。

2. 心肌梗塞危急者。

### 15.1.2. Serotonin-Norepinephrine Reuptake Inhibitors

#### Atomoxetine

C<sup>5</sup> Unknown<sup>3</sup>

#### Dosage Forms

Strattera® 40mg/tab <KATOMOX>

#### Use

Attention deficit hyperactivity disorder (ADHD)

#### Dose

<70 kg children and adolescent:

**PO** initial 0.5mg/kg/day qd, may increase after minimum of 3 days to 1.2mg/kg/day; **max: 1.4mg/kg/day or 100mg/day**

>70kg children, adolescent and adult:

**PO** initial 40mg/day qd, may increase after minimum of 3 days to 80mg/day; **max: 100mg/day**

## **Adverse Reactions**

Decrease appetite, insomnia, sedation, depression, tremor

## **Precautions**

- 1.粉末對眼睛具刺激性，膠囊不可打開，須整粒吞服。
- 2.使用 MAO I 二者投藥時間需至少間隔 14 天。

## **Contraindications**

狹角性青光眼。

## **Duloxetine**

C <sup>5</sup>	Unknown <sup>3</sup>
----------------	----------------------

### **Dosage Forms**

Cymbalta<sup>®</sup> 30mg/cap <KDULOXE>

### **Use**

Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathy pain

### **Dose**

Major depressive disorder

**PO** 40-60mg/day qd-bid; **max: 120mg/day**

Generalized anxiety disorder

**PO** 30mg/day qd; **max: 120mg/day**

Peripheral neuropathy pain

**PO** 60mg/day qd; **max: 60mg/day**

## **Adverse Reactions**

Nausea, xerostomia, dizziness, fatigue, constipation

## **Precautions**

- 1.為腸膜衣藥丸，不可打開膠囊、咀嚼、及壓碎。
- 2.正接受 MAO I 治療轉換為本品時，至少停藥間隔 14 天。

## **Contraindications**

嚴重腎功能不全 (Ccr < 30mL/min) 或肝能不全者

## **Venlafaxine**

C <sup>1</sup>	Unsafe <sup>3</sup>
----------------	---------------------

### **Dosage Forms**

Valosin<sup>®</sup> 37.5mg/tab <KVENLA1>

Rafax<sup>®</sup> 75mg/XR. cap <KVENLA2>

### **Use**

Depression, Generalized anxiety disorder, Social phobia, Panic disorder

### **Dose**

Valosin<sup>®</sup>

Depression

**PO** initial 75mg/day bid-tid, dose may be increased to 75mg at interval of at least 4 days. **max: 375mg/day**

Rafax<sup>®</sup> XR

Depression

**PO** 75mg qd; **max: 375mg/day**

Generalized anxiety disorder

**PO** 37.5mg qd; **max: 225mg/day**

Social phobia

**PO** 37.5mg qd; **max: 225mg/day**

Panic disorder

**PO** 37.5mg qd; **max: 225mg/day**

**Adverse Reactions**

Nausea, xerostomia, dizziness, weight loss, somnolence, insomnia

**Precautions**

正接受 MAO I 治療轉換為本品時，至少停藥間隔 14 天，停止使用本品至使用 MAO I 則需間隔 7 天。

### 15.1.3. Selective Serotonin Reuptake Inhibitors (SSRI)

#### Escitalopram

**C<sup>1</sup> [Unsafe]<sup>1</sup>**

**Dosage Forms**

Leeyo<sup>®</sup> 10mg/FC. tab <KESCITA>

**Use**

Major depressive disorder, generalized anxiety disorder

**Dose**

**PO** 10-20mg qd

**Adverse Reactions**

Nausea, insomnia, somnolence, ejaculation disorder, diaphoresis, fatigue

**Precautions**

接受 MAOI 治療轉換為本藥時，至少停藥間隔 14 天。

**Contraindications**

<18yrs 不建議使用。

#### Paroxetine

**D<sup>1</sup> [Unknown]<sup>1</sup>**

**Dosage Forms**

Setine<sup>®</sup> 20mg/tab <KPAROXE>

**Use**

Depression, panic disorder, obsessive-compulsive disorder, anxiety

**Dose**

Initial 20mg/day qd; **max: 60mg/day**

**Adverse Reactions**

Dizziness, insomnia, nervousness, somnolence, tremor, sweating, constipation, diarrhea, dry mouth, nausea

#### Sertraline

**C<sup>1</sup> [Unknown]<sup>1</sup>**

**Dosage Forms**

You-Jet<sup>®</sup> 50mg/tab <KSERTRA>

**Use**

Depression, obsessive-compulsive disorder (OCD), panic disorder

**Dose**

**PO** 25-50mg once daily, increased at intervals of at least 1 wk; **max: 200mg/day**

**Adverse Reactions**

Insomnia, somnolence, dizziness, tremor, rash, anorexia, diarrhea,

dyspepsia, dry mouth, nausea, abnormal ejaculation, headache  
**Precautions**

接受 MAOIs 治療者須停藥 14 天後，才可使用本品。

#### 15.1.4. 5-HT<sub>2</sub> Receptor Antagonists

##### Trazodone

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Mesyrel<sup>®</sup> 50mg/tab <KTRAZOD>

##### Use

Depression

##### Dose

50mg tid; max: 600mg/day

##### Adverse Reactions

Dizziness, restlessness, fatigue, hypotension

#### 15.1.5. Alpha-2 Antagonist

##### Mirtazapine

C<sup>5</sup> Unknown<sup>1</sup>

##### Dosage Forms

Mirtine<sup>®</sup> 30mg/F.C. tab<KMIRTAZ>

##### Use

Depression

##### Dose

Adult: initial 15mg/day hs or bid, mantaince dose 15-45mg/day hs or bid;  
max: 45mg/day

##### Adverse Reactions

Increased appetite, weight gain, dizziness, agranulocytosis.

##### Precautions

1. 本品會降低注意力及警覺性，操作機械及駕駛汽車須小心。
2. 如有發燒、喉嚨痛、口腔炎應盡速回診。
3. 本品與 Warfarin 併用時，建議監測 INR。

#### 15.1.6. Dopamine Reuptake Inhibitors

##### Bupropion

B<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Wellbutrin<sup>®</sup> 150mg/XL tab <KBUPROP>

##### Use

Depression

##### Dose

Initial 150mg/day; max: 300mg/day in 2 divided dose

##### Adverse Reactions

Agitation, constipation, dry mouth, tremor, sweating

#### 15.2. Antipsychotic Agents

### 15.2.1. Phenothiazine Derivatives

#### Prochlorperazine

C<sup>5</sup> **Unsafe<sup>3</sup>**

##### Dosage Forms

Novamin<sup>®</sup> 5mg/ml/amp <CPROCHL>

Novamin<sup>®</sup> 5mg/tab <KPROCHL>

##### Use

Nausea, vomiting, psychosis

##### Dose

###### IM

Infant > 6months: 0.1mg/kg/day

Adult: 5mg/day

###### PO

Child 2-6yrs: **max: 20mg/day**; 6-12yrs **max: 25mg/day**

Adult: 5-10mg tid-qid **max: 150mg/day**

##### Adverse Reactions

Extrapyramidal symptoms, drowsiness, constipation, urinary retention, hypotension

##### Precautions

口服錠劑可能導致尿液變色。

##### Contraindications

口服錠劑禁用於 2 歲或 9kg 以下兒童，針劑禁用於 6 個月以下嬰兒。

### 15.2.2. Benzisothiazoyl Piperazine Derivatives

#### Ziprasidone

C<sup>1</sup> **Unknown<sup>1</sup>**

##### Dosage Forms

Geodon<sup>®</sup> 40mg/cap <KZIPRAS>

##### Use

Schizophrenia, bipolar mania

##### Dose

PO 40mg bid; max: 80mg bid

##### Adverse Reactions

Asthenia, extrapyramidal syndrome, somnolence, headache, nausea

##### Contraindications

QT prolong patient, <18yrs.

### 15.2.3. Thioxanthene Derivatives

#### Deanxit<sup>®</sup>

**Unknown<sup>1</sup>**

##### Dosage Forms

1 tab: Flupentixol 0.5mg+ Melitracen 10mg <KDEANXI>

##### Use

Anxiety

##### Dose

PO 1 tab bid; **max: 6 tab/day**

### **Adverse Reactions**

Restlessness, insomnia

## **15.2.4. Phenylbutylpiperadine Derivatives**

### **Haloperidol**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Halosten® 1mg/tab <KHALOP5>

#### **Use**

Hyperactive children, psychotic disorders, several behavior problems in children, tourette's disorders

#### **Dose**

**PO initial 0.75-2.25mg/day; max: 25mg/day**

#### **Adverse Reactions**

Akathisia, dystonic extrapyramidal effects, hypotension, blurred vision, constipation

#### **Precautions**

急速增量時可能會引起惡性症狀(neuroleptic malignant syndrome; NMS)

## **15.2.5. Dibenzapine Derivatives**

### **Clozapine**

**B<sup>4</sup> Unsafe<sup>1</sup>**

#### **Dosage Forms**

Clozaril® 100mg/tab <KCLOZ02>

#### **Use**

Refractory schizophrenia, parkinsonism induced psychiatric disease

#### **Dose**

**PO 5mg qd-bid at 1<sup>st</sup> day, 25mg qd-bid at 2<sup>nd</sup> day, dosage adjustment to 300mg /day in 2-3 wks, therapeutic dosage is 300-450mg/day ; max: 900mg/day**

#### **Adverse Reactions**

Somnolence, dizziness, weight increase, excessive salivation, tachycardia, hypotension

#### **Precautions**

需密切監測病患之 WBC 及 ANC 值，病患出現類感冒症狀如發燒、喉嚨痛時需特別注意。

#### **Contraindications**

骨髓功能受損、未控制癲癇、毒性或特異性白血球減少、進行性肝疾病、麻痺性腸阻塞、無法定期接受血液檢查者。

### **Quetiapine**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Seroquel® 25mg/tab <KQUETI1>

Seroquel XR® 50mg/tab <KQUETI4>

Seroquel XR® 300mg/tab <KQUETI3>

## **Use**

Schizophrenia, depression and manic phase of bipolar disorder

## **Dose**

### Schizophrenia

Seroquel XR®:PO initial 300 mg once daily; **max:800 mg/day**

Seroquel®:PO initial 25-50mg bid, usual effective dosage 150-750mg/day; **max:800mg/day**

### Bipolar disorder, depressed phase

Seroquel XR®:PO 50, 100 , 200, and 300 mg given daily on days 1- 4

### Manic bipolar I disorder

Seroquel XR®:PO 300 mg on day 1 and 600 mg on day 2. Adjust the dose between 400 and 800 mg daily beginning on day 3

Seroquel®:PO 400-800mg/day bid

## **Adverse Reactions**

Hypertension, weight gain, TG and cholesterol raised, xerostomia, somnolence

## **Precautions**

1.Seizure disorder, cardiovascular disease, cerebrovascular disease

2.需依肝功能調整劑量。

3.Seroquel XR® 可撥半不可磨粉。

**C<sup>5</sup> [UnSafe]<sup>1</sup>**

## **Zotepine**

### **Dosage Forms**

Lodopin® 50mg/tab < KZOTEPI>

## **Use**

Schizophrenia

## **Dose**

PO 75-150mg/day divided dose; **max: 450mg/day**

## **Adverse Reactions**

Dizziness, strengthless, insomnia, thirsty, constipation

## **Precautions**

1.有肝功能障礙、血液障礙、疑似心臟疾病、重症氣喘、肺氣腫、癲癇等應慎重給藥。

2.可能造成嗜睡、注意力不集中，應避免開車或從事機械操作。

3.服藥期間應避免服用含酒精及咖啡因飲料。

## **Contraindications**

1.腦炎、腦腫瘤、頭部外傷之患者。

2.使用 Terfenadine 或 Astemizole 的患者(造成心室性心律不整)。

## **15.2.6. Benzisoxazole Derivatives**

## **Paliperidone**

**C<sup>5</sup> [UnSafe]<sup>1</sup>**

### **Dosage Forms**

Invega® 3mg/ER tab<KPALIPE>

Invega® sustenna 100mg/1ml/syringe<CPALIP1>

Invega® sustenna 150mg/1.5ml/syringe<CPALIP2>

## Use

Schizophrenia, Schizoaffective disorder

## Dose

**PO** 3-6mg qd, administered in the morning, may increase by 3 mg/day increments at intervals of more than 4 days. **Max: 12mg/day**

**IM** initial 150mg on day 1, followed by 100mg 1 week later. Maintenance dose is 25-150mg every monthly base on individual patient tolerability and efficacy.

## Adverse Reactions

Tachycardia, hyperprolactinemia, extrapyramidal disease, somnolence, orthostatic hypotension

## Precautions

- 1.錠劑為滲透壓控釋劑型，須整粒吞服，不可嚼碎、撥半或磨粉。
- 2.錠劑因劑型設計關係，藥錠會隨糞便整粒排出。
- 3.可能造成知能及運動障礙(如嗜睡、鎮靜、傷害判斷及思考或行動)，操作機械及駕駛汽車須小心。
- 4.需依腎功能調整劑量。
- 5.針劑僅供深部肌肉注射，勿將一劑分成數次施打。

## Contraindications

18 歲以下安全及有效性尚未建立，不建議使用。

## Risperidone

**C** **Unsafe**

## Dosage Forms

Risperdal® 1mg/tab <KRISPE1>

Seridol® soln 30mg/30ml/bot <KRISPE3>

## Use

Bipolar mania, schizophrenia

## Dose

**PO** initial 2mg/day, usual dose: 2-6mg/day; **max: 8mg/day**

## Adverse Reactions

Anxiety, extrapyramidal symptoms, akathisia, constipation

## Precautions

需依肝腎功能調整劑量。

## 15.2.7. Thienobenzodiazepine Derivatives

## Olanzapine

**C** **Unknown**

## Dosage Forms

Zyprexa® 10mg/vial<COLANZA>

Zyprexa® Zydis OD 5mg/tab <KOLANZ1>

## Use

Agitation associated with schizophrenia or bipolar mania

## Dose

**PO** 5-20mg/day qd; **max: 20mg/day**

**IM** initial dose is 10 mg, followed by 5-10 mg as required after 2 hours.

**Max: 20mg/day**, and injection less 3 times/day

>60 y/o older man: **IM** initial dose is 2.5 mg, followed by 2.5-5 mg as required after 2 hours. **Max: 20 mg/day and injection less 3 times/day.**

#### **Adverse Reactions**

Somnolence, weight gain, TG, cholesterol and prolactin raised, asthenia  
**Precautions**

- 1.需依腎功能調整劑量。
- 2.限用注射用水配製，配製後可貯放 1 小時，不得與其他不相容藥品 (diazepam, haloperidol)共用注射針筒。
- 3.不可靜脈或皮下注射且 24 小時內不可注射超過 3 次。

#### **Contraindications**

廣角性青光眼病患。

### **15.2.8. Selective D<sub>2</sub> Antagonists**

#### **Amisulpride**

**D<sup>1</sup> Unsafe<sup>1</sup>**

#### **Dosage forms**

Solian<sup>®</sup> 200mg/tab <KAMISUL>

#### **Use**

Acute and chronic schizophrenia

#### **Dose**

**PO** 400-800mg/day in divided doses; **max: 1200mg/day**

#### **Adverse Reactions**

Insomnia, anxiety, agitation, menstrual disorders, weight increases

#### **Precautions**

需依腎功能調整劑量。

#### **Sulpiride**

**D<sup>3</sup> Unsafe<sup>1</sup>**

#### **Dosage Forms**

Sunpylon<sup>®</sup> 50mg/tab <KSULP01>

#### **Use**

Schizophrenia, depression

#### **Dose**

##### Schizophrenia

**PO** 300-600mg/day in divided doses; **max: 1200mg/day**

##### Depression

**PO** 150-300mg/day in divided doses; **max: 600mg/day**

##### GI ulcer

**PO** 150mg/day tid

#### **Adverse Reactions**

Leukocytosis, sedation, extrapyramidal symptoms, tardive dyskinesia

#### **Precautions**

需依腎功能調整劑量。

### **15.2.9. Quinolinone Derivatives**

## Aripiprazole

C<sup>5</sup> Unknown<sup>3</sup>

### Dosage forms

Abilify® 15mg/OD tab <KARIPI1>

Abilify® 5mg/tab <KARIPI2>

### Use

Schizophrenia, bipolar disorder, depression, irritability associated with autistic disorder

### Dose

#### Schizophrenia

13~17yrs adolescents: **PO** initial 2mg/day, increase to 5mg/day after 2days and to 10mg/day (target dose) after 2 more days; **max: 30mg/day**

Adult: **PO** 10-15mg once daily, **max: 30mg/day**; Dosage titration should not be more frequent than every 2 weeks

#### Bipolar disorder

10-17yrs children: **PO** initial 2mg/day, increase to 5mg/day after 2days and to 10mg/day (target dose) after 2 more days, subsequent dose increases may be made in 5 mg increments

Adult: initial 15mg/day monotherapy or 10-15mg/day adjunct to lithium or valproate; **max:30mg/day**

#### Major depression

Adult: **PO** initial 2-5mg/day, dose adjust to 5 mg/day increments at intervals of more than 1 week; max: 15mg/day

#### Irritability associated with autistic disorder

6-17yrs children: **PO** initial 2mg/day, then increase to 5mg/day, subsequent dose increases may be made in 5 mg increments at intervals of ≥1 week as needed, **max: 15mg/day**

### Adverse Reactions

Akathisia, headache, somnolence, sedation, extrapyramidal sign

### Precautions

1. 口溶錠服藥前才可拆開藥片，撥開藥片時不可以推擠藥錠方式取藥，以避免藥錠受損。
2. 口溶錠，可放置於舌面上以唾液溶解後吞服。

## 15.3. Sedatives and Hypnotics

### 15.3.1. Barbiturates

## Phenobarbital

D<sup>4</sup> Unsafe<sup>1</sup>

### Dosage Forms

Phenobital® 100mg/ml/amp <CPHENOB>

Phenobarbital® 30mg/tab <KPHENOB >

### Use

Epilepsy, sedation, neonatal jaundice

### Dose

#### Sedation

Children: **PO**: 6mg/kg tid

Adults: **PO** 30-120mg/day tid, **max:400mg/day**

#### Hypnotic

Adults: **PO** 100-320mg hs

#### Neonatal jaundice

Neonate: **PO** 5-10mg/kg/day

<12yrs children: **PO** 1-4mg/kg tid

#### **Adverse Reactions**

Somnolence, nervousness, unsteadiness, dizziness, light headedness

#### **Precautions**

1.需依肝腎功能調整劑量。

2.Anticonvulsant 治療劑量可參考第 12 章，參閱 p.238。

3.注射劑禁用 IV 注射。

### **15.3.2. Non-Barbiturates**

#### **Hydroxyzine**

**C<sup>4</sup> Unsafe<sup>3</sup>**

#### **Dosage forms**

Vistaril® 25mg/cap <KHYDR04>

#### **Use**

Anxiety, pruritus

#### **Dose**

#### Anxiety

Children <6 yrs: **PO** 50 mg/day in divided doses

Children >6 yrs: **PO** 50-100mg/day in divided doses

Adult: **PO** 50-100mg qid

#### **Adverse Reactions**

Drowsiness, dry mouth, headache

#### **Zaleplon**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Sonaplon® 10mg/cap <KZALEP2>

#### **Use**

Insomnia

#### **Dose**

Adult: **PO** 10mg hs. **max:10mg/day**

Elderly: **PO** 5mg hs.

#### **Adverse Reactions**

Rebound insomnia, anxiety, memory impairment, depression.

#### **Precautions**

健規：非精神科醫師、神經科專科醫師若需開立本類藥品，每日不宜超過一顆，連續治療期間不宜超過 6 個月。

#### **Contraindication**

重症肌無力、嚴重肝功能不全、嚴重呼吸功能不全、未滿 18 歲。

### **15.3.3. Benzodiazepines**

## **Alprazolam**

**D<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Alpraline® 0.5mg/tab <KALPRA2>

### **Use**

Anxiety

### **Dose**

Anxiety

**PO** Initial 0.25-0.5mg tid, maintenance 0.5-4mg daily in divided doses;  
**max: 4mg/day**

### **Adverse Reactions**

Sedated, drowsiness, decreased libido, fatigue, increased or decrease appetite

### **Precautions**

需依肝功能調整劑量。

## **Diazepam**

**D<sup>1</sup> Unsafe<sup>1</sup>**

### **Dosage Forms**

Dianlin® 10mg/2ml/amp <CDIAZ01> 參閱 p.236

## **Estazolam**

**X Unknown<sup>1</sup>**

### **Dosage Forms**

ESZO® 2mg/tab <KESTAZO>

### **Use**

Insomnia

### **Dose**

**PO** 1-2 mg hs

### **Adverse Reactions**

Dizziness, drowsiness, light-headedness, lassitude

### **Precautions**

需依肝功能調整劑量。

## **Fludiazepam**

**Unknown<sup>1</sup>**

### **Dosage Forms**

Erispan-S® 0.25mg/tab <KFLUDIA>

### **Use**

Short-term treatment of anxiety disorders

### **Dose**

**PO** 0.25mg tid

### **Adverse Reactions**

Drowsiness, dizziness, confusion, GI discomfort, respiratory depression,

### **Precautions**

需依肝腎功能調整劑量。

## **Lorazepam**

**D<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Anxicam® 4mg/2ml/amp <CLORAZ1>

Lowen® 0.5mg/tab <KLORAZI>

**Use**

Anxiety disorders, preanesthetic, status epilepticus

**Dose**

Anxiety and sedation

Adults: **IV** 2mg or 0.044mg/kg; **PO** initial 1-3mg/day bid-tid, **max:**

**10mg/day**

Insomnia

**PO** 2-4mg hs

Pre-operation

>18yrs adult: **IM** 0.05mg/kg before 2 hours of surgical operation, **max:**

**4mg**

**Adverse Reactions**

Sedation, Dizziness, weakness, unsteadiness

**Precautions**

1.針劑須冷藏。

2.高齡及未滿 18 歲之患者使用針劑時須小心。

**Midazolam**

**D<sup>4</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Uzolam® 5mg/ml/amp <CMIDA01>參閱 p10.

Midatin® 15mg/3ml/amp <CMIDA02>參閱 p10.

**Triazolam**

**X<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Halcion® 0.25mg/tab <KTRIAZO>

**Use**

Insomnia

**Dose**

**PO** 0.25mg hs; **max: 0.5mg/day**

**Adverse Reactions**

Somnolence, dizziness, ataxia, lightheadedness

### 15.3.4. Sedative and Hypnotics Miscellaneous

**Buspirone**

**B<sup>1</sup> Unknown<sup>1</sup>**

**Dosage Forms**

Sepirone® 5mg/tab <KBUSPIO>

**Use**

Anxiety

**Dose**

**PO** Initial 5mg tid, may increase by 5mg q2-3 days; **max: 60mg/day**

**Adverse Reactions**

Dizziness, nausea, headache, nervousness

**Precautions**

需依肝腎功能調整劑量。

## 15.4. Antimanic Agents

### Carbamazepine

**D<sup>1</sup> Safe<sup>1</sup>**

#### Dosage Forms

Tegretol<sup>®</sup> CR 200mg/CR.tab <KCARB02> 參閱 p.235

### Lamotrigine

**C<sup>1</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Lamictal<sup>®</sup> 5mg/chewable tab <KLAMOT1> 參閱 p.241

Lamictal<sup>®</sup> 50mg/tab <KLAMOT2> 參閱 p.241

Lamictal<sup>®</sup> 100mg/tab <KLAMOT3> 參閱 p.241

### Lithium

**D<sup>1</sup> Unsafe<sup>1</sup>**

#### Dosage Forms

Lidin<sup>®</sup> 300mg/cap <KLITHIU>

#### Use

Manic episodes, bipolar disorder

#### Dose

Bipolar disorder, manic episode

**PO** 1800mg/day tid

Bipolar disorder, maintenance therapy

**PO** 900mg/day tid

#### Adverse Reactions

Albuminuria, oliguria, polyuria, glycosuria, ataxia, tremor, muscle hyperirritability, drowsiness, muscular weakness, diarrhea, dry mouth

#### Precautions

1. 需依腎功能調整劑量。
2. 開車或操作機械時須注意。

## 15.5. Sympathomimetics and Anorexiants

### Midodrine

**C<sup>1</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Midorine<sup>®</sup> 2.5mg/tab <KMIDODR>

#### Use

Symptomatic orthostatic hypotension

#### Dose

Symptomatic orthostatic hypotension

Adults: **PO** initial 2.5 mg bid-tid therapeutic response in increments of 2.5 milligrams 3 times daily at approximate weekly. **max:40mg/day**

Urinary incontinence

**PO** 2.5-5mg/day, **max:7.5mg/day**

#### Adverse reaction

Piloerection, pruritus, urinary retention, paresthesia

### Precautions

- 1.需依腎功能調整劑量。
- 2.需監控病患血壓及心跳。

## Methylphenidate

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Form

Ritalin<sup>®</sup> 10mg/tab 短效錠<KMETHYL>

Concerta<sup>®</sup> 18mg/ER. tab 長效錠<KMETHYL>

### Use

Attention deficit hyperactivity disorder (ADHD), narcolepsy

### Dose

#### ADHD

Ritalin<sup>®</sup>

Children >6yrs: **PO** Initial 0.3mg/kg/dose bid; usual dose: 0.5-1mg/kg/day;  
**max: 2mg/kg/day**

Adults: **PO** 20-30mg/day bid-tid **max:60mg/day**

Concerta<sup>®</sup> : **PO** 18 mg qd in the morning; **max : 54 mg/day**

#### Narcolepsy

Ritalin<sup>®</sup>

Adults: **PO** 10mg/day bid before breakfast and lunch ; **max: 60mg/day**

### Adverse reaction

Restlessness, behavior disturbances, slurred speech, loss of appetite

### Precautions

- 1.建議飯前服用。
- 2.Concerta<sup>®</sup>:整顆吞服，不可咀嚼、剝半或壓碎，外殼為不可溶成份會排出體外。

## Modafinil

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Provigil<sup>®</sup> 200mg/tab<KMODAFI>

### Use

Narcolepsy with excessive daytime sleepiness

### Dose

**PO** 200 mg once daily in the morning

### Adverse reactions

Piloerection, pruritus, urinary retention, paresthesia

### Precautions

- 1.從事機械性活動需小心。
- 2.需依肝功能調整劑量

## 15.6. Smoking Deterrents

## Nicotine patch

D<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Smokfree<sup>®</sup> patch 31.2mg/patch <WNICOTI>

**Use**

戒菸輔助劑

**Dose**

**Transdermal** one patch daily

**Adverse Reactions**

Skin irritation , red and swollen

**Precautions**

- 1.進行核磁造影需撕掉，避免掃描過程中過熱造成皮膚灼燒。
- 2.使用不宜超過 3 個月避免成癮。

**Varenicline**

**C Unknown**

**Dosage Forms**

Champix<sup>®</sup> 1mg/FC. tab <KVARENI>

**Use**

戒菸輔助劑

**Dose**

**PO** initial 0.5 mg qd for days 1 through 3, then 0.5 mg bid for days 4-7, then 1 mg bid; duration of treatment is 12 weeks

**Adverse Reactions**

Nausea, insomnia, headache, flatulence, constipation, dream disorder

# 16. RENAL AND GENITOURINARY AGENTS

## 16.1. Impotence Agents

### 16.1.1. Phosphodiesterase-5 inhibitor

#### Sildenafil

B<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Viagra® 100mg/FC. tab <KSILDEN>

Revatio® 20mg/tab<KSILDE1>

#### Use

Erectile dysfunction, pulmonary arterial hypertension (PAH)

#### Dose

##### Erectile dysfunction

PO 50mg taken as needed, 1 hr before sexual activity; **max: 100mg/day**

##### Pulmonary arterial hypertension (PAH)

PO 20mg 3 times daily, taken 4 to 6 hours apart; **max: 20mg 3 times daily**

#### Adverse Reactions

Headache, flushing, abnormal vision, nasal congestion, epistaxis, diarrhea

#### Precautions

1. Viagra®: Onset 30-60 min, duration 4 hrs

2. 若服用 Viagra® 4 hr內不可使用  $\alpha_1$  adrenergic blocker

3. Viagra®: Ccr<30ml/min，起始劑量應由 25mg 開始，最高可增加至 20-100mg

#### Contraindications

Concurrent use of nitrates (eg. nitroglycerin)

#### Tadalafil

B<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Cialis® 20mg/tab <KTADALA>

#### Use

Erectile dysfunction

#### Dose

Starting dose: 10mg, no more than once daily, 1 hr before sexual activity; may increase to 20mg

#### Adverse Reactions

Headache, flushing, abnormal vision, nasal congestion, dyspepsia

#### Precautions

1. Onset: 30-45 min, duration: 36 hrs

2. 若服用本品不建議使用  $\alpha_1$  adrenergic blocker

3. 本品不建議每日服用

#### Contraindications

1. Concurrent use of nitrates (eg. nitroglycerin)

2. 嚫重心血管疾病(如:近 90 天有心肌梗塞、未受控制的心律不整等)

#### Vardenafil

B<sup>4</sup> Unknown<sup>1</sup>

**Dosage Forms**

Levitra® 20mg/tab <KVARDE2>

**Use**

Treatment of erectile dysfunction

**Dose**

10-20mg 1 hr prior to sexual activity; **max: 20mg/ady**

**Adverse Reactions**

Flushing, headache, rhinitis

**Precautions**

1.Onset: 1 hr, duration: 1 hr

2.服用本品 6 小時之內不可使用  $\alpha_1$  adrenergic blocker

**Contraindications**

Concurrent use of nitrates (eg. nitroglycerin)

## 16.1.2. Impotence Miscellaneous

**Dapoxetine**

**X** Unknown<sup>1</sup>

**Dosage Forms**

Priligy® 20mg/tab <KDAPOXE>

**Use**

Premature ejaculation

**Dose**

30mg is taken 1 to 3 hours before sexual intercourse

**Adverse Reactions**

Dizziness, headache, nausea, diarrhea, insomnia

**Precautions**

1.服用時至少搭配 240cc 的水

2.不可磨粉或撥半

3.服藥後可能發生昏厥、頭暈，應小心從事駕駛或操作危險機械

**Contraindications**

顯著病理性心血管疾病:心臟衰竭、心律傳導異常、顯著缺血性心臟疾病、顯著心瓣膜疾病、中度以及重度肝功能不全的病人

## 16.2. Urinary Alkalinizers

**Potassium citrate**

**C** Unknown<sup>1</sup>

**Dosage Forms**

K-Stone® 5g/pk (1g contains: potassium citrate 660mg;K:30mEq)<KPOTAS4>

**Use**

Renal tubular acidosis (RTA) with calcium stones, prevention of calcium renal stones

**Dose**

1 pk qid or hs

**Adverse Reactions**

Hyperkalemia, metabolic alkalosis, nausea, vomiting, diarrhea  
**Precautions**

每包(5g)加 180ml 冷開水或果汁混均服用。

## 16.3. Benign Prostatic Hyperplasias (BPH)

### 16.3.1. Alpha-adrenergic Blockers

#### Alfuzosin

**B<sup>1</sup> Unknown<sup>1</sup>**

##### Dosage Forms

Xatral<sup>®</sup> XL 10mg/tab <KALFUZO>

##### Use

Benign prostatic hyperplasias

##### Dose

10mg qd

##### Adverse Reactions

Nausea, vomiting, diarrhea, dizziness, malaise, headache

##### Precaution

Ccr <30ml/min 需小心使用。

##### Contraindications

Moderate to severe hepatic impairment, co-administration with potent CYP 3A4 inhibitors

#### Doxazosin

**C<sup>1</sup> Unknown<sup>1</sup>**

##### Dosage Forms

Doxaben<sup>®</sup> XL 4mg/tab <KDOXAZ2> 參閱 p.117

##### Use

Hypertension and benign prostate hypertrophy (BPH)

##### Dose

##### BPH

PO 4-8mg qd; max: 8mg/day

##### Adverse Reactions

Dizziness, headache, hypotension, fatigue, vertigo, diarrhea

##### Precautions

本品不宜磨粉。

#### Silodosin

**B<sup>5</sup> Unknown<sup>1</sup>**

##### Dosage Forms

Urief<sup>®</sup> 4mg/cap <KSILODO >

##### Use

Benign prostate hypertrophy

##### Dose

PO initial 4mg bid with food

##### Adverse Reactions

Retrograde ejaculation, orthostatic hypotension, dizziness, diarrhea, nasal

congestion

### Precautions

1.需依腎功能調整劑量

2.進行白內障手術中可能發生虹膜鬆弛症候群(intraoperative floppy iris syndrome)

### Contraindications

嚴重腎功能障礙(Clcr<30ml/min)、嚴重肝功能障礙(Child-Pugh score≥10)、與強效 CYP3A4 抑制劑併用。

## Tamsulosin

**B** Unknown<sup>1</sup>

### Dosage Forms

Harnalide® D 0.2mg/tab <KTAMSU1>

### Use

Benign prostatic hyperplasias

### Dose

**PO** 0.2-0.4mg qd

### Adverse Reactions

Headache, dizziness, abnormal ejaculation, rhinitis, arthralgia

### Precautions

1.服藥時可將藥錠置於舌上，以唾液潤滑後吞服；也可以與水共服。

2.本品勿咬碎服用。

## 16.3.2. 5-Alpha Reductase Inhibitor

### Dutasteride

**X** Unknown<sup>1</sup>

### Dosage Forms

Avodart® 0.5mg/soft cap <KDUTAST>

### Use

Benign prostatic hyperplasia

### Dose

**PO** 0.5mg qd

### Adverse Reactions

Decreased libido, ejaculation disorders, gynecomastia, impotence

### Finasteride

**X** Unknown<sup>1</sup>

### Dosage Forms

Propecia® 1mg/tab <KFINAS1>

Finta® 5mg/tab <KFINAS2>

### Use

Benign prostatic hyperplasia

### Dose

**PO** 5mg qd

### Adverse Reactions

Decreased libido, ejaculation disorder, erectile dysfunction, impotence

### Precautions

Male pattern hair loss 參閱 p.139, 208

## 16.4. Bladder Spasms

### 16.4.1. Cholinergics

#### Bethanechol

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Dampurine® 25mg/tab <KBETHAN>

##### Use

Neurogenic bladder atony with retention, postoperative nonobstructive urinary retention

##### Dose

Urinary retention

**PO** 10-50 mg/day tid-qid AC, **max 50 mg**

##### Adverse Reactions

Abdominal cramps, diarrhea, excessive lacrimation, miosis, flushing of skin

### 16.4.2. Antimuscarinics

#### Propiverine

Unknown<sup>1</sup>

##### Dosage Forms

Urotrol® 15mg/tab <KPROPIV>

##### Use

Urinary incontinence

##### Dose

Urinary incontinence

children 4.5-11yrs: **PO** 0.2 - 0.4 mg/kg/day bid

Adults: **PO** 15mg bid-tid

##### Adverse Reactions

Dry mouth, fatigue, blurred vision, GI upset

#### Solifenacin

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Vesicare® 5mg/tab <KSOLIFE>

##### Use

Overactive bladder with symptoms of urinary frequency, urgency or urge incontinence

##### Dose

**PO** initial 5mg qd; may increase to 10mg/day

##### Adverse Reactions

Constipation, xerostomia, dry mouth, nausea

#### Tolterodine

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Detrusitol® 4mg/S.R cap <KTOLTE1>

## **Use**

Overactive bladder with symptoms of urinary frequency, urgency or urge incontinence

## **Dose**

**PO** 4mg qd

## **Adverse Reactions**

Headache, dyspepsia, nausea, vomiting, dry mouth

### **16.4.3. Bladder Spasm Miscellaneous**

#### **Imipramine**

**D<sup>5</sup>** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Fronil<sup>®</sup> 25mg/tab <KIMIPRA>

#### **Use**

Depression, childhood enuresis

#### **Dose**

##### Urinary incontinence

Adults: **PO** 25 mg hs; **max dose 150mg**

##### Childhood enuresis

6-12 yrs: **PO** initial 25mg hs; **max: 50mg**

>12 yrs: **PO** 25mg hs; **max: 75mg**

#### **Adverse Reactions**

Weight gain, constipation, dizziness, blurred vision, urinary retention

#### **Precautions**

1. 用於 childhood enuresis 不建議<6 yrs 使用。

2. Depression dose 參閱p.285。

### **16.5. Diuretics**

#### **16.5.1. Thiazides**

#### **Exforge HCT<sup>®</sup>**

**X** **Unsafe<sup>1</sup>**

#### **Dosage Forms**

1 tab: Amlodipine 5mg+Valsartan 160mg+ Hydrochlorothiazide 12.5mg  
<KEXFORG> 參閱 p.119

#### **Indapamide**

**B** **Unknown<sup>1</sup>**

#### **Dosage Forms**

Natrilix<sup>®</sup> 1.5mg/SR tab <KINDAP2>

#### **Use**

Edema associated with congestive heart failure, hypertension

#### **Dose**

##### Edema associated with congestive heart failure

Adult: **PO** 1.5mg qd may after 1 wk increase to 5 mg qd

##### Hypertension

Adult: **PO** 1.25 mg qd (in the morning), maintenance:2.5-5 mg qd

### **Adverse Reactions**

Hypokalemia, Dizziness, Headache

### **Precautions**

不宜磨粉。

### **Trichlormethiazide**

C<sup>5</sup> Unknown<sup>3</sup>

#### **Dosage Form**

Eazide® 2mg/tab <KTRICHL>

#### **Use**

Edema associated with CHF, renal and hepatic disorders, hypertension

#### **Dose**

##### Edema or hypertension

Pediatric: PO 0.07 mg/kg/24 hrs or 2 mg/m<sup>2</sup>/24 hours

Adult: PO 1-4mg qd-bid

#### **Adverse Reactions**

Hypokalemia, electrolyte imbalances, hyperglycemia, GI disturbances

#### **Contraindications**

Hypersensitivity to trichlormethiazide or other sulfonamides, anuria

## **16.5.2. Loop Diuretics**

### **Bumetanide**

C<sup>4</sup> Unknown<sup>1</sup>

#### **Dosage Forms**

Busix® 0.5mg/2ml/amp <CBUMET1>

Busix® 1mg/tab <KBUMETA>

#### **Use**

Congestive heart failure, edema, hypertension

#### **Dose**

##### Edema

Adult:

IM/IV 0.5-1mg over 1-2 min, give a second and third dose at intervals of 2-3 hrs; **max: 10mg/day**

PO 0.5-2 mg , usually given single dose **max: 10mg/day**

#### **Adverse Reactions**

Hyperuricemia, hypochloremia, hypokalemia

#### **Precautions**

不可與鋰鹽同時給藥，會導致高鋰血清濃度。

### **Furosemide**

C<sup>4</sup> Unknown<sup>1</sup>

#### **Dosage Forms**

Furosemide® 20mg/2ml/amp <CFUROSE>

Rasitol® 40mg/tab <KFUROS1>

#### **Use**

Hypertension, edema

#### **Dose**

##### Edema

##### IM/IV

Children: 1mg/kg/dose q6-12h; **max: 6mg/kg/dose**

Adults: 20-40mg (rate < 4 mg/min), repeat after 2 hours or increased 20 mg until response

#### PO

Children: 1-2mg/kg/dose; **max: 6mg/kg/dose** (no more frequently than 6 hrs)

Adults: 20-80mg q6-q8h; **max: 600mg/day**

#### Adverse Reactions

Hyperuricemia, hypomagnesia, electrolyte imbalance, hyperglycemia, muscle spasms

#### Precautions

1. 忌酸性溶液，必要時可以 NS, LR, D5W 調整 pH 值。

2. 須高劑量注射時，以不超過 4mg/min 之靜脈輸注速率給藥。

### 16.5.3. Potassium-Sparing Diuretics

#### Spironolactone

**C<sup>4</sup> Safe<sup>1</sup>**

#### Dosage Form

Spiron<sup>®</sup> 25mg/tab <KSPIRON>

#### Use

Essential hypertension, diagnosis and treatment of primary hyperaldosteronism, edema and ascites associated with congestive heart failure, liver cirrhosis or nephrotic syndrome

#### Dose

Edema, hypertension

**PO 25-200mg/day; max: 400mg/day**

Diagnosis of primary hyperaldosteronism

Long test **PO 400mg/day** for 3-4 wks, short test 400mg/day for 4 days

Primary hyperaldosteronism

**PO 100-400mg/day; max: 400mg/day**

#### Adverse Reactions

Gynecomastia, GI upset, somnolence, menstruation disorder, impotence

### 16.5.4. Carbonic Anhydrase Inhibitors

#### Acetazolamide

**C<sup>4</sup> Unknown<sup>1</sup>**

#### Dosage Form

Acetazolamide<sup>®</sup> 250mg/tab <KACETA4>

#### Use

Edema, epilepsy, glaucoma, altitude sickness

#### Dose

Edema

**PO 250-375mg/day**

Epilepsy

**PO 8-30mg/kg/day q8-12h**

Glaucoma

**PO 250-1000mg/day qd-qid**

Altitude sickness (prophylaxis)

**PO** 500-1000mg/day bid-qid

**Adverse Reactions**

Acidosis, hematuria, dysurea, glaucoma, dry mouth

### 16.5.5. Potassium-Sparing diuretics and Thiazides

#### Amizide®

**B** **Unknown<sup>1</sup>**

**Dosage Form**

1tab: Amiloride hydrochloride 5mg+Hydrochlorothiazide 50mg  
<KAMILOR>

**Use**

Edema, hypertension

**Dose**

**PO** 1-2 tab qd; **max:** 4 tab/day

**Adverse Reactions**

Headache, weakness, nausea, anorexia, rash, dizziness, orthostatic effects

**Contraindications**

高血鉀(K>5.5mEq/L)、嚴重腎功能損傷

### 16.5.6. Osmotic Diuretics

#### Glycetose®

**Dosage Form**

1ml: Glycerin 100mg+ Fructose 50mg+ NaCl 9mg, 300ml/bot<CGLYCE1>

**Use**

Brain edema, brain obstruction, post and during cranial surgery, brain trauma, high ocular pressure, intracranial hemorrhage

**Dose**

**IV** 200-500ml qd-bid, rate of 500ml > 2-3 hrs

**Adverse Reactions**

Hematuria, hemoglobinuria

**Precautions**

- 1.需依肝腎功能調整劑量。
- 2.糖尿病患者建議降低劑量。

#### Mannitol

**C** **Safe<sup>1</sup>**

**Dosage Form**

Maniton® 20%, 20g/100ml/bot <CMANNIT1>

**Use**

Prophylaxis and treatment of acute renal insufficiency during or after surgery, promotion of urinary excretion of toxic substances, reduction of intracranial pressure

**Dose**

**IVD** (rate: 3-10min) 0.25-0.5g/kg q4-6h, usual adults dose: 20-200g/day

**Adverse Reactions**

Electrolyte imbalance, chest congestion, dry mouth, chills

## **Precautions**

若貯存溫度太低產生結晶時，可以 40-50°C 的水浴法加溫，待溶解後即可供注射用。

### **16.5.7. Diuretic Miscellaneous**

#### **Tolvaptan**

**B<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage Form**

Samsca<sup>®</sup> 15mg/tab <KAMILOR>

#### **Use**

Hyponatremia

#### **Dose**

PO initial 15mg qd, may increase to 30 mg qd after at least 24 hours; **max: 60mg/day**

#### **Adverse Reactions**

Thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, hyperglycemia

#### **Precautions**

- 1.需每日監測血鈉濃度
- 2.血鈉濃度矯正速度：24 小時內 <10-12mEq/L 及 48 小時內 <18mEq/L
- 3.避免限制水分攝取，應告知病患依口渴狀況，繼續攝取水份

#### **Contraindications**

緊急需要快速升高血鈉濃度、患者無法產生口渴的感覺或無法對口渴產生適當的反應、低血容積性低血鈉症、與強力 CYP3A 抑制劑併用、無尿症患者、與高張生理食鹽水併用

# 17. RESPIRATORY AGENTS

## 17.1. Bronchodilators

### 17.1.1. Sympathomimetics Beta-2-Agonists

#### Fenoterol

**B<sup>1</sup>** Unknown<sup>1</sup>

##### Dosage Forms

Strolin® liquid 30mg/60ml/bot <KFENOT2>

##### Use

Prophylaxis and treatment of bronchospasm in bronchial asthma, obstructive bronchitis, chronic bronchitis, emphysema

##### Dose

Children <1 yr: **PO** 2.5ml bid

Children 1-6 yrs: **PO** 2.5-5ml tid

Children 6-14 yrs: **PO** 5ml tid

Adult: **PO** 5-10ml tid

##### Adverse Reactions

Tremor of the fingers, restlessness, dizziness, fatigue, sweating

##### Precautions

開封後於室溫下可存放 2 個月。

#### Indacaterol

**C<sup>1</sup>** Unknown<sup>1</sup>

##### Dosage Forms

Onbrez® Breezhaler 105mcg/cap, 30cap/box <WINDACA>

##### Use

Chronic obstructive pulmonary disease

##### Dose

**INHL** 150mcg once daily at the same time; **max: 300mcg once daily**

##### Adverse Reactions

Nasopharyngitis, cough, upper respiratory tract infection, headache

##### Precautions

1. 不可吞服膠囊。

2. 膠囊需存放於鋁箔中，需使用時才取出。

3. 不可用於 18 歲以下病患及氣喘治療。

#### Procateterol

Unknown<sup>1</sup>

##### Dosage Forms

Meptin® 25mcg/tab <KPROCA1>

Pocathma® liquid 5mcg/ml, 60ml/bot <KPROCA2>

##### Use

Bronchial asthma, chronic bronchitis, emphysema

##### Dose

###### Tablet

Children >6yrs: **PO** 25mcg bid or hs

Adults: **PO** 50mcg bid or hs

## Liquid

Children <6yrs: **PO** 0.25ml/kg bid

Children >6yrs: **PO** 5ml bid-hs

Adult: **PO** 10ml bid-hs

## Adverse Reactions

Palpitation, headache, tachycardia, tremor

## Precautions

開封後於室溫下可存放 2 個月。

## Salbutamol

**C<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

Ventolin® inhaler 100mcg/puff, 200puffs/bot <WSALBU3>

### Use

COPD, exercise-induced bronchospasm, asthma

### Dose

預防急性氣喘發作或運動前

Children: **INHL** 100mcg/dose before challenge, **max: 200mcg/dose**

Adult: **INHL** 200mcg/dose before challenge

急性氣喘治療

**INHL** 200mcg/dose, **max: 4dose/day**

## Adverse Reactions

Tremor of skeletal muscles, palpitation, peripheral vasodilatation, headache

## Precautions

使用前先充分振搖，第一次使用需對空氣試噴兩下

## Terbutaline

**B<sup>1</sup> Safe<sup>1</sup>**

### Dosage Forms

Bricanyl® 5mg/2ml/vial <WTERBUT>

### Use

Bronchial asthma, reversible bronchospasm in bronchitis

### Dose

Body weight <20kg: **INHL** 2.5mg qid

Body weight >20kg: **INHL** 5mg qid

## Adverse Reactions

Tremor, paradoxical, bronchospasm, headache, palpitation, tachycardia

## Precautions

開封後，若未用完可在噴霧劑之儲存槽存於 24 小時。

## 17.1.2 Methylxanthiens

## Aminophylline

**C<sup>1</sup> Unsafe<sup>1</sup>**

### Dosage Forms

Asiphylline® 250mg/10ml/amp <CAMIN04>

### Use

Asthma, chronic obstructive pulmonary disease, exercise-induced

bronchospasm

#### Dose

##### IV

Loading dose:

Children: 5mg/kg q6h

Adult: 6mg/kg given over 20 min

Maintenance dose:

Aminophylline maintenance infusion rate (mg/kg/hr)		
Patient group	First 12 hrs	Beyond 12 hrs
Neonates to infant 6 mons	individualized	
Children 6 mons-9 yrs	1.2	1
Children 9-16 yrs, young adult smoker	1	0.8
Otherwise healthy non smoker adult	0.7	0.5
Older patients and those with cor pulmonale	0.6	0.3
Patients with CHF, liver disease	0.5	0.1 - 0.2

#### Adverse Reactions

Insomnia, headache, GI disturbances, nervousness, dizziness

#### Theophylline

**C** **Unsafe**

#### Dosage Forms

Telin® 200mg/S.R. tab <KTHEOP4>

Ventol® liquid 5.34mg/ml, 60ml/bot <KTHEOP3>

#### Use

Asthma, chronic obstructive pulmonary disease

#### Dose

**Telin® SR:**

35-50 kg: **PO** 125mg bid-tid

>50 kg: **PO** 250mg bid-tid

**Ventol® liquid**

Neonates: **PO** 1-1.5mg/kg bid

Children 1-15yrs: **PO** initial 12-16mg/kg/day q4-6h, maintenance

20mg/kg/day q4-6h; **max: 600mg/day**

#### Adverse Reactions

GI upset, nervousness, headache, insomnia, tremor

#### Precautions

1. 需依肝功能調整劑量。

2. 喝茶、咖啡、可樂、巧克力及抽煙或大麻將影響茶鹼的作用。

3. Telin SR 不可咬碎。

### 17.1.3. Anticholinergics

#### Ipratropium

**B** **Unknown**

#### Dosage Forms

Atrovent® nebulizer soln 0.5mg/2ml/vial <WIPRAT2>

#### Use

Asthma, chronic obstructive pulmonary disease

**Dose**

Children ≥12 yrs and adults: **INHL** 0.5mg 3-4times/day

**Adverse Reactions**

Bitter taste, dry mouth, nasal congestion, nasal dryness

**Combivent UDV**

**C<sup>1</sup>** **Unknown<sup>1</sup>**

**Dosage Forms**

1vial: Ipratropium 0.5mg + Salbutamol 2.5mg/2.5ml/vial < WCOMBIV>

**Use**

Asthma, chronic obstructive pulmonary disease

**Dose**

Children ≥ 12 yrs and adults: **INHL** 1 vial 3-4 times/day

**Adverse Reactions**

Headache, dizziness, nervous, tachycardia, palpitations

**Tiotropium**

**C<sup>4</sup>** **Unknown<sup>1</sup>**

**Dosage Forms**

Spiriva respimat<sup>®</sup> inhalation solution 2.5mcg/puff, 60puff/bot <WTIOTR1>

**Use**

Chronic obstructive pulmonary disease

**Dose**

**INHL** 2 puff qd

**Adverse Reactions**

Xerostomia, upper respiratory infection, sinusitis, pharyngitis, constipation

**Precautions**

1. Narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction

2. 開封後保存期限：3 個月

3. 為維持性支氣管擴張劑，不可用於急性期急救用藥。

4. 當瓶身的劑量顯示器指針進入紅色區域時，表示大約僅剩 7 天藥量。

## 17.2. Leukotriene Receptor Antagonists

**Montelukast**

**B<sup>1</sup>** **Unknown<sup>1</sup>**

**Dosage Forms**

Singulair<sup>®</sup> 4mg/chewable tab <KMONT1>

Singulair<sup>®</sup> oral granules 4mg/pack < KMONT4>

Singulair<sup>®</sup> 5mg/chewable tab <KMONT2>

Montelukast<sup>®</sup> 10mg/F.C tab <KMONT3>

**Use**

Allergic rhinitis, seasonal asthma (prophylaxis and chronic treatment)

**Dose**

Children 2-5 yrs: **PO** 4mg hs

Children 6-14 yrs: **PO** 5mg hs

Adults: **PO** 10mg hs

## **Adverse Reactions**

Abdominal pain, headache, thirst

## **Precautions**

- 1.Singulair 4mg 及 5mg 為咀嚼錠請嚼碎後吞服。
- 2.顆粒劑可直接口服，或與一匙冷或室溫的軟性食物(如蘋果泥)混合服用，亦可溶於一茶匙(5ml)冷或室溫的嬰兒奶粉或母乳中。
- 3.開封後需立即服用(15 分鐘內)，已溶解或混合之顆粒劑切勿保存。

## **17.3. Respiratory Inhalant Products**

### **17.3.1. Inhaled Steroids**

#### **Budesonide**

**C<sup>1</sup> Safe<sup>1</sup>**

#### **Dosage Forms**

Pulmicort® respules nebulising suspension 1mg/2ml/vial <WPULM02>

Pulmicort® nasal spray 64mcg/dose, 120 doses/bot <WPULM01>

Pulmicort® turbuhaler 200mcg/dose, 100 doses/bot <WPULM03>

#### **Use**

Rhinitis, asthma

#### **Dose**

#### **Respules**

Children: **INHL** 0.5-1mg bid, maintenance 0.25-0.5mg

Adults: **INHL** 1-2mg bid, maintenance 0.5-1mg

#### **Nasal spray**

Children >6yrs and adults: **INHL** 64-128mcg qd-bid

#### **Turbuhaler**

Children ≥6yrs: **INHL** initial 1puff bid; **max: 2puffs bid**

Adults: **INHL** 1-2puff bid; **max: 4puffs bid**

#### **Adverse Reactions**

Candidiasis infection, nasal irritatin, hoarseness, throat irritation

#### **Precautions**

1.吸入劑用後請用清水漱口。

2.Pulmicort turbuhaler: 窗口出現紅色時，約剩下 20 次劑量。

#### **Fluticasone**

**C<sup>1</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Flixotide® evohaler 50mcg/dose, 120 doses/bot <WFLUT05>

Avamys® nasal spray 27.5mcg/spray, 120 spray/bot <WFLUT06>

Fluticosone® cream 0.05%, 5g/tube <WFLUT03>參閱 p.143

#### **Use**

Rhinitis, asthma

#### **Dose**

#### **Inhalation**

Children 4-11 yrs: **INHL** 50-100mcg bid

Children>12 yrs and adults: **INHL** 100-1000mcg bid

## **Intranasal**

Children 2-12 yrs: 55mcg once daily administered as 1spray in each nostril;  
**max: 110mcg/day**

Children >12 yrs and adults: initial 110mcg once daily administered as 2 sprays (27.5mcg/spray) in each nostril, maintain 55mcg once daily

## **Adverse Reactions**

Candidiasis infection, nasal irritatin, hoarseness, throat irritation

## **Precautions**

Inhalation: 使用後以清水漱口，避免口腔念珠菌感染。

## **Contraindications**

1.Inhalation: <4 yrs 禁用

2.Intranasal: 有鼻潰瘍、鼻手術、鼻傷口者，傷口癒合前請勿使用。

## **Mometasone**

**C<sup>6</sup> Unsafe<sup>1</sup>**

## **Dosage Forms**

Nasonex® aqueous nasal spray 50mcg/dose, 140dose/bot <WMOMET3>

## **Use**

Allergic rhinitis

## **Dose**

### Allergic rhinitis

Children >12yrs and adult: **Intranasal** 100mcg qd in each nostril, upon symptom control, may consider dose reduction to 50 mcg qd in each nostril  
 2~11yrs children: **Intranasal** 50 mcg qd in each nostril

### Nasal polyps

>18 yrs adult: **Intranasal** 100 mcg bid in each nostril, upon symptom control, may consider dose reduction to 50mcg qd in each nostril

## **Adverse Reactions**

Headache, epistaxis, pharyngitis

## **Contraidcations**

鼻腔手術、鼻腔有傷口或鼻腔黏膜有感染。

## **Triamcinolone**

**C<sup>1</sup> Unsafe<sup>1</sup>**

## **Dosage Forms**

Shincort® 40mg/ml/amp <CTRIAM2> 參閱 p.228

Nincort® oral paste 0.1% 6g/tube <WTRIAM3> 參閱 p.329

Nasacort® nasal spray 55mcg/puff, 120puffs/bot<WTRIAM4>

## **Use**

Nasal spray: symptoms of seasonal and perennial allergic rhinitis

## **Dose**

Children >12yrs and adult: **Intranasal** initial 2 sprays qd in each nostril , mantaince 1 spray qd in each nostril

Children 6-12yrs: **Intranasal** 1spray qd in each nostril

## **Adverse Reactions**

Rhinitis, headache, pharingitis, epistaxis, nasal irritation

## **Precautions**

1.開封後請於 2 個月內使用完畢。

2.12 歲以下兒童不建議使用超過 3 個月。

#### Contraindications

鼻噴劑禁用於 6 歲以下兒童。

### 17.3.2. Inhaled Steroids and Bronchodilators

#### Symbicort® turbuhaler

C Unknown<sup>1</sup>

#### Dosage Forms

1 dose: Budesonide 160mcg+Formoterol 4.5mcg, 120 doses/bot  
<WSYMBI2>

#### Use

Asthma, chronic obstructive pulmonary disease, exercise-induced bronchospasm

#### Dose

Adults and children >12 yrs: INHL 1-2 dose bid; max: 8dose/day,  
4puff/dose

Children >6yrs: INHL mantaince 1dose bid; max: 2dose/day

#### Adverse Reactions

Candidiasis infection, tremor, palpitation, throat irritation

#### Precautions

1. 使用後以清水漱口，避免口腔念珠菌感染。
2. 顯示視窗：每隔 10 個劑量才會有 1 次數字標示，窗口出現紅色時約剩下 10 次劑量。
3. 兒童不可使用於急性緩解。

#### Contraindications

<4 yrs 禁用。

#### Seretide®

C Unknown<sup>1</sup>

#### Dosage Forms

1 dose: Fluticasone 100mcg+ Salmeterol 50mcg, accuhaler 60DS/bot  
<WSERET1>  
1 dose: Fluticasone 250mcg+ Salmeterol 50mcg, accuhaler 60DS/bot  
<WSERET2>  
1 dose: Fluticasone 500mcg+ Salmeterol 50mcg, accuhaler 60DS/bot  
<WSERET6>  
1 dose: Fluticasone 50mcg+ Salmeterol 25mcg, evohaler 120DS/bot  
<WSERET4>  
1 dose: Fluticasone 250mcg+ Salmeterol 25mcg, evohaler 120DS/bot  
<WSERET5>

#### Use

Asthma, chronic obstructive pulmonary disease, exercise-induced bronchospasm

#### Dose

##### Accuhaler

Children >4 yrs: INHL 1 dose bid (Seretide® 100)

Children >12 yrs and adults: INHL 1 dose bid (Seretide® 100 or Seretide®

250 or Seretide<sup>®</sup> 500)

### Evohaler

Children >4 yrs: INHL 2 dose bid (Seretide<sup>®</sup> 50)

Adults: INHL 2 dose bid (Seretide<sup>®</sup> 50 or Seretide<sup>®</sup> 250)

### Adverse Reactions

Candidiasis infection, tremor, palpitation

### Precautions

1. 使用後以清水漱口，避免口腔念珠菌感染。

2. Seretide evohaler: 使用前須先充分振搖吸入器。

3. Seretide accuhaler: 吸入後有甜味；每使用 1 個劑量窗口數字標示 1 次，當窗口出現紅色時約剩下 5 次劑量。

### Contraindications

<4 yrs 禁用

## 17.3.3. Inhaled Anticholinergic agents and Bronchodilators

### Anoro<sup>®</sup> ellipta

**C<sup>4</sup> Unknown<sup>1</sup>**

### Dosage Forms

1 puff: Umeclidinium 55mcg+ Vilanterol 22mcg, 30 doses/bot

<WANORO>

### Use

Chronic obstructive pulmonary disease (COPD)

### Dose

INHL 1 puff qd; max: 1 puff/day

### Adverse Reactions

Pharyngitis, diarrhea, pain in extremity

### Precautions

1. 不適用於緩解急性支氣管痙攣或治療氣喘。

2. 藥品開始使用後可保存 6 週。

### Contraindications

嚴重乳蛋白過敏

## 17.3.4. Mast Cell Stabilizers

### Cromolyn

**B<sup>1</sup> Unknown<sup>1</sup>**

### Dosage Forms

Cromo<sup>®</sup> eye drops 20mg/ml, 10ml/bot <WCROM01> 參閱 p.279

Allergocrom<sup>®</sup> nasal spray 2.8mg/spray, 100sprays/15ml/bot <WCROM04>

### Use

Allergic rhinitis, asthma, prevention of exercise-induced bronchospasm

### Dose

Intranasal 1 spray in each nostril, 4-6spray/day

### Adverse Reactions

Irritation of nasal mucosa, throat irritation, coughing, transient bronchospasm

**Ketotifen****C** **Unknown<sup>1</sup>****Dosage Forms**

Asumalife® 1mg/cap &lt;KKETOTI&gt;

**Use**

Prophylactic and treatment of asthma, treatment of allergic condition

**Dose**Children >3 yrs and adults: **PO** 1mg bid**Adverse Reactions**

Drowsiness, dizziness, weight gain, dry mouth

## 17.4. Lung Surfactants

**Beractant****Unknown<sup>1</sup>****Dosage Forms**

Survanta® intratracheal suspension 200mg/8ml/vial &lt;CBERACT&gt;

**Use**

Neonatal respiratory distress syndrome

**Dose****Intratracheal administration only**

Prevention and treatment: 100mg/kg, preferably within 15min of birth, up to 4 dose if needed during first 48 hours of life, no more frequently than q6h

**Adverse Reactions**

Transient bradycardia and oxygen desaturation, endotracheal tube reflux, pallor, vasoconstriction, hypotension, hypocarbia, hypercarbia, apnea

**Precautions**

1.本品應避光冷藏 2-8°C。

2.未開封品項可在溫熱後 24 小時內放回冰箱，但此情形不應超過一次。

3.使用前應於室溫回溫 ≥ 20 分鐘或以手溫溫熱至少 8 分鐘。

## 17.5. Antihistamines

### 17.5.1. Sedations

**Chlorpheniramine****C** **Unsafe<sup>1</sup>****Dosage Forms**

Chlorpheniramine® 5mg/amp &lt;CDIPHEN&gt;

**Use**

Allergic rhinitis, allergic reactions

**Dose**Children: **IM/IV/SC** 0.0875mg/kg or 2.5mg/m<sup>2</sup> q6hAdults: **IM/IV/SC** 5-10mg q8h**Adverse Reactions**

Constipation, diarrhea, nausea, vomiting, somnolence

## Cyproheptadine

**B** **Unsafe**

### Dosage Forms

Pilian<sup>®</sup> 4mg/tab <KCYPR01>

Cypromin<sup>®</sup> 24mg/60ml/bot <KCYPR02>

### Use

Allergic rhinitis, allergic reactions, urticaria

### Dose

Children 2-6 yrs: **PO** 1mg tid-qid; max: 12mg/day

Children 7-14 yrs: **PO** 2mg tid-qid; max: 16mg/day

Adults: **PO** 4mg tid-qid

### Adverse Reactions

CNS depression, dry mouth, drowsiness, increased appetite

### Precautions

1. Hyperthyroidism, history of bronchial asthma, hypertension

2. 可能有思睡感；服藥期間請小心開車、操作機械及避免飲酒。

3. 水劑開瓶後，於常溫下可存放約 2 個月。

### Contraindications

Angle-closure glaucoma, concurrent MAOI therapy

## Dexchlorpheniramine

**B** **Unknown**

### Dosage Forms

Somin<sup>®</sup> 2mg/tab <KDEXCHL>

### Use

Allergic rhinitis, common cold

### Dose

Children 2-5 yrs: **PO** 0.5mg q4-6h

Children 6-11 yrs: 1mg q4-6h

Adults: **PO** 2mg q4-6h

### Adverse Reactions

Drowsiness, dry of mouth/nose, epigastric distress, nausea, vomiting

### Precautions

Narrow angle glaucoma, bladder neck obstruction, prostatic hypertrophy

## Hydroxyzine

**C** **Unknown**

### Dosage Forms

Vistaril<sup>®</sup> 25mg/cap <KHYDR04>

### Use

Anxiety, preoperative sedative, antipruritic

### Dose

#### Anxiety

Children <6yrs: **PO** 50mg/day

Children >6yrs: **PO** 50-100mg/day

Adult: **PO** 50-100mg qid

#### Preoperative sedative

Children: **PO** 0.6mg/kg

Adult: **PO** 50-100mg

### Antipruritic

Children  $\leq$  6 yrs: **PO** 50mg/day

Children >6 yrs: **PO** 50-100mg/day

Adults: **PO** 25mg tid-qid

### **Adverse Reactions**

Drowsiness, dry mouth, headache

### **Precautions**

1. Asthma, concurrent administration with central nervous system depressants

2. 需依肝功能調整劑量

## **Mequitazine**

**Unknown<sup>1</sup>**

### **Dosage Forms**

Mekin® 5mg/tab <KMEQUIT>

### **Use**

Allergic rhinitis, hay fever, urticaria, eczema, ocular allergies

### **Dose**

Children: **PO** 0.25mg/kg/day bid

Adults: **PO** 5mg bid

### **Adverse Reactions**

Dry mouth, disturbance of visual accommodation

### **Precautions**

Hepatic diseases, glaucoma, prostatic hypertrophy, epilepsy

### **Contraindications**

Premature infants

## **17.5.2. Non-Sedations**

### **Cetirizine**

**B<sup>1</sup> Unknown<sup>1</sup>**

### **Dosage Forms**

Cetia® 10mg/tab <KCETIR1>

Cetirizine® 60mg/60ml/bot <KCETIR2>

### **Use**

Seasonal rhinitis, conjunctivitis, allergic rhinitis, urticaria, allergic pruritus

### **Dose**

Children  $\geq$  6 years and adult: **PO** 10mg daily.

### **Adverse Reactions**

Headache, dry mouth, fatigue, somnolence

### **Precautions**

Hepatic dysfunction, renal insufficiency

### **Levocetirizine**

**B<sup>4</sup> Unsafe<sup>3</sup>**

### **Dosage Forms**

Xyzal® 5mg/tab <KLEVOCE>

### **Use**

Allergic rhinitis, chronic urticaria

### **Dose**

Children > 6 years and adult: **PO** 5mg qd

### **Adverse Reactions**

Dry mouth, fatigue, headache, dizziness

### **Precautions**

需依腎功能調整劑量

**B<sup>4</sup> Safe<sup>1</sup>**

## **Loratadine**

### **Dosage Forms**

Clatine<sup>®</sup> syrup 60mg/60ml/bot <KLORA02>

### **Use**

Seasonal allergic rhinitis, chronic idiopathic urticaria

### **Dose**

>30kg children 2-12 yrs: **PO** 10ml qd

≤30kg children 2-12 yrs: **PO** 5ml qd

>12 yrs Children and adults: **PO** 10mg qd

### **Adverse Reactions**

Headache, somnolence, fatigue, dry mouth

### **Precautions**

需依肝腎功能調整劑量

**C<sup>4</sup> Unknown<sup>1</sup>**

## **LoraPseudo<sup>®</sup>**

### **Dosage Forms**

1 tab: Loratadine 5mg+Pseudoephedrine 120mg <KLORA03>

### **Use**

Relief of symptoms associated with allergic rhinitis and the common cold

### **Dose**

Children >12yrs and adults: **PO** 1 tab qd-bid

### **Adverse Reactions**

Dizziness, headache, dry mouth, fatigue, insomnia, somnolence

### **Precautions**

Glaucoma, stenosing peptic ulcer, prostatic hypertrophy

### **Contraindications**

MAOI therapy, narrow angle glaucoma, severe coronary artery disease, hyperthyroidism

**C<sup>4</sup> Safe<sup>1</sup>**

## **Fexofenadine**

### **Dosage Forms**

Allegra<sup>®</sup> 180mg/tab <KFEXOFE>

### **Use**

Seasonal allergic rhinitis

### **Dose**

**PO** 180mg qd

### **Adverse Reactions**

Drowsiness, fatigue, dyspepsia, otitis media, headache, insomnia, nausea, upper respiratory infection

### **Precautions**

Safety and efficacy not established in children < 6 yrs of age

### 17.5.3. H<sub>1</sub> Antagonist

#### Cinnarizine

C<sup>1</sup> Unknown<sup>1</sup>

##### Dosage form

Cinnazine<sup>®</sup> 25mg/tab <KCINNAR> 參閱 p.186

## 17.6. Cold Preparations

#### Peace<sup>®</sup>

##### Dosage Forms

1 tab: Pseudoephedrine 60mg+Triprolidine 2.5mg <KACTI01>  
Syrup 60ml/bot, 1ml: Pseudoephedrine 6mg+Triprolidine 0.25mg  
<KACTI02>

##### Use

Nasal congestion, sneeze, allergic rhinitis

##### Dose

Tablet:

Children 3-6yrs: **PO** 0.25 tab tid-qid

Children 6-12yrs: **PO** 0.5 tab tid-qid

Children  $\geq$  12 yrs and adults: **PO** 1 tab tid-qid

Liquid:

Children 4 mons-2 yrs: **PO** 1.25ml tid-qid

Children 3-4 yrs: **PO** 2.5ml tid-qid

Children 5-6 yrs: **PO** 3.75ml tid-qid

Children 7-12yrs: **PO** 5ml tid-qid

Children >12yrs and adult: **PO** 10ml tid-qid

##### Adverse Reactions

Occasionally mild sedation or insomnia

##### Contraindications

Excessive sedation, hypertension, narrow angle glaucoma, urinary retention

##### Precautions

需依腎功能調整劑量

## 17.7. Antitussives and Expectorants

#### Benzonatate

C<sup>4</sup> Unknown<sup>1</sup>

##### Dosage Forms

Bensau<sup>®</sup> 200mg/cap <KBENZO1>

##### Use

Symptomatic relief of nonproductive cough

##### Dose

**PO** 200mg tid; **max: 600mg/day**

### **Adverse Reactions**

Sedation, dizziness, headache, skin eruption, GI upset, chills, allergy  
**Precautions**

不宜磨粉或咬碎。

### **Contraindications**

Safety and efficacy not established in children < 14 yrs of age

## **Consrine®**

### **Dosage Forms**

1ml: Codeine 0.48mg+Chlorpheniramine 0.25mg+Methylephedrin 1.6mg+Glycyrrhizic acid 0.25mg, 120ml/bot <KCOUNSON>

### **Use**

Symptomatic relief of common cold

### **Dose**

Adults: **PO** 5-10ml tid

### **Precautions**

Addiction on prolonged use

### **Contraindications**

含 codeine 不建議用於 2 歲以下幼兒。

## **Liquid Brown mixture®**

### **Dosage Forms**

1ml: Glycyrrhiza extract 0.12ml + Tincture opium camphor 0.12ml+ Potassium antimony tartrate 0.24ml, 120ml/bot <KLIQUII>

### **Use**

Symptomatic relief of cough

### **Dose**

**PO** 常用劑量 2-10ml，依年齡遞減

### **Adverse Reactions**

Respiratory depression, arrhythmia, abnormal blood pressure, somnolence, nausea, vomiting

### **Precaution**

1. 一歲以下嬰兒不宜長期使用。
2. 不得併服含酒精飲料。
3. 使用前請搖勻。
4. 開封後室溫可存放 15 天。

### **Contraindications**

1. 嚴重呼吸抑制病患、嚴重肝機能障礙、心肌不全、急性酒精中毒患者均禁用。
2. 孕婦及哺乳婦：動物試驗會產生畸型胎，且會由母乳產生新生兒呼吸抑制，故除非醫療上必要，一般不建議給藥。

## **Codicon-U® (Medicon-A)**

### **Dosage Forms**

1 cap: Dextromethorphan 20mg+ Lysozyme 20mg+ K cresolsulfonate 90mg <KMEDICO>

## **Use**

Antitussive and expectoration

## **Dose**

**PO** 1 cap tid-qid

## **Adverse Reactions**

Sleepiness, headache, nausea, vomiting, constipation, anorexia

## **Precautions**

1.Pregnancy

2.May affect ability to drive or operate machinery

## **Medicon®**

### **Doseage forms**

1ml: Dextromethorphan 2.5mg+ K cresolsulfonate 15mg, 60ml/bot

<KMEDI01>

## **Use**

Symptomatic relief of cough, expectoration

## **Dose**

Children 3 mon-7 yrs : **PO** 3-8ml/day;

Children 8-14 yrs: **PO** 9-16ml/day tid-qid

Adults: **PO** 18-24ml/day tid-qid

## **Secorine®**

### **Dosage Forms**

1ml: Chlorpheniramine 0.1mg+Guaifenesin 5.0mg+ DL- methylephedrine 1.0mg, 120ml/bot <KSECORI>

## **Use**

Symptomatic relief of common cold

## **Dose**

Children 6-12 yrs : **PO** 5ml tid-qid

Adults: **PO** 10ml tid-qid

## **17.8. Mucolytics**

### **Acetylcysteine**

**B<sup>1</sup>** **Unknown<sup>1</sup>**

### **Dosage Forms**

Hidonac<sup>®</sup> 5g/25ml/bot <CACETY1> 參閱p.330

Actein Effervescent Tablets<sup>®</sup> 600mg/tab<KACETYL>

## **Use**

Mucolytics

## **Dose**

Actein Effervescent Tablets<sup>®</sup>:

Adult and children ≥ 6yrs: **PO** 1 tab qd-bid. 置於玻璃容器中，加少量的水溶解混勻直接飲用。

## **Adverse Reactions**

Rhinorrhea, drowsiness, chest tightness, stomatitis, nausea, vomiting, fever, bronchospasm

## Ambroxol

Unknown<sup>1</sup>

### Dosage Forms

Musco® 30mg/tab <KAMBR01>

Musco® 3mg/ml, 180mg/60ml/bot <KAMBR02>

### Use

Mucolytics

### Dose

#### Tablet

Children 5-10yr: **PO** 15mg tid

Children ≥10 yrs and adults: **PO** 30mg tid

#### Liquid

Children: **PO** 1.2-1.6mg/kg/day bid-tid

### Adverse Reactions

Mild GI effects, allergic reactions

### Precautions

開封後常溫下可保存 7 天。

## Bromhexine

Unknown<sup>1</sup>

### Dosage Forms

Bisco® 8mg/tab <KBROMHE>

### Use

Expectorant and mucolytics, sicca syndrome, Sjogren's syndrome

### Dose

Children <6 yrs: **PO** 4mg tid

Children 6-14 yrs: **PO** 8mg tid

Adults: **PO** 8-16mg tid

### Adverse Reactions

Nausea, epigastric pain, vomiting, headache, dizziness, skin rash

## Mercaptoethanesulphonate(Mesna)

B<sup>1</sup> Unknown<sup>1</sup>

### Dosage Forms

Uromitexan® 400mg/4ml/amp <CMESNA> 參閱 p.86

Siruta® 200mg/ml,3ml/amp <WMESNA>

### Use

Mucolytics

### Dose

#### Nebulizations

**INHL** 1-2amp q6-24h

#### Instillations

**INHL** 滴注於氣管內或氣切之套管 1-2ml mesna 以等體積蒸餾水或生理食鹽水稀釋，每小時滴注一次，直到分泌物液化並排出。

治療上額竇炎時，灌洗後竇內滴注 2-3ml 不經稀釋的 mesna，每隔 2-3 天可重複一次

### Adverse Reactions

Irritable cough

### Precautions

- 1.不可直接注射
- 2.不可與其他藥品混合於噴霧器內，開瓶後未使用完之藥液須丟棄。
- 3.可不經稀釋或以等體積蒸餾水或生理食鹽水稀釋後使用
- 4.Sirutau<sup>®</sup> 因使用過程會產生白色結晶沉澱物，故不建議使用在呼吸器的病患，會導致機器阻塞；使用在霧化器的病人，則建議使用後立刻清洗白色沉澱物(此為正常現象，不影響藥物品質和療效)。

#### **Contraindications**

無黏液阻塞之氣喘、對噴霧劑耐受性缺乏者

### **17.9. Nasal Decongestants**

#### **Epinephrine**

**C<sup>4</sup> Unknown<sup>1</sup>**

#### **Dosage Forms**

Adrenaline<sup>®</sup> 1mg/ml/amp <CEPINEP> 參閱p.126

Bosmin<sup>®</sup> 0.1%, 500ml/bot <WEPINEP>

#### **Use**

Bronchodilator and vasoconstriction

#### **Dose**

##### **Severe anaphylactic shock**

Children: IM/SC initial 0.3mg, may be repeated q15min 3-4 times

Adults:

Slow IV 0.1-0.25mg, may be repeated q5-15 min;

SC/IM initial 0.5mg, 0.025-0.05mg may be repeated q5-15 min as needed

##### **Severe asthma**

Children: SC (1: 1000), 0.01mg/kg; **max: 0.5mg/dose**, may be repeated at 20 min to 4hr

Adults: SC 0.2-0.5 mg; **max: 1mg/dose**, may be repeated at 20 min to 4hr intervals

##### **Cardiac resuscitation**

Children: IV 0.005-0.01mg/kg

Adults: IV 0.1-1mg may be repeated q5min

Bosmin<sup>®</sup> 外用：

手術時外傷、鼻、拔牙後、齒齦等局部出血的預防與治療、鼻、口腔粘膜的充血、腫脹，以原液 2-5 滴或五倍的稀釋液。

#### **Adverse Reactions**

Palpitation, chest pain, anxiety, headache, tremor, dizziness

#### **Precautions**

Heart disease, coronary insufficiency (angina), hypertension

#### **Oxymetazoline**

**Unsafe<sup>1</sup>**

#### **Dosage Forms**

Sindecon<sup>®</sup> nasal spray 0.05%, 15ml/bot <WOXYME>

#### **Use**

Conjunctivitis, rhinitis

**Dose**

Children ≥ 6 yrs and adults: 1 spray qd-tid

**Adverse Reactions**

Local stinging or burning, sneezing, dry mouth and throat, nausea, headache

**Precautions**

Avoid excessive use in children, concurrently MAOI, hypertension, hyperthyroidism, cardiac diseases, diabetes mellitus

## 17.10. Ear Preparations

**Ofloxacin**

C <sup>4</sup>	Unknown <sup>1</sup>
----------------	----------------------

**Dosage Forms**

Tarivid® 0.3%, 5ml/bot <WOFLOXA>

**Use**

Otitis externa and acute otitis media

**Dose**

6-10 drops into the ear bid for 10days

**Adverse Reactions**

Earache, superinfection

**Precautions**

1. When inflammation is extended into the region around the tympanum

2. 健規：每次處方以一(十日)瓶為限。

## 17.11. Mouth and Lip Preparations

**Chlorhexidine****Dosage Forms**

Parmason® 0.2%, 200ml/bot <WCHLOR3>

**Use**

Cleansing and disinfection of mouth infection

**Dose**

10-20ml rinse for 20-30 seconds bid-tid

**Adverse Reactions**

Conjunctive irritation, discolouration of the tongue and teeth, burning sensation of the tongue, taste disturbances

**Dexamethasone**

Unsafe <sup>1</sup>
---------------------

**Dosage Forms**

Dexamethasone® 5mg/ml/amp <CDEXAME> 參閱 p.225

Decone® 0.5mg/tab <KDEXA01> 參閱 p.225

Dorison® 4mg/tab <KDEXA02> 參閱 p.225

Zine® orabase 0.1%, 5g/tube <WDEXA02>

**Use**

Intractable stomatitis or glossitis associated with erosion or ulceration

### Dose

Apply to the affected area once to several times daily

### Adverse Reactions

Infection of the oral cavity (fungal or bacterial)

### Precautions

Do not take food or fluid for a short time after application, not for eye use

### Contraindications

Tuberculotic, viral or other purulent infection of the oral cavity

## Pilocarpine

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Salagen® 5mg/tab <KPILOCA>

Isopto® Carpine oph drop 2%, 15ml/bot <WPILOC2> 參閱p.277

### Use

Sjogren's syndrome, radiotherapy-induced xerostomia

### Dose

Sjogren's Syndrome

**PO** 5mg q6h

Xerostomia

**PO** 5-10mg q8h; **max: 10mg/dose**

### Adverse Reactions

Sweating, chill, flushing, nausea, rhinitis, dizziness, urinary frequency

### Precautions

Significant cardiovascular disease, concurrent use of beta adrenergic antagonists

## Triamcinolone

C<sup>4</sup> Unknown<sup>1</sup>

### Dosage Forms

Shincort® 40mg/ml/vial <CTRIAM2> 參閱p.228

Nincort® oral paste 0.1% 6g/tube <WTRIAM3>

Nasacort® nasal spray 55mcg/puff, 120puffs/bot<WTRIAM4> 參閱p.316

### Use

Stomatitis and lesions of the oral mucosa

### Dose

Apply to the affected area qd-tid

### Adverse Reactions

Infection of the oral cavity (fungal or bacterial)

### Precautions

口內膏：使用後避免進食，建議飯後或睡前塗抹。

# 18. ANTIDOTES

## 18.1. For Acetaminophen

### Acetylcysteine

**B<sup>6</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Actein Effervescent Tablets<sup>®</sup> 600mg/tab < KACETYL > 參閱 p.325

Hidonac<sup>®</sup> 5g/25ml/bot < CACETY1 >

#### Use

Acetaminophen overdose

#### Dose

20 kg or less:

Loading Dose: **IV** 150 mg/kg in 3 mL/kg of body weight of diluent administered over 1 hr

Second dose: **IV** 50 mg/kg in 7 mL/kg of body weight of diluent administered over 4 hr

Third dose: **IV** 100 mg/kg in 14 mL/kg of body weight of diluent administered over 16 hr

>20kg to ≤40kg:

Loading dose: 150mg/kg in 100ml of NS or D5W **IVF** over 1hr

Second dose: 50 mg/kg in 250ml of NS or D5W **IVF** over 4hrs

Third dose: 100 mg/kg in 500ml of NS or D5W **IVF** over 16hrs

Children>40kg and adult:

Loading dose: 150mg/kg in 200ml of NS or D5W **IVF** for 15-30min

Second dose: 50 mg/kg in 500ml of NS or D5W **IVF** over 4hrs

Third dose: 100 mg/kg in 1000ml of NS or D5W **IVF** over 16hrs

#### Adverse Reactions

Rash, urticaria, pruritus, nausea, vomiting, diarrhea

#### Precautions

1. 開封後於室溫下可保存 24 小時。

2. 硫礦味是主成分本身的氣味，並非表示變質可能產生氣管痙攣，有支氣管氣喘或曾有氣喘病史者需小心使用

### Charcoal

**C<sup>6</sup>** Unknown<sup>1</sup>

#### Dosage Forms

Carbomix<sup>®</sup> 61.5g/bot (50g activated charcoal/bot) < KCHARCO >

#### Use

Emergency treatment in poisoning by drugs and chemicals

#### Dose

Children: **PO** 0.5-1g/kg, may be repeated as needed

Adults: **PO** 1-2g/kg, repeat initial dose as soon as possible or 20-50g q2-6h (about 1-2bot/day)

#### Adverse Reactions

Vomiting, constipation, diarrhea, pulmonary aspiration, gastrointestinal obstruction

#### Precautions

- 1.加入蒸餾水到標籤上之紅色線(約400ml)後徹底搖勻再使用。
- 2.本品對alkalis, boric acid, lithium, alcohols, ethylene glycol, iron salts, mineral acids, cyanide methanol poisoning 無效
- 3.服用後會造成黑便。

### Spherical absorptive carbon

Unknown<sup>1</sup>

#### Dosage Forms

Kremezin® 2g/pack<KKREMEZ>

#### Use

Emergency treatment in poisoning by drugs and chemicals

#### Dose

<12yrs children: **PO** 依體重及中毒程度給予10-50g (5-25包)

>12yrs children and adult: **PO** 盡快使用50-100g (25-50包), 嚴重中毒時服用初始劑量後，每4-6小時給予20g(10包)，連續數天。可於嘔吐或洗胃後使用。

#### Adverse Reactions

Constipation, diarrhea

#### Precautions

- 1.腐蝕性物質引起之中毒，應避免使用。
- 2.消化性潰瘍、食道靜脈曲張、便祕傾向之患者應小心使用。
- 3.與其他藥品應間隔使用，避免降低藥品藥效。
- 4.需自費。

## 18.2. For Irons

### Deferoxamine

C<sup>6</sup> Unknown<sup>1</sup>

#### Dosage Forms

Desferal® 500mg/vial <CDESFER>

#### Use

Acute iron intoxication, chronic iron overload, iron overload secondary to congenital anemias, hemochromatosis

#### Dose

##### Acute iron intoxication

IV rate<15mg/kg/hr

Children>3 yrs: 50 mg/kg/dose **IM** q6h or **IV** infusion 15mg/kg/hr, max: 6g/day

Adults: **IM/IV**: initial 1g then 0.5g q4h for 2 dose then subsequent 0.5g q4-12h PRN; max: 6g/day.

##### Chronic iron overload

Children>3 yrs: 20-40mg/kg/day **SC** over 8-24 hrs

Adults: **IM** 0.5-1g/day or 1-2 g/day **SC** over 8 to 24 h

#### Adverse Reactions

Injection site pain, fever, headache, nausea, decreased body growth, urticaria

## Precautions

1. 鐵複合物的排除可能使尿液變成紅棕色。
2. 限用注射用水當溶劑，溶解後可再加入 NS、D5W、Ringer、LR、腹膜透析液等進一步稀釋。
3. 快速靜脈輸注易造成低血壓及休克。
4. 高劑量特別是用於治療血清鐵蛋白含量低之患者時，可能導致視覺及聽覺障礙。

## Contraindication

配伍禁忌：Heparin

## 18.3. For Benzodiazepines

### Flumazenil

C<sup>6</sup> Unknown<sup>1</sup>

#### Dosage Forms

Anexate® 0.5mg/5ml/amp <CFLUMAZ>

#### Use

Reversal benzodiazepine induced sedation and benzodiazepine overdose

#### Dose

##### Benzodiazepine overdose

Children: IV 0.01-0.02mg/kg over 15 sec, may repeat dose after 1 min;  
**max: 1mg/dose**

Adults: IV 0.2mg over 30 sec, if no responses after 30 sec, then 0.3mg over 30 sec, may repeat with 0.5mg q60sec; **max: 3mg/dose**

##### Reversal benzodiazepine

Children: IV 0.01-0.02mg/kg over 15 sec, repeat dose after 1 min; **max: 1mg/dose**

Adults: IV 0.2mg over 15 sec, may repeat 0.2mg q60sec; **max: 1mg/dose**

#### Adverse Reactions

Dizziness, nausea, vomiting, headache, hyperventilation

#### Precautions

Drug and alcohol dependent patients, convulsion in epileptic patients

## 18.4. For High Dose Methotrexate

### Leucovorin calcium (Calcium folinate)

C<sup>4</sup> Unknown<sup>1</sup>

#### Dosage Forms

Folina® 50mg/5ml/vial <CLEUCO3> 參閱 p.182

Folina® 15mg/tab <KCALC04>

#### Use

Colorectal cancer (combination with 5-FU to prolong survival), rescue therapy after high-dose methotrexate, folic acid antagonist overdosage

#### Dose

##### Advanced or metsatic colorectal cancer

Adult: IV 200mg/m<sup>2</sup> followed by 370mg/m<sup>2</sup> 5-fluorouracil (or 20mg/m<sup>2</sup>

followed by 425mg/m<sup>2</sup> 5-fluorouracil) IV daily for 5 days repeat course q4w

#### Rescue therapy after high-dose MTX

Children and adult: **IM/IV/PO** 15mg (6-12mg/m<sup>2</sup>) q6h, start 12-24hrs after MTX infusion until serum MTX level <5×10<sup>-8</sup>M; when 48hrs after MTX administration, serum MTX level ≥ 10<sup>-6</sup>M, increase dose to 100mg/m<sup>2</sup> (if serum MTX level ≥ 2×10<sup>-6</sup>M, increase dose to 200mg/m<sup>2</sup>) for 48hrs or until serum MTX level <5×10<sup>-8</sup>M

#### Antidote to the folic acid antagonist

Trimetrexate toxicity: **IV** 40mg/m<sup>2</sup> q6h for 3days

Trimethoprim toxicity: **IV** 3-10mg/day until recovery of a normal blood count

Pyrimethamine toxicity: **IV** 5-50mg/day with pyrimethamine

#### Megaloblastic anemia due to folate deficiency

Children <12yrs: **PO** 0.25mg/kg/day

Adult: **PO** 10-20mg qd

#### **Adverse Reactions**

Diarrhea, nausea, vomiting, stomatitis, allergy

#### **Precautions**

1.未開封的針劑需避光儲存於 2~8°C

2.針劑可用 NS 或 D5W 稀釋，稀釋後於室溫下避光可穩定 24 小時

#### **Contraindication**

不可用於治療因維生素 B12 缺乏所引起的惡性貧血或其他巨紅血球性貧血

## **18.5. For Opioids**

### **Naloxone**

**B**<sup>6</sup> **Unknown<sup>1</sup>**

#### **Dosage Forms**

Naloxone<sup>®</sup> 0.4mg/ml/amp <CNALOXO>

#### **Use**

Narcotic overdose and complete or partial reversal opioid depression

#### **Dose**

##### Opioid overdose, known or suspected

Children: **IV/IM/SC** initial 0.01mg/kg, subsequent dose 0.1mg/kg

Adults: **IV/IM/SC** initial 0.4-2mg, repeat q2-3min as needed; if no response after 10mg, reconsider diagnosis of opioid toxicity

##### Postoperative opioid depression

Children: **IV** 0.005-0.01mg/kg, repeat q2-3min to desired degree of reversal

Adults: **IV** 0.1-0.2mg, repeat q2-3min to desired degree of reversal

##### Opioid addiction, diagnosis

Adults: **IV** 0.2mg, observe withdrawal symptoms for 30sec, if no responses, repeat 0.6mg then observe 20min; **SC** 0.8mg, observe for 20min

#### **Adverse Reactions**

Hypertension, hypotension, ventricular fibrillation, ventricular tachycardia, dyspnea, pulmonary edema, cardiac arrest

#### Precautions

1. 可用 NS 或 D5W 稀釋，稀釋溶液應於 24 小時內使用。
2. 不可與含有 bisulfite、metabisulfite、長鏈或高分子量陰離子或任何鹼性溶液混合使用。

## 18.6. For Organophosphates

### Pralidoxime (PAM)

C<sup>6</sup> Unknown<sup>1</sup>

#### Dosage Forms

Pampara<sup>®</sup> 500mg/20ml/amp <CPRALID>

#### Use

Organophosphate poisoning

#### Dose

Children: 20-50 mg/kg IV over 15-30 minutes; **not to exceed 2g/dose**, then 10-20 mg/kg/hr **IV infusion**

Adult: 1-2 g in 100 ml NS **IV infused** over 15-30 minutes, repeat after 1 hour if muscle weakness persists; **IV continuous infusion** 500mg/hr; **max:12g/day**, general use for 3-7days

#### Adverse Reactions

Increased creatine kinase level, cardiac arrest, seizure, apnea, laryngeal spasm

#### Precautions

1. Slow IV infusion( $\leq 200\text{mg/min}$ ) prevents tachycardia, laryngospasm, muscle rigidity
2. Renal impairment, myasthenia gravisNot effective in poisonings due to phosphorus/inorganic phosphates or organophosphates without anticholinesterase activity

## 18.7. For Anesthetics

### Dantrolene

C<sup>6</sup> Unknown<sup>1</sup>

#### Dosage Forms

Dantrolen<sup>®</sup> 20mg/vial <CDANTRO>

#### Use

Malignant hyperthermia

#### Dose

IV 1mg/kg by continuous rapid push and continue until symptoms subside or to the **max cumulative dose: 10mg/kg**

#### Adverse Reactions

Diarrhea, asthenia, dizziness, somnolence, fatigue, malaise

#### Precautions

1. Dilute each 20mg with 60mg sterile water without preservatives. Shake until clear, then give by rapid direct IV injection

2. 調配後需避光且於6小時內使用完畢。

## 18.7. For Methaemoglobinemia

### Methylthioninium

**X<sup>6</sup> Unsafe<sup>1</sup>**

#### Dosage Forms

Methylene blue<sup>®</sup> 100mg/10ml/amp <CMETHY1>

#### Use

Drug-induced methemoglobinemia

#### Dose

Children ≤ 3mon: **IV** initial 0.3-0.5mg/kg (= 0.03-0.05ml/kg) over 5min, repeat after 1hr as needed

Children > 3mon and adult: **IV** initial 1-2mg/kg (=0.2-0.4ml/kg) over 5min, repeat after 1hr as needed; **max cumulative dose: 7mg/kg**

#### Adverse Reactions

Nausea, abdominal and chest pain, headache, dizziness, arrhythmia

#### Precautions

1. 由 aniline 或 dapson 引起之變性血紅素血症，最高治療建議累積劑量為 4mg/kg
2. 以 D5W 50ml 稀釋，緩慢 IV 注射，注射時間須超過 5 分鐘。
3. 開封稀釋後請立即使用。
4. 會造成尿液及糞便成藍綠色，皮膚呈現藍色，可能會遮蓋氯化物中毒診斷。
5. 中重度腎疾病須小心使用，需給予較低劑量(<1mg/kg)。

#### Contraindications

1. 禁用 NS 稀釋及皮下或腦脊髓膜內注射
2. G6PD、氯化物中毒以 sodium nitrite 治療病患、chlorate 中毒、NADPH reductase 缺乏。

## 18.8. For Anticholinergic syndrome

### Physostigmine

**C<sup>6</sup> Unknown<sup>1</sup>**

#### Dosage Forms

Anticholium<sup>®</sup> 0.4mg/ml; 2mg/5ml/amp <CPHYSOS>

#### Use

Reversal of toxic anticholinergic effects

#### Dose

##### Anticholinergic agent toxicity

Children: **IM/IV**(≤ 0.5mg/min) 0.02mg/kg, repeated at 5-10min intervals if inadequate patient response up to max dose of 2mg

Adult: **IM/IV**(≤ 1mg/min) 2mg, repeated if there are life-threatening signs

##### Anticholinergic adverse reaction, post anesthesia period

Adult: **IM/IV**(≤ 1mg/min) 0.5-1mg, repeated at 10-30min intervals if

inadequate patient response

### **Adverse Reactions**

Nausea, vomiting, excessive salivation, diaphoresis, bradycardia, seizure

### **Precautions**

1. 麻醉後不建議 physostigmine 與 atropine 併用，因 atropine 會拮抗 physostigmine 作用。

2. 療程結束後請將病歷影本及解毒劑使用報告書送交藥劑部

### **Contraindications**

Asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or the urogenital tract, vagotonic state, concomitant choline ester or depolarizing neuromuscular blocker use(eg. succinylcholine)

## **18.9 For Cyanide**

### **Nithiodote®**

**C<sup>5</sup> Unknown**

### **Dosage Forms**

Sodium nitrite 300mg/10ml+ Sodium thiosulfate 12.5g/50ml <KLACTUL>

### **Use**

Acute, life-threatening cyanide poisoning

### **Dose**

Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate, may repeat at one-half the original dose if symptoms of cyanide toxicity return

Adult: **IV** sodium nitrite 300mg/10ml (rate: 2.5-5ml/min) then sodium thiosulfate 12.5g/50ml

Child: **IV** sodium nitrite 0.2mL/kg (6mg/kg) (rate: 2.5-5ml/min), **max: 10ml**, then sodium thiosulfate 1ml/kg (250mg/kg), **max: 50ml**

### **Adverse Reactions**

Hypotension, methemoglobinemia, headache, nausea, vomiting

### **Precautions**

1. 級藥期間應監測血壓，如發生低血壓症狀，應降低輸注速率

2. sodium nitrite 級藥期間建議監測變性血紅素濃度，當濃度>30%時應停止給藥

3. 不建議與其他藥物同一條管路給藥

4. 貧血、G6PD 缺乏症需小心使用。